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RIASSUNTO 
NUOVI METODI BIOTECNOLOGICI PER IL TRASPORTO INTRACELLULARE 
Le Nanotecnologie si basano sulla comprensione e la conoscenza approfondita delle 
proprietà della materia su scala nanometrica. I benefici di questa nuova scienza 
hanno apportato significative innovazioni in diverse aree della ricerca, quali: 
elettronica, cosmetica, agricoltura e medicina. In particolare l’applicazione delle 
nanotecnologie in campo biomedico si propone l'obiettivo di realizzare un 
monitoraggio completo e continuo dell'organismo umano e di contribuire alla tutela 
della salute, lavorando a livello molecolare per ottenere benefici medici e clinici 
mediante l'utilizzo di nanodispositivi e nanostrutture; l'ottimizzazione delle tecnologie 
già esistenti per una più completa applicazione nel settore medico; lo sviluppo di 
nuovi sistemi multifunzionali per la diagnosi delle malattie e la somministrazione 
mirata dei farmaci; un aumento delle competenze e delle conoscenze che consenta 
di produrre materiali sempre più affidabili, specializzati e riproducibili, aumentando 
l'efficacia e riducendo i costi. 
Questo progetto di ricerca si inserisce nell’ambito delle nanotecnologie ed ha come 
obiettivo l’identificazione, progettazione e caratterizzazione di nuovi nanodispositivi di 
natura peptidica in grado di mediare il trasporto e il rilascio intracellulare di molecole 
bioattive utilizzabili sia nel settore diagnostico che terapeutico.  
Ora, i sistemi utilizzati per il delivery sono principalmente di tipo virale e non virale. I 
vettori virali, che derivano da virus a DNA (vettori adenovirali, adenoassociati etc.) e 
a RNA (Retrovirus), sono utilizzati per il trasporto in cellule eucariotiche di sequenze 
geniche, per la regolazione di funzioni cellulari o per esprimere proteine terapeutiche. 
Sebbene le strategie virali siano potenzialmente efficienti, ad esse sono associati 
diversi svantaggi quali l’elevata immunogenicità e tossicità.  
La strategia non virale invece, comprende approcci sia di tipo fisico quali 
microiniezione ed elettroporazione, che di tipo chimico mediato dall’utilizzo di 
biomolecole come lipidi, proteine, peptidi, nanoparticelle etc. 
Sebbene le metodiche fisiche siano comunemente utilizzate sia per studi in vitro sia 
in vivo, esse risultano invasive e potrebbero col tempo danneggiare la membrana 
plasmatica delle cellule sottoposte a trattamento. Per questo motivo risulta di 
fondamentale importanza identificare sistemi meno invasivi da utilizzare per il 
trasporto intracellulare, e l’utilizzo di sequenze peptidiche, costituisce l’alternativa non 
virale attualmente più promettente.  
I Cell Penetrating Peptides (CPPs) sono peptidi carichi in grado di trasportare 
macromolecole attraverso la membrana plasmatica in modo efficiente ed il loro 
utilizzo è notevolmente aumentato negli ultimi anni. Il principale problema associato 
al loro utilizzo è il meccanismo di traslocazione che coinvolge principalmente 
processi di natura endocitica. Quindi, solo una piccola quantità della molecola cargo 
è in grado di sfuggire agli endosomi, dove avvengono le comuni reazioni di 
degradazione intracellulare, e di raggiungere il sito di azione. E' quindi necessario 
identificare nuovi peptidi ed eventualmente nanosistemi funzionalizzati con peptidi 
con diverse caratteristiche chimico-fisiche, che utilizzino solo parzialmente il 
meccanismo endocitico, migliorando così le proprietà farmacocinetiche e 
farmacodinamiche, la distribuzione e localizzazione intracellulare e di conseguenza 
l’attività sito-specifica. 
A tale scopo il gruppo di ricerca in cui ho condotto il lavoro di ricerca, si è 
recentemente occupato dello studio delle strategie utilizzate dai virus per infettare la 
cellula ospite. I virus sono classificati in virus con envelope e virus senza envelope, in 
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base alla presenza o meno di una membrana a doppio strato fosfolipidico che 
circonda il capside. Il processo di infezione utilizzato dipende dal tipo di virus; i virus 
senza envelope utilizzano principalmente meccanismi endocitici e, quelli con 
envelope utilizzano principalmente meccanismi di fusione. Tale processo è mediato 
da glicoproteine che durante la penetrazione sottostanno ad un cambio 
conformazionale che induce l’esposizione in superficie di sequenze idrofobiche, le 
quali interagendo e destabilizzando la membrana cellulare promuovono la 
penetrazione del virus attraverso un processo non endocitico ma di tipo passivo. 
Per tale motivo, risulta essere particolarmente interessante lo studio di sequenze 
membranotropiche di derivazione virale. 
In particolare il gruppo in cui lavoro ha precedentemente identificato la sequenza 
gH625-644 che deriva dalla glicoproteina gH presente sull’envelope del virus Herpes 
simplex di tipo 1. gH625 interagisce con le membrane biologiche ed è coinvolto nel 
processo di fusione con la membrana della cellula bersaglio. Il peptide contiene 
residui amminoacidici cruciali per l’interazione e destabilizzazione delle membrane. 
La sequenza è ricca in residui idrofobici quali glicine, leucine ed alanine, residui 
aromatici quali triptofano e tirosine. La struttura NMR del peptide mostra la sua 
natura di elica anfipatica dove tutti i residui idrofobici sono presenti su un lato 
dell’elica e quelli idrofilici sul lato opposto. La porzione idrofobica della molecola 
svolge sicuramente un ruolo attivo nel processo di interazione e fusione con le 
membrane. 
L’interazione peptide-lipide è probabilmente mediata, inizialmente, dall’arginina 
presente all’estremità C-terminale, infatti quando tale residuo è mutato l’attività 
fusogenica del peptide risulta fortemente alterata. Come già detto, anche il dominio 
idrofobico è cruciale nella fase di inserzione del peptide infatti le interazioni 
idrofobiche tra le proteine di fusione e i fosfolipidi di membrana, danno inizio ai 
processi di perturbazione di membrana tipici dello stadio precoce di infezione virale. 
L’internalizzazione di gH625 è probabilmente associata alla sua capacità di interagire 
con i fosfolipidi di membrana e di formare una struttura α-elica transiente che 
destabilizza temporaneamente la membrana facilitandone la sua inserzione e 
traslocazione. Studi di internalizzazione condotti mediante tecniche sia quantitative, 
quali citometria a flusso, che qualitative, quali microscopia confocale, dimostrano che 
il peptide gH625 attraversa la membrana cellulare utilizzando essenzialmente 
meccanismi di traslocazione passiva, mostrando solo una parziale colocalizzazione 
con vescicole endosomiali, infatti, le sue cinetiche non sono alterate quando gli 
esperimenti sono condotti a 4°C, temperatura a cui tutti i meccanismi attivi sono 
inibiti. I dati ottenuti confermano che il peptide attraversa il doppio strato lipidico 
soprattutto attraverso meccanismi energia-indipendenti, risultando quindi, da un 
punto di vista farmacocinetico, un ottimo candidato per il delivery intracellulare di 
molecole bioattive. 
Sulla base delle analisi chimico-fisiche e biologiche condotte su gH625 lo scopo di 
questa tesi di dottorato è stato l’identificazione, sintesi e caratterizzazione di un 
nuovo nanosistema opportunamente funzionalizzato con gH625 da utilizzare come 
sistema innovativo nel campo del delivery intracellulare. In particolare, mi sono 
occupata dell’analisi delle cinetiche e del meccanismo di internalizzazione 
intracellulare del peptide da solo, della coniugazione del peptide a nanostrutture di 
diversa natura quali Quantum Dots, Liposomi, Dendrimeri e Nanoparticelle di 
polistirene. L’idea è stata quella di unire i benefici chimici di questi nanosistemi al 
vantaggio associato all’utilizzo di gH625, e alla sua capacità di superare le barriere 
cellulari mediante un processo di traslocazione non attivo. 
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FUNZIONALIZZAZIONE DI QUANTUM DOTs 
I QDs sono una nuova classe di fluorofori che differiscono dai convenzionali fluorofori 
organici, per diverse caratteristiche chimico-fisiche quali: l’elevata luminescenza e 
fotostabilità, e picchi di emissione che variano in funzione delle loro dimensioni; tali 
caratteristiche li rendono particolarmente interessanti per le possibili applicazioni nel 
campo dell’imaging terapeutico. Tuttavia, nonostante essi costituiscono degli ottimi 
candidati per la progettazione di nuovi sistemi da utilizzare in teranostica, presentano 
scarsa efficienza di internalizzazione intracellulare. 
Alcuni studi in vivo dimostrano che, sebbene i QDs presentino una elevata tossicità 
cellulare, dovuta probabilmente alla loro degradazione intracellulare e successivo 
rilascio di ioni metallici tossici che producono specie reattive dell’ossigeno, quando 
passivati sulla loro superficie, la tossicità risulta notevolmente ridotta. Dunque, il 
legame di trasportatori peptidici sulla superficie dei QDs rappresenta una nuova 
strategia per migliorarne l’internalizzazione e ridurne la tossicità. Numerosi lavori 
riportano la funzionalizzazione dei QDs con la sequenza Tat o con altri CPPs carichi 
positivamente; le analisi dei risultati dimostrano che il meccanismo di 
internalizzazione adoperato è principalmente quello endocitico. Dunque, risulta di 
fondamentale importanza l’utilizzo di un peptide con proprietà chimico-fisiche diverse 
dai convenzionali CPPs, come gH625, che utilizzi meccanismi di internalizzazione 
alternativi al fine di aumentarne la biodisponibilità intracellulare.  
I QDs da soli alla concentrazione di 50nM hanno una bassa affinità per la membrana 
plasmatica di cellule HeLa. La coniugazione dei QDs con gH625 ne aumenta 
notevolmente l’internalizzazione intracellulare e da studi di inibizione dei processi 
endocitici si evince che il sistema QD-gH625 utilizza meccanismi di internalizzazione 
passivi, a differenza di quello che accade quando si utilizzano QDs funzionalizzati 
con il Tat nelle stesse condizioni; in quest’ultimo caso la cinetica e l’efficienza di 
internalizzazione sono notevolmente ridotte e i meccanismi di internalizzazione sono 
di tipo endocitico. In particolare, è stato precedentemente riportato che Tat quando 
legato a molecole di piccole dimensione attraversa la membrana plasmatica e 
raggiunge i compartimento nucleare, mentre quando Tat è complessato ai QDs resta 
intrappolato in vescicole endosomiali. Questo effetto è probabilmente dovuto alle 
maggiori dimensioni dei QDs che influenzano il processo con cui Tat è internalizzato. 
Al contrario, quando i QDs sono funzionalizzati con gH625 entrano nelle cellule con 
distribuzione extravescicolare. In conclusione peptidi con diverse proprietà biofisiche 
possono influenzare il processo di internalizzazione della stessa molecola cargo. 
 
FUNZIONALIZZAZIONE CON LIPOSOMI 
I liposomi sono vescicole non tossiche, non immunogeniche, biodegradabili e di 
diametro compreso tra 50-500 nm. La loro struttura si caratterizza per la presenza di 
uno o più doppi strati fosfolipidici esterni che delimitano all'interno un core. In questo 
modo, le sostanze idrosolubili contenute all'interno delle microsfere liposomiali 
possono essere facilmente veicolate all'interno delle cellule, riducendo la tossicità 
associata ad alcune molecole bioattive come i farmaci antineoplastici. Per questo 
motivo sono degli ottimi candidati per la veicolazione intracellulare di principi attivi. E’ 
stato dimostrato che la funzionalizzazione della superficie liposomiale, migliora in 
maniera notevole l’internalizzazione e quindi l’efficacia antitumorale del farmaco 
trasportato. La strategia sintetica utilizzata per la funzionalizzazione di liposomi con 
peptidi dipende dalla natura chimico-fisica del peptide; in particolare, l’utilizzo di un 
peptide idrofobico risulta più complicato a causa della sua bassa solubilità in 
ambiente acquoso e dalla sua tendenza a distribuirsi preferenzialmente nella regione 
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idrofobica del doppio strato lipidico piuttosto che in superficie. gH625 è stato legato a 
liposomi, preformati e caricati con Doxorubicina, utilizzando la click-chemistry; inoltre 
la sua capacità di attraversare le membrane plasmatiche è stata valutata attraverso 
esperimenti di microscopia confocale. 
Le cellule sono state incubate a 37°C con una soluzione 1µM di Doxorubicina libera, 
Doxorubicina caricata in liposomi e Doxorubicina caricata in liposomi e funzionalizzati 
con gH625. I risultati ottenuti dopo 5 ore di incubazione dimostrano che la Doxo e 
liposomi-Doxo hanno una localizzazione nucleare; al contrario il liposoma con Doxo e 
peptide ha una localizzazione citoplasmatica. Questa diversa distribuzione 
intracellulare è probabilmente dovuta alla presenza del peptide che altera il 
meccanismo di internalizzazione del sistema e il rilascio intracitoplasmatico del 
farmaco. Sebbene il meccanismo non sia ancora ben definito i risultati ottenuti, 
risultano utili per la progettazione di sistemi di trasporto e rilascio controllato di 
Doxorubicina, al fine di ridurne i suoi effetti indesiderati. 
 
FUNZIONALIZZAZIONE CON DENDRIMERI  
I dendrimeri sono molecole che contengono una serie di ramificazioni che si 
estendono da un nucleo centrale. Generalmente presentano diverse copie dello 
stesso gruppo funzionale al termine delle ramificazioni, hanno una struttura e 
dimensione ben definita rispetto a polimeri lineari aventi stessa composizione e peso 
molecolare. 
Vi sono essenzialmente due strategie sintetiche che possono essere utilizzate per la 
preparazione di dendrimeri: l’approccio convergente e l’approccio divergente. 
Con l’approccio divergente, il dendrimero è preparato a partire da un nucleo 
polifunzionale per successive aggiunte di ramificazioni. Con l’approccio convergente, 
si parte dalle unità funzionali superficiali e si aggiungono progressivamente 
ramificazioni interne. I dendrimeri hanno avuto un forte impatto nelle bioscienze e in 
particolare in campo biomedico come potenziali trasportatori di farmaci. Studi di 
internalizzazione condotti su dendrimeri PAMAM da soli e funzionalizzati con la 
sequenza Tat dimostrano che il meccanismo utilizzato è prevalentemente  di tipo 
endocitico. I nostri studi, condotti mediante esperimenti di interazione con le 
membrane, citometria in flusso e microscopia confocale, su dendrimeri poli-amidici 
funzionalizzati con la sequenza fusogenica gH625, dimostrano invece che il 
complesso fonde membrane modello, come liposomi, e che attraversa 
efficientemente  le membrane cellulari utilizzando un meccanismo di traslocazione 
passivo. 
 
FUNZIONALIZZAZIONE CON NANOPARTICELLE DI POLISTIRENE 
L’utilizzo di farmaci per le patologie neurologiche attualmente in via di 
sperimentazione, sono limitate dall’incapacità dell’agente terapeutico di attraversare 
efficientemente la barriera ematoencefalica (BBB). La BBB è una barriera dinamica e 
selettiva che protegge il sistema nervoso dall’invasione di sostanze e organismi 
indesiderati; ma rappresenta anche un notevole ostacolo da un punto di vista 
terapeutico in quanto limita l’attraversamento e il rilascio dei farmaci nel loro sito di 
azione. Per questo motivo è fondamentale identificare e sviluppare un sistema che 
permetta un migliore rilascio del farmaco nei compartimenti del sistema nervoso. La 
maggior parte delle strategie in fase di sperimentazione che hanno avuto un notevole 
impatto terapeutico, come la microiniezione diretta, risultano talvolta troppo invasive 
in quanto danneggiano in maniera irreversibile la BBB.  
Particolare interesse attualmente è rivolto allo studio di Nanoparticelle (NPs), 
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eventualmente funzionalizzate, per utilizzarle come trasportatori di farmaci attraverso 
la barriera ematoencefalica. Le Nanoparticelle sono costituite da aggregati atomici o 
molecolari con un diametro compreso approssimativamente fra 2 e 200 nm e si 
distinguono da gli altri nanosistemi per la loro piccola dimensione, elevata area 
superficiale, forma, composizione chimica e carica.  
Sono stati condotti esperimenti di internalizzazione con NPs di polistirene, di 100nm 
di diametro, opportunatamente funzionalizzate con la sequenza gH625, su cellule 
dell’endotelio cerebrale (bEnd3). I risultati ottenuti dimostrano che la presenza, sulla 
superficie delle NPs, di gH625 ne migliora la loro internalizzazione. Inoltre, il loro 
movimento intracitoplasmatico risulta di tipo casuale e non direzionale. Questo 
comportamento è indicativo di un meccanismo passivo di internalizzazione. I dati 
preliminari dimostrano che il nostro sistema, presenta delle caratteristiche ottimali, 
per il trasporto di molecole attraverso la barriera ematoencefalica e potrebbe essere 
utilizzato per la cura delle patologie del Sistema Nervoso Centrale. 
  
CONCLUSIONI 
La scelta di un sistema di natura peptidica per il trasporto intracellulare di molecole 
bioattive da utilizzare nel campo della teranostica, rappresenta attualmente una delle 
strategie chimiche, non virali e non invasive più promettenti. Il meccanismo di 
internalizzazione utilizzato da tali costrutti peptidici risulta di fondamentale 
importanza per il destino della molecola bioattiva eventualmente da loro trasportata. 
E’ stato dimostrato che la maggior parte dei CPPs utilizza processi endocitici che 
inducono una riduzione della biodisponibilità intracellulare della molecola 
internalizzata. A tale proposito l’identificazione di una sequenza di derivazione virale, 
capace quindi di mimare il processo di fusione utilizzato da alcuni virus per infettare 
la cellula ospite, ha avuto un forte impatto nella progettazione di nanosistemi 
utilizzabili sia nel campo della diagnostica che della terapia. In conclusione, i risultati 
ottenuti dalla funzionalizzazione con gH625, convergono tutti nella stessa direzione; 
non solo gH625 è capace di attraversare la membrana plasmatica in maniera 
efficiente, attraverso meccanismi di traslocazione passiva, ma è anche in grado di 
facilitare l’ingresso intracellulare di molecole biologicamente attive. 
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SUMMARY 
Biological membranes represent a critical hindrance for administering active molecules 
which are often unable to reach their designated intracellular target. 
In order to overcome this barrier-like behavior, not easily circumvented by many 
pharmacologically-active molecules, and to promote cellular uptake, synthetic peptide-
based transporters have been exploited. In fact, linking or complexing therapeutic 
molecules to peptides that can translocate through the cellular membranes could 
enhance their internal delivery, and consequently, a higher amount of active compound 
would reach the site of action. Use of Cell Penetrating Peptides (CPPs) is one of the 
most promising non invasive strategies to efficiently translocate macromolecules through 
the plasma membrane, and have, recently, attracted a great attention. A new viral 
traslocator peptide (gH625) is described in this thesis, which is derived from the Herpes 
simplex virus type 1 (HSV-1) glycoprotein H (gH). gH625 has proved to be a useful 
delivery vehicle due to its intrinsic properties of inducing membrane perturbation. 
Quantum dots (QDs), Liposomes, Dendrimers and Polystyrene Nanoparticles (NPs) 
have been used as powerful platforms for studying the behavior of gH625 as a nano-
vehicles. 
QDs are a new class of fluorescent probes under intense research and development for 
broad application in molecular, cellular and in vivo imaging. QDs do not significantly 
traverse the membrane bilayer on their own. On the contrary, when functionalized with 
gH625, are able to translocate through cellular plasma membranes by a mechanism 
which seems to be only relatively dependent on the endocytic route of entry. 
Liposomal aggregates have been successfully used as in vivo carriers of active 
principles; they display some unique pharmacokinetic properties and can be adapted to 
a wide range of therapeutic agents. An easy and versatile synthetic strategy, based on 
click chemistry, has been used to bind, in a controlled way, several copies of gH625 
peptide on the external surface of DOPG based liposomes. Liposomes have been also 
loaded with the cytotoxic doxorubicin drug and their ability to penetrate inside cells has 
been evaluated by confocal microscopy experiments. Results suggest that liposomes 
functionalized with gH625 may act as promising intracellular targeting carriers for 
efficient delivery of drugs, such as chemotherapeutic agents, into tumor cells. 
Dendrimers are perfectly hyperbranched macromolecules with a well-defined structure, 
which exhibit properties very different from linear polymers with the same composition 
and molecular weight. A poly(amide)-based dendrimer was synthesized and conjugated 
with gH625. The attachment of the peptide sequences to the termini of a dendrimer 
allows the conjugate to penetrate into the cellular matrix, whereas the unfunctionalized 
dendrimer is excluded from translocation. The peptide functionalized dendrimer is rapidly 
taken into the cells mainly through a non-active translocation mechanism. 
The surface of fluorescent aminated polystyrene nanoparticles (NPs) was functionalized 
with gH625 via a covalent binding procedure, and the NP uptake mechanism and 
permeation across in vitro Blood Brain Barrier (BBB) models were studied. At early 
incubation times, the uptake of NPs with gH625 by brain endothelial cells is greater than 
that of the NPs without the peptide, and their intracellular motion is mainly characterized 
by a random walk behavior. Most importantly, gH625 peptide decreases NP intracellular 
accumulation as large aggregates and enhances their BBB crossing. In summary, these 
results establish that gH625 may represent a good choice for the design of promising 
carriers to deliver drugs for the treatment of human diseases. 
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1 INTRODUCTION 
1.1 NANOTECHONOLGY FOR ADVANCED DRUG DELIVERY SYSTEMS 
Nanotechnology is the branch of science correlated to physics, chemistry, biology 
and medicine and dedicated to materials with dimensions in the order of 100 nm or 
less. It is actually receiving great attention with a never-seen-before enthusiasm 
because of its potentialities which can literally revolutionize any field in which it is 
applied.  
In particular, the main areas in which nanotechnology is bringing significant 
innovations are electronics, energy, heavy industry, foods and nanofoods, cosmetics, 
agriculture, medicine etc. The application of nanotechnology in the biomedical field is 
the objective of achieving a comprehensive and continuous monitoring of the human 
body and contributes to the protection of health, working at the molecular level to 
obtain clinical and medical benefits through the use of nanostructures and 
nanodevices, the optimization of existing technologies for a more complete 
application in the medical sector, the development of new multifunctional systems for 
disease diagnosis and targeted drug delivery, raising the skills and knowledge that 
allows the production of materials more reliable, specialized and reproducible, 
increasing efficiency and reducing costs. 
Nanoparticles are generally defined as clusters of atoms in the range of 1 to 100 nm, 
which possess defined chemical, optical and mechanical properties and are 
becoming extremely promising for their activities in many fields; their properties are 
believed to be linked to their large surface area to volume ratio. To put a nanometre 
in context: a strand of DNA is 2.5 nm wide, a red blood cell is 7,000 nm and a human 
hair is 80,000 nm wide. Reducing the particle size of materials has demonstrated to 
be an efficient and reliable tool for improving their biocompatibility; furthermore, 
nanomaterials thanks to the possibility of decorating their surface with functional 
groups can also be modified for better efficiency to facilitate their applications in 
bioscience and medicine, thus, opening up a whole new world of science and 
discovery. As their diameter decreases, the available surface area of the particle 
itself increases dramatically and as a consequence there is an increase over the 
original properties of their corresponding bulk materials, and this feature makes them 
superior and indispensable in many areas of human activity and excellent candidates 
for biomedical applications as a variety of biological processes occur at nanometer 
level. It suffices to consider that cells are typically of 10 µm across and proteins are 
usually of 5 nm, which are dimensions comparable with those of the smallest 
synthetic nanoparticle.  The biological interactions are generally multivalent and often 
involve multiple copies of receptors and ligands that bind in a coordinated manner, 
resulting in enhanced specificities, efficiencies, and strengths of such interactions 
that make nanosystems very versatile in that they can be involved in multiple 
interactions.  
These properties allow nanoparticulate systems to overcome current limitations of 
conventional formulations as they facilitate the intracellular uptake to specific cellular 
targets. Thus, nanotechnology is having a huge impact in the area of nanomedicine 
and in particular in several fields such as drug/gene delivery1, imaging2 and 
diagnostics3, therapy, biomaterials and tissue engineering (Table 1).  
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    Table 1. Applications of nanotechnology in medicine. 
 
In drug delivery, nanotechnology is just beginning to make an impact. Many of the 
current “nano” drug delivery systems, however, are remnants of conventional drug 
delivery systems that happen to be in the nanometer range, such as liposomes, 
polymeric micelles, nanoparticles, dendrimers, and nanocrystals. Liposomes and 
polymer micelles were first prepared in 1960’s; nanoparticles and dendrimers in 
1970’s and colloidal gold particles in nanometer sizes were first prepared by Michael 
Faraday more than 150 years ago, but were never referred to or associated with 
nanoparticles or nanotechnology until recently. Subsequently, as illustrated in Figure 
1, a variety of other organic and inorganic biomaterials for drug delivery were 
developed. The first controlled release polymer system for delivery of 
macromolecules was described in 1976. More complex drug delivery systems 
capable of responding to changes in pH which trigger drug release, as well as the 
first example of cell-specific targeting of liposomes4,5 were first described in 1980. 
The first long-circulating liposome was described in 1987, and the concept was later 
named “stealth liposomes”6. The use of polyethylene glycol (PEG) was shown to 
increase circulation times of liposomes7 and polymeric nanoparticles8 in 1990 and 
1994, respectively, paving the road for the development and subsequent approval of 
Doxil (doxorubicin liposome) in 1995, for the treatment of AIDS-associated Kaposi’s 
Sarcoma. 
A variety of organic/inorganic nanomaterials and devices have been used as delivery 
vehicles to develop effective therapeutic modalities (Figure 1). So far, there are over 
two dozen nanotechnology-based therapeutic products approved by Food and Drug 
Administration (FDA) for clinical use, and more are in clinical trials9-11. Of these 
products, the majority are composed of a non-targeted delivery system (e.g., 
liposomes and polymers) and a drug, and are therefore considered first generation 
nano-therapeutics12. 
The importance of nanotechnology in drug delivery is correlated to the possibility of 
manipulating molecules and supramolecular structures in order to produce devices 
with programmed functions, allowing to achieve: 1) improved delivery of poorly water-
soluble drugs; 2) targeted delivery of drugs in a cell- or tissue-specific manner; 3) 
transcytosis of drugs across tight epithelial and endothelial barriers; 4) delivery of 
large macromolecule drugs to intracellular sites of action; 5) co-delivery of two or 
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more drugs or therapeutic modality for combination therapy; 6) visualization of sites 
of drug delivery by combining therapeutic agents with imaging modalities; and 7) real-
time read on the in vivo efficacy of a therapeutic agent13. Additionally, the 
manufacturing complexity of nanotechnological therapeutics may also create a 
significant hurdle for generic drug companies to develop equivalent therapeutics 
readily.  
 
Figure 1. Organic and inorganic nanomaterials and devices.  
 
1.2 VIRAL AND NON VIRAL VECTORS FOR DRUG DELIVERY 
Actually, drug delivery is performed using viral and non-viral vectors. Viral vectors are 
used to deliver genes into eukaryotic cells to regulate cellular functions or to express 
therapeutically useful proteins. This strategy is still facing major technical hurdles 
which need to be more efficiently investigated, such as selectivity, tissue tropism, 
regulation and level of gene expression and immunogenicity; although, several 
strategies have been developed, their clinical application has often been drawn back 
by side effect and toxicity problems. Viral vectors can be based either on RNA 
viruses or DNA viruses. 
Nonviral delivery techniques include physical approaches (such as microinjection, 
particle bombardment and electroporation) and chemical approaches (such as 
cationic lipids, diethyl aminoethyl (DEAE)-dextran, calcium phosphate, proteins, 
peptides, dendrimers, liposomes and controlled-release polymers) that are mostly 
aimed at depositing DNA into cells. 
 
1.2.1 VIRAL VECTORS 
Vectors based on RNA viruses. 
Retroviruses were initially chosen as the most promising gene-transfer vehicles and 
about 60% of all approved clinical protocols utilize them. Retroviruses have minimal 
risks because they have evolved into relatively non-pathogenic parasites (although 
there are exceptions, such as the human immunodeficiency viruses (HIV) and human 
T-cell lymphotropic viruses (HTLV). The vectors themselves have all of the viral 
genes removed, are fully replication-defective and can accept up to about 8 kilobases 
(kb) of exogenous DNA. 
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The problems that investigators face in developing retroviral vectors, that are 
effective in treating diseases, are of four main types: obtaining efficient delivery, 
sustaining long-term gene expression, and developing a cost-effective way to 
manufacture the vector. 
 
Obtaining efficient delivery. 
Currently, the cells transduced by retroviral vectors possess a high level of the 
natural MuLV (amphotropic) receptor and an important target cell is the 
Hematopoietic Stem Cell (HSC) because gene transfer into these primitive cells 
would result in gene-engineered cells for the life of the recipient. Unfortunately, HSCs 
have a low level of amphotropic receptor resulting poorly transducible14. The broad 
range of cell types possessing the amphotropic receptor, known to be a phosphate 
symport, limits the target-specific utility of these vectors in the in vivo approach.  
Progress has been made using a second approach to targeting called 'tethering', 
consisting into the insertion of a ligand that recognizes any extracellular matrix (ECM) 
components, such as fibronectin and collagen15,16. 
 
Improving gene expression.  
Several factors are involved in maintaining the stable expression of genes after their 
transfer; first, the regulatory sequences that control gene expression often do not 
remain active and second, even if the gene stays active within the cell, the cell often 
dies because the immune system is designed to recognize and eliminate foreign 
gene products and cells that produce foreign proteins. 
Another important factor that could reduce the gene expression stability is that even if 
regulatory elements are active, they may not function without the proper signals and 
feedback mechanisms. The goal is to use regulatory sequences that respond to the 
body's own physiological signals or to drugs that can be used to control the level of 
gene activity.  
 
Manufacturing the vector. 
Retroviral vectors are biological agents: they can only be made by living cells that do 
not represent the easiest systems in which to carry out good manufacturing practice 
(GMP) and quality assurance/quality control (QA/QC) procedures mandated by the 
Food and Drug Administration (FDA). 
The possibility that a replication-competent retrovirus (RCR) could arise during the 
manufacturing process and the ability of retroviral vectors to integrate randomly into 
host cell DNA, limit considerably their manufacturing. These issues are resolvable, 
but it will take several years of product development to achieve a cost-effective 
system that will produce safe, efficient gene-therapy vectors on a sufficient scale to 
allow worldwide marketing. 
 
Vectors based on DNA viruses 
Adenoviral vectors 
Adenoviruses are DNA viruses, they have been isolated from a large number of 
different species, and more than 100 different serotypes have been reported. 
Adenoviruses are used as vehicles to administer targeted therapy; first-generation 
adenoviral vectors are replication attenuated by removal of the early region 1 (E1a 
and E1b). Without the E1A gene, viral genes are not expressed at high enough levels 
for effective replication and packaging, leaving the recombinant virus as a simple 
carrier of therapeutic genes. More recently, so-called second-generation vectors 
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have even more viral genes removed to allow for larger transgene packages and to 
minimize host immune response to viral gene products.  
Adenoviral vectors have several positive features: they are large and can therefore 
potentially hold large DNA inserts (up to 35 kb); they are human viruses and are able 
to transduce a large number of different human cell types with very high efficiency 
(often reaching nearly 100~% in vitro); they can transduce non-dividing cells; and 
they can be produced at very high titres in culture. Nevertheless adenoviral vectors 
have certain drawbacks; first generation vectors have to be deleted for several DNA 
regions in order to render them replication-defective and to create space for the 
insertion of transgenes and the deletion of more and more viral genes may not 
always be advantageous because some of these genes may have beneficial 
attributes, for example suppressing an immune response against the vector.  
Adeno-associated viral vectors. 
Another DNA virus used in clinical trials is the adeno-associated virus (AAV). This is 
a non-pathogenic virus that is widespread in the human population (about 80% of 
humans have antibodies directed against AAV). Interest in this virus has arisen 
because it is the only known mammalian virus showing preferential integration into a 
specific region in the genome; consequently its insertion site appears to be a 'safe' 
region in the genome. 
However, there are several disadvantages: some cells require a very high multiplicity 
of infection (the number of viral particles per cell required to achieve transduction); 
the AAV genome is small, only allowing room for about 4.8 kb of added DNA; and the 
production of viral particles is still very labour intensive because efficient packaging 
cells have not yet been developed.  
Other DNA virus-based vectors. 
Other DNA viruses are being studied as possible gene-therapy vectors for specific 
situations. For example, herpes simplex virus (HSV) vectors have a propensity for 
transducing cells of the nervous system17,18, as well as several other cell types. A 
stripped-down version of the HSV may have certain advantages, particularly when 
combined with components from other viral systems19. A number of other DNA virus 
vectors are under study including poxviruses.  
 
Although viral systems are potentially very efficient, two factors suggest that non-viral 
gene delivery systems will be the preferred choice in the future: safety, and easy of 
manufacturing. A totally synthetic gene-delivery system could be engineered to avoid 
the danger of producing recombinant virus or other toxic effects engendered by 
biologically active viral particles. Also, manufacturing a synthetic product should be 
less complex than using tissue culture cells.  
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1.2.2 NON VIRAL VECTORS 
1.2.2.1 Physical approaches: 
Multiple physical devices have been used to overcome biological barriers: 
Ultrasound devices (sonophoresis, sonoporation and acoustic ablation). 
The use of ultrasound to deliver drugs across the skin has a long history dating back 
to the middle of the 20th century, a phenomenon termed as sonophoresis or 
phonophoresis. A broad spectrum of ultrasound frequencies (20 kHz–16 MHz) has 
been used for sonophoresis. However, in early–mid 1990s, low-frequency ultra- 
sound (20–100 kHz) was shown to be more effective compared to high frequencies 
and was shown to deliver high molecular weight drugs including proteins and 
nucleotides20. Ultrasound induces nano-scale ultrastructural defects in the lipid 
regions of the stratum corneum, thus increasing its  permeability21. This opens up the 
possibility for using ultrasound in the treatment of diabetes by simultaneous 
continuous monitoring of blood glucose level and delivery of insulin. 
Ultrasound-induced disruption of the blood–brain-barrier has been used to enhance 
drug penetration into to the brain by disrupting the tight junctions between the 
capillary endothelial22-24.  
 
Electrical devices (iontophoresis and electroporation). 
Application of low amplitude electric currents has been shown to enhance 
transdermal transport of drugs, especially for charged molecules, a phenomenon 
referred to as iontophoresis25. This phenomenon has been used for transdermal 
delivery of various low molecular weight drugs including lidocaine26 and 
dexamethasone27 as well as high molecular weight drugs including insulin28 and 
luteinizing hormone-releasing hormone29. Iontophoretic delivery of lidocaine has been 
clinically approved for local anesthesia26 and of pilocarpine for diagnosis of cystic 
fibrosis30. 
 
High pressure devices (liquid and powder injections). 
Liquid jet injections employ a high-speed jet to puncture the skin and deliver drugs 
without the use of a needle. The basic design of liquid jet injectors consists of a 
compressed gas or spring, drug-loaded compartment and a nozzle with orifice sizes 
typically ranging between 150 and 300 µm. 
The key advantages of jet injectors include the ability to use currently approved 
formulations, ability to work without electronics and power and provision of small 
portable devices. 
Jet injectors have been used for mass immunization programs for diseases including 
measles, smallpox, cholera, hepatitis B, influenza and polio. They have also been 
used for delivery of insulin and growth hormones31. 
 
Microneedles (solid, hollow and degradable microneedles). 
Microneedles are arrays of short and thin needles that can penetrate into skin at least 
up to epidermis and enhance drug penetration into skin. Four different types of 
microneedle designs have been developed: (i) solid microneedles that pierce the skin 
and enhance skin permeability, (ii) solid microneedles that are coated with dry 
powder drugs or vaccines that dissolve in the skin upon piercing, (iii) polymer 
microneedles that encapsulate drugs and deliver them in the skin similar to implanted 
polymer devices, and (iv), hollow microneedles that infuse drugs in the skin. 
15	  	  
Microneedles have been made from various metals and organic polymers including 
biodegradable materials. 
Numerous studies have been performed that report the ability of microneedles to 
enhance the penetration of drugs in vitro, in animals and in humans. Microneedle 
application has been shown to enhance skin permeability to a variety of compounds 
ranging from low molecular weight tracers to proteins, DNA and nanoparticles. 
Human studies have shown delivery of various drugs including naltrexone, lidocaine 
and insulin32. 
 
Thermal and optical devices (lasers and radio-frequency heating). 
Several studies have reported on the use of thermal and laser sources for ablation of 
biological barriers. Thermal ablation of skin that selectively removes stratum corneum 
without damaging deeper tissues is achieved through careful control of skin surface 
temperature over a short duration of time. Rapid heating of skin restricts the ablation 
to stratum corneum while leaving deeper viable tissue cooler and structurally intact33 
Lasers have also been used to enhance drug delivery into various tissues including 
skin. In case of skin, lasers are used to ablate the stratum corneum of the skin by 
deposition of optical energy, which induces instant evaporation of water leading to 
the formation of microchannels in the skin. The depth of the channels can be 
controlled through exposure time and other parameters and is often controlled to less 
than 200 µm so as to avoid pain and bleeding. 
 
Although these methodologies are commonly used for both in vitro and in vivo 
studies, they appear invasive and over time they could damage cellular membrane; 
for this reason, the identification of a non invasive system, useful for intracellular 
delivery of a bioactive molecule, results indispensable. 
 
1.2.2.2 Chemical approaches 
Peptide vectors for intracellular delivery. 
Cell penetrating peptides (CPP) are among the most promising non-viral strategies. 
Although defining CPPs is rather difficult in view of the fact that new CPPs are 
continuously discovered; they can generally be considered as short peptides of less 
than 30 amino acids either derived from proteins or from chimeric sequences which 
are very promising for cellular uptake and membrane interaction studies. While 
individual CPPs differ in length and sequence, they share some common features, 
which include their amphipathic nature, net positive charge, hydrophobicity and 
helical moment, the ability to interact with lipidic membranes, and to adopt a distinct 
secondary structure upon association with lipids34-36. CPPs can be subdivided into 
two main classes; the first requiring chemical linkage with the cargo and the second 
involving the formation of stable, noncovalent complexes36,37. CPPs from both 
classes have been described to efficiently deliver a large number of cargos (plasmid 
DNA, oligonucleotide, siRNA, PNA, protein, peptide, liposome, nanoparticle, etc.) into 
a wide variety of cell types and in vivo models35. The idea of molecular transporters 
came about 20 years ago based on the observation that some proteins; mainly 
transcription factors; could move within cells and from one cell to another. The first 
protein able to translocate across cell membranes and to reach intracellular access 
was described in 1988. This was the human immunodeficiency virus (HIV) 
transactivator of transcription protein called Tat38. This key discovery was soon after 
followed by the identification of Antennapedia (Antp), a transcription factor of 
Drosophila melanogaster that was shown to be internalized by neuronal cells39. 
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These works laid the foundation for the discovery that selected portions of proteins 
could translocate inside cells. The first of these domains which was named Protein 
Transduction Domain (PTD), was a 16-mer peptide derived from the third helix of the 
homeodomain of Antennapedia named Penetratin. The first use of a PTD as a vector 
was described when penetratin was employed for the delivery of a small exogenous 
peptide in 199440. In 1997, Vives et al. reported the identification of the minimal 
sequence of Tat required for cellular uptake41 and the first application of PTDs in vivo 
was reported by Schwarze et al. for the delivery of a biologically active beta-
galactosidase protein into the mouse42. The concept of cell penetrating peptide (CPP) 
was introduced in 1998; with the design of the first synthetic peptide carrier, the 
Transportan, which is a 27 amino acid long peptide containing 12 functional amino 
acids from the amino terminus of the neuropeptide galanin and mastoparan (a wasp 
venom peptide) at the carboxyl terminy43. Nowadays the definitions PTD and CPP 
are overlapping. 
Since the early discoveries, the list of available CPPs has impressively grown and 
their number continues to increase (Table 2). 
Actually, CPPs constitute one of the most promising tool for the non-invasive 
intracellular transport of cargos and have been successfully applied for the delivery of 
therapeutic molecules varying from small chemical molecules, nucleic acids, proteins, 
peptides, liposomes to particles. 
Novel classes and applications of CPPs are being constantly discovered and have 
been reported through the study of proteins of the most various organisms. They 
differ significantly in their sequence, hydrophobicity, and polarity. Mainly, CPPs can 
be divided into three classes: a) protein derived peptides represented by short 
stretches of a protein domain that are the primary responsible for their translocation 
ability (examples: TAT, penetratin or pANTP, transportan, HSV-1 VP22); b) 
amphipathic peptides resulting from the sequential assembly of hydrophobic and 
hydrophilic domains (examples: MAP, MPG, Pep-1); c) synthetic or cationic peptides 
such as poliarginines (Arg9). Examples of known CPPs are reported. 
Penetratin 
The Antennapedia motif is derived from a family of Drosophila homeoproteins; a 
class of trans-activating factors involved in the developmental process. These 
proteins recognise and bind DNA through a 60 amino acid carboxy-terminal region 
arranged in three α-helical sequences; called the homeodomain. The third helix of 
the homeodomain, comprising just 16 amino acids, also possesses this unusual 
property, enabling small molecules to be taken up into live cells 44. Today, this 
peptide is commonly referred to as penetratin. The two residues of tryptophan 
present in penetratin are considered a necessary requirement for traslocation; their 
replacement with hydrophobic amino acids strongly decreases the internalization. 
The high arginine and lysine content of penetratin gives it a positive charge at 
physiological pH. Penetratin shows high propensity to adopt an helical conformation 
in membrane mimetic conditions; but in presence of phospholipids vesicles it adopts 
a β-sheet structure with a residual α-helical content at low concentrations45,46. 
Transportan 
Trasportan is a synthetic analogue of the peptide galanin synthesized by Poogie et 
al. and described in their study in 199843. It is a 27 amino acids long peptide and 
contains 12 functional amino acids taken from the neuropeptide galanin followed by a 
lysine connection and the remaining is made by mastoparan, a wasp venom peptide 
toxin. Transportan can, in contrast to the galanin and mastoparan peptides alone, 
translocate through biological membranes and carry large hydrophilic molecules into 
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the cell without destroying the membrane47 After entering the cell, the peptide can be 
detected in the nuclear membrane and subsequently in the nucleus. Circular 
dichroism studies of transportan revealed a random coil secondary structure in water 
which could reach 60% helical conformation in SDS mimetic conditions. Further 
studies by Nuclear Magnetic Resonance (NMR) in lipidic bicelles showed a well-
defined α-helix in the C-terminal mastoparan part of the peptide and a weaker 
tendency to form an α-helix in the N- terminal domain48. 
Model Amphipathic Peptides (MAP) 
Model amphipathic peptides (MAP) are derived from the α-helical amphipathic model 
peptide KLALKLALKALKAALKLA, designed by Steiner et al.49 in 1991. Lysine is the 
main positive charge contributor and is distributed on one face of the α-helix, while 
the opposite face is rich in alanine residues. 
This peptide has been shown to internalize by multiple, non-specific, energy-
dependent and -independent processes into several types of cells50. 
Arg9 
Arg9 is the prototype of the so-called polyarginine–based peptides, that simply derive 
from the observation that positive charged residues are crucial for translocation 
through biological membranes. Several studies using different cationic peptides 
showed the higher efficiency of polyarginines compared to the use of other residues 
such as histidines or lysine. As a result, homoarginine sequences have been 
investigated as drug delivery vehicles51. 
Other major viral-derived CPPs 
Peptides derived from viral proteins seem very interesting as intracellular transporters 
also in consideration that the first protein showing the ability to cross membranes was 
the HIV-1 Tat protein. Some examples of viral derived peptide investigated and 
included in the CPPs family are briefly described below. 
Tat 48-60 Peptide 
Tat is a transcription activating factor of 101 amino acids derived from HIV-1, 
necessary for the replication of the virus, which has the ability to cross the plasma 
membrane of neighbouring cells. In particular, a short basic sequence from amino 
acid 48 to 60 is required for the binding of Tat to its activator RNA, which has been 
shown to adopt an extended structure52. Several peptides carrying mutations within 
the cationic domain of the original peptide were useful in clarifying that the 
translocating activity of the Tat protein is controlled by this cationic cluster of amino 
acids and that deletion of arginine led to non-translocating peptide. 
MPG  
An amphipathic peptide whose primary sequence is composed of a motif mainly 
constituted of hydrophobic amino acids derived from the fusion sequence of the HIV-
1 protein gp41 (GALFLGFLGAAGSTMGA) associated to an hydrophilic domain with 
positively charged residues derived from the Nuclear Localization Sequence (NLS) of 
Simian virus 40 (SV40) large T antigen (PKKKRKV). These hydrophilic and 
hydrophobic segments are separated by a three amino-acid spacer (WSQ)53. It 
represents an interesting synthetic peptide that utilize the known properties of the 
glycine-rich region of viral gp41 essential for membrane fusion activity and structural 
stabilization in addition to the NLS of the SV40 large T antigen able to improve the 
nuclear targeting54. 
Pep-1 
It is at least partially derived from MPG; in fact, it conserves an identical C-terminal 
hydrophilic domain (the NLS of SV40 large T antigen) and spacer motif, while the 
hydrophobic region of Pep-1 corresponds to a tryptophan-rich segment 
18	  	  
(KETWWETWWTE) derived from the HIV-1 reverse transcriptase55. Pep-1 has been 
shown to be able to efficiently deliver a variety of peptides and proteins into several 
cell lines in a fully biologically active form. 
Herpes Simplex Virus Type 1 (HSV-1) Protein VP22 
VP22, the product of the UL49 gene of herpes simplex virus, is a major component of 
the tegument, a structure residing between the capsid and envelope of herpes virus 
particles and has been reported to traffic between cells56. The C-terminal 40 amino 
acids region of the 301 residues VP22 protein is principally responsible for the 
transduction property of the whole protein and can mediate the delivery of DNA and 
RNA oligonucleotides into cells. Sciortino et al.57 Have shown that VP22 can deliver a 
complete mRNA that is translated within the recipient cell. 
Hepatitis-B Virus (HBV) PreS2 Domain 
The property of cell permeability was observed in the PreS2- domain 
(PLSSIFSRIGDP; subtype ayw) of the hepatitis-B virus surface antigens. PreS2 has 
been shown to present an amphipathic α-helix between amino acids 41 and 52. This 
domain is involved in PreS2 dimerization and the mutagenesis of amino acid 
residues within the amphipathic α-helix resulted in a loss of the α-helical structure 
and led to β-sheet conformation58. These mutations also led to a reduced 
oligomerization tendency and no significant cell permeability.  
 
 
Table 2. Examples of commonly used CPPs and some of their properties related to interaction with membranes. 
 
1.3  BIOMOLECULES PASSAGE ACROSS THE CELL MEMBRANE 
Once a drug has been administered by any route it must be absorbed into the 
bloodstream from the site of administration. The drug then is distributed into various 
body fluids and tissues to attain an effective, yet safe, concentration for a sufficient 
period of time at the site of action. Subsequently, the drug is inactivated or eliminated 
from the body, generally by metabolism (usually lipid-soluble drugs) and excretion 
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(mainly renal and biliary routes). The effectiveness of these processes with respect to 
time (pharmacokinetics) varies with the particular drug and species of animal. Within 
species, it is further influenced by physiologic states (age, gender, pregnancy) and 
disease. Finally, combinations of drugs may lead to drug interactions that can alter 
both drug response and disposition. 
A drug usually must cross a number of cell or basement membranes before it 
reaches its site of action. Membrane barriers may be composed of several layers of 
cells (skin, vagina, cornea, placenta) or a single layer of cells (enterocytes, renal 
tubular epithelial cells), or they may consist only of a boundary less than 1 cell in 
thickness (hepatic sinusoids, mitochondrion, nucleus). 
A common feature of all cell membranes is the phospholipid bilayer, about 10 nm 
thick, arranged with the hydrophilic heads on the outside and the lipophilic chains 
facing inwards. This gives a sandwich effect, with two hydrophilic layers surrounding 
the central hydrophobic one. Spanning this bilayer or attached to the outer or inner 
leaflets are glycoproteins, which may act as ion channels, receptors, intermediate 
messengers (G-proteins) or enzymes. 
Nevertheless, the general cell membrane structure is modified in certain tissues to 
allow more specialized functions. Capillary endothelial cells have fenestrae, which 
are regions of the endothelial cell where the outer and inner membranes are fused 
together, with no intervening cytosol; these make the endothelium of the capillary 
relatively permeable; fluid in particular can pass rapidly through the cell by this route. 
In the case of the renal glomerular endothelium, gaps or clefts exist between cells to 
allow the passage of larger molecules as part of filtration. Tight junctions exist 
between endothelial cells of brain blood vessels, forming the blood brain barrier 
(BBB), intestinal mucosa and renal tubules. These limit the passage of polar 
molecules and also prevent the lateral movement of glycoproteins within the cell 
membrane, which may help to keep specialized glycoproteins at their site of action 
(e.g. transport glycoproteins on the luminal surface of intestinal mucosa). 
Therefore, an important function of a biological membrane is to serve as a barrier 
against the outside world. However, membranes are not impenetrable walls, 
obviously, nutrients must enter the cell and waste products have to leave in order for 
the cell to survive; for example, the movement of ions across membranes is 
important in regulating vital cell features such as cellular pH and osmotic pressure.  
For this and many other reasons, it is crucial that membranes are selectively 
permeable; membrane high selectivity and controlled permeability are indeed key 
determinant in the effectiveness of drug absorption, distribution, and elimination. 
Accordingly, approaches to knock down these barriers have received significant 
attention in the last few decades. 
The efficacy of a biomolecule, which should be used as a therapeutic and/or 
diagnostic agent in biomedical research and in the pharmaceutical industry, is subject 
to its pharmacodistribution properties. Thus, cell compartmentalization and 
impermeability of membranes represent the major obstacle for delivery of therapeutic 
molecules; in fact, many bioactive molecules are incapable of overcoming the 
membrane permeability barrier and this represents the major impediment for gene 
and drug targeting in theranostics. Although a wide variety of biodrugs, including 
peptides and proteins, are now produced on a commercial scale, one challenging 
task for pharmaceutical researchers is devise ways to deliver these drugs effectively 
and safely via non-invasive, patient-friendly routes.  
In particular, many pharmaceutical agents should be delivered intracellularly to exert 
their therapeutic action inside the cytoplasm or onto individual organelles, such as 
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nuclei (target for gene and antisense therapy), lysosomes (target for the delivery of 
deficient lysosomal enzymes), and mitochondria (target for pro-apoptotic anticancer 
drugs). Thus, intracellular delivery of therapeutic molecules is one of the key 
problems in drug delivery59. 
 
1.3.1 Factors influencing the rate of diffusion 
The drug rate of diffusion and consequently its intracellular bioavailability depend on 
several parameters relative to drug and membrane physicochemical properties, in 
particular: molecular size, concentration gradient, ionization, lipid solubility. 
Molecular size. 
The rate of passive diffusion is inversely proportional to the square root of molecular 
size (Graham’s law). In general, small molecules will diffuse much more readily than 
large ones.  
Concentration gradient. 
Fick’s law states that the rate of transfer across a membrane is proportional to the 
concentration gradient across the membrane. Thus, increasing the plasma 
concentration of the unbound fraction of drug will increase its rate of transfer across 
the membrane and will accelerate the onset of its pharmacological effect. 
Ionization. 
The lipophilic nature of the cell membrane only permits the passage of the uncharged 
fraction of any drug. The degree to which a drug is ionized in a solution depends on 
the molecular structure of the drug and the pH of the solution in which it is dissolved 
and is given by the Henderson–Hasselbalch equation. 
Lipid solubility. 
The lipid solubility of a drug reflects its ability to pass through the cell membrane; this 
property is independent of the pKa of the drug. However, high lipid solubility alone 
does not necessarily result in a rapid onset of action. 
 
1.3.2 Cell membranes crossing mechanisms 
The efficacy of a macromolecule to be internalized into the cytoplasm and to exercise 
its intracellular action also depends on the mechanism used to cross the plasmatic 
membrane.  
Several basic cellular mechanisms can be exploited for the intracellular delivery of a 
compound across the plasma membrane (Figure 2). There are active mechanisms, 
such as endocytosis, and passive mechanisms, such as translocation across the lipid 
bilayer; alternatively, there are highly invasive procedures, such as microinjection 
and/or electroporation, which could cause transient damage to membranes.  
The internalization processes are mainly classified in three types and a brief 
description is reported below.  
Passive diffusion 
This is the commonest method for crossing the cell membrane. Drug molecules move 
down a concentration gradient, from an area of high concentration to one of low 
concentration, and the process requires no energy to proceed. Many drugs are weak 
acids or weak bases and can exist in either the unionized or ionized form, depending 
on the pH. The unionized form of a drug is lipid-soluble and diffuses easily by 
dissolution in the lipid bilayer. Thus the rate at which transfer occurs depends on the 
pKa of the drug in question.  
In addition, there are specialized ion channels in the membrane that allow intermittent 
passive movement of selected ions down a concentration gradient. 
Ion channels may have their permeability altered by endogenous compounds or by 
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drugs. 
Facilitated diffusion 
Facilitated diffusion refers to the process where molecules combine with membrane- 
bound carrier proteins to cross the membrane. The rate of diffusion of the molecule– 
protein complex is still down a concentration gradient but is faster than would be 
expected by diffusion alone. Examples of this process include the absorption of 
steroids and amino acids from the gut lumen. The absorption of glucose, a very polar 
molecule, would be relatively slow if it occurred by diffusion alone and requires 
facilitated diffusion to cross membranes (including the BBB) rapidly. 
Active transport 
It is an energy-requiring process, like the endocytosis. The molecule is transported 
against its concentration gradient by a molecular pump, which requires energy to 
function. Energy can be supplied either directly to the ion pump, or indirectly by 
coupling pump-action to an ionic gradient that is actively maintained. 
Pinocytosis 
Pinocytosis is the process by which an area of the cell membrane invaginates around 
the (usually large) target molecule and moves it into the cell. The molecule may then 
be released into the cell or may remain in the created vacuole, until the reverse 
process occurs on the opposite side of the cell. 
The process is usually used for molecules that are too large to traverse the 
membrane easily via another mechanism. 
 
 
Figure 2. Cell membranes crossing mechanisms. 
 
1.3.3 CPPs cell entry 
The entry mechanism of CPPs into cells is still a matter of debate. Historically, two 
hypotheses were put forward to explain how these peptides could cross the plasmatic 
membrane and possibly deliver various kinds of molecules into the cell60 It was first 
proposed that CPPs, especially Tat and Antennapedia, but also others such as poly-
Arg61, Transportan62, MPG53 or Pep-155, could pass through the plasma membrane 
via an energy-independent pathway. This hypothesis of a direct translocation through 
the plasma membrane became less popular when the entry mechanism for the Tat 
and the poly-arginine CPPs had to be re-evaluated following evidences of fixation 
artifacts during the preparation of samples for microscopic observation63. Indeed, 
fixation has been described to interfere with the sub-cellular localization of constructs 
with a high content of cationic residues, such as histones and the VP22 protein64. 
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As a consequence, the majority of the new microscopic studies on CPPs localization 
have been conducted on living cells and the conclusions that can be drawn from 
these very elegant works could be that CPPs mainly follow a cellular endocytosis-
mediated uptake65-67.  
According to this mechanism, CPPs, particularly those with a high content in cationic 
residues, are first simply adsorbed at the cell surface thanks to the numerous anionic 
moieties, such as heparan sulfate, sialic or phospholipidic acid68-70, then CPP-
mediated transport proceeds through different endocytosis routes63: caveolae71, 
macropinocytosis72,73, clathrin-dependent pathway74, cholesterol-dependent clathrin-
mediated pathways75 or the trans-Golgi network76. 
Moreover, the way of entry into the cell is also influenced by the nature of the cargo 
(eventually transported), the type of CPP, the cell line and the conditions of 
incubation.  
Since the endosomial pathway is mainly involved in the cellular delivery of CPPs and 
CPPs-conjugated molecules independent from initial route, a strong enzymatic 
degradation within this compartment and consequently a poor cytoplasmic release of 
intact molecules are expected, leading to a global weak drug transfer into the 
cytoplasm. In conclusion, the endosomal entrapment may limit the utility of CPPs. 
 
 
Figure 3. Proposed mechanisms of cellular internalization pathways of different CPPs. For simplicity; the 
pathways described have been indicated for specific peptides; none of the pathways proposed is mutually 
exclusive. 
 
Toxicity of cationic CPPs.  
Several groups work on the determination of in vitro and in vivo cellular toxicity of 
CPPs. When the minimal membrane-translocating Tat domain was discovered, no 
toxicity was found in very extreme conditions on HeLa cells (24 h incubation at 100 
micromolar concentration), this absence of toxicity was also shown in other studies 
for example, Toro et al. confirmed that the short Tat peptide was not toxic for 
lymphocytes at dose up to 300 µM77 and no toxicity was observed in HeLa or Jurkat 
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cells up to 20-30 µM concentrations of Antp, Rev and VP2278. Nevertheless, because 
of their highly cationic nature, some CPPs could be as toxic as other cationic 
polymers such as poly-L-Lysine or poly-ethylene imine (PEI)79. 
Finally, the internalization mechanism used by CPPs, as well as their supposed 
toxicity, seems to reduce considerably their applications in the planning of novel 
useful drug delivery systems (Figure 3). 
Although the uptake mechanism of CPPs is largely debated it seems to involve 
mainly the endocytic pathway, trapping the conjugated cargo (eventually transported) 
in endosomes lastly ending in lysosomes where common enzymatic degradation 
processes take place decreasing its intracellular bioavailability. 
Therefore, it is of paramount importance to identify novel peptides and peptide-based 
drug delivery tools, with different physicochemical properties and which use 
alternative internalization routes in order to optimize the uptake kinetic/rate and the 
intracytoplasmatic distribution improving thus their target-specific bioactivity.  
 
1.4 VIRAL INFECTION STRATEGIES 
Viruses can be classified as enveloped and non-enveloped viruses according to the 
presence or absence of a membrane bilayer surrounding the capsid. The 
mechanisms of genome release are widely different between enveloped and non-
enveloped viruses. In fact, enveloped viruses fuse with the plasma or endosome 
membranes, thereby exposing the genome or capsid to the cytosol; whereas non-
enveloped viruses partially disrupt membranes to release viral nucleic acids80-82. 
But, in any case, the transfer of the genome through the barrier of a cellular 
membrane into the cytosol is imperative for viral infections to occur. 
Non-enveloped viruses 
Non-enveloped viruses can seize the cytoplasm of the host cell by direct penetration 
through the plasma membrane or by a variety of endocytotic mechanisms that 
collectively lead to the penetration of internal membranes. In such way they do not 
differ much from what enveloped viruses do while invading cells; that is taking control 
of common cellular pathways. The main difference with enveloped viruses is posed 
by the absence of a membrane surrounding the proteinaceous capsid; therefore 
fusion events cannot happen; but capsid-dependent mechanisms for penetrating the 
cell membrane or, alternatively, for lysing the endosome are likely to be required. 
The process of non-enveloped viruses entry is generally started by an interaction with 
a cellular stimulus (e.g.; receptors, low pH, proteases) at the penetration site which 
drives a conformational change that in some instances triggers the release of viral 
components with membrane lytic activity. This is followed by the binding of the 
hydrophobic component or lytic factor to the cell membrane. 
Therefore, membrane penetration seems to be mediated by short, membrane 
interacting, amphipathic or hydrophobic sequences contained in proteins which have 
undergone a conformation transition, allowing the exposure of such sequences and 
consequently their interaction with membranes83. 
Enveloped Viruses 
All enveloped viruses use two main routes to enter cells, either by the endocytic or 
non-endocytic routes, and share common steps. Clathrin coated vesicles, but non-
clathrin-coated pits; macropinocytosis or caveolae are all pathways exploited by 
viruses preferring the endocytic route; while the non-endocytic path involves direct 
crossing of the plasma membrane at neutral pH.  
Essentially the basic mode of entry by enveloped viruses is through membrane 
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fusion; an essential and ubiquitous mechanism in most cellular events. Virally-
induced fusion is mediated by viral membrane proteins which undergo remarkable 
conformational modifications as a consequence of a trigger that is represented either 
by low endosomal pH or receptor binding. These conformational changes lead to the 
exposure of hydrophobic peptides, loops or patches (the so called fusion peptides), 
which then interact with and destabilize one or both of the opposing membranes. 
Three different classes of viral fusion proteins have been identified to date based on 
their common post-fusion structural motifs80,84. These are: (i) class I fusion proteins, 
characterized by trimers of hairpins containing a central α-helical coiled-coil structure; 
(ii) class II fusion proteins, characterized by trimers of hairpins composed of β-
structures; (iii) class III fusion proteins, that show features of both classes. 
Viruses, like all obligate intracellular pathogens, must overcome numerous barriers in 
the host cell to deliver their nucleic acid into the cytosol or nucleus. This is the key to 
initiating their infectious cycle and involves a number of distinct and subsequent 
steps like binding to one or more cellular receptors and entry, capsid destabilization 
and genome uncoating, ending in the release of viral nucleic acids at the proper site 
of replication. The most critical barrier is represented by the complex membranous 
system surrounding the host cell. 
Since viruses may enter cells either through a endosomal pathway or via direct fusion 
on the plasma membrane through the activity of membranotropic peptides; great 
attention has been devoted to the study of hydrophobic peptides that efficiently 
traverse biological membranes, promoting lipid-membrane reorganizing processes, 
such as fusion or pore formation and involving temporary membrane destabilization 
and subsequent reorganization85,86, which may be able to circumvent the endosomal 
entrapment either favouring the escape from the endosome or by translocating a 
cargo through the plasma membrane directly into the cytosol. Delivery across cellular 
membranes involves several mechanisms such as direct transfer through cell surface 
membrane by lipid membrane fusion or transient permeabilization of the cell 
membrane. Alternatively, following endocytosis, transfer across vesicular membranes 
by lipid disruption, pore formation or fusion may take place. Several of these 
membrane reorganization steps are also involved in the cell entry of viruses and 
other microorganisms, as well as being triggered by protein toxins and defence 
peptides87. Several related processes, such as intracellular vesicle budding, cell to 
cell fusion86, sperm-egg fusion or the immune response share common features to 
the mechanism of viral-induced membrane fusion. 
Therefore, it is of paramount importance to discover new methodologies to reproduce 
enveloped viruses non endocytic-behaviour assumed during the host cells infection 
phase. 
Recently, great attention has been devoted to the study of virus derived hydrophobic 
peptides that efficiently traverse biological membranes, promoting membrane-
reorganizing processes, like fusion or pore formation for the design of novel 
delivering tools.  
 
1.4.1 Herpes simplex virus type 1 fusion machinery 
Herpes simplex virus (HSV), the prototype of the alpha herpes viruses, is a human 
pathogen that infects epithelial cells before spreading to the peripheral nervous 
system to establish a life-long latent infection. HSV-1 infection, similarly to other 
enveloped viruses, is achieved through fusion of the lipid bilayer of the viral envelope 
with a host cell membrane. The core fusion machinery of herpesviruses is well 
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conserved and consists of the envelope glycoprotein B (gB) and the heterodimeric 
complex of gH/gL88. Although numerous studies have indicated that both gB and 
gH/gL exhibit varying degrees of fusogenic properties, the complete fusion is only 
achieved when the three proteins act together89. Because both glycoproteins (gB and 
gH) are conserved in all herpesvirus subfamilies, it is likely that they perform a 
common function in all members of this virus family; they appear to be triggered by 
the action of glycoprotein gD, which binds cellular receptors, e.g. nectin1, and either 
bridges gB and gH/gL into a larger complex or interacts with gB/gH/gL-preformed 
complexes90. Notwithstanding how the active complex is assembled, the quartet of 
envelope glycoproteins promotes fusion of the virion envelope with cellular 
membranes, and both gB and gH appear to be directly involved in membrane fusion, 
i.e. in mixing of lipids. 
Structural knowledge of the proteins participating in herpes-virus fusion is essential 
for understanding the molecular mechanism of the entry process. The recently solved 
crystal structure of the HSV-1 gB ectodomain revealed an unexpected structural 
homology with the fusogenic protein G of vesicular stomatitis virus91. 
The fusogenic properties of gB are now well established92 and its structural details 
suggested that it belongs to a third class of fusion proteins where the fusion peptide 
is represented by a bipartite loop domain. HSV-1 gH is an 838-residue glycoprotein, 
the ectodomain contains 7 N-glycosylation sites and 8 cysteine residues forming at 
least 2 disulfide bonds between cysteines 5 and 6 (residue 554 and 589) and 
cysteines 7 and 8 (residues 652 and 706)93. Several domains likely to be important 
for membrane fusion have been identified in the C-terminal region of gH. For 
example, mutations in the pretransmembrane domain94, transmembrane region, and 
cytoplasmic tail95 affect fusion. Furthermore, peptides matching a number of regions 
of the gH ectodomain have been shown to interact with membranes and proposed to 
play a role in the fusion process. 
 
 
 
Figure 4 Crystal structure of gH-gL complex. White: H1 Domain; Blue: H2 Domain and Red: H3 Domain of gH. 
Yellow: gL interacting with H1of gH. 
 
Moreover, peptides spanning the heptad-repeat region of gH inhibit the entry of both 
human cytomegalovirus96 and HSV-1, while others have the ability to bind and disrupt 
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model membranes. The recently solved crystal structure of the gH-gL complex 
(Figure 4) showed that gH has no structural homology with any known fusion protein 
supporting the hypothesis that gH may act as a regulator of fusion through 
interactions with gB, while the crystal structure of the gH-gL complex of EBV presents 
considerable differences in the structural arrangements of domains supporting the 
view that the complex can undergo dynamic rearrangements. 
 
1.4.2 Identification of a membranotropic peptide: gH625  
To determine the best sequence able to induce HSV fusion, several gH and gB 
derived peptides were synthesized and modified; these studies brought to the 
identification of gH-625. 
The nineteen residues peptide gH625 (from aa 625 to aa 644), is a membrane-
perturbing domain derived from the gH fusion glycoprotein of Herpes simplex virus 
type 188,97. gH625 interacts with biological membranes and is implicated in the 
merging of the viral envelope and the cellular membrane98,99. The peptide gH625 
contains particular residues that are crucial for the capacity of the peptide to interact 
and destabilize target lipid membranes. It is rich in hydrophobic residues including 
glycines, leucines, alanines, and aromatic residues such as tryptophan and tyrosines, 
which are known to be located preferentially at the membrane interface. An 
amphipathic α-helix is believed to be an important feature of fusion peptides playing a 
crucial role in mediating lipid-protein interactions during the binding of proteins to 
membranes and once bound, the hydrophobic face of the amphipathic peptide would 
then allow the peptide to enter the membrane interior, thereby triggering local fusion 
of the membrane leaflets, pore formation, cracks and membrane fusion. gH625 has 
been shown to strongly interact and to spontaneously penetrate the lipid-phase and 
insert into membranes100. The peptide–lipid interactions are initiated by the arginine 
residue located at the C-terminus, in fact, when the arginine is mutated the fusogenic 
activity of the peptide is strongly impaired. The hydrophobic domain is also crucial for 
insertion of the peptide into the membrane and corroborates the notion that 
hydrophobic interactions between fusion proteins and cell-membrane phospholipids 
initiate membrane perturbation in the early stages of viral fusion. gH625 cellular 
uptake is thus associated with its ability to interact with membrane lipids and to form 
a transient helical structure that temporarily affects membrane organization, thereby 
facilitating insertion into the membrane and translocation59. Compared to Tat peptide 
which mainly exploits the endocytic pathway, the viral membranotropic peptide 
gH625 crosses membrane bilayers mainly through a translocation mechanism. A one 
aminoacid shorter version of this fusogenic peptide from HSV-1 gH (missing the 
histidine at position 625) was also found to improve the endosomal release of 
DNA/Lipofectamine lipoplexes and transgene expression up to 30-fold in human cell 
lines101. 
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AIM OF WORK 
This project targets major advances in the design and realization of a new 
nanotechnological system for theranostics. A fundamental limitation of current 
diagnostics and therapeutics is the lack of a single delivery system that has the 
potential to deliver therapeutics not only to the disease site of interest with high 
fidelity, i.e. target delivery, but also allows for diagnostics and cell delivery, i.e. cell 
penetration and uptake. The goal of this research project was to overcome this 
limitation and to create a toolbox that allows an efficient intracellular delivery of 
bioactive molecules. As a first step toward this goal, the objective was to engineer 
novel peptide based scaffolds with controlled architecture groups to enhance cellular 
uptake and present a drug, and group(s) for imaging. This goal was addressed with a 
multidisciplinary approach involving peptide design and synthesis, organic synthesis 
and cellular biology knowledges. The overall objective of the project of this thesis has 
been accomplished following two specific aims: 
 
1. Identification and characterization of a novel viral derived peptide able to 
efficiently enter into the cells; 
2. Synthesis and physicochemical characterization of several viral peptide based 
nano-vehicles useful in theranostic. 
 
Over the past years, my research team 
has worked extensively on antiviral 
peptides derived from HSV-1 
glycoproteins B and H and they have 
identified the gH-625 membranotropic 
sequence, derived from gH, as a 
potential intracellular transporter. 
While the complete fusion mechanism is 
not completely understood, they 
showed that gH625 interacts with 
biological membranes, i.e. lipid bilayers, 
and is implicated in the merging of the 
viral envelope and the cellular membrane.  
Peptide gH625 cellular uptake is thus associated with its ability to interact with 
membrane lipids and to form a transient helical structure that temporarily affects 
membrane organization, thereby facilitating insertion into the membrane and 
translocation. Compared to the commonly used cell penetrating peptide (CPP) Tat 
(RKKRRQRRR, derived from HIV-1), which mainly exploits the endocytic pathway, 
the viral membranotropic peptide gH625 crosses membrane bilayers mainly through 
a translocation mechanism. While poly(cationic) species like the Tat peptide have 
been known to produce cytotoxic effects, my research team has shown that gH625 is 
non-toxic to cells up to a concentration of 400 µM, and is at all times less toxic than 
the Tat peptide.  
This PhD thesis research project started from the working hypothesis that gH625 
could be exploited to develop a novel nanosystem for theranostics. In particular, we 
proposed to explore its ability to cross the lipidic bilayer and to transport, inside 
different cell lines, a cargo which could be drug-loaded, and could be used for the 
study and care of human diseases. 
The rate of diffusion across the cellular barrier, that may depend on the 
internalization mechanism adopted, represents one of the most important factors that 
Figure 5. Three-dimensional NMR structure of 
gH625-644. 
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a new pharmacological system has to increase in order to explicate, efficiently, its 
intracellular functions. Thus, the project objective focused on the identification, 
synthesis and characterization, through different kinds of physicochemical and 
biological analysis, of gH625 based nanosystems applicable in the drug delivery field. 
In particular, several nanosystems (Quantum Dots, Liposomes, Dendrimers and 
Nanoparticles, described in detail below) with different composition, shape and size, 
were complexed to gH625 and characterized.  
The specific goal was to combine the benefits of the chemistry of these molecules 
with a cell-internalization unit that can overcome the cell membrane mainly via a non-
active translocation mechanism. 
 
Quantum Dots (QDs) 
Quantum dots are inorganic nanoparticles that have emerged a few years ago as 
drug and gene delivery systems, imaging agents and diagnostic biosensors102,103. 
Magnetic drug targeting (such as the use of iron) is characterized by conjugating a 
magnetic material under the action of the external magnetic field, which can 
accumulate in target tissue areas under the action of the external magnetic field104. 
They are a new type of fluorescence probe with high luminescence efficiency and 
with their emission peak tunable depending on their size. In addition, the excellent 
photostability of QDs gives them great potential in cellular labeling and bioimaging, 
and a number of works have shown these characteristics in different kinds of 
biological systems. QDs are advantageous due to their nanometer size, broad 
excitation, narrow emission, bright photoluminescence and high photostability. 
However, wide application of QDs to intracellular and molecular imaging has been 
hampered by their insufficient ability to traverse cell membranes. Thus, to use QDs 
as biological probes for intracellular applications, their delivery has to be improved 
significantly. Several authors recently reported on the functionalization of QDs with 
the Tat peptide or other positively charged CPPs as enhancer of cell penetration and 
reported on the endosomal uptake of QDs and escape from the endosomal system. 
Similar delivery methods may enable the implementation of the next generation of 
QDs capable of long-term intracellular monitoring. 
 
Liposomes 
Liposomes are phospholipid based vehicles composed of a bilayer membrane that 
can be divided into small unilamellar vesicles (or SUV from 20 nm to 100 nm), large 
unilamellar vesicles (LUV from 100 to 500 nm) and multilamellar vesicles (MVL 
exceeding 500 nm)105. These systems have the ability to encapsulate both lipophilic 
drugs within their membrane and hydrophilic drugs inside or outside the aqueous 
core and the membrane of these carriers can be altered and tuned106. Liposomes, 
which are most commonly produced with phosphatidylcholine, show great 
compatibility, ease of preparation, wide range of drug compatibilities, increased 
solubility of drugs (e.g. cycloporin A)107, tuned pharmacokinetic profile and improved 
oral absorption. Commonly, they present difficulties when orally delivered due to the 
poor stability of the vesicles under the physiological conditions typically found in the 
GI tract.  
Liposomal aggregates have attracted great attention due to their success as in vivo 
carriers of active principles. Liposomes display some unique pharmacokinetic 
properties and can be adapted to a wide range of therapeutic agents; in particular, 
they are non-toxic, biodegradable and non-immunogenic. Benefits associated with 
liposomal drugs can arise from protection of encapsulated drugs from chemical or 
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metabolic degradation after injection; reduced toxicity through decreased exposure of 
antineoplastics to susceptible healthy tissues and increased antitumor activity 
resulting from a relatively long systemic circulation time, an extended exposure and 
tumor selective accumulation in sites of tumor growth. Moreover, liposomes exhibit 
preferential extravasation and accumulation at the site of solid tumors due to 
increased endothelial permeability and reduced lymphatic drainage in these tissues, 
which has been defined as enhanced permeability and retention effect. Thus, 
associating a drug with liposomes markedly changes its pharmacokinetic and 
pharmacodynamic properties and lowers systemic toxicity; furthermore, the drug is 
prevented from early degradation and/or inactivation108,109. 
 
Dendrimers 
Dendrimers are perfectly branched macromolecules with well-defined structures110. 
They exhibit different properties compared to linear polymers with the same 
composition and molecular weight111. The high concentration of terminal functional 
groups on a dendrimers surface will generally dictate the solubility of the entire 
compound; dendrimers have been used as unimolecular micelles, that is, 
hydrophobic dendrimers, that are water soluble due to peripheral hydrophilic groups 
or vice versa112. Traditional dendrimers are synthesized from monomers with the 
structure ABn113-115. Addition of another generation of monomers causes the 
dendrimer to grow radially with an exponential increase in both mass and number of 
free termini compared to the previous generation, but only a minimal increase in the 
physical size of the structure. This causes the termini to become more closely 
packed. 
Unlike many other scaffolds, dendrimers have the benefit of a highly controlled 
synthesis as well as yielding a single monodisperse compound, giving perfect control 
over the size, weight, and terminal functionalities of the resulting structure. Moreover, 
highly branched structures generally exhibit longer blood circulation times due to their 
inability to reptate through renal pores116. Dendrimers have been shown to have 
extended lifetimes in vivo117 whereas lipid complexes are usually rapidly cleared from 
circulation by splenic and hepatic phagocytes118. Dendrimers represent a very 
promising tool for drug delivery, combining the advantageous features of 
nanoparticles (ideal size as in vivo carriers, multivalency), polymeric materials (low 
cost, tunable proper- ties, biocompatibility) and small molecules (monodispersity and 
detailed control of their properties)119. Little information is available on the 
mechanism of dendrimer uptake and intracellular trafficking. Studies performed on 
PAMAM dendrimers120 and PAMAM dendrimers functionalized with the Tat121 
indicate that endocytosis mechanisms contribute to the internalization and 
intracellular trafficking. Some reports show that the cellular internalization mechanism 
of PAMAM dendrimers can be tuned by altering surface charges or hydrophobicity, 
but these uptake mechanisms are still mainly endocytic122. Other reports show that 
dendrimers can successfully deliver cargoes when terminated by guanidinyl units; 
however, in one case, it was shown that adding the Tat peptide failed to enhance 
delivery efficiency over the native PAMAM dendrimer. Studies using cationic PAMAM 
dendrimers, showed that they tend to insert into the lipid bilayer, which has the 
potential of weakening or forming holes in the membrane123. 
 
Nanoparticles (NPs) 
Particles with at least one dimension smaller than 1 micron and potentially as small 
as atomic and molecular length scales (~0.2 nm). Many authors limit the size of 
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nanomaterials to 50 nm or 100 nm124, the 
choice of this upper limit being justified by 
the fact that some physical properties of 
nanoparticles approach those of bulk 
when their size reaches these and they 
can therefore be classified as either 
nanoparticles NP (any dimension smaller 
than 1 micron) or microparticles MP (all 
dimensions larger than one micron). 
Generally, the sizes of nanomaterials are 
comparable to those of viruses, DNA and 
proteins, while microparticles are 
comparable to cells, organelles, and 
larger physiological structures (Figure 6).  
Nanoparticles are generally classified 
based on their dimensionality, 
morphology, composition, uniformity, and 
agglomeration.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure 6. Nano and micro material sizes	  
	  
Dimensionality 
1D nanomaterials. Materials with one dimension in the nanometer scale are typically 
thin films or surface coatings, and include the circuitry of computer chips and the 
antireflection and hard coatings on eyeglasses. Thin films have been developed and 
used for decades in various fields, such as electronics, chemistry, and engineering 
2D nanomaterials. These include 2D nanostructured films, with nanostructures firmly 
attached to a substrate, or nanopore filters used for small particle separation and 
filtration. Free particles with a large aspect ratio, with dimensions in the nanoscale 
range, are also considered 2D nanomaterials. Asbestos fibers are an example of 2D 
nanoparticles. 
3D nanomaterials. Materials that are nanoscaled in all three dimensions are 
considered 3D nanomaterials. These include thin films deposited under conditions 
that generate atomic-scale porosity, colloids, and free nanoparticles with various 
morphologies. 
Morphology 
Morphological characteristics to be taken into account are: flatness, sphericity, and 
aspect ratio. A general classification exists between high and low aspect ratio 
particles. High aspect ratio nanoparticles include nanotubes and nanowires, with 
various shapes, such as helices, zigzags, belts, or perhaps nanowires with diameter 
that varies with length. Small-aspect ratio morphologies include spherical, oval, cubic, 
prism, helical, or pillar. Collections of many particles exist as powders, suspension, or 
colloids. 
Composition 
Nanoparticles can be composed of a single constituent material or be a composite of 
several materials. The nanoparticles found in nature are often agglomerations of 
materials with various compositions, while pure single-composition materials can be 
easily synthesized today by a variety of methods. 
Uniformity and agglomeration 
Based on their chemistry and electromagnetic properties, nanoparticles can exist as 
dispersed aerosols, as suspensions/colloids, or in an agglomerate state. For 
example, magnetic nanoparticles tend to cluster, forming an agglomerate state, 
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unless their surfaces are coated with a non-magnetic material. In an agglomerate 
state, nanoparticles may behave as larger particles, depending on the size of the 
agglomerate. Hence, it is evident that nanoparticle agglomeration, size and surface 
reactivity, along with shape and size, must be taken into account when deciding, 
considering health and environmental regulation of new materials.  
Currently materials composed by NPs are being used in a wide variety of applications 
such as engineering, food industry, cosmetics and medicine125,126. In medicine there 
are major expectations for the use of nanoparticles to facilitate targeted drug 
delivery127. Due to the novelty of these applications and to ensure their success, a 
precise characterization of the interactions between NPs and cells is essential. 
Polystyrene (PS) NPs are widely used as a model to study interactions between NPs 
and cells due to various practical reasons including their commercial availability, high 
quality and wide variety of size and surface chemistry. These NPs have been 
reported to enter different cell types including hepatocytes128 macrophages129 and 
lung130. One general conclusion is that particles smaller than 100 nm are able to 
enter mammalian cells. The specific uptake pathways of these NPs, as well as the 
uptake rates, have been shown to be cell type131 NP size132 and shape-dependent133 
but are also related to the surface chemistry of the NP  and its hydrophobicity134. 
The nanoparticles toxicity is widely discussed in literature; the total number of papers 
on toxicity, however, remains low compared to the total number of publications on 
nanomaterials, with only around 500 publications in the year 2013. 
Thus, it is very important to recognize that not all nanoparticles are toxic; toxicity 
depends on at least chemical composition and shape in addition to simply size and 
particle ageing. In fact, many types of nanoparticles seem to be non-toxic135, others 
can be rendered non-toxic while others appear to have beneficial health effects136. 
 
RESEARCH MANAGEMENT  
The internalization of bioactive molecules is one of the most critical problems to 
overcome in theranostics. In order to improve pharmacokinetic and 
pharmacodynamic properties, synthetic transporters were widely investigated. A new 
nanotechnological transporter, gH625, based on a viral peptide sequence derived 
from the Herpes simplex virus type 1 glycoprotein H (gH) has proved to be a useful 
delivery vehicle, due to its intrinsic properties of inducing membrane perturbation. 
The peptide functionalization with several kinds of nanoparticles like quantum dots, 
dendrimers, and liposomes could be of particular interest in biomedical applications 
to improve drug release within cells, to increase site-specific action, and eventually to 
reduce related cytotoxicity. 
This PhD project is inherently multidisciplinary. The overall project has been 
organized and coordinated by my group (Prof. Stefania Galdiero) from the 
Department of Pharmacy at the University of Naples and was also partially performed 
at the Molecular Design Institute & Department of Chemistry at New York University 
(Prof. Marcus Weck). The research team of NYU brought the following expertise to 
the project: functionalized monomer synthesis, dendrimer synthesis, dendrimer 
multifunctionalization, self-assembly, polymer characterization and fabrication, while 
the “Federico II” research team was involved in the planning and organization of the 
project, in the identification of the peptides for the delivery and in the establishment of 
the best synthetic strategy for the coupling of the peptide to the nanomaterial; 
moreover the structural characterization was performed in Naples and partially in 
New York. 
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2 MATERIAL AND METHODS 
2.1 MATERIALS 
Peptides were synthesized by standard solid-phase techniques on a Syro I 
MultiSynThec GmbH automatic synthesizer. Protected Fmoc-amino acid derivatives, 
coupling reagents and Rink amide p-methylbenzhydrylamine (MBHA) resin were 
purchased from Calbiochem-Novabiochem (Laufelfingen, Switzerland), Wang resin 
was purchased from Fluka. The Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-AdOO-
OH) and Fmoc-L-propargylglycine (Fmoc-Pra-OH) were purchased from Neosystem 
(Strasbourg, France). Fmoc-l-propargylglycine (Fmoc-Pra-OH) was purchased from 
Neosystem. 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPG) was purchased by 
Avanti Polar Lipids (Alabaster, AL). Fmoc-TOAC-OH ((2,2,6,6-tetramethylpiperidine-
N-oxide-4-(9-fluorenylmethyloxycarbonyl-amino)-4-carboxylic acid) spin-label was 
kindly provided by Prof. C. Toniolo of the University of Padua (Italy). 4-Chloro-7-
nitrobenzofurazan (NBD-Cl), Doxorubicin Hydrochloride (Dox) and  the other 
chemicals were purchased from Sigma-Aldrich, Fluka (Buchs, Switzerland) or 
LabScan (Stillorgan, Dublin, Ireland) and were used as received, unless otherwise 
stated.  
Dendron 1 was synthesized as previously reported137,138 from starting materials 
purchased from Frontier Scientific. 3-Azidopropylamine139 and 7-nitro-4-(prop-2-
ynylamino) benzofurazan (NBD-CCH)140 were synthesized as previously reported. 
Orange fluorescent amine-modified polystyrene, 100 nm, (NP-NH2) were purchased 
by Sigma-Aldrich. Amine-functionalized eFluor Nanocrystals composed of CdSe were 
purchased by eBioscience. 
Dialysis membranes (SpectraPor 6) were purchased from Spectrum Labs and used 
after rinsing the membrane in water for 30 min. 
LCMS data were recorded on an Agilent LCMSD Trap XCT spectrometer using 
electrospray ionization (ESI) and methanol as eluent.  
NMR Spectra were recorded using a Bruker AV-400 spectrometer (1H: 400.1 MHz; 
13C: 100.6 MHz). Deuterated solvents were purchased from Cambridge Isotope 
Laboratories.  
IR spectra were recorded with a Magna 550 FTIR on poly(ethylene) cards. Circular 
dichroism spectra were recorded on an Aviv model 202SF stopped flow circular 
dichroism spectrometer. Scanning transmission electron microscopy was performed 
on a Zeiss Merlin FESEM. Peptide purification was performed on LC8 Shimadzu 
HPLC with a Phenomenex C18 column (300Å, 250x21.20 mm, 5µ) and a UV lambda-
Max model 481 detector. Peptide purity was analyzed by a Finnigan Surveyor MSQ 
single quadrupole ESI LC-MS with a Phenomenex C18 column and the same eluent 
system.  
Size-exclusion chromatography was performed using a 1 x 18 cm Sephadex G-50 
column.  
Cell media (Phosphate buffered saline [PBS, pH 7.4], Fetal bovine serum [FBS], 
0.25% trypsin in EDTA, Eagle’s minimum essential medium [EMEM], and 
penicillin/streptomycin solution) were purchased from Invitrogen. 
Cell microscopy was done by a Nikon Eclipse Ti inverted microscope equipped with a 
FITC filter set for fluorescence imaging. Dynamic light scattering (DLS) was 
performed at 25°C on a DynaPro Protein Solutions DLS in aqueous solution. 
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2.2 SOLID-PHASE PEPTIDE SYNTHESIS. 
Peptides (Table 1) were synthesized using standard solid-phase-9-
fluorenylmethoxycarbonyl (Fmoc) procedures using a Syro I MultiSynThec GmbH 
(Wullener, Germany) automatic synthesizer. The Rink-amide MBHA resin 
(substitution 0.51 mmol/g) was used as the solid-phase support, and syntheses were 
performed on a scale of 20 µmol. Fmoc-amino acids, 4 equivalents relative to resin 
loading, were coupled according to the PyBop/HOBt/DIPEA (benzotriazol-1-yl-
oxytris(pyrrolidino)phosphonium / N-hydroxybenzotriazole / Di-iso-propylethylamine) 
method: 1 equivalent of Fmoc-amino acid, 1 equivalent of PyBOP, 1 equivalent of 
HOBt (0.5 mM HOBt in DMF) and 2 equivalents of DIPEA (2 mM DIPEA in DMF). 
The Fmoc protecting group was removed with 30% piperidine in DMF (v/v). All 
couplings were performed twice for 35 minutes. 
NBD labeling of peptides was performed on resin-bound peptides as previously 
reported by Rapaport & Shai141 . Briefly, 30-70 mg of resin-bound peptide (10-25 
µmol) was treated with piperidine in DMF in order to remove the Fmoc protecting 
group of the N-terminal amino-acid of the linked peptide. The resin-bound peptide 
was then reacted with 4-chloro-7-nitrobenz-2-oxa-1,3-diazole (NBD-Cl) in DIPEA 2 M 
(3-4 equiv.) in DMF. After 24 h, the resin-bound peptides were washed thoroughly 
with methylene chloride, and the peptides were cleaved from the resin and purified. 
When necessary peptides-Pra were synthesized coupling Fmoc-Pra-OH once for 45 
min with 2 equivalents of PyBop/HOBt and 2 equivalents of DIPEA.  
Peptides labeled with TOAC (A628K(TOAC)-gH625-Pra, A635K(TOAC)-gH625-Pra, 
A639K(TOAC)-gH625-Pra and A643K(TOAC)-gH625-Pra) were synthesized 
introducing the spin label directly in solid phase. For the incorporation of the TOAC 
moiety, peptides containing Lys(Mtt) in substitution of Ala residues were first 
synthetized: A628K(Mtt)-gH625-Pra, A635K(Mtt)-gH625-Pra, A639K(Mtt)-gH625-Pra 
and A643K(Mtt)-gH625-Pra. The Mtt (4-Methyltrityl) from the side chain of the lysine 
residue was cleaved by treatment with 1% TFA, 5% TIS (triisopropylsilane), 94% 
DCM, 10 times for 1 min. The TOAC residue was doubly coupled for 3h using 2-fold 
Fmoc-TOAC-OH molar excess (40 µmol) and HATU (40 mmol) as activating agent in 
presence of DIPEA (1:1:2). The Fmoc protecting group was removed with 30% 
piperidine in DMF (v/v). 
Fully-synthesized peptides were deprotected from the resin with trifluoroacetic acid 
(TFA) with 2.5% (v/v) water, 2.0% (v/v) anisole, 2.0% (v/v) thioanisole as scavengers, 
at room temperature, and then precipitated in ice-cold ethyl ether, filtered, dissolved 
in water and lyophilized. After TFA cleavage and HPLC purification, TOAC containing 
peptides were submitted to alkaline treatment with aqueous ammonia (pH 9.5) for 6 h 
at room temperature to regenerate the chemical integrity of the nitroxide moiety 142. 
The crude peptides were purified by RP-HPLC on a LC8 Shimadzu HPLC system 
(Shimadzu Corporation, Kyoto, Japan) equipped with a UV lambda-Max Model 481 
detector using a Phenomenex (Torrance, CA) C18 (300 Ǻ, 250x21.20 mm, 5 µm) 
column eluted with an H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B) from 20% to 
80% over 20 minutes at 20 mL/min flow rate. Purity and identity were assessed by 
analytical LC–MS Analysis by using Finnigan Surveyor MSQ single quadrupole 
electrospray ionization (Finnigan/Thermo Electron Corporation San Jose, CA), 
column: C18-Phenomenex eluted with H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B) 
from 20% to 80% over 10 minutes at 0.8 mL/min flow rate. The final yields of purified 
peptides ranged between 20 and 40%.  
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PEPTIDES SEQUENCES MW 
 
gH625 NH2-HGLASTLTRWAHYNALIRAF-CONH2 2297.1 
 Tat 
 
 
NH2-GRKKRRQRRR-CONH2 
 
1395.6 
 
 
 
NBD-gH625 NBD-HGLASTLTRWAHYNALIRAF-CONH2 2461,1 
NBD-Tat NBD-GRKKRRQRRR-CONH2 1559,6 
Ac-gH625-GGG Ac-HGLASTLTRWAHYNALIRAF-GGG-COOH 2512.8 
Ac-Tat-GGG Ac-GRKKRRQRRR-GGG-COOH 1610,8 
gH625-Pra NH2-HGLASTLTRWAHYNALIRAF-Pra-CONH2 2391.3 
 NBD-gH625-Pra NBD-HGLASTLTRWAHYNALIRAF-Pra-CONH2 2537.9 
NBD-Pra NBD-Pra-CONH2 258.9 
A643K(TOAC)-gH625-
Pra 
NH2-HGLASTLTRWAHYNALIRK(TOAC)F-Pra-CONH2 2644.6 
A639K(TOAC)-gH625-
Pra 
NH2-HGLASTLTRWAHYNK(TOAC)LIRAF-Pra-CONH2 2644.6 
A635K(TOAC)-gH625-
Pra 
NH2-HGLASTLTRWK(TOAC)HYNALIRAF-Pra-CONH2 2644.6 
A628K(TOAC)-gH625-
Pra 
NH2-HGLK(TOAC)STLTRWAHYNALIRAF-Pra-CONH2 2644.6 
Table 1. Peptide sequences and their molecular weights. 
 
2.3 PREPARATION OF TRIFLYL AZIDE (TFN3) 
Sodium azide (650 mg, 10 mmol) was dissolved in distilled water (1.5 mL) and then 
dichloromethane (DCM, 2.4 mL) was added. The mixture was cooled on ice bath for 
20 min. Triflyl anhydride (336 µL, 2 mmol) was added slowly over 5 min and the 
mixture was stirred for 2 h. The mixture was extracted with DCM two times. The 
organic portions, containing the trifyl azide, were pooled, washed once with saturated 
Na2CO3, and evaporated to dryness. 
 
2.4 SYNTHESIS OF AZIDE-ADOO-LYS(C(O)CH2CH2C(O)N-(C18H37)2)-
AMIDE ((C18)2L-N3)  
(C18)2L-N3 monomer was synthesized in solid phase under standard conditions using 
Fmoc/tBu strategy. Rink-amide MBHA resin (0.51 mmol/g, 0.1 mmol scale, 0.196 g) 
was used as polymeric support. The Fmoc protecting group on the resin was 
removed by a DMF/Piperidine (70/30) mixture. Fmoc-Lys(Mtt)-OH residue (0.125 g, 
0.2 mmol) was activated by 1 equiv of PyBop and HOBt and 2 equiv of DIPEA in 
DMF and coupled on the resin stirring the suspension for 1 h. The Nα amine function 
of the lysine residue was deprotected from Fmoc group, and two equivalents of 
Fmoc-AdOO-OH were coupled under standard condition in DMF for 1h. After Fmoc 
removal from linker, peptidyl-resin was washed three times with DMF and three times 
with MeOH, and treated by 1 mL of solution containing K2CO3 (0.04 mmol) 
CuSO4·5H2O (0.01 mol) and TFN3 (2 mmol). The resin was stirred at room 
temperature overnight. The solution was filtered and the resin was washed 4 times 
with DCM; the Mtt-protecting group on the Nε amino function of lysine was removed 
by treatment with the DCM/TIS/TFA (94:5:1) mixture. The peptide resin was stirred 
with 5.0 mL of this solution for 2 min. This procedure was repeated several times until 
the solution became colorless. The resin was washed 3 times by DCM and 3 times 
by DMF. Then, N,N-dioctadecylsuccinamic acid (0.249 g, 0.4 mmol) was coupled 
twice for 1 h in the NMP (N-methylpyrrolidone)/DCM (1/1) mixture. N,N-
dioctadecylsuccinamic acid was synthesized according to published procedure.The 
lipophilic moiety was activated in situ by the standard HOBt/PyBop/DIPEA procedure. 
36	  	  
The coupling was monitored by the qualitative Kaiser test. The resin was washed 3 
times by DMF, 3 times by DCM, and 3 times by ethyl ether. (C18)2L-N3 was removed 
from the resin by treatment with TFA containing TIS (2.5%) dithiothreitol (DTT, 2.5%) 
and water (2.5%) under vortexing for 2 hours. The crude product was slowly 
precipitated at 0 °C by adding water drop-wise, washed several time with small 
portions of water, and lyophilized in order to remove the solvent. The white solid was 
recrystallized from MeOH/H2O and recovered with high yields (>85%). The product 
was identified by MS (ESI+) and NMR spectra. 1H NMR and 13C-NMR spectra were 
recorded on a Varian 400 MHz spectrometer (Palo Alto, CA).  
(C18)2L-N3: MS (ESI+): m/z (%): 915 (100) [M-H+]= 916.64  
1H-NMR (CDCl3/CD3OD 50/50) (chemical shifts in δ, CHCl3 as internal standard 7.26) 
= 4.3 (m, 1H, CH Lys α),  4.04 (m, 2H, OCH2CONH), 3.70 (s, 4H, OCH2CH2O), 3.42 
(t, 2H, N3CH2CH2O), 3.25-3.20 (m, 4H, N-CH2), 3.23 (t, 2H, CH2 Lys ε), 3.20 (t, 2H, 
N3CH2CH2O), 2.64-2.49 (m, 4H, NHCOCH2CH2CO), 1.74 (m, 2H, CH2 Lys β), 1.55 
(m, 2H, CH2 Lys δ), 1.45 (m, 2H, CH2 Lys γ), 1.40 (m, 4H, RCH2CH3), 1.25 (m, 60 
CH2 aliphatic), 0.88 (t, 6H, CH3).    
13C-NMR (CDCl3/CD3OD 50/50) (chemical shifts in δ, CDCl3 as internal standard 
77.00) = 173.98 (CONH2), 173.27 (CONH), 171.94 (CH3(CH2)17NCO), 170.55 
(CONH), 72.3 (COCH2O), 70.0 (CH2N3), 69.4(OCH2CH2O), 52.4 (NH(CH2)4CH), 
51.05 (NHCH2(CH2)3CH), 48.6 (CH3(CH2)16CH2N), 46.8 (CH3(CH2)15CH2CH2N), 39.3 
(NH(CH2)3CH2CH), 32.4-32.0 (NHCH2(CH2)2CH2CH), 29.2 (NCOCH2CH2CONH), 
30.2-27.5 (CH3CH2(CH2)14CH2CH2N), 23.17 (CH3CH2(CH2)16), 14.60 
(CH3CH2(CH2)16). 
2.5 SYNTHESIS OF AZIDE-TERMINATED DENDRIMER 
2.5.1 Synthesis of Dendron 3 
 
Second generation dendron 2 (1.003 g, 694.50 µmol) and succinic anhydride (0.222 
mg, 2.22 mmol) were placed in a schlenk flask and the atmosphere was replaced 
with nitrogen. Anhydrous pyridine (30 mL) was added and the reaction was left to stir 
at room temperature for 15 h, after which the solvent was removed under vacuum.  
To the remaining oil, water was added. The mixture was agitated for 1 hour, after 
which the white residue was separated with ether. The organic phase was dried over 
sodium sulfate and concentrated to give pure 3 as a white foam (0.916 g, 85%) and 
compared exactly to a reference standard143. 1H NMR (MeOD, 400 MHz, δppm vs. 
MeOH): 2.66 (br t, J = 5.6 Hz, 2H, CH2COOH); 2.40 (br t, J = 5.6 Hz, 2H, 
CH2CH2COOH); 2.25-2.17 (m, 24H, CH2COO); 2.01-1.91 (m, 24H, CqCH2CH2); 1.44 
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(s, 81H, C(CH3)3). MS-ESI (M-H)- m/z calcd for C80H137N4O24: 1537.962, found 
1538.1.  
 1H NMR spectra of Dendron 3 
 
2.5.2 Synthesis of Dendrimer 4 
 
Dendron 3 (0.916 g, 594.82 µmol) and dendron 2 (0.946 g, 656.99 µmol) were placed 
in a schlenk flask with HATU (0.306 g, 804.78 µmol) and the atmosphere was 
replaced with nitrogen. Anhydrous DMF (30 mL) was added, and then DIPEA (0.3 
mL, 1.72 mmol). The reaction was left to stir at room temperature for 2 d. After 
concentration, the product was dry-packed onto a basic alumina plug and purified by 
silica column chromatography (hexane → 1:1 hexane:EtOAc → 2:3). Concentration 
afforded 4 as a white foam (1.383 g, 79%). 1H NMR (CDCl3, 400 MHz, δppm vs. TMS): 
7.35 (s, 2H, NHCOCH2CH2CONH); 6.32 (s, 6H, CONH); 2.41 (s, 4H, COCH2CH2CO); 
2.25-2.12 (m, 48H, CH2CO); 2.00-1.91 (m, 48H, CqCH2); 1.43 (s, 81H, C(CH3)3). 13C 
NMR (CDCl3, 400 MHz, δppm vs. TMS): 172.9 (CqCH2CH2CONHCq); 172.8 
(COOC(CH3)3); 171.9 (COCH2CH2CO); 80.4 (C(CH3)3); 57.8 (COCH2CH2CONCq); 
57.4 (CONCq); 31.5 (CH2CH2CONH); 31.4 (CH2CONCq); 29.9 (CH2CH2CONH); 29.8 
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(CH2COOC(CH3)3); 28.2 (C(CH3)3); 28.1 (CH2CH2COOH). MS-ESI (M+2Na)2+ m/z 
calcd for C156H270N8O44Na2: 1502.947, found 1503.7. MALDI-TOF/TOF m/z calcd for 
C156H270N8O44Na: 2982.903, found 2983.216. 
 
 1H NMR spectra of Dendrimer 4 
 
2.5.3 Synthesis of Dendrimer 5 
 
	  
Dendrimer 4 (0.328 g, 110.74 µmol) was dissolved in formic acid (25 mL) and water 
(2.5 mL). This was left to stir for 1 day.  After concentration, the residue was 
dissolved in a minimal amount of methanol and precipitated from ether.  After 
centrifugation, decantation, and drying, dendrimer 5 was obtained as a white powder 
(0.197 g, 91%). 1H NMR (MeOD, 400 MHz, δppm vs. MeOH): 2.47 (s, 4H, 
COCH2CH2CO); 2.36-2.14 (m, 48H, CH2CO); 2.09-1.87 (m, 48H, CqCH2).  13C NMR 
(MeOD, 400 MHz, δppm vs. MeOH): 177.3 (COOH); 175.8 (CqCH2CH2CONHCq); 
174.6 (COCH2CH2CO); 59.1 (COCH2CH2CONCq); 58.7 (CONCq); 33.5 
(CH2CH2CONH); 32.0 (CH2CONCq); 31.9 (CH2CH2CONH); 30.6 (CH2COOH); 29.4 
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(CH2CH2COOH).  MS-ESI (M-H)- m/z calcd for C84H125N8O44: 1949.779, found 
1950.0. MALDI-TOF/TOF m/z calcd for C84H125N8O44Na: 1973.777, found 1973.902. 
 1H NMR spectra of Dendrimer 5 
 
2.5.4 Synthesis of Dendrimer 6 
 
	  
Dendrimer 5 (31 mg, 15.88 µmol) and HATU (383.98 µmol) were introduced into a 
schlenk flask and placed under nitrogen. Anhydrous DMF (2 mL) was added, then 
DIPEA (0.11 mL, 631.52 µmol), and finally 3-azidopropylamine (125 mg, 1.25 mmol). 
The reaction was left to stir for 2 d. The solvent was then removed and the resulting 
oil was purified by dialysis against methanol (1000 MWCO) to afford a dendrimer 6 
as a colorless film (34.78mg, 64%). 1H NMR (MeOD, 400 MHz, δppm vs. MeOH): 3.37 
(t, J = 6.7 Hz, 36H, NHCH2CH2CH2N3); 3.25 (t, J = 6.8 Hz, 36H, CH2N3); 2.46 (s, 4H, 
COCH2CH2CO); 2.27-2.15 (m, 48H, CH2CO); 2.05-1.91 (m, 48H, CqCH2); 1.76 (p, J = 
6.8 Hz, 36H, CH2CH2CH2N3). 13C NMR (MeOD, 400 MHz, δppm vs. MeOH): 175.8 
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(CONHCH2CH2CH2N3); 175.6 (CqCH2CH2CONHCq); 175.3 (COCH2CH2CONH); 59.3 
(CH2CH2CONCq); 59.1 (CONCq); 50.3 (CH2CH2CH2N3); 38.0 (CH2N3); 32.2 
(CH2CH2CONH); 32.0 (CH2CONCq); 31.8 (CH2CONCH2); 31.4 (CH2CH2CONH); 29.9 
(CH2CH2CH2N3). MS-ESI (M+2H)2+ m/z calcd for C138H236N80O26: 1714.980, found 
1715.0. MALDI-TOF/TOF m/z calcd for C138H234N80O26Na: 3450.935, found 
3450.853. IR 2098.5 cm-1 (azide stretch). 
 
 1H NMR spectra of Azide-terminated dendrimer 
 
2.6 LIPOSOME PREPARATION 
Large unilamellar vesicles (LUVs) consisting of PC/Chol (1:1 molar ratios), when 
necessary containing also Rho-PE and NBD-PE, and DOPG/(C18)2L-N3 (90:10 molar 
ratios)  were prepared, according to the extrusion method of Hope et al. 144. The 
compounds were dissolved and mixed in a small amount of chloroform, and 
subsequently evaporating the solvent by slowly rotating the tube containing the 
solution under a stream of nitrogen, and lyophilized overnight. In this way a thin film 
of amphiphiles was obtained.  
Dry lipid film was suspended in 10 mM HEPES buffer, when required  in 5 mM 
HEPES, 100 mM NaCl, at pH 7.4 by vortexing; then the lipid suspension was freeze-
thawed 10 times and extruded 20 times thought a polycarbonate membrane with 100 
nm pore size, using a Mini-extruder purchased from Avanti Polar Lipids (Usa, 
Canada). Lipid concentrations were determined by phosphate analysis145. 
 
2.7 DOXORUBICIN LOADING  
Doxorubicin was remote-loaded in DOPG/(C18)2L-N3 liposomes via an ammonium 
sulfate gradient method and the free Dox was removed by gel filtration. Briefly, 1 mM 
liposomal solution was prepared as above reported in 250 mM ammonium sulfate at 
pH 5.5. Next, liposomes were passed on Sephadex G-50 column pre-equilibrated 
with 10 mM HEPES buffer at pH 7.4 and 27 µL of 2.54×10-3 M Dox solution in water 
were added to 500 µL of liposomal solution. This suspension was stirred for 30 min at 
60°C and subsequently unloaded doxorubicin was removed by Sephadex G50 
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column. The Dox concentration was determined by spectroscopic measurements (UV 
and fluorescence) using calibration curves obtained by measuring absorbance at 480 
nm or fluorescence emission at 590 nm. Emission spectra were recorded at room 
temperature. The Dox loading content (DLC, defined as the weight ratio of 
encapsulated Dox versus the amphiphilic moieties) was quantified by subtraction of 
the amount of Dox removed from the total amount of Dox loaded. Finally, Dox pre-
loaded liposomes were modified with gH625 peptides using the click reaction 
procedure, as above reported for empty liposomes. 
 
2.8 PEPTIDES CONJUGATION TO QUANTUM DOTS 
Solution of peptides, EDC (1-Ethyl-3(3-dimethylamino-propyl)-carbodiimide, 
hydrochloride) and NHS (N-Hydroxysuccinimide) was prepared in PBS buffer at 
pH7.2 in molar ratio of 4:4:1. QDs were conjugated with the preactivated-peptides in 
a molar ratio of 1:200, in MES buffer at pH 5.5 for 3 hours. The fluorescence spectra 
of peptide-QDs and un-conjugated QDs were measured in a Cary Eclipse Varian 
fluorescence spectrophotometer in the same condition. In all the reported confocal 
experiments we used the same peptide concentration and thus the QDs 
concentration was 200 times lower. 
 
2.9 PEPTIDES CONJUGATION TO LIPOSOMES 
Click-reaction was carried out on DOPG/(C18)2L-N3 liposomes at 1⋅10-3 M 
concentration in 10 mM HEPES buffer at pH 7.4. The reaction was carried out by 
adding 4.4 equivalents of CuSO4⋅5H2O, 6.7 equivalents of ascorbic acid and 1 
equivalent of peptide derivative with respect to the azido moiety. In particular, 
solutions containing 40 mM CuSO4⋅5H2O (solution A), 57 mM ascorbic acid (solution 
B), and 0.8 mM of alkyne modified peptide (solution C) were freshly prepared in 
water. 43.6µL of solution A, 48 µL of solution B and 408.4 µL of solution C were 
added to 500 µL of a suspension of azido functionalized liposomes in HEPES. 
Concentration of solution C was determined by absorbance on a UV-vis Jasco V-
5505 spectrophotometer.  
The reaction mixture was stirred at 40°C for 30 minutes and successively left 
overnight at room temperature. After the conjugation step, liposomes were purified by 
exclusion chromatography on a 1 × 18 cm Sephadex G-50 (Amersham Biosciences) 
column pre-equilibrated in HEPES buffer.  
The number of functional groups present on the external surface of the liposomes 
and the number of molecules of gH625 that were effectively linked to the liposome 
were determined by using NBD-labeled Pra and NBD-labeled gH625-Pra. The 
amount of NBD-Pra or NBD-gH625-Pra grafted to the liposome surface were 
estimated by fluorescence spectroscopy using calibration curves obtained by 
measuring fluorescence emission at 530 nm. Fluorescence spectra were recorded at 
room temperature on a Jasco Model FP-750 spectrofluorophotometer in 1.0 cm path 
length quartz cell. Equal excitation and emission bandwidths were used throughout 
experiments, with a recording speed of 125 nm/min and automatic selection of the 
time constant. The percentage of functionalization was calculated as the ratio of 
bound NBD-Pra or NBD-gH625-Pra to their total amount. 
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2.10 PEPTIDES CONJUGATION TO DENDRIMER  
A methanol/water (1:1) solution of peptide gH625–Pra (660 µL, 30.33 equiv), an 
aqueous solution of CuSO4·5 H2O (10 µL, 1.46 mmol, 1 equiv), and an aqueous 
solution of sodium ascorbate (50 µL, 1.17 mmol, 4 equiv) were added to dendrimer 6 
(50 mg, 0.0146 mmol) in a 1:1 water/methanol solution (280 µL). The mixture was 
stirred, overnight. Then, the mixture was concentrated and purified by size-exclusion 
chromatography. Peptides 1 and 1–NBD were obtained in quantitative yield. IR (cast 
on polyethylene)): v ̃=3295, 1658, 1545, 1471, 1203 cm-1. No peak at 2098 cm-1 was 
observed. CD: 208 nm; UV/Vis (water): λmax = 193, 273 nm. Synthesis of dendrimer 
7, due to its poor solubility, was performed in a 1:1 mixture of THF/H2O as solvent, 
and purification was carried out by dialysis (1000 MWCO) against 1:1water/methanol. 
Yield: approximately 20 %; UV/Vis (MeOH): λmax = 452 nm. 
 
2.11  PEPTIDES CONJUGATION TO NPS 
A solution of the peptide, EDC (1-ethyl-3(3-dimethylamino-propyl)-carbodiimide, 
hydrochloride) and NHS (N-Hydroxysuccinimide) in molar ratio of 4:4:1 was prepared 
in PBS buffer at pH 7.4, at room temperature under stirring for 30 min. NPs were 
conjugated with the preactivated-peptide, in MES 0.1 M buffer at pH 5.5 for 3 h at 
room temperature in presence of Tween 20 and the yield of the reaction was higher 
than 90%. The peptide-NPs were purified from the unconjugated-NPs by exclusion 
chromatography on a 1 × 18 cm Sephadex G-50 (Amersham Biosciences) column 
pre-equilibrated in PBS buffer at pH7.4. The fluorescence spectra of peptide-NPs and 
unconjugated NPs were measured in a Cary Eclipse Varian fluorescence 
spectrophotometer in the same condition. Peptide-NPs were prepared with several 
degrees of functionalization: 25%, 35% and 50%. 
 
2.12 MEMBRANES INTERACTION EXPERIMENTS OF PEPTIDES AND 
CONIUGATED-PEPTIDES 
Large unilamellar vesicles (LUVs) consisting of PC/Chol (55:45) and, when 
necessary, containing Rho-PE and NBD-PE, were prepared according to the 
extrusion method of Hope et al. 146 in 5 mM HEPES containing 100 mM NaCl at pH 
7.4.  
Peptide and conjugated-peptides ability to induce the fusion of model membranes, 
like liposomes, was evaluated by the Lipid Mixing Assays. Membrane lipid mixing 
was monitored using the resonance energy transfer assay reported by Struck et al. 
147. The assay is based on the dilution of the NBD-PE (donor) and rhodamine-PE 
(acceptor). Dilution because of membrane mixing results in an increase in NBD-PE 
fluorescence. Thus, we monitored the change in donor emission as aliquots of 
peptides were added to vesicles. Vesicles containing 0.6 mol % of each probe were 
mixed with unlabeled vesicles at a 1:4 ratio (final lipid concentration, 0.1 mM). Small 
volumes of peptides in dimethyl sulfoxide (DMSO) were added; the final 
concentration of DMSO in the peptide solution was no higher than 2%. The NBD 
emission at 530 nm was followed with the excitation wavelength set at 465 nm. A 
cutoff filter at 515 nm was used between the sample and the emission 
monochromator to avoid scattering interferences. The fluorescence scale was 
calibrated such that the zero level corresponded to the initial residual fluorescence of 
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the labeled vesicles, and the 100% value corresponding to complete mixing of all 
lipids in the system was set by the fluorescence intensity of vesicles upon the 
addition of Triton X-100 (0.05% v/v) at the same total lipid concentrations of the 
fusion assay. All fluorescence measurements were conducted in PC/Chol (1:1) LUVs 
and at 37°C. 
Peptides and conjugated peptides induced phospholipid-mixing of the inner 
monolayer was measured by a modification of the phospholipid-mixing measurement 
as reported elsewhere. The concentration of each of the fluorescent probes within the 
liposome membrane was 0.6% mol. LUVs were treated with sodium dithionite to 
completely reduce the NBD-labelled phospholipid located at the outer monolayer of 
the membrane. The final concentration of sodium dithionite was 100 mM (from a 
stock solution of 1 M dithionite in 1 M TRIS, pH 10.0) and it was incubated for 
approximately 1 h on ice in the dark. Sodium dithionite was then removed by size 
exclusion chromatography through a Sephadex G-75 filtration column (Pharmacia, 
Uppsala, Sweden) eluted with buffer containing 10 mM TRIS, 100 mM NaCl, and 1 
mM EDTA, pH 7.4. The NBD emission at 530 nm was followed with the excitation 
wavelength set at 465 nm. A cut off filter at 515 nm was used between the sample 
and the emission monochromator to avoid scattering interferences. The fluorescence 
scale was calibrated such that the zero level corresponded to the initial residual 
fluorescence of the labelled vesicles and the 100% value corresponding to complete 
mixing of all lipids upon the addition of Triton X-100 (0.05% v/v). All fluorescence 
measurements were conducted in PC/Chol (1:1) LUVs, were repeated at least three 
times and results were averaged. All the experiments were performed at 37°C. 
The ANTS/DPX assay was used to measure the ability of the peptides and 
conjugated peptides to induce leakage of ANTS/DPX pre-encapsulated in liposomes. 
Details of this assay can be found elsewhere148. To initiate a leakage experiment, the 
compounds, in a stock solution at pH 7.4 containing 5 mM HEPES and 100 mM 
NaCl, were added to the stirred vesicle suspension (0.1 mM lipid).  
Data points were recorded at 0.5-s intervals over a 10-min period after which vesicles 
were lysed with the detergent Triton X-100 to obtain the maximal fluorescence value, 
which was set to 100% leakage. Fluorescence from intact vesicles in buffer was set 
to 0% leakage, and results were normalized according to this scale.  
 
2.13 FLOW CYTOMETRY OF CELL ASSOCIATION OF PEPTIDES AND 
CONIUGATED-PEPTIDES 
HeLa cells were cultured in RPMI medium supplemented with 10% fetal bovine 
serum. Cells were diluted at 3 x 105 cells mL-1 1 day before the experiment. Cell 
association was measured by flow cytometry using a FACScan (Becton Dickinson). 
NBD-labelled peptides, NBD-dendrimer and NBD-peptidodendrimer (1, 5, 10, 20 µM) 
were incubated with HeLa cells (5 x 105 cells mL-1) in Opti-MEM medium at 37°C for 
various periods of time (10, 30, 60 min) in a final volume of 0.5 mL. Thereafter, the 
cells were washed twice and then resuspended in 0.5 mL of ice-cold NaCl/Pi for flow 
cytometric analysis. Cell-associated fluorophores were excited at 465 nm and 
fluorescence was measured at 530 nm. A histogram of fluorescence intensity per cell 
(1 x 104) was obtained and the calculated mean of this distribution was considered as 
representative of the amount of cell associated peptide. A stock solution of dithionite 
was freshly prepared in 1 M Tris solution (pH 10). Following flow cytometric analysis, 
5 µL of dithionite stock solution was added to cells maintained at 4°C and the 
fluorescence of internalized peptides was measured after 5 min. 
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To further study the mechanism of internalization, experiments were performed at low 
temperature. In particular, cells were preincubated for 30 min at 4°C before being 
incubated with the compound solution.  
 
2.14 FLUORESCENCE AND CONFOCAL MICROSCOPY STUDIES ON 
PEPTIDES AND CONIUGATED-PEPTIDES  
Cellular uptake experiments. NBD labelled peptides and conjugated-peptides were 
diluted in cell culture medium; in particular the final concentration of NBD conjugated 
to the peptides was 1, 10 and 20 µM; while the final concentration of QDs conjugated 
to the peptide was 5, 50 and 100 nM. 70% confluent HeLa cells, seeded on 12 mm-
diameter glass coverslips, were incubated with 200 µl of peptide conjugated to the 
NBD or to QDs at 37°C for 1 h and at 4°C for 10 min. For localization of peptides in 
lysosome organelles, LysoTracker reagent (Molecular Probes, Invitrogen) was added 
to cell culture medium containing peptides and incubated with cells for 1 h at 37°C 
according to manufacturer’s procedure. After incubation, cells were rinsed twice with 
PBS to remove non internalised peptides and fixed with 4% paraformaldehyde for 20 
min.  
For peptides and conjugated-peptides uptake kinetics experiments on non-fixed living 
cells, HeLa cells were incubated with 10 µM of NBD-peptide solutions and with 50 nM 
QD-peptide solutions, with liposomes functionalized with gH625 and pre-loaded with 
Dox with a concentration of Dox of 1 µM at 37°C for 1, 5 and 17 hours and with NBD-
peptidodendrimer and NBD-Dendrimer (10 or 20 µM relative to peptides, 0.56 or 1.11 
µM dendrimer) at 37°C for either 1 or 2 h. After incubation, cells were rinsed twice 
with PBS and fresh cell culture medium without phenol red was added. 
To inhibit the endocytosis pathway sodium azide and low-temperature experiments 
were conducted: 40 µM sodium azide was added to the cell culture medium for 30 
min followed by 1h incubation with peptides, 20 µM of peptides and conjugated 
peptides solution were incubated for only 10 minutes at  4°C before imaging. 
All the samples were observed by a confocal laser scanning microscope 
(CLSM)(LSM510, Zeiss) equipped with a He-Ne and an Argon laser lines at the 
wavelengths of 543 nm and 488 nm, respectively, with a 63x objective and by a 
Nykon Eclipse Ti inverted microscope equipped with a FITC filter set for fluorescence 
imaging.  
Colocalization with Lysosomes and Caveolae. For indirect immunofluorescence, after 
NPs incubation, cells were firstly rinsed twice with PBS to remove non internalized 
NPs and fixed with paraformaldehyde 4% for 20 min. Then, cells were incubated with 
Triton 100 X 0.1% in PBS for 10 min and with PBS-BSA 0.5% for 15 min at room 
temperature (RT). Caveolae were localized by incubating samples first with rabbit 
anti-caveolin 1 (Abcam) primary antibodies. After primary antibodies incubation, 
Alexa-fluor 568 goat anti-rabbit secondary antibodies (Molecular Probes, Invitrogen) 
were used. Afterward, samples were rinsed three times with PBS. For lysosomes 
localization, LysoTracker Red DND-99 (Molecular Probes, Invitrogen) was used 
following manufacturer’s procedure on non-fixed cells. Immunofluorescence analyses 
were performed by means of confocal laser scanning microscope (CLSM)(LSM510, 
Zeiss), equipped with an argon laser, at a wavelength of 488 nm, and a He–Ne laser, 
at a wavelength of 543 nm, and 63x objective. Images were acquired with a 
resolution of 1024 × 1024 pixels. Colocalization was estimated by an ImageJ 
software plugin. 
Cytochalasin D Treatment: to disassemble actin microfilaments, cells were treated 
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with 30 µM cytochalasin D in cell culture medium for 30 min at 37°C before NP 
incubation. After cytochalasin D treatment, cells were incubated with a NP 
suspension for 15 min. Then, cells were rinsed with PBS to remove non-internalized 
NPs, fixed with paraformaldehyde 4% for 20 min and observed by CLSM. 
Quantification of NP uptake was performed as described above. 
Quantification of NP Aggregates: to measure the size of NP aggregates within cell 
cytoplasm, bEnd3 cells were incubated with NP suspension for 30, 90, 1440 minutes 
at 37°C. After incubation, cells were rinsed twice with PBS, fixed with 
paraformaldehyde 4% for 20 min and observed by confocal microscope (Leica). 
Images were analyzed by an ImageJ software plugin. About 50 cells per each sample 
were analyzed. The size distribution of NP aggregates was split in four intervals 
(0.01÷0.03 µm2; 0.04÷0.10 µm2; 0.11÷0.30 µm2; >0.31 ìm2) and data reported as 
percentage of NP aggregates respect to the total number of NP aggregates per cell. 
 
2.15  STRUCTURAL STUDIES OF PEPTIDES AND CONIUGATED-PEPTIDES  
Circular Dichroism Measurements Far-UV CD spectra were recorded from 260 to 195 
nm on a Jasco J-810 spectropolarimeter equipped with a NesLab RTE111 thermal 
controller unit using a 1.0 , 0.1 cm or 0.1 mm quartz cell at 25 °C. CD spectra of 
gH625-Pra and of its analogs in which each Ala residues were replaced by 
Lys(TOAC) residues were recorded at 8·10-4 M concentration in HEPES buffer in 
presence and in absence of 20% TFE (trifluoroethanol). Moreover peptidodendrimer 
spectra were recorded at 8 µM solution in HEPES buffer containing various 
percentages of trifluoroethanol, and NPs spectra were conducted at different 
percentages (25-50%) of functionalization with gH625 peptide. Other experimental 
settings were: scan speed, 10 nm/min; sensitivity, 50 mdeg; time constant, 16 s; 
bandwidth, 1 nm. Each spectrum was obtained averaging three scans, subtracting 
contributions from other species in solution, and converting the signal to mean 
residue ellipticity.  
Size and Z-potential. For Dynamic light scattering characterizations self-assembled 
liposomes in isotonic HEPES solution were prepared at the final concentration of 
1x10-4 M. Samples were centrifuged at room temperature at 13,000 rpm for 5 min. 
gH625 NPs and blank-NPs measurements were conducted at 25 °C using a 3.6 
× 1010 NP/ml suspension at pH 4, 7, 8 and 9. 
The measurements were performed with a setup composed of a Photocor compact 
goniometer, a SMD 6000 Laser Quantum 50 mW light source operating at 5325 
Å and a PMT and correlator obtained from Correlator.com. All the measurements 
were performed at (25.00 ± 0.05)°C with use of a thermostat bath, other 
measurements were conducted on a Zetasizer Nano-ZS (Malvern Instruments, 
Worcestershire, UK).  
For Z-potential analysis gH625 NPs and blank-NPs were made with a Zetasizer 
Nano-ZS (Malvern Instruments, Worcestershire, UK). The measurements were 
conducted at 25 °C using a 3.6 × 1010 NP/ml suspension at pH 4, 7, 8 and 9. All 
measurements were performed in triplicate for each sample. 
EPR Measurements. EPR spectra of spin-labeled peptides chemically linked to the 
liposome surface were recorded on an Elexys E-500 EPR spectrometer from Bruker 
(Rheinstetten, Germany) operating in the X band. As references, spectra of the “free” 
spin-labeled peptides in aqueous buffer and in the presence of liposomes were also 
registered. Flame-sealed capillaries containing the samples were placed in a 
standard 4 mm quartz sample tube. The temperature of the sample was regulated 
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and maintained constant during the measurement by blowing thermo stated nitrogen 
gas through a quartz Dewar. The samples were investigated at 25 °C. The 
instrumental settings were as follows: sweep width, 120 G; resolution, 1024 points; 
modulation frequency, 100 kHz; modulation amplitude, 1.0 G; time constant, 20.5 ms; 
sweep time, 42 s; incident power, 5.0 mW. For samples subjected to the click 
chemistry reaction up to 128 scans were accumulated to improve the signal-to-noise 
ratio149. For all the other samples, 8 scans were accumulated. 
InfraRed measurements- Infrared data for dendrimers was performed by dropping a 
methanol solution of the compound on poly(ethylene) IR cards at room temperature. 
 
2.16 SPECTROFLUORIMETRIC STUDIES ON PEPTIDES AND CONIUGATED-
PEPTIDES 
Quantification of Nanoparticle Uptake Kinetics: To evaluate cell uptake of NPs as a 
function of NP surface functionalization with gH625 peptide, about 5 × 104 cells were 
seeded in a 96-well. Blank-NPs and gH625-NPs were dispersed in cell culture 
medium at the final concentration of 3.6 × 1010 NP/mL. Cells were incubated with NP 
suspensions for 0, 10, 60, 180, and 300 min. After incubation, cells were rinsed with 
PBS and lysed with 1% Triton ×100 in PBS. Cell lysates were analyzed by a 
spectrofluorometer (Wallac 1420 Victor2, Perkin–Elmer, USA) to measure the 
amount of internalized NPs. 
Permeability Experiments. Cells were seeded at a density of 5 × 104 cells/cm2 on 
Transwell permeable inserts (6.5 mm in diameter, 3 µm pores size; Corning 
Incorporated, Corning, NY). Transendothelial electrical resistance (TEER) was 
measured by using Millicell1-ERS voltohmmeter (Millipore, Billerica, MA) to assess 
the growth of cells on inserts. Permeability experiments were performed on the 
monolayer 7 days after cell seeding, allowing sufficient time for the cells to develop 
the junctions between cells. On the day of experiment, Transwell insert filter was 
washed with PBS, and then the media of the donor chamber was filled with 150 
ìL cell culture medium w/o phenol red containing 0.5 mg/ mL rhodaminated BSA and 
3.6 × 1010 NPs/mL while the acceptor chamber was filled with 400 ìL cell culture 
medium without phenol red. The samples of 100 µL were drawn every 10 min for 90 
min from the acceptor chamber and were then replaced with the same amount of 
fresh medium. The fluorescence tracer concentration in the samples was determined 
by a spectrofluorometer (Victor, Wallac, PerkinElmer), and the excitation and 
emission wavelengths were set to 540 and 615 nm and 485 and 535 nm, 
respectively, for BSA and NPs. The solute permeability P of the monolayer was 
calculated according to the following equation: 
 
Where ΔCA /Δt is the increase in fluorescence concentration in the acceptor chamber 
during the time interval Δt, CD is fluorescence concentration in the donor chamber 
(assumed to be constant during the experiment), VA is the volume of the acceptor 
chamber, and S is the surface area of the filter. The experiments were performed in 
triplicate. 
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2.17  MULTIPLE PARTICLE TRACKING  
Images of NPs internalized in End3 cells were collected in real time for about 100 s 
with a time resolution of ∼1 s by using Olympus Cell-R system equipped with 60× oil 
immersion objective. Tracking algorithm has been described in detailed elsewhere 
150. From the NP trajectories the mean square displacement (MSD) was derived. 
Indicated with〈r2〉, MSD was related to the NPs diffusion coefficient D by the 
Equation 
〈r2〉= nDtα+υ2t2 
where D is the diffusion coefficient, υ the NP rate and a represents the time 
dependence. The first term of the equation is related to the random diffusion of the 
nanoparticles, whereas the second one reflects the active motion along the filaments 
due to the action of molecular motors (for NPs that undergo to Brownian motion such 
term becomes negligible). By fitting the MSD curve of each tracked bead using the 
equation, informations concerning the nature of particle motion into the cells were 
gained. In particular, nanoparticles, exhibiting MSD curve that undergo a power law 
with exponent minor or equal to unity, were classified as Brownian (α = 1) or sub-
diffusive (α < 1). Particles presenting MSD, whose dependence on time was well 
described by the power law with α> 1, were indicated as super-diffusive. During the 
experiments the MSD of 226 (NPs-NH2), 105 (NPs-gH625 25%), 38 (NPs-gH625 
35%) and 574 (NPs-gH625 50%) distinct objects was evaluated. For each degree of 
peptide functionalization, at least, 3 cells were analyzed. 
 
2.18 SCANNING ELECTRON MICROSCOPY (SEM) 
Dendrimer Sem microscopy was performed by drop-casting a 5 nM solution in water 
(20% TFE v/v) of dendrimer on a Cu grid and drying at room temperature.  The 
sample was stained by placing it in a closed container containing a solution of RuO4.  
NPs SEM microscopy was performed incubating the cells for 10 min  with blank NPs 
and gH625-NPs, then the cells were rinsed with PBS, fixed with 2.5% glutaraldehyde 
for 2 h at 4 °C and dehydrated in increasing ethanol series (70%, 80%, 95%, and 
100%) and by critical point. The samples were gold-sputtered and analyzed by ESEM 
Quanta 200 (FEI Company) at 25 kV and 6.8 mm working distance. 
 
2.19 TRANSMISSION ELECTRON MICROSCOPY (TEM) 
TEM was performed to precisely localize the intracellular nanoparticles. After 24 h 
incubation with blank NPs and gH625-NPs, cells were rinsed with PBS and fixed with 
2% paraformaldehyde + 0.2% glutaraldehyde for 2 h at room temperature. 
Afterwards, cells were scraped, harvested in centrifuge tubes, embedded in 12% 
gelatine solution in PBS and infused in 2.3 M sucrose at 4 °C. Sections were cut with 
a Leica Cryo-ultramicrotome and examined with Leica EM FC7. 
 
2.20 STATISTICAL ANALYSES 
Quantitative data were reported as mean ± standard deviation (SD). Statistical 
analyses were performed using a one-way analysis of variance (ANOVA). Results 
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repeats were compared by analysis of variance (ANOVA), and a p value < 0.05 was 
considered statistically significant. 
 
2.21 PEPTIDES AND CONIUGATED-PEPTIDES CITOTOXICITY 
MTT assay for cell viability. Methylthiazolyldiphenyl-tetrazolium (MTT) bromide 
reduction was used to examine the metabolic activity of the cells. The MTT assay is 
based on the reduction of the yellowish MTT to the insoluble and dark blue formazan 
by viable and metabolically active cells 151. HeLa cells were subcultured in 96-well 
plates at a seeding density of 2 x 104 cells/well. For assessing the cytotoxic effect of 
gH625 and Tat peptides, HeLa cells were incubated with different concentration of 
peptides (10, 50, 100, 200, 400 µM) for 24 h. For assessing the cytotoxicity of 
dendrimer and peptidodendrimer, Vero cells were incubated with different 
concentrations (1.1, 2.8, 5.5 µM) for 3 and 24 h. Then, the medium was gently 
aspirated and MTT solution (5 mg/mL) was added to each well and cells were 
incubated for a further 3 h at 37°C. The medium with MTT solution was removed, and 
the formazan crystals were dissolved with DMSO. The absorption values were 
measured at 570 nm using a Bio-Rad Microplate Reader (Bio-Rad Laboratories, 
Inc.). The viability of HeLa cells in each well was presented as a percentage of 
control cells. 
Lactate dehydrogenase (LDH) assay. LDH released into the culture medium was 
measured by monitoring fluorometrically the production of NAD+ from NADH during 
the conversion of pyruvate to lactate 152. For assessing the plasma membrane 
integration upon the exposure to gH625 and Tat peptides, HeLa cells were 
subcultured in 96-well plates at a seeding density of 2 x 104 cells/well. Twenty-four 
hours later cells were incubated with different concentration of peptides (10, 50, 100, 
200, 400 µM) for 24 h. The cell supernatant (100 µl) was incubated with 0.18 mM 
NADPH and 0.60 mM pyruvate in 50 mM phosphate buffer (pH 7.4). The rate of 
NAD+ formation was monitored for 1 min by reading the fluorescence in a 
fluorescence reader with the excitation filter set at 360 nm and the emission filter set 
at 460 nm. LDH leakage was expressed as a percentage of untreated or control cells 
which was designated as 100%. 
49	  	  
3 RESULTS AND DISCUSSION 
3.1 gH625 MEMBRANE INTERACTION AND INTRACELLULAR 
INTERNALIZATION 
3.1.1 NBD-peptides synthesis 
Peptides were synthesized, using standard solid-phase-Fmoc method, with 4-chloro-
7-nitrobenz-2-oxa-1,3-diazole (NBD) at the N terminus (gH625: NBD-
HGLASTLTRWAHYNALRAF-COOH, Tat: NBD-GRKKRRQRRRGGG-COOH). All 
purified peptides were obtained with good yields ( 30-40%). 
 
3.1.2 NBD-Peptide interaction with liposomes (LUVs)  
To support the hypothesis that the peptide is able to diffuse inside lipidic vesicles 
without involving pore formation, we performed the fusion, inner monolayer, and 
leakage experiments as indicators of the interaction and perturbation of the lipid 
membrane caused by the peptide.  
Membrane disturbance upon peptide insertion was evaluated by vesicle fusion 
experiment in liposomes composed of different lipids. The best fusogenic activity was 
obtained using PC/Chol lipids and Figure 1A shows that 20-30% of fusion is already 
reached at 0.01 peptide/lipid ratio. 
 
 
 
Figure 1. Peptide interaction with PC/Chol LUVs (A,B,C), the dose dependence is reported and each trace 
represents an average of 3 independent experiments. (A) Lipid mixing; (B) Inner monolayer assay. (C) Leakage of 
ANTS/DPX. NBD-peptide cellular uptake (D-E-F), the percentage of internalized and bound peptides are reported. 
HeLa cells were incubated with (D) increasing concentrations of NBD-peptides (1, 5, 10, 20 µM) for 60 min. (E) 10 
µM NBD-peptides for 10, 30 and 60 min. (F) NBD-peptides at 37° and 4°C. 
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In the inner monolayer, the fluorescence from the vesicle membranes' outer 
monolayer is eliminated by the addition of an aqueous reducing agent, and this 
experiment reveals the extent of lipid mixing between the inner monolayers of 
vesicles in solution. Figure 1B shows that a small fusion of the inner monolayer is 
observed only at a peptide lipid ratio of approximately 0.8. This assay clearly 
indicates that the peptide gH625 induces only hemifusion at peptide-to-lipid ratios 
between 0 and 0.1. A contents-mixing assay was employed to monitor any mixing of 
internal vesicle components as a consequence of vesicle exposure to gH625. 
Release of ANTS and DPX from vesicles is commonly used as a measure of bilayer 
perturbation and interpreted as “transient pore formation”. Contents mixing is 
manifested by a decrease in fluorescence intensity if vesicles encapsulating a 
fluorescent cargo (e.g., ANTS) merge contents with those containing a quencher 
(e.g., DPX). 
Figure 1C shows that no contents mixing occurs over the same P/L range where 
substantial outer monolayer lipid mixing occurs, corroborating the presence of vesicle 
hemifusion in our system. The agreement of contents mixing assays and inner 
monolayer lipid-mixing assays gives full confidence in the finding of peptide-induced 
hemifusion for gH625. These results can be used as qualitative indicators of peptide 
translocation or bilayer perturbation with relevance for the direct-penetration mode of 
cell entry, or for the steps of endosomal membrane translocation or endosomal 
escape. We have not detected any significant pore formation; vesicle fusion events 
not accompanied by leakage of the aqueous contents of the vesicle were also 
reported for other peptides in a study published by Thoren et al.153. 
 
3.1.3 NBD-peptides cellular uptake by flow cytometry analysis (FACS) 
The fraction of NBD-labeled peptide taken up into HeLa cells was determined by flow 
cytometry. The experiment is based on a method previously introduced by McIntyre 
and Sleight148 to measure the transbilayer distribution of NBD phospholipid 
analogues. The distribution is determined by comparing the fluorescence intensity 
before and after addition of sodium dithionite, an essentially membrane-impermeant 
molecule, which suppresses irreversibly the fluorescence of the accessible NBD-
moiety localized on the external cell surface.  
We incubated gH625-NBD with HeLa cells at 37°C at different concentrations (1, 5, 
10, 20 µM). After 1 hour of incubation, we measured the quenching of the peptide by 
dithionite treatment. The dithionite reaction was performed at low temperature (4°C) 
because the dithionite crossing of biological membranes is strongly reduced in 
comparison with high temperatures. Upon stabilization of the initial fluorescence, 
dithionite was added to initiate quenching. Before the addition of dithionite we 
observed that approximately 90% of gH625-NBD was not washed away and thus 
was internalized or bound to the membrane bilayer; after the addition of dithionite the 
internalized peptide was 80% (Figure 1D). We performed the same experiment on 
Tat-NBD as a reference; and before the addition of dithionite we observed that 
approximately 70% of the peptide was internalized or bound to the membrane 
bilayer; after the addition of dithionite, the internalized peptide was approximately 
60% (Figure 1D). Increasing dithionite concentration did not result in a modification of 
the extent of quenching, indicating that the entire accessible NBD label was 
quenched by 1 M dithionite (data not shown). These results show that the use of 
dithionite allows efficient measurement of the fraction of internalized peptide inside 
the cells. To exclude the possibility that the fluorescence signal could have been due 
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to the internalization of the fluorochrome itself, the NBD moiety was used in the same 
in vitro assay conditions, and no cellular fluorescence was observed at 
concentrations up to 20 µM (data not shown).To measure the kinetics of import of 
gH625-NBD into cells, we incubated the peptide with cells at 37°C for various times 
(10, 30, and 60 minutes) and then determined the remaining fluorescence following 
treatment with dithionite. Figure 1E shows the fraction of peptide taken up by cells. 
The uptake is very rapid and seems to reach a plateau after 1 hour of incubation. The 
influence of temperature on the intracellular accumulation was studied to see whether 
the uptake depended on a translocation mechanism or a cellular process. We 
incubated the peptide with HeLa cells at both 37°C and 4°C; the amount of 
internalized gH625-NBD at low temperature (Figure 1F) is reduced for both peptides, 
with an increase in the quantity bound to the membrane and a substantial decrease 
of the quantity of internalized peptide. The reduction of internalized or bound peptide 
was more significant for Tat peptide. 
 
3.1.4 NBD-peptides intracellular delivery by confocal microscopy 
To confirm the peptide internalization, we examined its uptake and intracellular 
localization by confocal microscopy. We used concentrations of 1 and 10 µM and a 
time of 60 minutes as selected by the flow cytometry experiments. Both peptides are 
efficiently internalized and we observe a significant colocalization with the 
LysoTracker, indicating a partial confinement within the endosomal compartments 
(Figure 2).  
 
 
 
Figure 2. Fluorescence images of NBD-peptides, at 1 and 10 µM. Panel A shows the peptide in green; Panel B 
shows the LysoTracker in red and Panel C shows the merge of the two images. Bar = 10 µm. 
 
Recently, it has been reported that cell-fixation protocols induce the apparent 
translocation and nuclear localization of positively charged peptides and this has 
been previously proved for the Tat peptide. We have examined the possibility that the 
translocation observed for gH625 could be the result of such an effect. As shown in 
Figure 3, although the penetration of the Tat-NBD in living cells is lower than with 
fixed cells, indicating that a portion of surface-bound peptide diffuses into the 
cytoplasm during the fixation step, the penetration of gH625-NBD is not affected by 
fixing protocols. The NBD alone at a concentration of 10 µM is almost unable to 
penetrate inside cells (Figure 3). 
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Figure 3. Uptake kinetics of NBD-peptides (10 µM) in HeLa cells after 1, 5 and 17 h of incubation at 37°C. Bar = 
50 µm. 
 
3.1.5 Inhibition of active intracellular internalization of NBD-peptides 
The influence of metabolic inhibitors on the intracellular penetration of NBD-peptides 
was studied to see whether the uptake depended on a translocation mechanism or a 
cellular process. The analysis of the results indicates that the endocytosis is more 
significant for Tat than for gH625. Sodium azide is an oxidative phosphorylation 
inhibitor commonly used to abolish ATP production within the cell membrane.  
 
 
 
Figure 4. Endocytosis inhibition experiments of HeLa cells incubated for 1 h with 10 µM NBD peptides. (A) Non 
treated cells and (B) 40 µM NaN3 treated cells; bar = 50 µm. 
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As shown in Figure 4A, B, a marked decrease of Tat internalization was observed 
when conjugated to NBD indicating that endocytosis is the main process involved in 
Tat penetration. On the contrary, gH625 penetration is not influenced significantly by 
the treatment with sodium azide, indicating that endocytosis does not affect gH625 
transduction. 
 
3.1.6 gH625 and TAT toxicity 
The cell viability was measured using MTT and LDH assays. LDH is of great value as 
an in vitro marker for cellular toxicity. Figure 5A shows the results obtained with the 
MTT assay, and Figure 5B shows the results of the LDH assay. To evaluate the cell 
toxicity of both gH625 and Tat peptides, increasing doses of the peptides were 
applied to HeLa cells. The addition of Tat or gH625 did not affect HeLa cell viability 
up to 200 µM. A low level of toxicity was observed when the peptides' concentration 
reached 400 µM. In the conditions used, different sensitivity was observed for the 2 
assays, with the MTT assay being slightly more sensitive in detecting cytotoxic 
events in comparison with the LDH leakage assay. In conclusion, both peptides were 
not toxic at concentrations lower than 400 µM, and at this concentration, Tat was 
slightly more toxic than gH625. 
 
 
 
 
Figure 5. Effect of peptides on the viability of HeLa cells. Cytotoxic effect of gH625 and Tat peptides determined 
by the MTT (panel A) assay and by measuring the efflux of lactate dehydrogenase (LDH) into the culture medium 
(panel B). HeLa cells were treated with the indicated concentrations of peptides for 24 h. The values shown are 
the percentages of viable cells and LDH release relative to control cells. 
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3.2 gH625 FUNCTIONALIZED QUANTUM DOTS (QDS) 
3.2.1 gH625 synthesis and functionalization of QDs  
The gH625 peptide sequence was synthesized with an acetyl protecting group at the 
N terminus by solid-phase methods according to standard SPPS protocols with 
Fmoc/tBu chemistry (Ac-HGLASTLTRWAHYNALIRAF-COOH). The purified peptide 
was obtained with good yields (30-40%). Functionalization of QDs was performed in 
PBS buffer and the functionalization degree was confirmed by determining the 
amount of peptide attached by UV analysis (εgH625 = 7000 M-1 cm-1 at λ = 280 nm) 
and corresponded at 100%.  
 
3.2.2 QDs-peptides intracellular delivery by confocal microscopy 
To confirm the QDs-gH625 internalization, we examined its uptake and intracellular 
localization by confocal microscopy using QDs-Tat as reference. We used 
concentrations of 5 and 50 nM and a time of 60 minutes as selected by the flow 
cytometry experiments. Both QDs-peptides are efficiently internalized and we 
observe a significant colocalization with the LysoTracker, indicating a partial 
confinement within the endosomal compartment (Figure 6). 
 
 
 
Figure 6. Fluorescence images of QD-peptides at 5 and 50 nM Panel A shows the peptide in green; Panel B 
shows the LysoTracker in red and Panel C shows the merge of the two images. Bar = 10 µm. 
 
Intracellular uptake experiments on living cells were performed in order to avoid not 
real results due to the use of cell-fixation protocols, as previously described for NBD-
peptides. Delivery of QDs to living cells consists of 2 phases: QDs are initially bound 
to plasma membrane of cells, and then are gradually internalized by cells. QDs alone 
have a poor affinity for the plasma membrane of HeLa cells at the concentration of 50 
nM (Figure 7). The peptide conjugation to QDs enhanced their membrane bound 
ability providing a favorable condition for the cellular internalization. Figure 7 clearly 
shows their intracellular distribution in HeLa cells at concentrations of 5 and 50 nM. 
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Figure 7. Uptake kinetics of QD-peptides (50 nM) in HeLa cells after 1, 5 and 17 h of incubation at 37°C. Bar = 50 
µm. 
3.2.3 Inhibition of active intracellular internalization of QDs-peptides 
The influence of metabolic inhibitors on the intracellular penetration of QDs-peptides 
was studied to see whether the uptake depended on a translocation mechanism or a 
cellular process. The analysis of the results indicates that the endocytosis is more 
significant for Tat than for gH625.  
 
 
 
Figure 8. Endocytosis inhibition experiments of HeLa cells incubated for 1 h with 50 nM QD peptides. (A) Non 
treated cells and (B) 40 µM NaN3 treated cells; bar = 50 µm. Panel C reports the fluorescence images of gH625 
QD and TAT QD at 100 nM incubated with HeLa cells at 4°C; bar = 10 µm. 
 
As shown in Figure 8 A, B, a marked decrease of QDs-Tat internalization was 
observed indicating that endocytosis is the main process involved in Tat penetration. 
56	  	  
On the contrary, QDs-gH625 penetration is not influenced significantly by the 
treatment with sodium azide, indicating that endocytosis does not affect gH625 
membrane crossing. 
 
3.3 gH625 FUNCTIONALIZED LIPOSOMES 
3.3.1 Peptides synthesis and functionalization of liposomes 
The coupling of a bioactive ligand on the surface of liposomes can be obtained 
according to several synthetic approaches. The choice of the strategy depends on 
whether it is necessary to perform the coupling before or after the liposome 
assembly. The coupling before the assembly of liposomes is, in principle, chemically 
less complicate, but has the disadvantage that a fraction of the ligand remains 
entrapped in the liposome inner region and is not available to play its biological 
function. This strategy is the preferred choice for amphiphilic peptides, anyway it 
remains unsuitable for poorly hydrophilic or mainly hydrophobic peptides. In these 
cases the coupling of the ligand can be performed after the assembly of the 
liposomes using activated functional groups introduced onto the external side of 
unilamellar liposomes. Activated functional groups must be compatible with liposome 
preparation and they should remain available on the surface for an efficient chemical 
ligation of the ligand. 
gH625 is a hydrophobic peptide (see in Table 1 the amino acid sequence of gH625 
peptide and of the gH625 derivatives used in this study) with high tendency to locate 
in the hydrophobic portion of liposomes; thus, for the preparation of liposomes 
decorated by gH625 a post-aggregation pathway based on click chemistry methods 
was chosen. 
  
PEPTIDES SEQUENCES M.W 
gH625 NH2-HGLASTLTRWAHYNALIRAF-CONH2 2297.1 
gH625-Pra NH2-HGLASTLTRWAHYNALIRAF-Pra-CONH2 2391.3 
A643K(TOAC)-gH625-Pra NH2-HGLASTLTRWAHYNALIRK(TOAC)F-Pra-CONH2 2644.6 
A639K(TOAC)-gH625-Pra NH2-HGLASTLTRWAHYNK(TOAC)LIRAF-Pra-CONH2 2644.6 
A635K(TOAC)-gH625-Pra NH2-HGLASTLTRWK(TOAC)HYNALIRAF-Pra-CONH2 2644.6 
A628K(TOAC)-gH625-Pra NH2-HGLK(TOAC)STLTRWAHYNALIRAF-Pra-CONH2 2644.6 
NBD-gH625-Pra NBD-HGLASTLTRWAHYNALIRAF-Pra-CONH2 2537.9 
NBD-Pra NBD-Pra-CONH2  258.9 
 
Table 1. Peptide sequences and their molecular weight. 
 
This procedure involves a copper(I)-catalyzed Huisgen 1,3-dipolar cyclo-addition 
reaction of azides and alkynes yielding 1,4-disubstituted1,2,3-triazole linked 
conjugates. The unreactive nature of both azides and alkynes towards any other 
functional group present in the biomolecules, as well as the thermal and hydrolytical 
stability of their cycloaddition product make this reaction particularly appealing for 
liposome functionalization with peptides. 
Click-reaction was performed between DOPG/(C18)2L-N3 liposomes (90/10 molar 
ratio), obtained according to classical procedures for the preparation of mixed 
liposomes, and the peptide gH625 bearing a propargylglycine moiety (gH625-Pra). 
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The click- reaction, performed in an aqueous solvent system, was catalyzed by Cu(I) 
generated, in situ, by reduction of CuSO4 with ascorbic acid (Figure 9C). 
 
Figure 9. (A) Schematic representation of (C18)2L-N3 synthetic monomer; (B) Scheme for the solid-phase 
synthesis of the (C18)2L-N3 monomer. Rink-amide Resin is schematically represented as an empty circle; (C) 
Coupling of the gH625-Pra peptide to azide functionalized liposomes by click-chemistry reaction. 
 
The click chemistry reactants gH625-Pra peptide and the liposome component 
(C18)2L-N3 were synthesized by solid-phase methods according to standard SPPS 
protocols with Fmoc/tBu chemistry. In the case of gH625-Pra peptide (see Table 1), 
the alkyne moiety was introduced in the peptide sequence in the C-terminal position 
as L- propargylglycine (Pra). (C18)2L-N3 (Figure 9A) was synthetized on solid phase 
following a modified protocol of the classical Fmoc/tBu strategy, as indicated in 
Figure 9B. The Fmoc-Lys(Mtt)-OH was anchored to the Rink amide resin. After 
removing of the Fmoc protecting group, an ethoxylic linker was introduced, and its 
NH2 function was converted in azide by diazo transfer using a sulfonyl azide, as 
previously reported in the literature. After removal of the Mtt group from the Nε  lysine 
amino function, the lipid chains were added. As expected, no reductive side reaction 
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of azide functionalized derivative was observed during the cleavage step of the lysine 
derivative from the resin (data not shown)148. Both gH625-Pra and (C18)2L-N3 were 
collected in good yields (20÷40% and 85%, respectively) after HPLC-RP purification, 
and analyzed by mass spectrometry (Maldi-Tof), 1H and 13C-NMR (for (C18)2L-N3) 
and HPLC to confirm compound identity and purity. 
In order to determine the number of functional groups present on the external surface 
of the liposomes and the number of molecules of gH625 that were effectively linked 
to the liposome NBD-labeled Pra and NBD-labeled gH625-Pra fluorescent derivatives 
were used. NBD fluorescence emission at 530 nm was measured, after click 
reaction, on both the liposome and the NBD-Pra containing fractions, and the 
percentage of functionalization was calculated as the ratio of bound NBD-Pra to its 
total amount. The results confirm that about 50% of the total of azido functions is 
located on the external leaflet of the liposome. When starting with an equimolar 
mixture of NBD-gH625-Pra and azido functions on the liposome surface, the 
expected gH625 functionalized liposomes were obtained with a yield higher than 90% 
after 12h at room temperature. In the absence of copper catalyst no reaction was 
observed.  
gH625-Pra analogues, labeled with the TOAC radical group through a site- directed 
spin-labeling approach, were synthesized for EPR studies. Since the spin label is 
relatively hydrophobic154, it was introduced in the peptide sequence at the Ala 
positions. Being the four Ala almost equally spaced along the peptide sequence (in 
position 628, 635, 639 and 643, the numbering being that of the entire gH protein), 
we obtained four labeled peptides (A628K(TOAC)-gH625-Pra, A635K(TOAC)-gH625-
Pra, A639K(TOAC)-gH625-Pra and A643K(TOAC)-
gH625-Pra) bearing the reporter moiety in positions 
regularly distributed from the N- to the C-termini. For the 
synthesis of the four TOAC labeled peptide derivatives, 
the four alanine residues were replaced one by one by 
Lys(Mtt). After removal of the Mtt moiety from the side 
chain of the lysine, the coupling of the TOAC residue 
was performed using HATU as activating agent 155. The 
TOAC containing Pra-peptides have been purified by 
HPLC using standard TFA-containing eluents and 
gradients; treatment of the peptide in aqueous ammonia 
(pH 9.0) for 6h at room temperature is required in order 
to restore the chemical integrity of the nitroxide moiety 
after HPLC elution. Liposomes derivatized with TOAC 
containing Pra-peptides were obtained by using click 
chemistry procedures, as above reported in the case of 
gH625-Pra peptide derivative. 
 
3.3.2 Dynamic Light Scattering (DLS) of liposome- 
peptides.  
DLS measurements were performed at q =90° on 
liposomes composed of DOPG/(C18)2L-N3 at 90/10 
molar ratio and on liposomes functionalized with gH625 
as well as liposomes functionalized with TOAC peptide 
derivatives. Inspection of Figure 2 shows that all 
liposome solutions present a monomodal distribution due 
Figure 10. DLS spectra at 25°C with 
a liposome concentration of 1·10-4 
M. (A) DOPG/(C18)2L-N3 (90/10 
molar ratio) liposomes; (B) 
DOPG/(C18)2L-gH625 liposomes 
obtained after click reaction; (C) 
DOPG/(C18)2L-A635K(TOAC)-gH625 
. 
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to a translational diffusion process, which could be attributed to liposome aggregates. 
The Stokes-Einstein equation (1) RH =
KBT
6πηD0
 is used to evaluate the hydrodynamic 
radius, RH, at infinite dilution where D0 is the translational diffusion coefficient at 
infinite dilution, KB is the Boltzmann constant, T is the absolute temperature, and η is 
the solvent viscosity. Due to the high solution dilution (C = 1·10-4 M) of the studied 
systems, we have approximately D ~ D0, and equation (2) can be reasonably used to 
estimate the hydrodynamic radius of the aggregates. Diffusion coefficients, together 
with hydrodynamic radius values obtained through Eq. (2) (see experimental section), 
are reported in Table 2. The hydrodynamic radius of DOPG/(C18)2L-N3 liposome 
(90/10 molar ratio) is 69.43 ± 23.36 nm. As expected the introduction of a small 
amount of (C18)2L-N3 synthetic monomer does not influence the size of DOPG 
liposomes156. Figure 2B and 2C display the structural evolution of liposomes obtained 
after click reaction of gH625-Pra and four TOAC labeled Pra-peptides. In all cases 
liposome decorated by peptides show an increase of about 30% in diameter (see 
Table 2). From a structural point of view, this increase in size is in good agreement 
with the other targeted liposomal systems reported in literature157,158 moreover, the 
TOAC moieties do not cause additional significant structural variations in the size of 
the aggregates. 
 
 
Systems D*10-12/m2s-1 RH /nm 
DOPG/(C18)2L-N3 2.9 ± 0.7 69.43 ± 23.36 
DOPG/(C18)2L-gH625 2.2 ± 0.3 90.38 ± 13.50 
DOPG/(C18)2L-A643K(TOAC)-gH625 2.1 ± 0.5 95.40 ± 23.80 
DOPG/(C18)2L-A639K(TOAC)-gH625 2.1 ± 0.5 92.32 ± 25.22 
DOPG/(C18)2L-A635K(TOAC)-gH625 2.0 ± 0.5 97.60 ± 25.01 
DOPG/(C18)2L-A628K(TOAC)-gH625 2.2 ± 0.5 91.32 ± 24.45 
 
Table 2. Diffusion coefficients and hydrodynamic radius RH obtained from Dynamic Light Scattering 
measurements for the studied systems.  
 
3.3.3  Circular Dichroism of gH625 and analogues with TOAC 
The secondary structures of gH625 and of all the analogues with Lys(TOAC) in 
substitution of alanine residues were determined by CD spectroscopy (Figure 11). As 
gH625 assumes a random conformation in aqueous buffer while it assumes a α-
helical  structure in membrane mimetic environments. gH625 and the Lys(TOAC) 
derivatives, in water solution containing 20% TFE, show a helical structure with a 
slightly increase in ellipticity for the peptides where the modification are localized in 
the center of the peptide, as clearly evident from the spectra of the gH625 native 
peptide and of the Lys(TOAC) peptide derivatives. These data clearly show that the 
introduction of the TOAC moiety does not modify the gH625 peptide conformation, 
and Lys(TOAC) gH625 derivatives could be used in EPR studies to define peptide 
positioning. 
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Figure 11. Circular dichroism spectra of gH625 peptides and of analogues with Lys(TOAC) in substitution of 
alanine residues, obtained in HEPES buffer at 20% TFE. 
 
3.3.4 Determination of the position of gH625 on liposomes by EPR 
spectroscopy. 
The peptide positioning relative to the liposome surface was investigated by EPR 
spectroscopy. To this aim gH625-Pra analogues, labeled with the TOAC radical 
group through a site- directed spin-labeling approach, were used. The EPR spectra 
of the free labeled peptides dissolved in 10 mM HEPES buffer consist of three narrow 
lines (see Figure 12A for an example), typical of an unstructured peptide with few 
constraints on the motion of the reporter group and consistent with the observed 
random coil CD spectrum. Subsequently, the labeled peptides were chemically linked 
to the DOPG/(C18)2L-N3 liposomes by following the same procedure used for the 
parent unlabeled peptide, obtaining four suspensions of functionalized liposomes. 
The analysis of their EPR spectra, reported in Figure 4A, gives information on the 
positioning of the gH625 relative to the surface of the liposome to which it is linked. In 
all cases a clearly defined axially anisotropic line shape is observed, indicating that 
the reporter group, wherever positioned along the peptide sequence, assumes a well 
defined orientation relative to the bilayer. This behavior indicates that the peptide 
does not protrude in the aqueous medium surrounding the liposome, in which the 
label would have assumed a much higher mobility freedom, but rather interacts with 
the surface of the lipid bilayer. Analysis of the figure shows that the spectrum 
anisotropy increases in going from A628K(TOAK)-gH625 to A643K(TOAC)-gH625, 
indicating that the peptide segments closer to the C-terminus, which is chemically 
linked to the lipid, are more strictly oriented relative to the bilayer. This evidence can 
be easily quantified by measuring the outer hyperfine splitting, 2Amax, which is a 
reliable and easy to perform estimate of the segmental chain mobility. 2Amax is 
defined as separation, expressed in gauss, between the low-field maximum and the 
high-field-minimum of the spectrum, and tends to increase with increasing the 
restriction in the label mobility. Figure 12B shows that, as the label position is moved 
from position 628 to 643, 2Amax increases. This evidence suggests that the peptide 
does not insert in the bilayer hydrophobic core, but rather remains adsorbed on its 
surface remaining exposed to aqueous environment. This result confirms the 
possibility of using our synthetic strategy to bind a hydrophobic peptide on the 
liposome external surface; the use of a short linker may also provide steric 
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restrictions for the peptide insertion inside the liposome. 
 
 
 
 
Figure 12. (A) EPR spectra of TOAC peptides linked to DOPG/(C18)2L-N3 liposomes. An EPR spectrum of the 
free peptide A639K(TOAC)-gH625-Pra in aqueous buffer is also shown. (B) Dependence on spin-label position 
along the peptide sequence of the outer hyperfine splitting, 2Amax, of TOAC peptides linked DOPG/(C18)2L-N3 
liposomes. 
 
3.3.5 Liposomes Doxorubicin loading. 
Cytotoxic doxorubicin was loaded into DOPG/(C18)2L-N3 liposomes using the well-
assessed procedures based on ammonium sulfate gradient159	   160 in particular, 
doxorubicin solution was incubated under stirring for 30 min at 60°C. Subsequently, 
unloaded doxorubicin was removed by Sephadex G50 column pre-equilibrated with 
10 mM HEPES buffer at pH 7.4. The drug/lipid weight ratio chosen for the loading 
experiments was 0.1. 
The doxorubicin loading content (DLC) was calculated by UV-Vis measurements at 
480 nm and was above 95% of the total. The resulting Dox-loaded liposomes were 
then efficiently modified with gH625-Pra peptide according the click chemistry 
procedure used in the case of empty liposomes. 
 
3.3.6 Liposome- gH625 cellular uptake by confocal microscopy.  
To study the cellular internalization of doxorubicin loaded liposomes functionalized 
with gH625 peptide, we examined their uptake and intracellular localization in living 
HeLa cells by confocal microscopy. Cells were incubated with 1 µM of Dox free and 
encapsulated in liposomes for 1, 5, 17 hours at 37 °C. The results obtained after 5 
hours of incubation are reported in Figure 5. As expected, after 5 hours free Dox is 
able to enter the cell and translocate into the nucleus as indicated by the green 
fluorescence in the center of the cell body (Figure 13 A-C). Also in the case of 
DOPG/(C18)2L-N3/Dox liposomes, cell nuclei appear fluorescent due to Dox 
accumulation in DNA and a slight diffuse fluorescence in the cytoplasm is observed 
suggesting a Dox release from the liposomes (Figure 13 D-F). Conversely, gH625 
functionalized liposomes encapsulating Dox accumulate in the cytoplasm, without 
entering into the nucleus (Figure 13 G-I). Indeed, cell nuclei are dark and only green 
fluorescent spots, distributed in the cytoplasm, are visible. These results suggest that 
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the functionalization of liposomes with gH625 peptide could affect uptake mechanism 
of liposomes and, thus, their intracellular distribution and Dox release. This evidence 
could be useful in the design of carriers for a controlled delivery and release of Dox in 
order to avoid side effects associated to Dox itself. 
 
 
 
Figure 13. Confocal microscopy images of HeLa cells after 5 h incubation with 1µM of A, D, G fluorescence 
images of Dox accumulation within the cells; B, E, H transmission line indicates the cell boundaries. Bar 20 µm. 
 
3.4 FUNCTIONALIZED DENDRIMERS  
3.4.1 Synthesis of the octadecaazide dendrimer 
The second generation Newkome-style dendron 2 was first functionalized at the 
amine terminus with succinic anhydride to afford the hemisuccinate dendron 3. 
Coupling dendrons 2 and 3 by using 2-[7-aza-1H-benzotriazol-1-yl]-1,1,3,3-
tetramethyluronium hexafluorophosphate (HATU) as coupling agent afforded the 
symmetrical dendrimer 4. Acidic deprotection of the terminal tert-butyl esters resulted 
in the formation of the octadecaacid dendrimer 5. Reaction between the terminal 
carboxylic acid groups and an azido-terminated amine linker afforded the 
octadecaazide dendrimer 6 (Scheme 1). 
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Scheme 1. Synthesis of the azide-terminated dendrimer used in this study. 
 
3.4.2 gH625 synthesis and functionalization of the dendrimers 
The gH625 peptide sequence was synthesized with a propargylglycine residue (Pra) 
at the C terminus to provide a handle for the CuAAC reaction. Functionalization of 6 
was performed in a water/ methanol solution (1:1 v/v) by using CuSO4·5H2O as 
catalyst and sodium ascorbate as reducing agent (Scheme 2). The complete 
functionalization of peptidodendrimer 1 was confirmed by determining the amount of 
peptide attached by UV analysis (εgH625 = 7000 M-1 cm-1 at λ = 280 nm88 and 
comparing this to the amount of dendrimer initially used for reaction (18 mol peptide 
per mol dendrimer). IR analysis showed the disappearance of the azide stretch at 
2098 cm-1 confirming that within the instrumental error range, all azides were 
consumed, thus suggesting complete functionalization of the dendrimer with peptides 
was obtained. The functionalization was also performed by using the same peptide 
containing a nitrobenzo-furazan fluorescent tag (1–NBD) and an alkynyl 
fluorophore41,161. All sequences used for functionalization are shown in Table 3. 
Functionalization of dendrimer 7 was also confirmed by UV/Vis spectroscopy (εNBD = 
1696 M-1 cm-1 at λ = 452 nm ).  
 
Name Sequence[a] Compound 
gH625 NH2-HGLASTLTRWAHYNALIRAFX-CONH2 1 
gH625-NBD NBD-HGLASTLTRWAHYNALIRAFX-CONH2 1-NBD 
NBD-CCH NBD-CH2C≡CH 7 
 
Table 3. Sequences used to functionalize dendrimer X = propargylglycine, NBD = (7-nitrobenzofurazanyl)amino) 
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Scheme 2. Functionalization of dendrimer 6 by CuAAC reaction. Shown is the functionalization with gH625 to 
synthesize 1. 
 
3.4.3 Structure of the peptidodendrimer 
As previously reported88, the gH625 peptide adopts a random coil in aqueous media, 
but forms a helix in membrane-mimetic environments. Circular dichroism (CD) 
spectra in several percentages of trifluoroethanol (TFE, allowing the solution to mimic 
the environment of the membrane) show that gH625 at a concentration of 8µM 
adopts a a-helix (Figure 14A). The CD spectra of the peptidodendrimer at a peptide 
concentration of 8 mM (18 peptides per dendrimer; concentration of 
dendrimer=0.4 mM) exhibited a shape indicative of a α-helix, suggesting that the 
secondary structure of the peptide was not disturbed by attachment to a dendrimer 
(Figure 14 B). 
 
 
Figure 14. CD spectra of: A) peptide gH625, and B) peptidodendrimer 1 at 8 µM (8 µM peptide corresponds to a 
dendrimer concentration of 0.4 µM) in aqueous solution with varying amounts of TFE: 0% (c), 20% (g), 40% (a). 
 
The size of peptidodendrimer 1 increased greatly upon the addition of the peptide 
sequences. Dendrimer 6 is too small to be accurately resolved by most techniques, 
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but the increase in size after the addition of the peptides makes it resolvable by light 
scattering and non-optical microscopy techniques. Dynamic light scattering (DLS) 
measurements were complicated by significant aggregation, most likely due to the 
dendrimers relatively hydrophobic terminal peptides in aqueous solution. At low 
concentrations, a signal was observed corresponding to a hydrodynamic radius of 
5.6nm. This was confirmed by scanning transmission electron microscopy (STEM), 
which gave an average particle diameter of 12.66nm. 
 
3.4.4 Fusogenic properties of the peptidodendrimer  
In order to understand the membrane interacting behavior of the peptide when linked 
to the dendrimer, we performed lipid mixing, inner-monolayer fusion, and leakage 
experiments as indicators of the interaction and perturbation of the lipid membrane 
caused by the peptidodendrimer (Figure 15). 
We carried out lipid-mixing experiments (Figure 15 A); for these studies, a population 
of 55:45 phosphatidylcholine/cholesterol with nitrobenzoxadiazole and (PC/Chol) 
LUVs labeled rhodamine-phosphatidylethanolamine (NBD-PE and Rho-PE) was 
mixed with a population of unlabeled LUVs, and increasing amounts of gH625, 
dendrimer 6, or peptidodendrimer 1 were added. Dilution of the fluorescently labeled 
vesicles by membrane fusion induced a reduction in the fluorescence energy transfer 
efficiency, hence dequenching of the donor fluorescence. In order to compare data, 
the percentage of lipid mixing as a function of the peptide to lipid molar ratio was 
calculated. The peptide and dendrimer 6 induced low levels of fusion at the 
concentration at which peptidodendrimer 1 induced high levels of fusion. In particular, 
we observed a significant increase of activity with the peptidodendrimer system. This 
shows that the peptidodendrimer is even more effective than the native peptide at 
interacting with and fusing lipid membranes, showing its efficacy as a membrane-
perturbing agent. 
In the inner-monolayer fusion assay, the fluorescence from the vesicle membranes 
outer monolayer is eliminated by the addition of an aqueous reducing agent, and this 
experiment reveals the extent of lipid mixing between the inner monolayers of 
vesicles in solution. Figure 15 B shows that gH625, dendrimer, and peptidodendrimer 
show only slightly lower inner-monolayer fusion than the total fusion observed from 
the lipid- mixing experiment. This indicates that under these experimental conditions, 
all three compounds were able to induce fusion significantly to both the inner and 
outer lipid monolayers; thus, we can confirm that the peptide, dendrimer, and 
peptidodendrimer are all able to interact strongly with and penetrate inside the lipid 
bilayer.  
A contents-mixing assay was employed to monitor any mixing of internal vesicle 
components as a result of vesicle exposure to the peptide or the peptidodendrimer 1. 
Release of ANTS (1-aminonaphthalene-3,6,8-trisulfonate) and DPX (p-xylene-
bispyridinium bromide) from the vesicle is commonly used as a measure of bilayer 
perturbation and is interpreted as “transient pore formation”162,163. Contents-mixing is 
manifested by a decrease in fluorescence intensity if vesicles encapsulating the 
fluorescent cargo (e.g., ANTS) merge contents with those containing quenchers (e.g., 
DPX). No content-mixing occurs under the same conditions and peptide/lipid ratio 
range at which substantial outer monolayer lipid-mixing was observed (data not 
shown); this corroborates the presence of vesicle hemifusion within our system not 
only for the peptide alone but also for the peptide–dendrimer system. 
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The present results can be used as qualitative indicators of the peptidodendrimer 
translocation or bilayer perturbation, with relevance for the direct penetration mode of 
cell entry, or for the steps of endosomal membrane translocation or endosomal 
escape. Using peptidodendrimer 1, we have not detected any significant pore 
formation; vesicle fusion events were not accompanied by leakage of the aqueous 
contents of the vesicle as was previously reported for gH625 and for other 
peptides59,153. 
 
 
 
Figure 15. Interaction of peptide gH625 (filled squares), dendrimers  (open circles), and peptidodendrimer 1 (filled 
circles) with PC/Chol LUVs; the dose dependence is reported according to the concentration of the peptides (18 
peptides per dendrimer) and each trace represents an average of three independent experiments. A) Lipid-mixing, 
B) inner- monolayer assays. 
 
3.4.5 Peptidodendrimer uptake by Flow cytometry 
We have determined the fraction of the labeled peptide gH625–NBD and labeled 
peptidodendrimer 1–NBD taken up by HeLa cells using flow cytometry based on a 
method previously described.   
We incubated the peptide and the peptidodendrimer with HeLa cells at 37°C at 
different concentrations (1, 5, 10, and 20 µM in peptide). After 1 h incubation, we 
measured the quenching of the NBD by dithionite treatment. The dithionite reaction 
was performed at low temperature (4°C) because the dithionite crossing of biological 
membranes is strongly reduced compared to high temperatures 164. Before the 
addition of dithionite, we observed that approximately 90% of peptide gH625–NBD or 
1–NBD was not washed away, suggesting they were internalized or bound to the 
membrane bilayer. After the addition of dithionite, the fluorescence of the internalized 
peptide and 1–NBD were slightly reduced (Figure 16A).  Increasing the dithionite 
concentration did not result in a modification of the extent of quenching, indicating 
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that the entire accessible NBD label was quenched by 1M dithionite (data not 
shown). To exclude the possibility that the fluorescence signal could have been due 
to the internalization of the fluorochrome itself, the NBD moiety was used in the same 
in vitro assay conditions; no cellular fluorescence was observed at concentrations up 
to 20 µM. 
To measure the kinetics of import into cells, we incubated gH625–NBD and 1–NBD 
with cells at 37°C for 10, 30, and 60 min, and then determined the remaining 
fluorescence following treatment with dithionite. Figure 16B shows the fraction of 
molecules taken up by cells. The uptake is very rapid and seems to reach a plateau 
after 1 h incubation. 
 
 
 
Figure 16. Percentage uptake graphs of peptidodendrimer 1–NBD versus gH625–NBD in HeLa cells under 
various conditions: A) 1 h incubation with various concentrations of peptide; B) incubation at 10 µM (in peptide) for 
various times; C) incubation at 10 µM (in peptide) for 15 min at various temperatures: 37°C (black bar); 4°C ( grey 
bar). 
 
The influence of temperature on the intracellular accumulation was studied to 
investigate whether the uptake depended on a passive translocation mechanism or 
an active process. We incubated gH625–NBD and 1–NBD with HeLa cells at both 
37°C and 4°C; the amounts of internalized peptide and 1 at low temperature (Figure 
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16C) are reduced for both molecules with an increase in the amount bound to the 
membrane and a decrease of the internalized quantity. The reduction of internalized 
or bound molecule was less significant for 1, indicating a minor involvement of active 
mechanisms of internalization. 
 
3.4.6 Peptidodendrimer intracellular delivery by confocal microscopy 
The cellular uptake ability of 1 was explored by incubating an aqueous solution of 1 
with live cells (Figure 17). HeLa cells were incubated for 2 h with a 20 µM solution of 
the fluorescently labeled 1–NBD (concentration relative to peptides; concentration of 
dendrimer=1.1µM). After incubation, excess fluorophore was washed away and the 
cells were imaged. The cells exhibited fluorescence even after being washed, 
suggesting that the NBD-labeled dendrimer was interacting with the cellular 
membranes. Control experiments against dendrimer 7, containing the fluorophore but 
no peptide, showed extremely little fluorescence in the cells, suggesting the peptides 
were required for efficient membrane interaction. 
 
 
 
Figure 17. Fluorescence microscopy images from the cellular uptake study. A)–C) Incubation at 37°C with 
peptidodendrimer 1 (20 µM) for 2 h; D)– F) incubation at 37°C with dendrimer 7 (20 µM) for 2 h; G)–I) incubation 
at 4°C with peptidodendrimer 1 (20 µM) for 15 min; J)–L) same as (A– C), but after preincubating the cells with 
NaN3 (40 µM) for 30 min. A), D), G), J) Transmission images; B), E), H), K) fluorescence images; C), F), I), L) 
overlay; scale bars: 20 µM. 
 
In order to explore the mechanism of interaction, the cellular uptake studies were 
69	  	  
also performed under conditions that inhibit active translocation mechanisms. First, 
incubation was carried out with the 20 µΜ (in peptide) peptidodendrimer solution for 
15 min at 4°C. At 4°C, the cells are almost unable to take up the dendrimers 
endocytically. The fluorescence intensity of the cells was decreased but still 
observed, suggesting that the compound is able to enter into cells without undergoing 
an active translocation mechanism (Figure 17G). The cells were also incubated with 
1 after preincubating with sodium azide (40 mm), which is a known inhibitor of 
oxidative phosphorylation165. After this preincubating, the cells were unable to 
produce ATP in the membrane and to perform endocytosis. Again, the cells were 
able to fluoresce after this preincubating, suggesting that 1 can enter the cells 
through a non-active mechanism (Figure 17 J). 
We also incubated the cells with the 20 µΜ (in peptide) solution of 1–NBD for 
different lengths of time to observe the uptake kinetics. As we showed with the flow 
cytometry measurements, the cells exhibited fluorescence as early as 30 min after 
addition, showing the rapid uptake of the peptidodendrimer (Figure 18). 
 
 
 
Figure 18. Fluorescence microscopy images from the cellular uptake kinetic study, incubating with dendrimer 1–
NBD (20 µM) at 37°C for various times : A)–C) 30 min ; D)–F) 1 h ; G)–I) 2 h ; A), D), G) transmission images ; B), 
E), H) fluorescence images ; C), F), I) overlay ; scale bars : 20 µm. 
 
3.4.7 Peptidodendrimer toxicity  
To confirm that dendrimer and gH625 functionalized dendrimer do not exert toxic 
effects on cells, monolayers of Vero cells were exposed to different concentrations 
(0.28, 0.55, 1.1, 2.8, 5.5 µM) of each compound for 3 and 24 hours, and cell viability 
was quantified by the MTT assay. No statistical difference was observed between the 
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viability of control (untreated) cells and that of cells exposed to the peptidodendrimer 
(Figure 19) up to the concentration used in antiviral testing. Minimal toxicity was 
observed for the dendrimer without the peptides linked to its termini, but only at 
concentrations that were considerably higher than those required for antiviral activity. 
 
 
 
Figure 19. Cell viability measured by the MTT assay for 3 and 24 hours for the dendrimer (1) and peptidodendrimer 
(2). 
 
3.5 gH625 FUNCTIONALIZED NANOPARTICLES (NPS) 
3.5.1 gH625 synthesis and functionalization of Nanoparticles 
The gH625 peptide sequence was synthesized with an acetyl protecting group at the 
N terminus and with 3 glycines at the C terminus in order to increase the space 
between the peptides and the nanoparticle (Ac-HGLASTLTRWAHYNALIRAFGGG-
COOH). The peptide synthesis was performed using solid-phase methods according 
to standard SPPS protocols with Fmoc/tBu chemistry. The purified peptide was 
obtained with good yields (30-40%). Functionalization of NPs was conducted in Mes 
buffer. Peptide-nanoparticles were prepared at several functionalization degrees (25-
35 and 50 %), confirmed by determining the amount of peptide attached by UV 
analysis (εgH625 = 7000 M-1 cm-1 at λ = 280 nm). 
 
3.5.2 Circular Dichroism of gH625-Nanoparticles 
To verify the secondary structure of the peptide bound to the nanoparticles we 
performed circular dichroism (CD) experiments. CD data confirmed that gH625 
retains its structure (helical) when bound to the nanoparticle surface as previously 
reported also for other peptides166. The spectra obtained at different percentages of 
functionalization indicate a helical structure in all conditions (Figure 20A, B). 
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Figure 20. Circular dichroism spectra of polystyrene NPs at 25% (a) and 50% (b) degrees of functionalization with 
gH625 peptide. 
 
3.5.3 Dynamic Light Scattering (DLS) and zeta potential of gH625-
Nanoparticles 
To further investigate the effect of the peptide functionalization (25, 35, and 50%) on 
the size of nanoparticles, we performed dynamic light scattering (DLS) 
measurements. After functionalization, the hydrodynamic size of nanoparticles with 
25, 35, and 50% of gH625 in aqueous medium at pH 7 was found to be respectively 
96.68 ± 0.43 nm, 95.64 ± 0.19 nm and 96.76 ± 0.07 nm, with polydispersity values of 
ca. 0.08, indicating a narrow distribution of the particle size at the pH used for all the 
experiments (Table 4).	 To elucidate the colloidal stability of functionalized 
nanoparticles at different pH values, which is a crucial parameter correlated to their 
functionalization, measurements of the zeta potential and of the hydrodynamic radius 
(DH) were carried out (Table 4). For NPs alone, the colloidal stability is strongly pH-
dependent because it is mainly due to electrostatic repulsion between particles. It is 
widely accepted that at high values of z-potential (over 30 mV, positive or negative) 
the electrostatic interactions between particles are strong enough for electrostatic 
stability, while at intermediate values of z-potential, near their isoelectric point, 
particles can flocculate. Table 4 shows both z-potential and mean hydrodynamic 
diameter of blank NPs and NPs at different degrees of functionalization as a function 
of pH. In presence of peptide, the DH of the functionalized NPs remained nearly 
constant over the entire pH range, with no sign of aggregation in spite of the lower 
values of the zeta potential observed at pH 8. Such a behavior highlights that their 
stabilization is via steric hindrance rather than electrostatic repulsion. In particular, by 
increasing the percentage of functionalization NPs zeta potential increases from 
about +30 mV to +35 mV at pH 7. At these zeta potential values, NPs DH remains 
nearly about 100 nm. Only at pH 8, we observed a lower zeta potential for 25% 
functionalized NPs, indicating that in this condition the functionalized nanoparticles 
are still partially aggregated and their behavior is similar to non-functionalized NPs. 
These data indicate that the peptide bound to the NPs is able to retain its helical 
structure in all the conditions tested and is able to completely prevent NPs 
aggregation at 35 and 50% of functionalization. 
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NP 
 pH 4 pH 7 pH 8 pH 9 
ζ potential (mV) [a] 44.9 ± 5.26 51.6 ± 1.08 -11.1 ± 0.60 -32 ± 1.22 
Size (d.nm) [a] 106.5 ± 2.52 137 ± 1.19 848.4 ± 48.33 473.6 ± 1.81 
PDI 0.18 0.31 0.25 0.30 
NP-gH625 25% ζ potential (mV) [a] 33.13 ± 1.11 30.77 ± 2.40 10.93 ± 0.76 -33.33 ± 1.36 
Size (d.nm) [a] 242.3 ± 1.39 96.58 ± 0.43 103.37 ± 1.14 231.77 ± 6.67 
PDI 0.25 0.08 0.13 0.28 
NP-gH625 35% ζ potential (mV) [a]  34.13 ± 2.42 30.9 ± 0.79 18.43 ± 0.91 -33.17 ± 1.07 
Size (d.nm) [a] 114.93 ± 1.40 95.64 ± 1.09 96.27 ± 0.67 99.92 ± 0.50 
PDI 0.14 0.08 0.08 0.10 
NP-gH625 50% ζ potential (mV) [a]  33.83 ± 1.98 35.1 ± 2.43 17.77 ± 0.76 -28.03 ± 1.82 
Size (d.nm) [a] 102.1 ± 0.36 96.76 ± 0.07 97.53 ± 0.20 99.65 ± 0.70 
PDI 0.12 0.09 0.09 0.10 
 
Table 4. Zeta potential and size measurements of NP and NP at different degrees of functionalization as a 
function of pH. ([a](mean value ±SD,n=3). 
 
3.5.4 Multiple Particle Tracking (MPT) of gH625-Nanoparticles 
We previously demonstrated that the conjugation of the peptide gH625 enhances 
cellular uptake of quantum dots59, liposomes167 and dendrimers168 in HeLa cells in 
vitro. However, no evidences of the effect of gH625 on nanoparticle uptake in brain 
endothelial cells have been previously reported. Moreover, the exact mechanism 
used by gH625 to facilitate cargos transport through cell membranes has not yet 
been understood in details. Therefore, in this work we studied the effect of gH625 on 
polystyrene NP uptake mechanisms on mouse brain endothelial bEnd3 cells. 
We first tested the cytotoxicity of blank NP and gH625-NP on bEnd3 cell line by 
Alamar Blue Assay and we verified that blank NPs and gH625-NPs at 50% 
functionalization did not affect cell viability in the experimental conditions used for the 
assay compared to non-treated control cells (data not shown). 
Once internalized, NPs can follow different fates: i.e., particle degradation inside 
lysosomal compartments, accumulation in other organelles, recycling to the plasma 
membrane or transcytosis to the basal surface of endothelium. Furthermore, the 
routes of NP intracellular trafficking might give some indications not only about the 
fate of NP, but also about the mechanisms driving cellular uptake150,169. To address 
this issue, multiple particle tracking (MPT) gives a strong contribution compared to 
traditional techniques (spectroscopy, microscopy, etc.)170. In particular, MPT 
technique can provide quantitative (diffusivity and velocity) and qualitative (transport 
mode and directionality) information of internalized NPs, by evaluating the time-
resolved trajectories of tens of NPs. Therefore, in order to study the effect of NP 
surface functionalization with gH625 on NP internalization mechanism, we followed 
and analyzed their intracellular motion. Figure 21 shows a snapshot of the detected 
trajectories generated by MPT routines. By shape, trajectories can already be split in 
two different types: i) Brownian-like trajectories, suggesting NPs random movement 
between cytosolic structures, and ii) pearls-on-a-string trajectories, derived by a 
combination of random and linear walk, indicative of motor protein facilitated 
transport, mediated by endocytic vesicles and motor proteins171. Evaluating the time 
dependence of mean square displacement (MSD) of each tracked NP we classified 
the particles transport mechanisms into diffusive and super-diffusive motion. In 
particular, to perform NPs diffusive mode classification we evaluated the exponent of 
each fitting MSD curve by the equation described in the Methods section. 
Particle trajectories revealed a substantial heterogeneity in particle intracellular 
dynamics, both for blank NPs and gH625-NPs. However, for blank NPs, most 
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trajectories resulted in a combination of random and linear walk with a pearls-on-a-
string trajectory, indicative of motor protein facilitated transport, mediated by 
endocytic vesicles (Figure 21). Whereas, only a lower percentage of blank NPs 
appeared to follow a purely diffusive behavior (random walk), suggesting no 
particular interaction between NPs and cytosolic structures (Figure 21). 
Conversely, in presence of peptide functionalization, we observed that most 
trajectories showed a random walk behavior while a lower percentage resulted in a 
pearls-on-a- string trajectory. In particular, this behavior is more evident at lower 
percentages of functionalization with an optimum at 35% peptide functionalization 
degree. 
These data suggest that the effect of the peptide could depend on its 
concentration/density on the NP surface. In fact, we theoretically estimated the 
surface density of peptide of about 3, 4, and 6 peptides/nm2 for 25%, 35% and 50% 
functionalized NPs, respectively. We hypothesized that a lower peptide surface 
density (3 and 4 peptides/nm2) could promote the correct peptide orientation and 
interaction with membrane lipids. Conversely, a higher peptide surface density (6 
peptides/nm2) hinders the correct orientation of peptide aminoacidic residues and 
their interaction with cell membrane. Indeed, recently, we structurally characterized 
gH625 peptide in a membrane-mimicking DPC micellar environment to gain insight 
into how gH fuses with the cell membrane 172. We reported a model of gH625 peptide 
structure and orientation indicating that both electrostatic and hydrophobic 
interactions work in concert to mediate membrane penetration. In particular, the 
function of the aromatic residues is to cause the peptide insertion into the membrane 
interface while the basic residues stabilize this interaction by linking the negatively 
charged headgroups as shown in other systems using both NMR173,174 and EPR175. 
Since we observed that the 35% functionalized NPs showed a good stability in 
aqueous suspension and the ability to penetrate cells using a random walk behavior, 
we performed all the other experiments at this percentage of functionalization. 
 
 
 
Figure21.	  MPT analysis of blank and gH625-NPs. Examples of “random walk” (a) and “pearls on a string” (b) 
trajectories. c) Percentage of “random walk” and “pearls on a string” trajectories as a function of functionalization 
degree. 
 
3.5.5 gH625-Nanoparticles Uptake Kinetics  
To study the effect of surface functionalization with gH625 on NPs internalization, we 
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performed NP uptake experiments. Figure 22A shows that after 10 minutes of 
incubation, both functionalized and blank NPs were internalized by bEnd3 cells and 
the number of internalized nanoparticles increases as a function of incubation time. 
However, the amount of internalized gH625-NPs is higher than blank NPs and this 
effect is more evident at early time of NP uptake kinetic. While after longer incubation 
time the amount of internalized NPs is quite similar, probably due to the saturation of 
the uptake mechanism mediated by the gH625 peptide. 
bEnd3 cells are able to form a confluent monolayer that mimics permeability 
properties of primary culture models of early passages 176 177. We tested the ability of 
gH625 peptide to enhance NPs crossing of a bEnd3 confluent monolayer. Data 
reported in Figure 3B show that gH625-NPs cross more efficiently the endothelial 
layer than blank NPs. More precisely, the permeability (P) of the monolayer was 
(0.43 ± 0.02) × 10−6 cm/s for gH625-NPs, almost two fold higher than P value 
reported for blank-NPs ((0.24 ± 0.02) × 10−6 cm/s). These data are in agreement with 
cell uptake kinetic results. In fact, by focusing at early incubation time, also the 
uptake rate of peptide-conjugated NPs was approximately double compared to blank 
NPs (see the insert in Figure 22A). Moreover, no changes in BSA-TRITC 
permeability were observed after exposure to both blank and gH625-NPs, indicating 
that these NPs did not perturb the integrity of the cell monolayer in the experimental 
conditions used for the assay (data not shown).  
 
 
Figure 22. Uptake kinetics of blank and 35% functionalized gH625-NPs in bEnd3 cells (a). Effect of peptide 
functionalization in NP crossing of a confluent bEnd3 cell monolayer (b). 
 
3.5.6 gH625-Nanoparticles Uptake Mechanisms  
Nanoparticles usually enter the cells using a cell-mediated mechanism, called 
endocytosis. After endocytosis, endosomes can fuse with lysosomes or can deliver 
their cargo across the cell by transcytosis processes. Several works reported that 
caveolae are involved in the endocytosis and transcytosis processes in brain 
endothelial cells178. Thus, in order to study if the nanoparticle functionalization with 
gH625 could affect the mechanisms of NP internalization, we performed confocal 
microscope analyses to investigate the colocalization of NPs with lysosomes and 
caveolae in absence of peptide and with 35% of peptide functionalization. Figure 23 
shows that both blank and gH625-NPs partially colocalized with lysosomes. 
However, the percentage of colocalization was about 4.68% for blank and 62% for 
gH625-NPs. 
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Figure 23. Colocalization of non-functionalized (a, b) and gH625-functionalized (c, d) NPs with caveolae (a, c) 
and lysosomes (b, d) after 24h incubation in bEnd3 cells. Green: NPs; red: caveolin1 and lysotracker. 
Magnification bar: 20 µm.. 
 
On the other hand, concerning caveolin1, a molecular marker for caveolar structures, 
no colocalization of gH625-NPs was observed, while blank NPs showed 0.74% of 
colocalization. These data indicate that the peptide could change the mechanism of 
nanoparticle uptake by inducing an alternative penetration pathway. To further 
investigate this issue, we treated cells with cytochalasin D that inhibits 
macropinocytosis by disrupting microfilaments. Results demonstrate that the uptake 
of blank NPs was drastically reduced after cytochalasin D treatment (Figure 24A–F). 
On the other hand, gH625-NPs uptake was almost not affected by microfilament 
depolymerization (Figure 24G–L). Indeed, confocal microscope z-sectioning analysis 
demonstrate that the most part of gH625-NPs were inside the cells and only a small 
amount (less than 30%) was just adsorbed on cell membrane (Figure 24M). 
Moreover, quantitative analysis of NP uptake showed a decrease of about 85% and 
15% for blank-NP and gH625-NP uptake, respectively, after cytochalasin D treatment 
(Figure 24N). Taken all together these data indicate that blank NPs might enter the 
cells mainly by macropinocytosis. Conversely, gH625-NPs could use a different 
mechanism to cross cell membrane. 
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Figure 24. Cytochalasin D treated bEnd3 cells incubated with blank NPs (d–f) and gH625-NPs (j–m) for 10 min at 
37°C. Non-treated control cells incubated with blank NPs (a–c) and gH625-NPs (g–i) for 10 min at 37°C. 
Nanoparticles (a, d, g, j); phalloidin stained microfilaments (b, e, h, k); merge (c, f, i, l). Green fluorescent 
nanoparticles and red fluorescent WGA stained cell membrane confocal z-sectioning (m). Section thickness: 0.2 
µm. . Z-stack size: 10 µm. Magnification bar: 20 µm.. 
 
Previous works demonstrated that gH625 peptide shows a particular tropism for 
lipidic membranes, which is strongly dependent on its amphipathic nature 179 99 180. 
Thus, we hypothesized that the presence of the peptide on the NP surface could 
enhance its interaction with the cell membrane and promote NPs passage through 
cell membranes. To verify this hypothesis, scanning electron microscopy (SEM) 
analyses were performed. SEM micrographs showed that, after 5 min of incubation, a 
high number of gH625-NPs was visible on the cell surface (Figure 25A, B). 
Conversely, very few blank NPs were present on the cell surface and some of these 
formed small aggregates (Figure 25C, D). SEM results suggest a different interaction 
of gH625-NPs with cell membrane compared to blank-NPs. Moreover, accordingly to 
cell uptake kinetics (Figure 22), these observations indicate a better and more rapid 
adsorption of gH625-NPs on cell membrane, compared to blank-NPs after 10 min 
incubation, probably due to the membrane tropism of the peptide and, thus, an 
enhancement of gH625-NP internalization. 
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Figure 25. SEM micrographs of bEnd3 cells incubated with gH625-NPs (a, b) and blank NPs (c, d) for 5 min at 37 
°C. Dashed squares in panels (a, c) indicate the zoomed areas shown in panels (b, d). Magnification bar: 10 µm  
(a, c) and 1 µm  (b, d). 
 
In order to understand if the different behavior of gH625-NPs implied a different 
intracellular fate of NPs, we performed transmission electron microscopy (TEM) 
analyses. Figure 26 shows TEM micrographs of gH625-NPs and blank NPs after 24 
h incubation with bEnd3 cells. Inside the cells, gH625-NPs were organized in very 
small aggregates of 3-4 particles within the cytoplasm, mainly localized in vesicular 
structures, probably early endosomes (Figure 26A) and multi-vesicular bodies 
(MVBs) (Figure 26C). On the other hand, for blank-NPs, many and larger aggregates 
associated to vesicular structures within the cytoplasm were observed (Figure 26B–
D). Furthermore, no gH625- or blank-NPs were localized in the nucleus. 
 
 
 
Figure 26. TEM micrographs of bEnd3 cells incubated 24 h with gH625-NPs (a, c) and blank NPs  (b, d) at 37 
°C. Magnification bar: 1 µm.. 
  
For obtaining deeper details on the intracellular distribution of gH625-NPs, we 
followed the formation and the growth of gH625- or blank-NP aggregates with time by 
a confocal microscope image analysis. Figure 27 shows gH625- and blank-NP 
aggregates within bEnd3 cell cytoplasm after 10 min and 24 h incubation. At early 
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times, gH625-NPs formed a huge number of small aggregates (Figure 27A, E). 
Moreover, increasing the incubation time, the average size of the aggregates 
remained almost unchanged (Figure 27B, E). Conversely, for blank NPs, at early 
times, the average size of aggregates increased with time indicating that these NPs 
tend to accumulate in the cell (Figure 27C, D, F). 
Taken altogether, these observations demonstrate a different behavior between 
gH625- and blank-NPs. In particular, NP conjugation with gH625 peptide changes NP 
destination by reducing their accumulation and promoting NP escape/exit from the 
cell. However, further investigations are needed to better understand which 
intracellular compartments gH625-NPs are localized in and what the intracellular 
pathways are followed by these functionalized NPs that dictate their fate. 
 
 
 
Figure 27. Confocal microscope images of bEnd3 cells incubated with gH625-NPs for 10 min (a) and 1440 min 
(b) and blank-NPs for 10 min (c) and 1440 min (d). Blue: nuclei; Green: NPs; Magnification bar: 20 µm; . gH625- 
(e) and blank-NP (f) aggregate analysis. Charts show the size distribution of NP aggregates at different 
observation time (10, 30, 90, 300, and 1440 min). NP aggregate sizes were split in four intervals: 0.01÷ 0.03 
ìm2; 0.04÷ 0.10 µm2; 0.11÷ 0.30 µm2; >0.31 µm2. 
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4 CONCLUSION 
 
The main objective of this study was to identify innovative peptide based systems 
with a higher impact in the pharmacodynamics and pharmacokinetic fields compared 
to the conventional systems used in drug delivery.  
In particular, this thesis describes a new molecule, classified as a new CPPs, that 
could be used for effective intracellular delivery. The ability of gH625, a peptide 
derived from glycoprotein gH of Herpes simplex virus type 1, to be internalized was 
analysed both in presence and absence of cargoes for a better understanding of the 
mechanism of uptake of this membranotropic domain and to verify the possibility to 
use it for delivering  bioactive macromolecules into cells. 
Cell penetrating peptides are considerably important for the purpose of delivering 
cargoes to the inside of cells and hundreds of sequences fall within CPP 
classification. The process by which membrane translocation is achieved has 
received great attention with the aim of gaining higher efficiency of penetration. Most 
CPP are able to cross the membrane bilayer and to deliver a cargo across the 
membrane although their mechanism of uptake involves essentially endocytic 
pathways. The discovery of novel systems which use non-canonical mechanisms for 
internalization may lead to greater efficiency both from a therapeutical and a 
diagnostic point of view. In fact, most drugs are actually internalized by endocytosis 
mechanisms with consequently a set of limitations in biodistribution, bioactivity, 
specificity and toxicity; on the contrary, novel delivery tools able to cross biological 
membranes using completely or at least partially a different mechanism of 
internalization may open up new avenues for the administration of drugs with a lower 
impact on the health of patients. 
This thesis focuses on recent data obtained on the viral membranotropic peptide 
gH625 and its use as well as its advantages compared to other CPPs as a drug 
delivery tool. 
This thesis, firstly, describes the ability of gH625 alone to cross efficiently the plasma 
membranes and then few examples of applications of gH625 to the delivery of 
several kinds of cargos into the cells. 
Labelling the peptide with the NBD group allowed the comparison of cellular uptake 
and phospholipid binding and analysis of the physico-chemical properties required for 
translocation. To measure cellular uptake of NBD-labelled peptide we have used the 
dithionite method, which allows the estimation of the peptide fraction localized inside 
the cell. We determined by flow cytometry that after 1 h of incubation with HeLa cells 
at 37°C and 4°C, most of gH625-NBD was localized intracellularly; our results show 
that the peptide internalization in HeLa cells can occur at 37°C and to a slightly lesser 
extent at 4°C, supporting the view that the internalization mechanism does not 
involve entirely endocytosis. 
The kinetic of internalization of gH625-NBD is rapid and reaches a plateau after 1 h. 
We confirmed by confocal microscopy that indeed the NBD-peptide is inside the cell 
and its penetration is not induced by cell fixation protocols as previously found for the 
Tat peptide181. 
The amount of cell-associated peptide represents the sum of internalized peptide and 
of peptide remaining on the cell surface after cell wash. Furthermore, the membrane 
interaction experiments showed that the peptide stably inserts into the PC/Chol 
membranes but it is unable to form pores; and it is unable to fuse the inner 
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monolayer as well as to induce leakage of vesicles; further supporting the view that 
the mechanism of lipid/peptide association plays a key role in the translocation 
activity. gH625 cellular uptake is associated with its ability to interact with membrane 
lipids and to form a transient helical structure that temporarily affects membrane 
organization, thereby facilitating insertion into the membrane and translocation.  
gH625 showed very low toxicity in in vitro studies when used at concentrations up to 
400 µM, therefore it seems suitable for being used as a delivery system. 
The first application of our peptide for the delivery of a cargo was the uptake of 
Quantum Dots (QDs). Quantum dots are a new class of fluorescent probes under intense 
research and development for broad applications in molecular, cellular and in vivo imaging. 
QDs have unique functional and structural properties, such as size and composition tunable 
fluorescence emission, large absorption cross sections and exceptional brightness and 
photostability compared with organic dyes and fluorescent proteins. Although considerable 
success has been achieved in using QDs for labelling fixed cells and for imaging cell 
membrane proteins, only limited progress has been made for molecular imaging inside living 
cells. A major problem is the lack of efficient methods for delivering single QDs into the 
cytoplasm of living cells. 
The results obtained from the gH625 functionalization with QDs clearly indicate that 
the nanosystem is efficiently internalized, more effectively than Tat-QDs, and its 
internalization only partially involves the endocytic pathway. 
In particular, when conjugated with QDs, gH625 translocates through cellular plasma 
membranes with a mechanism only relatively dependent on the endocytic route of 
entry. It has been previously reported that Tat peptide conjugated with small 
molecules enters cytoplasm and eventually the cell nuclei, while Tat-QDs remain 
trapped in vesicles. This difference in the intracellular fate of Tat peptide-conjugated 
molecules and Tat-QDs is likely caused by differences in the sizes of the cargos. 
QDs are much larger than standard molecules and are thus more difficult to escape 
from vesicles. On the contrary, gH625-QDs are present in the cytoplasm in a more 
punctuated form compared to Tat-QDs. Therefore, we can hypothesise a different 
mechanism of entry between Tat-QDs and gH625-QDs, and this is of particular 
interest since peptides with different biophysical characteristics are able to condition 
the entry pathway of the same macromolecular cargo. These results make gH625-
QDs an interesting compound for recognising specific targets in the cytoplasm 
resulting thus potentially applicable to the diagnosis and therapy of human diseases. 
The second application was the study of the uptake of liposomes loaded with 
anticancer drugs such as doxorubicin. 
Liposomes, composed of a phospholipid bilayer which entirely surrounds an internal 
aqueous core used for drug encapsulation, have been shown to be optimal for the 
delivery of chemotherapeutic agents to tumor cells. Being larger than micelles they 
have the ability to deliver greater amounts of the chemotherapeutic agent to the 
tumor site while minimizing the risks associated with premature leakage. In addition, 
liposomes also have the ability to accommodate both hydrophilic as well as 
hydrophobic drugs either in the internal aqueous core or in the lipid bilayer. When 
compared with conventional drugs, liposomal treatment has been shown to 
dramatically reduce some of the traditional side effects associated with 
chemotherapy, such as nausea and vomiting 182. 
This nanosystem is characterized by the conjugation of the gH625 peptide on the 
surface of liposomes. Being the peptide hydrophobic, click chemistry appeared to be 
very useful for the decoration of the external surface of DOPG based liposomes. 
According to this synthetic procedure, azide modified DOPG based liposomes react, 
under mild conditions, with Pra modified gH625 peptides giving stable and well 
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defined peptide modified liposomes. The click chemistry procedure described 
appears of general utility for liposome functionalization; in fact, azide modified 
liposomes could constitute a stable and ready-to-use suspension of reactive 
liposomes that could be functionalized with different Pra modified peptides. In this 
case, an increase of liposome diameter of approximately 30% after peptide 
introduction is observed by DLS measurement. Moreover, the peptide positioning 
relative to the liposome surface has been investigated by EPR spectroscopy; the 
data obtained indicated that the peptide does not insert in the bilayer hydrophobic 
core, but rather remains exposed to the aqueous environment and, thus, able to 
perform its biological function.  
In order for a chemotherapeutic agent to be effective, it has to be active against 
cancer cells while having minimal toxic effects on healthy cells, tissues and organs. 
Thus, once carriers loaded with chemotherapeutic agents are systemically 
introduced, their uptake by the reticuloendothelial system (RES) must be minimized, 
allowing prolonged circulation of the carriers in the blood. The longer the drug 
circulates in the blood, the more likely it encounters the tumor as a result of the 
enhanced permeability of leaky tumor blood vessels. The enhanced permeability and 
retention effect is considered the primary mechanism of preferential accumulation of 
long-circulating nanoparticulates in solid tumors. Polymeric drug carrier systems that 
use various approaches to address these challenges have been intensively 
developed; while adding a targeting moiety, such as a peptide or an antibody, helps 
the cellular uptake and reduces systemic clearance of anticancer drug. The exact 
mechanism of doxorubicin antitumor activity still remains unclear; it is known that it 
intercalates into DNA, which results in the blocking of topoisomerase II activity, 
preventing DNA replication and cell division. For encapsulated Dox, the reduced 
toxicity is associated to the presence of the carrier that hinders the intercalation of 
Dox into DNA. Confocal microscopy revealed differences between the uptake 
mechanism of free Dox and encapsulated Dox. The nuclear accumulation of free Dox 
can be attributed to diffusion. In contrast, encapsulated Dox remain mostly in the 
cytoplasm with negligible nuclear accumulation.  
The conducted experiments provided proof of principle for efficient gH625 peptide 
mediated delivery of DOPG based liposomes into cells. gH625 attached to the 
liposome surface needs to be non-shielded and accessible for cell membrane 
experiments and it was showed that coupling the peptide on the pre-assembled 
liposomes allows the obtainment of liposomes decorated on their surface with the 
peptide. 
The third application was the preparation of a peptidodendrimeric scaffold, that has 
the potential to be used as a cellular delivery platform. The dendrimer cellular uptake 
is significantly enhanced thanks to the attachment of the gH625 peptide at the 
termini. The peptide does not rely on heavily positively charged residues (Arg, Lys) 
for translocation. Previously Kang et al.121 reported the failure of Tat to enhance the 
intracellular delivery of PAMAM dendrimers, which they attributed to the highly 
positive charges of both the dendrimer and the peptide121. Our dendrimer is made in 
a facile and scalable synthesis, and can be functionalized efficiently. We showed that 
the peptidodendrimer is able to fully fuse lipidic vesicles, even more significantly than 
the peptide alone; moreover, it is able to do so without inducing leakage of vesicles. 
These data further support the view that the mechanism of lipid–peptide association 
plays a key role in the translocation activity. The gH625 cellular uptake is associated 
with its ability to interact with membrane lipids and to form a transient helical structure 
that temporarily affects membrane organization, thereby facilitating insertion into the 
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membrane and translocation. The cellular uptake of the peptidodendrimer was 
measured by flow cytometry and fluorescence microscopy. After 1 h of incubation 
with HeLa cells at 37 °C and 4 °C, most of the gH625 functionalized dendrimer was 
localized intracellularly. The internalization in HeLa cells can occur at 37°C, and to a 
lesser extent at 4°C, supporting the view that the internalization mechanism does not 
involve entirely endocytosis. The kinetics of internalization is rapid and reaches a 
plateau after 1 h. It was confirmed, by fluorescence microscopy, that indeed the 
peptidodendrimer is inside the cells. Our studies have shown that dendrimer 
functionalized with the gH625 peptide sequence is not only an effective vehicle for 
intracellular delivery but it can do so via a passive translocation mechanism. This 
allows the cargo to be released directly into the intracellular milieu as opposed to 
being entrapped in endosomes, from which the cargo might not be able to escape 
before lysosomal degradation. 
The last application of our peptide was the delivery of polystyrene nanoparticles and 
we further investigated its ability to translocate through the BBB in an in vitro model. 
The functionalized nanoparticles were thoroughly characterized using a variety of 
complementary techniques to gain a better understanding of their properties and 
showed that gH625-NPs only 
slightly modified the particle 
sizes with a z-potential 
indicative of colloidal stability 
at pH 7. gH625-NPs 
translocated efficiently across 
cell membranes and cell 
internalization does not seem 
to exclusively involve classical 
endocytosis mechanisms. In 
fact, conjugation with gH625 
facilitated the delivery of 
nanoparticles across the BBB, 
leading to significant higher 
cell uptake and crossing. To 
the best of our knowledge, 
gH625 represents the first cell translocation motif reported for the crossing of the 
BBB and further studies could allow the application to the design of a drug delivery 
system specific for the brain. Therefore, it might be regarded as a promising strategy 
to design delivery systems for administration of therapeutical compounds to the brain, 
deserving further investigations to more precisely characterize the mechanism by 
which gH625 crosses the BBB and to address the cell specificity issue by linking to 
the nanosystem also molecules specifically recognized by the brain endothelium. 
In conclusion, the data described in this thesis suggest that membranotropic 
sequences represent a new valuable tool for intracellular delivery for applications in 
theranostics. The opportunity to use a delivery tool with a different internalization 
mechanism may represent the possibility of reducing the doses and thus increase the 
results of therapies, contemporary reducing toxicity.  
Although  the internalization mechanism og gH625 functionalized nanosystems still 
remains to be fully established, our results seem to support the hypothesis that the 
peptide allows a better penetration of QDs, liposomes, Dendrimers and 
Nanoparticles. Thus, the approaches described may have important application for 
gH625 as new shuttle toward drug delivery 
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drug and DNA delivery into the cell cytoplasm in different protocols for drug 
administration or ex vivo treatments. 
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Abstract. The internalization of bioactive molecules is one of the most critical problems to
overcome in theranostics. In order to improve pharmacokinetic and pharmacodynamic proper-
ties, synthetic transporters are widely investigated. A new nanotechnological transporter, gH625,
is based on a viral peptide sequence derived from the herpes simplex virus type 1 glycoprotein
H (gH) that has proved to be a useful delivery vehicle, due to its intrinsic properties of inducing
membrane perturbation. The peptide functionalization with several kinds of nanoparticles like
quantum dots, dendrimers, and liposomes could be of particular interest in biomedical applica-
tions to improve drug release within cells, to increase site-specific action, and eventually to
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1 Introduction
The membrane bilayer is a semipermeable barrier defining the interior (or cytoplasm) of an
individual cell. The existence of this finely tuned barrier confers to cells their potential to survive
and function properly. Nevertheless, crossing the cellular membranes remains a major obstacle
for the delivery of therapeutics.1,2 The lipophilic nature of biological membranes restricts the
direct intracellular delivery of most compounds, and whereas small molecules and ions can dif-
fuse across the barrier, large molecules (more than 1kD) are generally excluded from simple
diffusion into the cell. The differing hydrophobicity/hydrophilicity of the lipid membrane
can make transfer across this barrier extremely difficult, due to differences in solubility.
Novel compounds with therapeutic potential are strictly dependent on their pharmaco-
distribution properties to reach the stage of pharmaceutical preparations and stimulate industrial
interest. In particular, many pharmaceutical agents should be delivered intracellularly to exert
their therapeutic action inside the cytoplasm or on individual organelles, such as nuclei (targets
for gene and antisense therapy), lysosomes (targets for the delivery of deficient lysosomal
enzymes) and mitochondria (targets for pro-apoptotic anticancer drugs).
Several basic cellular mechanisms can be exploited for the intracellular delivery of a com-
pound across the plasma membrane. There are active mechanisms, such as endocytosis, and
passive mechanisms, such as translocation across the lipid bilayer; alternatively, there are highly
invasive procedures, such as microinjection and/or electroporation, which could cause transient
damage to membranes. The use of viral particles as delivery tools, which seemed very promising
for gene therapies, presents several problems in terms of side effects and toxicity.3
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Recently, cell-penetrating peptides (CPPs) have been used extensively, due to their capability
to transport several kinds of macromolecules across the bilayer in vitro and in vivo.4–6
CPPs are short and usually basic amino acid rich peptides that can cross biological barriers.
Although the mechanism of cellular uptake is still unknown, CPPs are able to deliver various
entities into cells, including small molecules, peptides, proteins, DNA/RNA, liposomes, and
other supramolecular aggregates. They are usually divided into three classes: protein derived
peptides (such as TAT, penetratin or pANTP, transportan, and HSV-1 VP22), amphipathic pep-
tides resulting from the sequential assembly of hydrophobic and hydrophilic domains (such as
MAP, MPG, and Pep-1), and synthetic or cationic peptides such as poliarginines (such as Arg9).7
The uptake mechanism of CPPs is still debated and is believed to involve mainly the endo-
cytic pathway, trapping the conjugated cargo in endosomes and eventually ending in lysosomes,
where common enzymatic degradation mechanisms take place, decreasing its intracellular bio-
availability. In order to avoid the endocytic pathway completely or partially, it is paramount to
discover new molecules with different mechanism of uptake.
Recently, great attention has been devoted to viruses; in fact, many viruses have evolved
quite efficient systems for endosomal release.8 Therefore, the discovery of new methodologies
to reproduce their behavior represents a key objective. Since viruses may enter cells either through
a endosomal pathway or via direct fusion on the plasma membrane through the activity of
membranotropic peptides, great attention has been devoted to the study of hydrophobic peptides
that traverse biological membranes efficiently, promoting lipid-membrane reorganizing processes
such as fusion or pore formation and involving temporary membrane destabilization and
subsequent reorganization,7,9 which may be able to circumvent the endosomal entrapment by
favoring the escape from the endosome or by translocating a cargo through the plasma membrane
directly into the cytosol. Delivery across cellular membranes involves several mechanisms, such as
direct transfer through the cell surface membrane by lipid membrane fusion or transient perme-
abilization of the cell membrane. Alternatively, following endocytosis, transfer across vesicular
membranes by lipid disruption, pore formation, or fusion may take place. Several of these mem-
brane reorganization steps are also involved in the cell entry of viruses and other microorganisms,
as well as being triggered by protein toxins and defense peptides.10 Several related processes, such
as intracellular vesicle budding, cell-to-cell fusion,9 sperm-egg fusion, and the immune response,
share common features with the mechanism of viral-induced membrane fusion.
The 19-residue peptide gH625 (from aa 625 to aa 644) is a membrane-perturbing domain
derived from the gH fusion glycoprotein of herpes simplex virus type I.11,12 It interacts with
biological membranes and is implicated in the merging of the viral envelope and the cellular
membrane.13,14 The peptide contains particular residues that are crucial for its capacity to interact
with and destabilize target lipid membranes. It is rich in hydrophobic residues, including gly-
cines, leucines, alanines, and aromatic residues such as tryptophan and tyrosines, which are
known to be located preferentially at the membrane interface. This hydrophobic domain is
also crucial for insertion of the peptide into the membrane.
An amphipathic α-helix is believed to be an important feature of fusion peptides, playing a
crucial role in mediating lipid-protein interactions during the binding of proteins to membranes.
Once bound, the hydrophobic face of the amphipathic peptide would allow the peptide to enter
the membrane interior with an oblique orientation, thereby triggering local fusion of the mem-
brane leaflets, pore formation, cracks, and membrane fusion.
The viral membranotropic peptide gH625 has been shown to interact strongly with and
penetrate the lipid-phase spontaneously and insert into membranes.15 The peptide-lipid inter-
actions are initiated by the arginine residue located at the C-terminus; in fact, when the arginine
is mutated, the fusogenic activity of the peptide is strongly impaired.16 Compared with the TAT
peptide, which mainly exploits the endocytic pathway, gH625 crosses membrane bilayers mainly
through a translocation mechanism. A version of this fusogenic peptide one amino acid shorter
than HSV-1 gH (missing the histidine at position 625) was also found to improve the endosomal
release of DNA/Lipofectamine lipoplexes and transgene expression up to 30-fold in human cell
lines.17 It has been recently demonstrated that gH625 can traverse the membrane bilayer and
transport into the cytosol several compounds, such as quantum dots (QDs),16 liposomes,18
NPs,19 and dendrimers.20
This review focuses on different delivery applications of gH625.
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2 Functionalization of Quantum Dots
QDs are a new class of fluorescent probes under intense research and development for broad
applications in molecular, cellular, and in vivo imaging; compared with organic dyes and fluo-
rescent proteins, they have unique functional and structural properties, such as size and
composition-tunable fluorescence emission, large absorption cross sections, and exceptional
brightness and photostability.21 Furthermore, QDs are a well-characterized family of engineered
nanostructures that provide an excellent model system to test toxicity. Many in vitro studies have
suggested that nanomaterials almost always induce toxic responses, which is essentially corre-
lated to the particle breakdown and subsequent release of toxic metal ions22,23 and the production
of reactive oxygen species.24 However, properly coated and passivated QDs do not exhibit acute
toxicity in vivo.25,26 Thus, the coating of QDs with peptide delivery molecules represents a novel
strategy to enhance delivery and reduce toxicity.
In addition, the excellent photostability of QDs gives them great potential in cellular labeling
and bioimaging, which have been exploited in different kinds of biological systems.21 Although
considerable success has been achieved in using QDs for labeling fixed cells and for imaging cell
membrane proteins, only limited progress has been made for molecular imaging inside living
cells. Thus, wide application of QDs to intracellular and molecular imaging has been hampered
by their insufficient ability to traverse cell membranes. Therefore, in order to use QDs as bio-
logical probes for intracellular applications, their delivery needs to be significantly improved,
and the methods actually used are still inefficient. Several authors have recently reported on the
functionalization of QDs with the TAT peptide or other positively charged CPPs as an enhancer
of cell penetration, and they have established that the main route of entrance is via endosomal
uptake; therefore, escape from the endosomal system is paramount.27–29 There is thus a great
need to identify novel molecules that use different internalization mechanisms and may prove
useful in the delivery of QDs.11
In order to assess the ability of gH625 to deliver a cargo inside the cell, QDs were used as a
model. QDs alone have a poor affinity for the plasma membrane of HeLa cells at the concen-
tration of 50 nM. The peptide conjugation of QDs enhanced their membrane-bound ability, pro-
viding a favorable condition for cellular internalization. Moreover, the gH625-QDs are
internalized more effectively than TAT-QDs, and their internalization only partially involves
the endocytic pathway. Furthermore, gH625 showed very low toxicity during in vitro studies
when used at concentrations of up to 400 μM. Therefore, QDs conjugated with gH625 may
represent a novel and useful delivery tool.
It is important that, when conjugated with QDs, gH625 exerts an action of translocation
through cellular plasma membranes, which seems to be only relatively dependent on the endo-
cytic route of entry. It has been previously reported that TAT peptides conjugated with small
molecules enter cytoplasm and eventually the cell nuclei, while TAT QDs remain trapped in
vesicles. This difference in the intracellular fate of TAT peptide-conjugated molecules and TAT
QDs is likely to be a consequence of the difference in the size of the cargo. QDs have a diameter
of about 1 to 10 nm and cannot escape efficiently from vesicles. On the contrary, gH625-QDs are
present in the cytoplasm in a more punctuated form in comparison with TAT QDs.16 Therefore, a
difference in mechanism of entry between TAT-QDs and gH625-QDs has been hypothesized,
and this is of particular interest because peptides with different biophysical characteristics can
condition the entry pathway of the same macromolecular cargo. These results provide new
insights into the mechanism of gH625-mediated delivery and for the development of nanopar-
ticle probes for intracellular targeting and imaging (Fig. 1). Similar delivery methods may enable
the implementation of the next generation of QDs capable of long-term intracellular monitoring.
3 Functionalization of Lipid-Based Nanocarriers
Liposomal aggregates have been successfully used as in vivo carriers of active principles;30 they
display some unique pharmacokinetic properties and can be adapted to a wide range of thera-
peutic agents. Liposomes are nontoxic, biodegradable, and non-immunogenic, and their size
ranges in mean diameter from 50 to 300 nm. The use of liposomal drugs could help in protecting
the encapsulated drugs from chemical or metabolic degradation after injection, in reducing
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toxicity through decreased exposure of anti-neoplastics to susceptible healthy tissues, and in
enhancing antitumor activity resulting from a relatively long systemic circulation time, an
extended exposure, and tumor-selective accumulation at specific sites of tumor growth. In par-
ticular, liposomes exhibit preferential extravasation and accumulation at the site of solid tumors,
due to increased endothelial permeability and reduced lymphatic drainage in these tissues, which
has been defined as enhanced permeability and retention effect.31 A drug encapsulated in lip-
osomes shows marked changes in its pharmacokinetic and pharmacodynamic properties and
lower systemic toxicity, while being also protected from early degradation and/or inactivation.32
To enhance the antitumor efficacy of liposomal drugs, many research groups are working
toward the improvement of their cellular internalization through the addition of surface ligands.
Several peptides, such as penetratin and TAT, have been successfully used for the intracellular
delivery of liposomes.33 Liposomes decorated with gH625 and loaded with doxorubicin can be
prepared by different synthetic procedures which involve the coupling of the peptide to the lipid
moiety before or after the assembly of the liposome. The ideal strategy depends strongly on the
peptide and on the drug. The coupling of a hydrophobic peptide is complicated by the low solu-
bility of the compound and by the higher tendency of the peptide to locate in the hydrophobic
region of the bilayer, rather than on the external surface. Thus, the preferable way to obtain
liposomes functionalized on the surface with a hydrophobic peptide consists of the coupling
of peptide derivatives on pre-assembled liposomes. gH625-modified liposomes were prepared
by using a post-aggregation strategy according to click-chemistry procedures.18 The ability of
gH625-functionalized liposomes loaded with doxorubicin to penetrate inside cells was evaluated
by confocal microscopy experiments.
Cells were incubated with a 1-μm solution of free Dox, of Dox-loaded liposomes, and of
gH625-functionalized liposomes at 37°C. The results obtained after five hours of incubation
show that, as expected, free Dox can enter the cell and translocate into the nucleus. Dox-loaded
liposomes also enter cell nuclei, where fluorescence due to Dox accumulation in DNA can be
observed together with a slight diffuse fluorescence in the cytoplasm suggestive of Dox release
from the liposomes. Conversely, gH625-functionalized liposomes encapsulating Dox accumu-
late in the cytoplasm without entering the nucleus. These results suggest that the functionaliza-
tion of liposomes with gH625 could affect the uptake mechanism of liposomes, escaping the
lysosome accumulation, allowing a more homogeneous intracytoplasmic distribution, and
modulating the Dox release. Although the mechanism still remains to be established, the
Fig. 1 Intracellular delivery: endocytic mechanisms compared to translocation.
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obtained results could be useful in the design of carriers for a controlled delivery and release of
Dox in order to avoid side effects associated with Dox itself.
4 Functionalization of Polymeric Nanocarriers
Dendrimers are perfectly branched macromolecules with a well-defined structure34 that exhibit
properties very different from linear polymers with the same composition and molecular
weight.35 The high concentration of terminal functional groups on a dendrimer’s surface deter-
mines the solubility of the entire compound—dendrimers have been used as unimolecular
micelles, i.e., hydrophobic dendrimers that are water soluble due to peripheral hydrophilic
groups or vice versa.36,37 Traditional dendrimers are synthesized from monomers with the struc-
ture ABn;
38–40 from one generation to the following, the dendrimers grow radially with an expo-
nential increase in both mass and number of free termini but only a minimal increase in the
physical size of the structure. This causes the termini to become more closely packed. Unlike
many other scaffolds, however, dendrimers have the benefit of a highly controlled synthesis, as
well as yielding a single monodisperse compound, giving perfect control over the size, weight,
and terminal functionalities of the resulting structure. Moreover, highly branched structures gen-
erally exhibit longer blood circulation times, due to their inability to pass through renal pores.41
Dendrimers have been shown to have extended lifetimes in vivo,42 whereas lipid complexes are
usually cleared from circulation rapidly by splenic and hepatic phagocytes.43
Dendrimers are now considered a very promising tool for drug delivery, thus combining
the advantageous features of nanoparticles (such as ideal size as in vivo carriers and multiva-
lency) of polymeric materials (such as low cost, tunable properties, and biocompatibility) and of
small molecules (such as monodispersity and detailed control of their properties).35,44 The
mechanism of dendrimer uptake and intracellular trafficking is yet to be established.45 PAMAM
dendrimers46 and PAMAM dendrimers functionalized with the TAT peptide47 have been proved
to involve essentially endocytosis mechanisms for internalization and intracellular trafficking,
indicating that the addition of TAT failed to enhance delivery efficiency. Other studies using
cationic PAMAM dendrimers showed that the dendrimers can insert themselves into the lipid
bilayer, thanks to their potential to weaken the membrane bilayer or form holes.48
The combination of the benefits of dendrimers and peptide chemistry may prove useful for
the development of a selective carrier that could cross the membrane and be efficiently targeted
inside the cell. Targeted dendrimeric systems offer several advantages in their delivery, and their
surface modification by means of conjugation or adsorption of a biospecific ligand may allow
their delivery to specific sites and the modulation of drug release, minimizing toxic effects and
increasing intracellular bioavability.49
The binding of gH625 to the dendrimer combines the benefits of dendrimer chemistry with
those of a cell internalization unit that can cross the cell membrane mainly via a non-active
translocation mechanism. The synthesis of a poly(amide)-based dendrimer containing terminal
peptide chains and their cell uptake in vitro has been reported recently. The chosen dendrimers
had been previously shown to exhibit high biocompatibility, due to their peptide-like back-
bone.50,51 The structure of peptidodendrimer, the poly(amide) dendrimer terminated by gH625
peptides, is shown in Fig. 2. The peptidodendrimer can fuse model membranes like liposomes
even more significantly than the peptide alone. Moreover, it is unable to fuse the inner monolayer
or induce leakage of vesicles. The peptidodendrimer’s ability to enter the cells was confirmed by
using both qualitative and quantitative methods, and evidence showed that the peptidodendrimer
is able to enter cells through a passive translocation mechanism, allowing the cargo to be released
directly into the cytoplasm, as opposed to entrapment in endosomes, from which the cargo may
not be able to escape before lysosomal degradation. Thus, the dendrimeric scaffolds may be a
promising tool for an efficient drug delivery engine.20
5 Functionalization of Polystyrene Nanoparticles
Therapies for neurological disorders actually are limited by the inability of the therapeutic agents
to cross the blood-brain barrier (BBB) efficiently.52 The BBB is a selective and dynamic barrier
Falanga et al.: Review of a viral peptide nanosystem. . .
Journal of Nanophotonics 071599-5 Vol. 7, 2013
protecting the brain against invading organisms and unwanted substances; it also represents a
formidable obstacle to the effective delivery of drugs to the central nervous system (CNS). For
this reason, it is fundamental to identify and develop more effective strategies to enhance drug
delivery to the brain for the therapy and diagnosis of neurological pathologies.
It is now well known that there are several invasive or non-invasive transport routes by which
drugs enter the brain. The invasive approaches mainly consist of a temporary disruption of the
BBB, allowing the entry of a drug into the CNS, or of direct injection by means of intraven-
tricular or intracerebral administration,53 while the non-invasive ones involve the systemic appli-
cation of colloidal drug carriers undergoing a receptor or adsorptive mediated transcytosis
mechanism54 or the passing of the BBB via intranasal delivery.55
To overcome this problem, fluorescent polystyrene nanoparticles could be functionalized
with the membranotropic peptide gH625. Nanomaterials, such as nanoparticles, differ from
other materials, due to a number of special characteristics, including small particle size,
large surface area, shape, chemical composition, and charge. Together these characteristics
give nanoparticles numerous advantages over other delivery systems, and the targeted delivery
of drugs using nanocarriers for the treatment of diseases is a major focus of interest.56
The effect of gH625 on the penetration of 100-nm polystyrene nanoparticles (NPs) was ana-
lyzed using an in vitro BBB model based on bEnd3, an immortalized mouse cerebral endothelial
cell line. The intracellular uptake of NPs with gH625 by brain endothelial cells was greater than
that of the unfunctionalized NPs, and their intracytoplasmatic motion was mainly characterized
by a random-walk behavior indicative of a passive mechanism of internalization. Most impor-
tantly, the gH625 peptide decreased NP intracellular accumulation as large aggregates and
enhanced the NPs’ crossing of the BBB.
This system represents a cell translocation motif never reported before in a BBB in vitro
analysis and could be applied to the design of a drug delivery system homing to the brain
and bypassing the endocytosis entrapment. Therefore, these novel nanoshuttles could be
regarded as a promising strategy for engine delivery systems for the administration of therapeu-
tical compounds to the brain.19
6 Conclusions
Cell-penetrating peptides are considerably important for the purpose of delivering cargoes to the
insides of cells, and hundreds of sequences fall within CPP classification. The process by which
membrane translocation is achieved has received great attention with the aim of raising the effi-
ciency of penetration. Most well-studied peptides are able to deliver themselves as well as a
cargo across the plasma membrane, although there is strong support for the involvement of endo-
cytic pathways. The discovery of novel systems that use non-canonical mechanisms for inter-
nalization may lead to greater efficiency, both from a therapeutic and a diagnostic point of view.
Most drugs are internalized by endocytosis mechanisms with a consequential set of limitations in
biodistribution, specificity, and toxicity. On the contrary, novel delivery tools that are able to
Fig. 2 Structure of peptidodendrimer. The helices represent the gH625 peptide sequence.
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cross biological membranes using a completely or at least partially different mechanism of inter-
nalization may open up new avenues for the administration of drugs with a lower impact on the
health of patients. This review focuses on recent data obtained on a viral membranotropic peptide
gH625 derived from herpes simplex type 1 and its use, as well as the advantages over other CPPs
as a drug delivery tool. The data summarized in this review suggest that membranotropic sequen-
ces represent a new and valuable tool for intracellular delivery for applications in theranostics.
The opportunity to use a delivery tool with a different internalization mechanism may represent
the possibility of reducing the dosages and thus increasing the results of therapies, contempo-
raneously reducing toxicity.
In conclusion, nanothechnology is developing rapidly and is addressing the safety issue
correlated with the use of nanosystems as drug delivery systems, especially for long-term
applications. The use of QDs is also particularly important, as they represent a versatile platform
which combines unique physical, chemical, and optical properties that may facilitate in-depth
studies of interactions of nanosystems with biological systems through real-time monitoring of
biodistribution, intracellular uptake, drug release, and long-term fate. QDs offer a powerful plat-
form for studying the behavior of a diverse set of nanovehicles, leading to the design of novel
systems for drug delivery.
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Peptide inhibitors against herpes simplex virus
infections
Stefania Galdiero,a,b,c* Annarita Falanga,a,c Rossella Tarallo,a,c Luigi Russo,e
Emilia Galdiero,d Marco Cantisani,a,b,c Giancarlo Morellia,b,c and
Massimiliano Galdierob,e*
Herpes simplex virus (HSV) is a signiﬁcant human pathogen causing mucocutaneous lesions primarily in the oral or genital
mucosa. Although acyclovir (ACV) and related nucleoside analogs provide successful treatment, HSV remains highly prevalent
worldwide and is a major cofactor for the spread of human immunodeﬁciency virus. Encephalitis, meningitis, and blinding
keratitis are among the most severe diseases caused by HSV. ACV resistance poses an important problem for immunocompro-
mised patients and highlights the need for new safe and effective agents; therefore, the development of novel strategies to erad-
icate HSV is a global public health priority. Despite the continued global epidemic of HSV and extensive research, there have been
few major breakthroughs in the treatment or prevention of the virus since the introduction of ACV in the 1980s. A therapeutic
strategy at the moment not fully addressed is the use of small peptide molecules. These can be either modeled on viral proteins
or derived from antimicrobial peptides. Any peptide that interrupts protein–protein or viral protein–host cell membrane interac-
tions is potentially a novel antiviral drug and may be a useful tool for elucidating the mechanisms of viral entry. This review
summarizes current knowledge and strategies in the development of synthetic and natural peptides to inhibit HSV infectivity.
Copyright © 2013 European Peptide Society and John Wiley & Sons, Ltd.
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HSV Infections
Human herpesviruses (Herpesviridae family) consist of large,
enveloped, double-stranded DNA viruses that produce a pleteora
of infections ranging from skin ulcers to chickenpox to devastat-
ing diseases such as encephalitis. There are eight members of the
family that infect humans and are divided into three subfamilies,
a, b, and g. Such division is based on biological and genomic
similarities, and herpes simplex virus types 1 and 2 (HSV-1 and
HSV-2) and varicella-zoster virus belong to the a subfamily,
whereas cytomegalovirus and human herpesvirus types 6 and 7
belong to the b subfamily, and Epstein–Barr virus and human
herpesvirus type 8 are in the g subfamily. In addition, there is
a further a herpesvirus called herpes B virus, a simian herpesvirus
that can occasionally infect humans [1]. HSV infections are
among the most common diseases in humans, with an estimated
60–95% of the adult population being infected by at least one
of them.
All herpesviruses share the same structural characteristics that
render them undistinguishable at the mere observation under
the electron microscope. There is an electron-dense central core
containing the linear double-stranded DNA genome, which is
surrounded by an icosahedral capsid and a proteinaceous
tegument layer. This is further enclosed in a lipid envelope
presenting spike structures corresponding to virally encoded
glycoproteins.
Herpes simplex virus infections have a worldwide distribution
and have been described in the medical literature for centuries.
The spectrum of disease caused by both HSV-1 and HSV-2 is
impacted by the portal of entry, the host’s immune response,
and whether the infection is the result of primary infection or
viral reactivation. In particular, HSV-1 is more frequently
associated with oral disease, whereas HSV-2 is more frequently
associated with genital disease.
Following a primary infection of mucosal surfaces, HSV is
transported by retrograde axonal transport from the infected
mucosal area to ganglia of sensory neurons and then establishes
a latent infection. The viral DNA is maintained in neuronal nuclei
in the absence of any viral production, where the virus persists
for the whole lifetime of the host. Because latent infection does
not appear to require synthesis of viral polypeptides, antiviral
drugs are not able to eliminate the virus in the latent state.
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Despite the development of an immune response, reactivations
able to cause symptomatic or asymptomatic recurrent infection are
triggered by various internal or external stimuli, such as emotional
stress, trauma, fever, UV-light exposure, and immunosuppression.
From a clinical standpoint, HSV can cause diseases ranging
from mild conditions to lethal infections, especially in neonates
and immunocompromised patients. Primary infections and
reactivations are often subclinical. Asymptomatic shedding of
HSV, prompted by subclinical reactivations, occurs frequently in
infected individuals. HSV causes mucocutaneous lesions present
as vesicles or ulcerations on various parts of the body. Oropha-
ryngeal infection often results in gingivostomatitis, which is the
most common form of symptomatic, primary HSV infection of
the oropharynx. The acute illness usually lasts 5–12 days and
may be complicated by auto-inoculation at other sites such as
ﬁngers, nose, eyes, and genital area. After this initial infection,
HSV may become latent within the sensory nerve root ganglia
of the trigeminal nerve, and recurrent infections, deﬁned ‘herpes
labialis’, may occur, generally signaled by premonitory tingling or
burning in the area, and last for about 7 days. Reactivation may
happen without apparent mucosal lesions, but virus excretion is
present in the saliva.
Herpes simplex virus type 1 is involved in ocular infections and
may cause keratitis followed by the characteristic dendritic ulcer.
With recurrence of disease, there may be deeper involvement
with corneal scarring that can result in loss of vision; in fact, in
developing countries, ocular HSV infection is the prominent
cause of corneal blindness.
Genital HSV infection is often more severe and associated
with symptoms such as pain. Each episode lasts longer in primary
infection compared with reactivation. Genital herpes may be
complicated by aseptic meningitis. Both HSV-1 and HSV-2
can cause genital disease, and symptoms and signs of acute
infection are similar for both viruses. The main difference, how-
ever, can be considered the rare association with reactivations
of HSV-1, whereas HSV-2 may be associated with several reactiva-
tions per year.
Neonatal herpes is a serious infection predominantly caused
by HSV-2 as a result of the transmission of the virus during
delivery through infected genital secretions. HSV-1 can also be
responsible, as transmission may occur with a primary HSV-1
genital infection or via oral herpes from the mother or other
infected individuals that may have close contacts with the
newborn. The disease may be localized to skin, eye, and/or
mouth infections, or may be associated with neurological symp-
toms, or even as a disseminated disease with or without internal
organ involvement. In the absence of antiviral therapy, the mortal-
ity rates can reach 80% in the case of disseminated disease.
Another serious form of HSV infection is encephalitis, which is
conﬁned to the frontotemporal and parietal areas of the brain
and may progress rapidly to coma and death. HSV encephalitis
is a concern for all age groups, in both men and women. Most
cases are caused by HSV-1 and occur in adults with high levels
of anti-HSV-1 antibodies, suggesting that encephalitis generally
results from a reactivation of latent virus. In untreated patients,
mortality rates reach 70%, and only 2.5% of surviving patients
have no neurological sequelae.
Less common skin infections, due to auto-inoculation or skin-
to-skin contact, include ‘herpetic whitlow’, ‘eczema herpeticum’,
and ‘herpes gladiatorum’.
Herpes simplex virus may be particularly severe in immuno-
compromised patients, especially those with depressed cell-mediated
immunity. These patients present frequent reactivation episodes
that may be associated with prolonged viral shedding and persis-
tence of lesions [2].
HSV Replication Cycle
Over the past decades, scientiﬁc advances have heightened
the understanding of the life cycle and pathogenesis of HSV,
providing the framework for the development of novel treatment
compounds. At the start of infection, the virus attaches to, and
enters, the host cell. Although initial studies indicated that HSVs
enter cells by direct fusion with the plasma membrane at neutral
pH, further analyses revealed that HSV may also exploit endocy-
tosis for its penetration [3,4]. The reason why endocytosis is
required in some cell types is unclear, but it is possible that
multiple pathways may facilitate productive infection according
to different conditions encountered.
Attachment and entry are mediated by a subset of viral
envelope glycoproteins present on the herpesvirus envelope
(Figure 1); thus, the entry of herpesviruses is a complex process
in which multiple glycoproteins are required, and whereas some
of them are imperatively needed, others simply enhance entry.
The ﬁrst cellular receptor for HSV is heparan sulfate glycosamino-
glycans that have a strong afﬁnity for gC, but this interaction is
Figure 1. Schematic representation of HSV-1 membrane fusion mecha-
nism. The ﬁgure shows (starting from the left) the three fundamental steps
including herpesvirus entry mediator (HVEM)/gD complex formation, the
exposure of the gB fusion peptides with the formation of the trimer, and
the accomplishment of fusion.
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not essential for entry per se nor does it trigger downstream
fusion events. Following this large spectrum of interactions, the
main HSV receptor-binding protein is gD that binds three classes
of receptors: (i) herpesvirus entry mediator, a member of the
tumor necrosis factor receptor family, (ii) nectin 1 and nectin 2,
which are cell adhesion molecules of the immunoglobulin
superfamily, and (iii) 3-O-sulfated heparan sulfate [5–7].
Soluble forms of gD are able to trigger fusion; therefore, the
gD–receptor interaction is not only needed to tether the viruses
to the cell [8–10]; in fact, the C-terminal region of gD (the so-
called ‘pro-fusion domain’) is required to trigger fusion [8]. Once
gD is bound to one of its receptors, its C terminus undergoes a
side movement necessary for triggering the fusion [11]. Besides
binding heparan sulfate, gB can bind to paired immunoglobu-
lin-like type 2 receptor-a, an immune system regulator [12]. This
gB binding can also trigger fusion in the presence of gD, but
the in vivo signiﬁcance of the gB–paired immunoglobulin-like
type 2 receptor-a interaction is waiting to be investigated. A
receptor-binding role for gH–gL has also been reported, but it
has not been shown to be necessary for triggering for HSV entry,
at least in the available systems. The gH of HSVs contains an RGD
motif, which is thought to mediate attachment to integrins [13].
A soluble form of gH–gL binds to avb3 integrin-expressing
cells in an RGD motif-speciﬁc manner [14], and the engagement
of avb3 integrin by gH–gL in the virion may direct the route
of entry of HSV-1 [15].
After binding to one or multiple receptors and engaging a
series of protein–protein interactions, the virion fuses its enve-
lope with the host cell membrane. The envelope glycoproteins
gH/gL, gB, and gD are all essential for the entry process [16],
and the expression of this quartet of glycoproteins induces the
fusion of cellular membranes in the absence of virus infection
[17]. Recently, it was shown that gB and gH/gL interact with each
other concomitantly with fusion and that this interaction is
triggered by the binding of gD to its cellular receptor [18,19].
The recently solved crystal structures of the gH/gL ectodomains
showed that the gH/gL complex has no structural homology with
any known fusion protein [20–22]. Furthermore, in recent ﬁndings,
gH/gL was shown unable to induce hemifusion [23], and cells
transfected with varicella-zoster virus gH/gL in a vaccinia virus-free
model needed gB to accomplish fusion [24]. Thus, structural and
indirect data support the current model where gH/gL is mainly a
regulator of fusion through its interactions with gB. Nevertheless,
several studies suggest that gH/gL has intrinsic fusogenic capabil-
ity, which may be utilized by the virus under circumstances
different from the actually analyzed models of viral entry. In fact,
peptides derived from the gH ectodomain block virus entry
[25,26], whereas others have the ability to bind and disrupt model
membranes [27–35]. Moreover, gH/gL from HSV-1 was shown to
promote fusion of the virion envelope with the outer nuclear mem-
brane during viral egress [36]. On the other hand, the structures of
gB from HSV-1 [37] and Epstein-Barr virus [38] demonstrated that
gB has structural homology to other viral fusion proteins such as
the vesicular stomatitis virus G protein [39] and the baculovirus pro-
tein gp64 [40], and it is a key fusion protein of the HSV envelope.
Moreover, several synthetic gB peptides induced the fusion of large
unilamellar vesicles and inhibited herpes virus infection [41,42].
The described fusion process delivers the viral nucleocapsids
into the cytoplasm, where they latch onto microtubules, and
are transported to the nuclear envelope. There, they bind to
nuclear pores, and the viral DNA is released into the nucleus
where replication ensues.
Anti-Herpetic Drugs: Identiﬁcation and
Development of Peptide Inhibitors
Herpes simplex virus remains a major global health problem,
and diverse treatments are available for primary and recurrent
diseases. However, being many infections asymptomatic, the
diffusion of the virus is constantly increasing. Despite the fact
that evaluation of vaccination strategies against HSV has been
extensively pursued in the past, the virus resulted elusive at the
point that an HSV vaccine is still not available.
However, over the past 40 years, antiviral agents for the
treatment of infections due to HSV have been developed, and
currently, three classes of drugs are licensed for the treatment
of HSV infections, and all target the viral DNA replication. These
are the following: (i) the nucleoside analogs [acyclovir (ACV),
famciclovir, and valaciclovir], (ii) the acyclic nucleotide analog
cidofovir, and (iii) the pyrophosphate analog foscarnet [43].
Despite the efforts, ACV remains the reference treatment for
HSV infections and the prototypic antiviral agent. The success
of ACV is due to the notably safety proﬁle of the compound that
needs to be activated by the virally encoded thymidine kinase,
therefore enabling the drug to overcome the main safety
problems encountered by previous antiviral drugs and separating
interference with viral replication from the killing of the host cell.
Resistance of HSV to ACV has become an important clinical
problem, especially among immunocompromised patients
undergoing long-term therapy [44]. Viral resistance to ACV usually
arise from mutations in the viral thymidine kinase gene, although
mutations in the viral DNA polymerase gene may rarely occur.
Resistant isolates can cause severe, progressive, debilitating
mucosal disease, and, rarely, visceral dissemination [45,46].
The other two drugs used in the therapy of HSV infections
are cidofovir, which is an acyclic nucleotide phosphonate, and
foscarnet, a pyrophosphate. Both are independent of phosphoryla-
tion by viral enzymes and, therefore, not susceptible to thymidine
kinase mutations. However, being both nephrotoxic, they are
reserved for conﬁrmed cases of ACV resistance [47–49]. Although
these agents have proven to be efﬁcacious in the treatment
of HSV infections, the risk of adverse effects and the frequent
development of drug-resistant strains of HSV make it imperative
to discover new antiviral agents with lower toxicity, more
convenient regimens, and less susceptible to resistance emer-
gence. Several viral and cellular products have been investigated
in recent years to ﬁnd different targets with different mechanisms
of action, and literature has been ﬁlled by scientiﬁc reports of the
in vitro anti-herpetic activity of a wide variety of natural products
and synthetic compounds [50–54].
Besides the numerous strategies being pursued for the
development of traditional molecules with enhanced efﬁcacy,
the antiviral research is now exploring new avenues, such as anti-
viral peptides. These peptides may prevent viral attachment to
host cell receptors (such as heparan sulfate) or inhibit the replica-
tion complex by interfering with protein–protein interactions,
dissociating the complex and/or inhibiting its formation
[25–31,41,55]. In recent years, a further promising strategy to de-
velop anti-HSV compounds is the use of the so-called antimicro-
bial peptides (AMP) (Table 1) [56].
Peptides have several advantages over traditional chemical
compounds. In fact, they can be highly speciﬁc and effective, they
can be biodegraded by peptidases limiting their accumulation in
tissues and resulting in lower toxicity, and, most importantly, they
can exert a broad activity on different microorganisms. Potential
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drawbacks of the use of peptides are their limited ability to cross
membrane barriers (at least for some of them), a short half-life
(rapid blood clearance) and potential immunogenicity [57],
complex modes of action, high production costs, and poor oral
absorption, thus often necessitating intravenous administration
[58,59]. Nevertheless, it is possible to overcome these limitations
through the use of new technologies for modifying these
molecules and their stability/delivery properties. Various attempts
have been made to improve peptide’s characteristics toward the
optimization of physicochemical parameters through the introduc-
tion of D-amino acid or ﬂuorinated amino acids, by constraining
their conformations and by modiﬁcation with polymers. These
methodologies are useful for improving resistance to natural
proteases and thus half-life in serum and oral administration. Further-
more, lipidization and glycosylation may enhance cell adhesion of
the peptides and transmembrane delivery [60]. Synthetic analogs
are also useful for disclosing the structural requirements for peptide
antiviral activity, which are often correlated to both high cationic and
amphiphilic character as well as to the spatial positioning of
the charged residues. Moreover, it has also been demonstrated that
peptide analogs with arginine residues have a higher afﬁnity to
heparin sulfate than analogs substituted with lysines [61]. The chal-
lenge in the near future will be to overcome the current limitations
of antimicrobial peptides and develop them, at a reasonable cost,
into therapeutics with powerful antiviral activity.
Antiviral Activity of Antimicrobial Peptides
Antimicrobial peptides are a class of peptides with a broad
spectrum of antimicrobial activity, which have been isolated from
vertebrates and invertebrates [62]. A huge number of host
defense peptides has been described to date, and most of them
are present in databases for eukaryotic host defense peptides
(http://www.bbcm.units.it/~tossi/pag1.htm; http://cnbi2.ca/cgi-
bin/amp.pl) [63].
Antimicrobial peptides are widely distributed in nature and
appear to play important roles in innate host defenses against
bacteria and fungi [64]. These peptides usually display a broad-
range activity as they act on bacteria, fungi, metazoans and other
parasites, viruses, and even cancer cells. The most common
classes of cationic peptides comprise the following: b-sheet
peptides stabilized by disulﬁde bridges and unstructured
peptides that fold into amphipathic a-helices upon contact with
membranes. Less common are unstructured peptides with a
predominance of one or two amino acids such as histidine,
glycine, proline, or tryptophan. Most AMPs carry a positive net
charge and adopt an amphipathic structure.
Although antibacterial activity of cationic peptides has been
extensively studied, little is known about their ability to act as
antiviral agents. In particular, the lack of sequence homology
among the different peptides makes it difﬁcult to predict their
antiviral and cytotoxic activities; moreover, their mechanism of
action is still poorly understood. However, the mechanism of
antiviral activity may be related to the viral adsorption and entry
process [65] or to a direct effect on the viral envelope [66],
indicating that the amphiphilic conformation assumed upon
membrane interaction plays a key role.
Among the selected examples of HSV antiviral AMPs reported
in Table 1, the most noteworthy mammalian AMPs are defensins.
These are characterized by a triple-stranded b-hairpin structure,
six conserved cysteine residues forming three disulﬁde bonds,
and a positive net charge. On the basis of the pattern of disulﬁde
bonds, two main subfamilies are distinguished: the a-defensins
and the a-defensins. Six a-defensins (human neutrophil peptides
1–4 and human defensins 5 and 6) and four b-defensins (hBD-1
to hBD-4) have been identiﬁed in humans. The a-defensins and
b-defensins show broad antibacterial activity and have
antifungal and antiviral properties. a-Defensins and θ-defensin
(retrocyclin 2) target viral glycoproteins involved in membrane
fusion. In particular, it has been demonstrated that θ-defensin
directly binds HSV-2 glycoprotein B with high afﬁnity, thus
protecting cells from HSV-2 infections [67]. The antiviral activity
of human b-defensins against enveloped viruses such as HSV-1
and HSV-2, immunodeﬁciency virus type 1 (HIV-1), vesicular
stomatitis virus, inﬂuenza virus, and cytomegalovirus has been
ascribed to the direct inactivation of viral particles [68]. The
antimicrobial activity of hBDs 1, 2, and 4, but not hBD3, is
impaired by high salt levels. Novel hBD analogs, constituted by
different domains of hBD1 (which is constitutively expressed in
humans) and of hBD3 (which is induced by microorganisms and
inﬂammatory factors in humans), have been engineered to
maintain their antimicrobial activities and be salt-resistant.
Antiviral activity against HSV was enhanced by the hybrid chimera
constituted by the hBD1 internal region and the hBD3 C-terminal
region [69,70].
Tachyplesin I (TP) is a disulﬁde-linked 17-residue antimicrobial
peptide produced from the hemocytes of the horseshoe crab
Tachyplesus tridentatus [69]. It causes calcein leakage in phospha-
tidylglycerol-containing lipid vesicles and forms anion-selective
pores. In a process that is concomitant with pore formation, TP
translocates across the membrane. It adopts a b-hairpin confor-
mation with straight strands, suggesting that TP is immersed in
the glycerol backbone region of the membrane and is oriented
roughly parallel to the plane of the membrane. This depth of
insertion and orientation differs from those of the analogous
b-sheet antimicrobial peptide protegrin-1 and suggests the
importance of structural amphiphilicity in determining the
location and orientation of membrane peptides in lipid bilayers.
TP has been found to exhibit antiviral activity against HSV but
with a more pronounced ability to inactivate HSV-2 [71].
Mytilin is a 34-residue antibacterial peptide from the mussel
Mytilus galloprovincialis and possesses signiﬁcant in vitro antiviral
activity. The three-dimensional solution structure of the synthetic
mytilin consists of the common cysteine-stabilized ab motif close
to the one observed in the mussel defensin MGD-1. Mytilin is
active against HSV-1 and presents a low percentage of inhibition
in an assay where peptides and viruses were added simultaneously
to the cells, but a complete inhibition of viral replication in a cell
pretreatment assay. Therefore, it is possible that it exerts its antiviral
activity through a competition with the viral attachment/entry sites
for binding to cell surface [72].
Penaeidins are a family of antimicrobial peptides of 47–62 residues
isolated from several species of shrimp [73]. These peptides display
a proline-rich domain (N-terminal part) and a cysteine-rich domain
(C-terminal part) stabilized by three conserved disulﬁde bonds.
Penaeidin-3 of Litopenaeus vannamei is a 63-residue peptide; the pro-
line-rich domain, spanning residues 1–28, is unconstrained, whereas
the cysteine-rich domain, spanning residues 29–58, displays a well-
deﬁned structure, which consists of an amphipathic helix (residues
41–50) linked to the upstream and downstream unstructured
sequences by two disulﬁde bonds (Cys32–Cys47 and Cys48–Cys55).
These two unstructured portions are in turn linked together by the
third disulﬁde bond (Cys36–Cys54). Such a disulﬁde bond packing
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gives rise to the amphipathic character required for antimicrobial
peptides. Penaeidin-3 exhibited a signiﬁcant activity against
HSV-1 in an assay where peptides and viruses were added
simultaneously; at 100-mM concentration, it inhibited over 85%
of the viral replication [72].
It has been reported that a-helical peptides can act as virucidal
agents or as inhibitors of virus multiplication. a-Helical peptides have
been isolated from diverse organisms. Two major types of a-helical
peptides have been isolated from insects: melittin, a 26-amino-acid
peptide that is the major component of bee venom, and cecropins,
a family of antibacterial peptides, 35–39 amino acid residues in
length[74]. Whereas melittin, at high concentrations, is lytic for blood
red cells, cecropins appear to be nontoxic for mammalian cells [75].
The antiviral activity of melittin against several enveloped viruses
has been attributed to the direct lysis of viral membranes; however,
at lower non-virolytic concentrations, melittin exhibits inhibitory ac-
tion against HSV-1, HSV-2, and HIV-1 [76,77]. Even though the mech-
anism of action of melittin has not been completely elucidated, its
broad spectrum of antiviral action might be related to the ability
of this peptide to affect ion gradients across the cell membrane.
However, this compound is too toxic to consider it as a valuable
antiviral agent. Among cecropins, it has been demonstrated that
cecropin A inhibits HIV-1 multiplication in acutely and chroni-
cally infected cells.
Magainins I and II are 23-residue a-helical peptides isolated from
the skin of the frog Xenopus laevis, which differ by substitutions in
positions 10 and 22 [78,79]. Magainins I and II were found to be ac-
tive against HSV-1 and HSV-2. The antiviral activity of several syn-
thetic derivatives of magainin against HSV-1 has been attributed
to their virucidal action [80], and similarly, also synthetic analogs
of magainins display virucidal action toward HSV-1 [80].
Among microbicidal peptides, a family of ﬁve linear, lysine-rich
peptides designated dermaseptins S1–S5 were isolated from
the skin of a tree-dwelling, South American frog (Pyllomedusa
sauvagei) [81]. They are 28–34 membered peptides with high
levels of sequence homology (94% amino acid positional
identity). These peptides can adopt an amphipathic a-helical
conformation that appears to play an essential role in selective
membrane recognition. In this respect, they are similar to other
families of amphipathic helical peptides, such as bombinins and
magainins, isolated from other frog species [78]. Even structurally
unrelated antimicrobial peptides from distant species such as
insects and mammalians tend to be amphipathic. The marked
cationic character of vertebrate peptides and their ability to form
amphipathic structures in the presence of biological membranes
allow these peptides to be inserted into phospholipid bilayers
and to disturb their organization, thus resulting in membrane
permeation and lysis of target cells. Dermaseptin S4 has been
shown to inhibit HSV-1 multiplication in Hep-2 cells, probably
through interference with virus–cell surface interactions [65].
The other four dermaseptins, despite their high degree of
sequence homology to dermaseptin S4, were less effective. This
suggests the importance of speciﬁc parameters such as charge
distribution and hydrophobicity in the polar site for the expres-
sion of the antiviral activity.
Cathelicidins are a major family of mammalian proteins that play
various roles in host defense and inﬂammation [82]. Cathelicidins
are characterized by a conserved N-terminal domain that is proteo-
lytically cleaved to generate the mature, active peptides contained
within the C-terminus. The prosequence is highly homologous to
cathelin, an inhibitor of the cysteine protease cathepsin L. The
C-terminal domain consists of a-helical or b-hairpin portions or
contains unusual amino acids [83]. In some mammals, multiple
cathelicidins are found, whereas in humans, only one cathelicidin
is present, representing an a-helix-type AMP called LL-37. Consider-
ing its small size and relatively simple structure, it is remarkable that
LL-37 contains all of the necessary information to perform its di-
verse functions, including antimicrobial activity, chemotactic effects
that contribute to immune responses, release of inﬂammatory
mediators, transcriptional responses, and wound healing as well
as antiviral activity against herpes virus. LL-37 is water soluble, but
it spontaneously binds to bacterial LPS and lipid bilayers and
permeabilizes microbial membranes, leading to rapid cell death.
LL-37 binds to lipid bilayers in an a-helical conformation with the
helical axis lying parallel to the plane of bilayer [84]. Bovinemyeloid
antimicrobial peptide, BMAP-28, also belongs to the cathelicidin
family. BMAP-28 structure is characterized by an N-terminal region
that forms an a-helical conformation in membrane-mimicking
environments and a non-helical, hydrophobic C-terminal region. It
kills Gram-negative and Gram-positive bacterial and fungal species
at micromolar concentrations. It retains strong and broad-spectrum
antimicrobial activity in the presence of physiologic salt concentra-
tions [85], and it exhibits antiviral activity against HSV [86].
A further bovine cathelicidin with broad-spectrum activity is
indolicidin. Indolicidin, a 13-amino-acid peptide with unordered
structure and a high content of tryptophan, isolated from bovine
neutrophils showed direct viral inactivation against HIV-1[66]; it also
showed a strong virucidal action against HSV-1 and HSV-2. The
reduction of HSV yields caused by indolicidin can be ascribed to a
direct inactivation of progeny viruses released from indolicidin-
treated cells. However, an inhibitory effect of indolicidin on HSV
multiplication cannot be excluded.
Brevinin I was ﬁrst isolated from an extract of the skin of the
Japanese pond frog Rana brevipoda porsa [87], but subsequent
work has shown that orthologous peptides are synthesized in
the skins of a wide range of Eurasian and North American species
belonging to the family Ranidae.
Brevinin and indolicidin also showed that peptide-mediated
inactivation of HSVs is not simply a manifestation of indiscriminate
damage to target cell membranes. Although both peptides were
potently antiviral, they showed little (indolicidin) or none ((carbox-
amidomethylated) CAM -brevinin) hemolytic activity, and they
caused minimal cytotoxicity[71]. Antiviral compounds are consid-
ered to have promise when there is a tenfold difference between
the ID50 for antiviral potency and the EC50 for cytotoxicity using
a range of drug doses. By this criteria, both CAM-brevinin and
indolicidin show great potential as antiviral agents against HSVs.
The milk protein lactoferrin (LF) is a multifunctional glycopro-
tein, which plays an important role in immune regulation and
defense mechanisms against bacteria, fungi, and viruses [88,89].
Upon peptic digestion of LF, a peptide called lactoferricin (Lfcin)
is generated. Lfcin corresponds to the N-terminal part of the
protein [90]. Lfcin peptides have also shown anti-HSV activity
[88,89,91]. It was recently reported [92] that Lfcin can block
genital herpes infections in mice and perhaps also be used for
post-infection treatments. In the LF molecule, the Lfcin sequence
forms an amphipathic a-helical sequence [93,94], but after pepsin
cleavage, the peptide changes into a distorted b-sheet [95].
Alloferon is a tridecapeptide isolated from the bacteria-
challenged larvae of the blow ﬂy Calliphora vicina [96]. It is
interesting that not only its primary structure is similar to some func-
tionally relevant proteins, such as inﬂuenza virus B hemagglutinin,
bovine prion protein I and II, and Sarcophaga peregrina antifungal
protein, but also that it has antiviral activity against HSV.
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Antiviral Activity of Peptides Derived from
HSV-1 Envelope Glycoproteins
Infection of a target cell by enveloped viruses requires a virally
mediated mechanism to promote membrane fusion [97,98]. This
mechanism seems surprisingly conserved across several diverse
viral families, which makes the fusion process a potentially
attractive target for antiviral drugs [99,100]. Enveloped viruses use
transmembrane viral proteins to mediate fusion with host cell
membranes [101–103]. These glycoproteins undergo several con-
formational rearrangements during the fusion process, and several
domains that are buried in the prefusion structure may be exposed
in the fusogenic structure. As reported earlier, the fusion mecha-
nism of HSV is still unknown, and several domains of fusion glyco-
proteins have shown antiviral activity. Recent evidences suggest
that helical domains as well as surface loops may play an important
role in the viral fusion process and represent possible targets for
therapeutic interference. In particular, helical sequences derived
from gH [25] and gB [25] have shown the ability to inhibit HSV-1
infection of susceptible cells. Moreover, sequences showing fuso-
genic ability were also demonstrated to exhibit inhibitory activity
[25–31,41,42,104,105]. Several laboratories reported that peptides
homologous to heptad repeat (HR) regions of gB and gH of HSV-
1, bovine herpes virus type 1, and human cytomegalovirus and thus
with high probability of forming coiled coils are able to inhibit
infection, thus indicating that these regions of the proteins are
functionally signiﬁcant [25,35,106,107]. These studies were fostered
by the appreciable results obtained analyzing the counterpart
regions of HIV-1. Assuming that viral–cell fusion progresses by
formation of an intermediate, a ‘prehairpin’ conformation, this
structure places the N-terminal fusion peptide near or in the target
cell membrane, exposing the HR1 and HR2 regions [97]. In this
intermediate, both HR regions can bind synthetic peptides, which
can thus inhibit viral infection by preventing formation of the
fusogenic trimer-of-hairpins. Indeed, HR2 peptides analogs (among
which is Enfuvirtide) are potent inhibitors of HIV-1, active at low
nanomolar concentration [108,109]. A competitive interaction with
the HR1 domain and prevention of the six-helix bundle conforma-
tion has been proposed as the mechanism of inhibition [110].
In HSV-1, two helical regions in gH and two in gB were identiﬁed,
and peptides of different lengths that correspond to the predicted
coiled-coil regions were produced and tested in inhibition assays
[25,34,35]. gH-Derived peptides weremore effective than gB-derived
peptides in inhibiting virus infectivity especially when added to virus
before or during inoculation onto cells. The mechanism of action of
HSV-derived peptides must differ from the ‘canonical’ dominant-
negative refolding inhibition of the HIV HR-fusion inhibitors. The
probable existence of interactions between gB and gH during fusion,
also involving unknown domains of these glycoproteins, represents
an explanation for the inhibitory effect on virus infectivity exerted
by peptides that may disrupt protein–protein interactions essential
for the fusion process.
Those studies clearly indicated that peptide-based approaches
can be useful in identifying functionally important regions of
herpesvirus glycoproteins and, therefore, potential inhibitors.
Furthermore, analogs of the orthomyxovirus, paramyxovirus,
and HIV fusion peptides [111–113] block viral infection, presum-
ably by forming inactive heteroaggregates. Development of
peptide fusion inhibitors based on non-HR regions of the viral
fusion protein has also been performed. It is by using a physico-
chemical algorithm, the Wimley–White interfacial hydrophobicity
scale in combination with other structural details, that different
regions of gH and gB were predicted to be involved in mem-
brane interactions during the entry and fusion process [27].
Because of the nature of the membrane fusion process, func-
tional regions in these viral glycoproteins need to be accessible
(surface exposed), hydrophilic, and ﬂexible, because these prop-
erties have been found to be important for the protein–protein
interactions, necessary for the activation of the fusion event.
Therefore, these regions could be used for the design of antiviral
peptides. Two recent studies analyze with bioinformatic tools,
through improvements of existing algorithms, the druggable
regions in viral fusion proteins to optimize peptide hits as
potential inhibitors capable of disrupting the protein–protein
interactions in membrane fusion events mediated by viral fusion
proteins [114,115].
Five peptides (gH220–262, gH381–420, gH493–537, gH493– 512,
and gH626–644), corresponding to the domains with high scores of
the Wimley and White hydrophobicity, which are able to interact
with biological membranes[27], have been screened for their ability
to inhibit plaque formation in a dose-dependent inhibition assay of
HSV entry[26]. Two of them, peptides gH493–537 and gH626–644
were able to inhibit HSV entry by approximately 50–60% at
250mM and 60–70% at 500mM. The shorter peptide gH493–512,
corresponding only to the N-terminal part of gH493–537, was able
to inhibit HSV entry even more effectively, resulting in approxi-
mately 60% inhibition at 250mM and 90% at 500mM. Their inhibitory
effect appears conditioned by their ability to partition into
membranes and aggregate within them. Because the peptides
self-associate in aqueous and lipidic solutions, it is possible that
they bind to their counterparts in the HSV-1 gH fusion protein, thus
suggesting that the inhibition of viral entry may occur via peptides
association with their counterpart on wild-type gH. Further studies
are required to deﬁne the exact inhibitory mechanism, but it is
conceivable that gH493–512 and gH626–644 may sterically hinder
their relative domain either in a pre-fusogenic or in an intermediate
conformation, preventing a complete and functional interaction
between gH and the membrane to fuse.
The pre-transmembrane domain of HIV-1 gp41 has been
found able to inhibit fusion in a dose-dependent manner [116]. This
suggested the possibility of using peptides derived from such
domains for the development of fusion inhibitors. Synthetic peptides
derived from amino acid residues 761–810 (the pre-transmembrane
region of HSV-1 gH) have been proved capable of inhibiting HSV-1
entry [28]. This region might undergo sequential conformational
transitions, from an extended arrangement to a helical structure
capable of intimately interacting with the viral membrane and
concomitantly with the cell membrane. Thereby, isolated peptides
modeled on the pre-transmembrane region of gHmay interfere with
completion of the fusion step during viral entry.
Also, the amino acid sequence of gB has been screened
for regions of highly interfacial hydrophobicity, applying the
hydrophobicity-at-interface scale proposed by Wimley and White
[117], and synthetic peptides corresponding to such regions
have been tested for their ability to inhibit virus infection. Peptides
HB168–186, HB491–514, and HB632–650 showed dose-dependent
inhibition of HSV infectivity when present on the cell monolayers to-
gether with the virus inoculum for a 45-min period prior to low pH
treatment. The most active peptides were HB632–650 and HB491–
514 with approximately 90% inhibition at peptide concentrations
of 250mM. These results have been conﬁrmed in an independent
study [118] where a library of 138 overlapping 15-mer peptides
encompassing the ectodomain of gB was tested in search of pep-
tides able to inhibit HSV infection. Seven of the 138 peptides tested
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positive by reducing infection by 50% or more at a presumed con-
centration of 100mM in the initial high-throughput screen. When
highly puriﬁed peptides were retested, three of the seven peptides
(gB94, gB122, and gB131) had (half maximal effective concentration)
EC50 values of less than 20mM. These peptides, especially gB94 and
gB 122 that partially overlap with HB491–514 and HB632–650[41],
represent useful lead compounds to be further developed as inhibi-
tors of HSV-1 infection.
In response to the increasing need for improved antiviral drugs,
dendrimer-based molecules have a large number of potential thera-
peutic applications [119,120]. Dendrimers are highly branched
macromolecules that are built up in layers (generations) from a
reactive core group by the use of branched building blocks and
represent a very promising tool for drug delivery[121] and cellular
inhibition combining the advantageous features of nanoparticles
(ideal size as in vivo carriers andmultivalency), of polymeric materials
(low cost, tunable properties, and biocompatibility), and of small
molecules (monodispersity and detailed control of their properties)
[104,122–124].
Their hyperbranched structures allow the exposure of a given
molecular motif in a highly multivalent fashion, thus offering the op-
portunity to present multiple ligands, or sites of contact, on a single
molecule [119]. This feature provides an array of options for interfer-
ing with the infectivity of a virus particle and/or with the multivalent
binding interactions between a virus and its target cell. In fact, most
of the antiviral dendrimers identiﬁed to date have been found to
inhibit infection by blocking attachment of the virus to its target cell
following their binding to either the virus or the cell surface [125,126].
Thus, the ability of dendrimers to prevent virus–cell binding has
prompted the idea that they might also be used as topical microbi-
cides for reducing the spread of sexually transmitted infections
[126]. Proof of this concept has been provided from the develop-
ment of polyanionic dendrimers, such as SPL7013, a lysine-based
dendrimer with naphthalene disulfonic acid surface groups,
currently undergoing the expanded safety/phase II stage of clinical
development as a vaginal microbicide (known as ViVagel) for the
prevention of the transmission of sexually transmitted viral diseases
[127–130].
The functionalization of a perfectly symmetrical dendrimer
with the peptide sequence, gH(625–644), derived from viral
fusion proteins of HSV-I allowed the obtainment of a signiﬁcant
inhibition of HSV-1 (Figure 2), indicating that the dendrimer can
inhibit the interactions used by viruses to infect cells physically
blocking or otherwise interfering with the fusion mechanism
between the virus and the cell [131].
Conclusion
Despite the extensive research efforts in the battle against
the continuous increasing epidemic of HSV, there has been
limited advancement in the treatment of HSV infections since
the introduction of ACV. Mainly, the use of ACV and related drugs
has been optimized with respect to the different clinical necessi-
ties, but options for patients who develop drug-resistant variants
are still tremendously limited. Therefore, it is time to pursue
alternative approaches, and AMPs offer much promise for the
future as a complement to the limited number of actual antiviral
therapies. The idea of small peptide molecules displaying
antibacterial activity has been well established in the past few
decades, but the possibility of exploiting their bioactivity against
viruses is more recent.
A wide variety of organisms produce AMPs as part of their
ﬁrst defense. Indeed, AMPs have been isolated from single-cell
microorganisms, insects, and other invertebrates, plants, amphi-
bians, birds, ﬁsh, and mammals, including humans. In addition,
a huge number of synthetic peptides have been constructed
and among them are the so-called fusion inhibitors that have
been designed from a scaffold directly derived by the viral
fusogenic glycoprotein ectodomains.
Despite the huge diversity of source of origin, amino acidic
sequence as well as secondary structures, they share similar
general physical and membranotropic properties. They target
various steps in the viral cycle from receptor binding to replica-
tion and may be virucidal. In addition, some AMPs can also be
translocated into the cell cytoplasm and interact with intracellular
targets, interfering with nucleic acid or protein synthesis and
with enzymatic activity. Although most of these peptides are
in the initial stages of scientiﬁc study, the ﬁeld of antiviral
peptides is impressively growing. Therefore, it is of chief impor-
tance to understand the mechanisms underlying the antiviral
action of AMPs in order to consider this type of compounds as
potential useful antiviral agents against HSV and other viruses.
The use of viral peptides that could interfere in one of the
many steps of membrane fusion is also very attractive and
may represent another alternative to existing strategies against
herpesviruses.
The actual understanding has provided indications that the
strategy of developing antiviral peptides may be particularly
useful in this family of viruses, but the use of peptide drugs for
antiviral treatment is still in its infancy and needs novel efforts
and implementation of new technologies to make a substantial
contribution to the never-ending ﬁght against viral infections. In
summary, for antiviral peptides to effectively treat an infection,
some level of physical (structural), chemical, or composition
modiﬁcations is probably required to improve its overall pharma-
cokinetic properties. A therapeutic peptide will be likely to bemore
effective in vivo if used in conjunction with an appropriate delivery
system that can extend longevity of the therapeutic action or
improve its targeting to the site of infection. Therefore, the
application of nanomedicine to the issue of drug delivery makes it
possible that therapeutic antiviral peptides will expand to include a
wide range of viral infections.
Figure 2. Structure of the poly(amide)-based dendrimer functionalized
with the viral peptide gH625.
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Introduction
Crossing of the cellular membranes remains a major obsta-
cle for the delivery of therapeutics.[1] The aqueous extra-
and intracellular matrices are separated by a hydrophobic
lipid bilayer, which acts as a barrier separating the cellular
components from the extracellular milieu. Although small
molecules and ions can diffuse across this barrier, large con-
jugates with molecular weight over 500 amu are generally
excluded from simple diffusion into the cell.[2] Larger mole-
cules can be taken up endocytically, which allows them to
exist in the cell. However, the molecule is still separated
from the cytoplasm by an endosomal lipid bilayer.[3] In addi-
tion to size, membrane permeability is dependent on the hy-
drophilicity or lipophilicity of the molecule in question.[2]
Even the delivery of a potent drug can be foiled due to its
insolubility in either the aqueous cell environment or the
lipid membrane. These problems can be alleviated by com-
plexation to a macromolecular conjugate which assists the
cargos solubility and permeability into desired areas.[4]
Indeed, there are several recent reports of successful intra-
cellular delivery of macromolecular conjugates, which re-
lease their cargo through biological triggers (e.g., pH
changes or enzymatic cleavage).[5]
However, as many macromolecular drug conjugates are
internalized via active translocation mechanisms, for exam-
ple, endocytosis, they can exhibit poor activity due to the
cargo being unable to escape the endosome before lysoso-
mal degradation occurs.[1,3,4] Certain peptide sequences have
been shown to efficiently cross the cellular membrane.[6]
These cell-penetrating peptides (CPPs) are useful for the
transport of larger macromolecules across the membrane.[7]
Many CPPs act by an endocytic mechanism, trapping the
conjugate in an endosome.[8]
Our approach is based on a membrane-interacting peptide
that operates through a different internalization mechanism.
In particular, we are interested in viral peptides, such as
those derived from the herpes simplex virus type 1 (HSV-1).
These peptides are capable of internalizing cargo by induc-
ing membrane perturbation.[9] HSV-1 uses four glycopro-
teins, glycoproteins B (gB), D (gD), H (gH), and L (gL), to
mediate the viral–cell fusion and subsequent infection.[10]
We have previously reported that HSV-1 gH contains sever-
al domains that are mostly hydrophobic, suggesting that
these regions are those that interact with cellular mem-
branes.[11] One of these domains, His625–Phe644 (gH625),
showed great effectiveness in inducing lipid mixing of large
unilamellar vesicles (LUVs), showing its membrane-inter-
acting potential. These results suggest that this sequence
could be important in the interaction of viruses with
cells.[11–12] Figure 1 shows the sequence of this peptide. When
folded into an a helix, nonpolar residues tend to concentrate
on one side of the helix giving the peptide an amphiphilic
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character. We have described the use of this peptide for
membrane translocation and delivery of quantum dots into
cells.[13] These studies also showed that gH625 is nontoxic to
cells up to a concentration of 400 mm. Beyond this concen-
tration, gH625 was less toxic than the commonly used Tat
peptide. We further analyzed the properties of this peptide
by attaching it to liposomes. The conjugated liposomes
could successfully be used to deliver doxorubicin to cells,
showing that the peptide is able to deliver larger cargoes
inside cells.[14]
Liposomes are just one of the many scaffolds used to de-
liver drugs to cells.[15] Other widely used scaffolds include
micelles,[16] nanoparticles,[17] and dendrimers.[18] The benefits
and drawbacks of each have been reviewed previously.[18a,19]
Unlike many other scaffolds, however, dendrimers have the
benefit of a highly controlled synthesis as well as yielding a
single monodisperse compound, giving perfect control over
the size, weight, and terminal functionalities of the resulting
structure. Moreover, highly branched structures generally
exhibit longer blood circulation times due to their inability
to reptate through renal pores.[20] Dendrimers have been
shown to have extended lifetimes, in vivo,[21] whereas lipid
complexes are usually rapidly cleared from circulation by
splenic and hepatic phagocytes.[22]
Dendrimers are perfectly branched macromolecules with
well-defined structures.[23] They exhibit different properties
to linear polymers with the same composition and molecular
weight.[18a] The high concentration of terminal functional
groups on a dendrimers surface will generally dictate the
solubility of the entire compound; dendrimers have been
used as unimolecular micelles, that is, hydrophobic dendrim-
ers, that are water soluble due to peripheral hydrophilic
groups or vice versa.[24] Traditional dendrimers are synthe-
sized from monomers with the structure ABn.
[25] Addition of
another generation of monomers causes the dendrimer to
grow radially with an exponential increase in both mass and
number of free termini com-
pared to the previous genera-
tion, but only a minimal in-
crease in the physical size of
the structure. This causes the
termini to become more closely
packed.
Dendrimers represent a very
promising tool for drug deliv-
ery, combining the advanta-
geous features of nanoparticles
(ideal size as in vivo carriers,
multivalency), polymeric mate-
rials (low cost, tunable proper-
ties, biocompatibility) and small
molecules (monodispersity and
detailed control of their proper-
ties).[18a,26] Little information is
available on the mechanism of
dendrimer uptake and intracel-
lular trafficking.[27] Studies per-
formed on PAMAM dendrimers[28] and PAMAM dendrim-
ers functionalized with the CPP, Tat,[29] indicate that endocy-
tosis mechanisms contribute to the internalization and intra-
cellular trafficking. Some reports show that the cellular in-
ternalization mechanism of PAMAM dendrimers can be
tuned by altering surface charges or hydrophobicity, but
these uptake mechanisms are still mainly endocytic.[30] Other
reports show that dendrimers can successfully deliver car-
goes when terminated by guanidinyl units;[31] however, in
one case, it was shown that adding the Tat peptide failed to
enhance delivery efficiency over the native PAMAM den-
drimer.[29] Studies using cationic PAMAM dendrimers,
showed that they tend to insert into the lipid bilayer, which
has the potential of weakening or forming holes in the mem-
brane.[32]
Our goal is to combine the benefits of dendrimer chemis-
try with a cell-internalization unit that can cross the cell
membrane mainly via a non-active translocation mechanism.
Here we present the synthesis of a dendrimer containing ter-
minal peptide chains, and follow its cell uptake, in vitro. Our
dendrimers are poly ACHTUNGTRENNUNG(amide)-based following the 1!3 con-
nectivity scheme first reported by Newkome and co-work-
ers.[33] We chose these materials since poly ACHTUNGTRENNUNG(amide)-based
dendrimers have been shown to exhibit both high biocom-
patibility, due to the peptide-like backbone,[34] and low to no
toxicity to cells.[35] In order to attach the desired peptides to
the dendrimer scaffold, we synthesized a derivative of
gH635 containing a propargylglycine (PrA) residue to intro-
duce an alkynyl handle. Our synthetic scheme involves the
synthesis of a monofunctional dendrimer with azide termini,
to which the peptides could be coupled by copper-catalyzed
azide–alkyne cycloaddition (CuAAC). The structure of pep-
tidodendrimer 1, the poly ACHTUNGTRENNUNG(amide) dendrimer terminated by
gH625 peptides, is shown in Figure 2.
Figure 1. Top: sequence of the gH625 peptide. Bottom: helical wheel projection of gH625. Nonpolar residues
are signified by circles, uncharged polar residues by squares, and basic residues by diamonds.
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Results and Discussion
Synthesis of the octadecaazide dendrimer : The second gen-
eration Newkome-style dendron 2 was first functionalized at
the amine terminus with succinic anhydride to afford the
hemisuccinate dendron 3. Coupling dendrons 2 and 3 by
using 2-[7-aza-1H-benzotriazol-1-yl]-1,1,3,3-tetramethyluro-
nium hexafluorophosphate (HATU) as coupling agent af-
forded the symmetrical dendrimer 4. Acidic deprotection of
the terminal tert-butyl esters resulted in the formation of the
octadecaacid dendrimer 5. Reaction between the terminal
carboxylic acid groups and an azido-terminated amine
linker afforded the octadecaazide dendrimer 6 (Scheme 1).
Functionalization of the dendrimer : The gH625 peptide se-
quence was synthesized with a propargylglycine residue
(PrA) at the C terminus to provide a handle for the CuAAC
reaction. Functionalization of 6 was performed in a water/
methanol solution (1:1 v/v) by using CuSO4·5H2O as catalyst
and sodium ascorbate as reducing agent (Scheme 2). The
complete functionalization of peptidodendrimer 1 was con-
firmed by determining the amount of peptide attached by
UV analysis (lgH625=7000m
1 cm1 at l=280 nm)[11] and
comparing this to the amount of dendrimer initially used for
reaction (18 mol peptide per mol dendrimer). IR analysis
showed the disappearance of the azide stretch at 2098 cm1
confirming that within the instrumental error range, all
azides were consumed, thus suggesting complete functionali-
zation of the dendrimer with peptides was obtained (see the
Supporting Information). The functionalization was also per-
formed by using the same peptide containing a nitrobenzo-
furazan fluorescent tag (1–NBD) and an alkynyl fluoro-
phore (7). All sequences used for functionalization are
shown in Table 1. Functionalization of dendrimer 7 was also
confirmed by UV/Vis spectroscopy (lNBD=1696m
1 cm1 at
l=452 nm; see the Supporting Information).
Structure of the peptidodendrimer : As previously report-
ed,[11] the gH625 peptide adopts a random coil in aqueous
Figure 2. Structure of peptidodendrimer 1. The helices represent the
gH625 peptide sequence.
Scheme 1. Synthesis of the azide-terminated dendrimer used in this study.
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media, but forms an a helix in membrane-mimetic environ-
ments. Circular dichroism (CD) spectra in several percen-
tages of trifluoroethanol (TFE, allowing the solution to
mimic the environment of the membrane) show that gH625
at a concentration of 8 mm adopts an a helix (Figure 3A).
The CD spectra of the peptidodendrimer at a peptide con-
centration of 8 mm (18 peptides per dendrimer; concentra-
tion of dendrimer=0.4 mm) exhibited a shape indicative of
an a helix, suggesting that the secondary structure of the
peptide was not disturbed by attachment to a dendrimer
(Figure 3B).
The size of peptidodendrimer 1 increased greatly upon
the addition of the peptide sequences. Dendrimer 6 is too
small to be accurately resolved by most techniques, but the
increase in size after the addition of the peptides makes it
resolvable by light scattering and non-optical microscopy
techniques. Dynamic light scattering (DLS) measurements
were complicated by significant aggregation, most likely due
to the dendrimers relatively hydrophobic terminal peptides
in aqueous solution. At low concentrations, a signal was ob-
served corresponding to a hydrodynamic radius of 5.6-
ACHTUNGTRENNUNG(1.5) nm (see the Supporting Information). This was con-
firmed by scanning transmission electron microscopy
(STEM), which gave an average particle diameter of 12.66-
ACHTUNGTRENNUNG(0.82) nm (see the Supporting Information).
Fusogenic properties of the peptidodendrimer : Peptide
gH625 has been previously characterized,[12b,13] indicating its
strong interaction with LUVs, although the exact mecha-
nism of interaction awaits complete understanding. We have
previously shown that gH625 penetrates into the membrane,
but the peptide does not form pores inside the bilayer.
Here, in order to understand
the membrane interacting be-
havior of the peptide when
linked to the dendrimer, we
performed lipid mixing, inner-
monolayer fusion, and leakage
experiments as indicators of the
interaction and perturbation of
the lipid membrane caused by
the peptidodendrimer
(Figure 4).
After establishing the size
and degree of functionalization
of our peptide dendrimers, we
carried out lipid-mixing experi-
ments (Figure 4A). For these
studies, a population of 55:45
phosphatidylcholine/cholesterol
(PC/Chol) LUVs labeled with nitrobenzoxadiazole- and
rhodamine-phosphatidylethanolamine (NBD-PE and Rho-
PE) was mixed with a population of unlabeled LUVs, and
increasing amounts of gH625, dendrimer 6, or peptidoden-
drimer 1 were added. Dilution of the fluorescently labeled
vesicles by membrane fusion induced a reduction in the flu-
orescence energy transfer efficiency, hence dequenching of
Scheme 2. Functionalization of dendrimer 6 by CuAAC reaction. Shown is the functionalization with gH625 to
synthesize 1.
Table 1. Sequences used to functionalize dendrimer 6.
Name Sequence[a] Compound
gH625 NH2-HGLASTLTRWAHYNALIRAFX-CONH 1
gH625–NBD NBD-HGLASTLTRWAHYNALIRAFX-CONH2 1–NBD
NBD–CCH NBD-CH2CCH 7
[a] X=propargylglycine, NBD= (7-nitrobenzofurazanyl)amino.
Figure 3. CD spectra of: A) peptide gH625, and B) peptidodendrimer 1
at 8 mm (8 mm peptide corresponds to a dendrimer concentration of
0.4 mm) in aqueous solution with varying amounts of TFE: 0% (c),
20% (g), 40% (a), 60% (c).
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the donor fluorescence. In order to compare data, the per-
centage of lipid mixing as a function of the peptide to lipid
molar ratio was calculated. The peptide and 6 induced low
levels of fusion at the concentration at which 1 induced high
levels of fusion. In particular, we observed a significant in-
crease of activity with the peptidodendrimer system. This
shows that the peptidodendrimer is even more effective
than the native peptide at interacting with and fusing lipid
membranes, showing its efficacy as a membrane-perturbing
agent.
In the inner-monolayer fusion assay, the fluorescence
from the vesicle membranes outer monolayer is eliminated
by the addition of an aqueous reducing agent, and this ex-
periment reveals the extent of lipid mixing between the
inner monolayers of vesicles in solution. Figure 4B shows
that gH625, 6, and 1 show only slightly lower inner-mono-
layer fusion than the total fusion observed from the lipid-
mixing experiment. This indicates that under these experi-
mental conditions, all three compounds were able to induce
fusion significantly to both the inner and outer lipid mono-
layers; ergo, we can confirm that the peptide, dendrimer,
and peptidodendrimer are all able to interact strongly with
and penetrate inside the lipid bilayer.
A contents-mixing assay was employed to monitor any
mixing of internal vesicle components as a result of vesicle
exposure to the peptide or the peptidodendrimer 1. Release
of ANTS (1-aminonaphthalene-3,6,8-trisulfonate) and DPX
(p-xylene-bispyridinium bromide) from the vesicle is com-
monly used as a measure of bilayer perturbation and is in-
terpreted as “transient pore formation”.[36] Contents-mixing
is manifested by a decrease in fluorescence intensity if vesi-
cles encapsulating the fluorescent cargo (e.g., ANTS) merge
contents with those containing quenchers (e.g., DPX). No
contents-mixing occurs under the same conditions and pep-
tide/lipid ratio range at which substantial outer monolayer
lipid-mixing was observed (data not shown); this corrobo-
rates the presence of vesicle hemifusion within our system
not only for the peptide alone but also for the peptide–den-
drimer system.
The present results can be used as qualitative indicators
of the peptidodendrimer translocation or bilayer perturba-
tion, with relevance for the direct penetration mode of cell
entry, or for the steps of endosomal membrane translocation
or endosomal escape. Using peptidodendrimer 1, we have
not detected any significant pore formation; vesicle fusion
events were not accompanied by leakage of the aqueous
contents of the vesicle as was previously reported for gH625
and for other peptides.[13,37]
Flow cytometry measurements : We have determined the
fraction of the labeled peptide gH625–NBD and labeled
peptidodendrimer 1–NBD taken up by HeLa cells using
flow cytometry based on a method previously introduced by
McIntyre and Sleight to measure the transbilayer distribu-
tion of NBD–phospholipid analogues.[38] The distribution
was determined by comparing the fluorescence intensity
before and after addition of sodium dithionite, an essentially
membrane impermeant molecule, which suppresses irrever-
sibly the fluorescence of the accessible NBD moiety local-
ized on the external cell surface.
We incubated the peptide and the peptidodendrimer with
HeLa cells at 37 8C at different concentrations (1, 5, 10, and
20 mm in peptide). After 1 h incubation, we measured the
quenching of the NBD by dithionite treatment. The dithion-
ite reaction was performed at low temperature (4 8C) be-
cause the dithionite crossing of biological membranes is
strongly reduced compared to high temperatures.[39] Before
the addition of dithionite, we observed that approximately
90% of peptide gH625–NBD or 1–NBD was not washed
away, suggesting they were internalized or bound to the
membrane bilayer. After the addition of dithionite, the fluo-
rescence of the internalized peptide and 1–NBD were slight-
ly reduced (Figure 5A). Increasing the dithionite concentra-
tion did not result in a modification of the extent of quench-
ing, indicating that the entire accessible NBD label was
quenched by 1m dithionite (data not shown). To exclude the
possibility that the fluorescence signal could have been due
to the internalization of the fluorochrome itself, the NBD
Figure 4. Interaction of peptide gH625 (filled squares), dendrimer 6
(open circles), and peptidodendrimer 1 (filled circles) with PC/Chol
LUVs; the dose dependence is reported according to the concentration
of the peptides (18 peptides per dendrimer) and each trace represents an
average of three independent experiments. A) Lipid-mixing, B) inner-
monolayer assays.
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moiety was used in the same in vitro assay conditions; no
cellular fluorescence was observed at concentrations up to
20 mm.
To measure the kinetics of import into cells, we incubated
gH625–NBD and 1–NBD with cells at 37 8C for 10, 30, and
60 min, and then determined the remaining fluorescence fol-
lowing treatment with dithionite. Figure 5B shows the frac-
tion of molecules taken up by cells. The uptake is very rapid
and seems to reach a plateau after 1 h incubation.
The influence of temperature on the intracellular accumu-
lation was studied to investigate whether the uptake de-
pended on a passive translocation mechanism or an active
process. We incubated gH625–NBD and 1–NBD with HeLa
cells at both 37 8C and 4 8C; the amounts of internalized
peptide and 1 at low temperature (Figure 5C) are reduced
for both molecules with an increase in the amount bound to
the membrane and a decrease of the internalized quantity.
The reduction of internalized or bound molecule was less
significant for 1, indicating a minor involvement of active
mechanisms of internalization.
Fluorescence microscopy studies : The cellular uptake ability
of 1 was explored by incubating an aqueous solution of 1
with live cells (Figure 6). HeLa cells were incubated for 2 h
with a 20 mm solution of the fluorescently labeled 1–NBD
(concentration relative to peptides; concentration of den-
drimer=1.1 mm). After incubation, excess fluorophore was
washed away and the cells were imaged. The cells exhibited
fluorescence even after being washed, suggesting that the
NBD-labeled dendrimer was interacting with the cellular
membranes. Control experiments against dendrimer 7, con-
taining the fluorophore but no peptide, showed extremely
little fluorescence in the cells, suggesting the peptides were
required for efficient membrane interaction.
Figure 5. Percentage uptake graphs of peptidodendrimer 1–NBD versus
gH625–NBD in HeLa cells under various conditions: A) 1 h incubation
with various concentrations of peptide; B) incubation at 10 mm (in pep-
tide) for various times; C) incubation at 10 mm (in peptide) for 15 min at
various temperatures; &: 37 8C, &: 4 8C.
Figure 6. Fluorescence microscopy images from the cellular uptake study.
A)–C) Incubation at 37 8C with peptidodendrimer 1 (20 mm) for 2 h; D)–
F) incubation at 37 8C with dendrimer 7 (20 mm) for 2 h; G)–I) incubation
at 4 8C with peptidodendrimer 1 (20 mm) for 15 min; J)–L) same as (A–
C), but after preincubating the cells with NaN3 (40 mm) for 30 min. A),
D), G), J) Transmission images; B), E), H), K) fluorescence images; C),
F), I), L) overlay; scale bars: 20 mm.
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In order to explore the mechanism of interaction, the cel-
lular uptake studies were also performed under conditions
that inhibit active translocation mechanisms. First, incuba-
tion was carried out with the 20 mm (in peptide) peptidoden-
drimer solution for 15 min at 4 8C. At 4 8C, the cells are
almost unable to take up the dendrimers endocytically. The
fluorescence intensity of the cells was decreased but still ob-
served, suggesting that the compound is able to enter into
cells without undergoing an active translocation mechanism
(Figure 6G). The cells were also incubated with 1 after pre-
incubation with sodium azide (40 mm), which is a known in-
hibitor of oxidative phosphorylation.[40] After this pre-incu-
bation, the cells were unable to produce ATP in the mem-
brane and to perform endocytosis. Again, the cells were
able to fluoresce after this pre-incubation, suggesting that 1
can enter the cells through a non-active mechanism (Fig-
ure 6J).
We also incubated the cells with the 20 mm (in peptide)
solution of 1–NBD for different lengths of time to observe
the uptake kinetics. As we showed with the flow cytometry
measurements, the cells exhibited fluorescence as early as
30 min after addition, showing the rapid uptake of the pepti-
dodendrimer (Figure 7).
Conclusion
We have synthesized a peptidodendrimeric scaffold that has
the potential to be used as a cellular delivery platform. The
dendrimer is able to enter the cells due to the attachment of
the gH625 peptide at the termini. The peptide, derived from
herpes simplex virus type I, does not rely on heavily posi-
tively charged residues (Arg, Lys) for translocation. Previ-
ously Kang et al. reported the failure of Tat to enhance the
intracellular delivery of PAMAM dendrimers, which they at-
tributed to the highly positive charges of both the dendrimer
and the peptide.[29] Our dendrimer is made in a facile and
scalable synthesis, and can be functionalized efficiently. We
showed that the peptidodendrimer is able to fully fuse lipo-
somes, even more significantly than the peptide alone;
moreover, it is able to do so without inducing leakage of
vesicles.
These data further support the view that the mechanism
of lipid–peptide association plays a key role in the transloca-
tion activity. The gH625 cellular uptake is associated with its
ability to interact with membrane lipids and to form a tran-
sient helical structure that temporarily affects membrane or-
ganization, thereby facilitating insertion into the membrane
and translocation.
The cellular uptake of the peptidodendrimer was meas-
ured by flow cytometry and fluorescence microscopy. After
1 h of incubation with HeLa cells at 37 8C and 4 8C, most of
the gH625 functionalized dendrimer 1 was localized intra-
cellularly. The internalization in HeLa cells can occur at
37 8C, and to a lesser extent at 4 8C, supporting the view that
the internalization mechanism does not involve entirely en-
docytosis. The kinetics of internalization is rapid and reaches
a plateau after 1 h. We confirmed, by fluorescence microsco-
py, that indeed the peptidodendrimer is inside the cells. Our
studies have shown that not only is a dendrimer functional-
ized with the gH625 peptide sequence an effective vehicle
for intracellular delivery it can do so via a passive transloca-
tion mechanism. This allows the cargo to be released direct-
ly into the intracellular milieu as opposed to being entrap-
ped in endosomes, from which the cargo might not be able
to escape before lysosomal degradation.
Experimental Section
Peptide functionalization of dendrimer : A 1:1 methanol/water solution of
peptide gH625–PrA (660 mL, 30.33 equiv), an aqueous solution of
CuSO4·5H2O (10 mL, 1.46 mm, 1 equiv), and an aqueous solution of
sodium ascorbate (50 mL, 1.17 mm, 4 equiv) were added to dendrimer 6
(50 mg, 0.0146 mmol) in a 1:1 water/methanol solution (280 mL). The mix-
ture was stirred, overnight. Then, the mixture was concentrated and puri-
fied by size-exclusion chromatography. Peptides 1 and 1–NBD were ob-
tained in quantitative yield. IR (cast on polyACHTUNGTRENNUNG(ethylene)): v˜=3295, 1658,
1545, 1471, 1203 cm1. No peak at 2098 cm1 was observed. CD: 208 nm;
UV/Vis (water): lmax=193, 273 nm. Synthesis of dendrimer 7, due to its
poor solubility, was performed in a 1:1 mixture of THF/H2O as solvent,
and purification was carried out by dialysis (1000 MWCO) against 1:1
water/methanol. Yield: approximately 20%; UV/Vis (MeOH): lmax=
452 nm.
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 1. Introduction 
 Neurological disorders contribute signifi cantly to the global 
burden of disease and are likely to increase in the coming 
years due to an aging population; thus, signifi cant efforts have 
been devoted towards the development of improved therapies 
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of drugs to the CNS and poses a major challenge to drug 
development efforts. Therefore, the development of effective 
strategies to enhance drug delivery to the brain, that is, the 
availability of a drug at its site of action in the brain for suf-
fi cient time to exert its biological effect, is the ultimate aim of 
any CNS clinical and pharmaceutical program. 
 Most strategies to transport pharmaceutical compounds 
inside the CNS causes disruption of the anatomical texture of 
the BBB, therefore impairing its natural function. Effective 
delivery approaches should be cautiously assessed considering 
their impact on the overall protective function of the BBB. It is 
now well-known that there are several invasive or non-invasive 
transport routes by which brain drugs cross the BBB. [ 2 ] The inva-
sive approaches consist of a temporary disruption of the BBB 
allowing the entry of a drug into the CNS or the direct drug 
delivery by means of intraventricular or intracerebral admin-
istration [ 3 ] while the non-invasive ones involve the systemic 
application of colloidal drug carriers undergoing a receptor or 
adsorptive mediated transcytosis mechanism [ 4 ] or the passing 
of the BBB via intranasal delivery. [ 5 ] In particular, targeted 
delivery of a therapeutic cargo to the intended site of action in 
the brain appears to be one of the most promising noninvasive 
approach to overcome the BBB, combining the advantages of 
brain targeting, high incorporation capacity, reduction of side 
effects and circumvention of the multidrug effl ux system. [ 6 ] 
 Nanocarriers (linear and hyperbranched polymers, den-
drimers, liposomes, micelles, niosomes and cyclodextrins) [ 7 ] 
are an emerging class of drug delivery systems that can be 
easily tailored to deliver drugs to various compartments of 
the body, including the brain. Nanocarriers possess unique 
features due to their size and the possibility of being func-
tionalized with multiple copies of the drug molecule of 
interest. In particular, they allow the transport of a range of 
drugs, therefore modifi cation of nanocarrier surface proper-
ties ensues. These properties make nanocarriers an attractive 
alternative to existing methods for transporting drugs across 
the BBB. Despite a large variety of nanocarriers developed 
so far for cellular internalization, it is noteworthy that only 
amphiphilic molecule-formed liposomes and polymeric nan-
oparticles have been extensively exploited for brain drug 
delivery. [ 8 ] Several of those systems are now in clinical trials 
mainly for anticancer drug delivery. 
 An essential role for nanoparticles is to help drugs gaining 
increased water stability, better pharmacokinetics, reduced 
toxicity and improved therapeutic effi cacy. [ 9 ] Because of 
nanoparticles versatility, diagnostic and therapeutic drugs can 
be either physically encapsulated or covalently conjugated to 
nanoparticles. In this context, the conjugation of therapeutic 
molecules to shuttles that can cross the BBB and thus carry 
drugs into the brain emerges as an attractive alternative. A 
key mechanism to further enhance nanoparticle delivery is to 
improve their transport by modifi cation of their surface with 
bioactive peptides such as cell-penetrating peptides (CPPs). 
 CPPs are a group of relatively short peptides (5–40 amino 
acids) deriving either from natural sources or from syntheti-
cally designed constructs, that are able to penetrate cell mem-
branes and transport a large variety of cargo molecules/
materials inside cells. [ 10 ] While individual CPPs differ in length 
and sequence, they all share some common features, which 
include their amphipathic nature, net positive charge, theoret-
ical hydrophobicity and helical moment, the ability to interact 
with lipidic membranes, and to adopt a distinct secondary struc-
ture upon association with lipids. [ 11 ] The general application of 
CPPs in cellular delivery has been hampered by the contro-
versy regarding the uptake mechanism used by these peptides. 
The major dogma has been that CPPs enter cells by a receptor 
and energy-independent process although the exact mecha-
nism is not yet fully understood; but it is now evident that for 
most CPPs, endocytosis is an almost exclusive mechanism of 
internalization. By following this pathway, cargos transported 
by CPPs, such as therapeutic molecules or functionalized nan-
oparticles, may experience lysosomal pH (around 5), which 
can strongly accelerate drug degradation, and/or nanoparticle 
accumulation within late endosomes by making less effective 
the transport of nanoparticles through the BBB. 
 Although several studies demonstrate the effectiveness 
of CPPs, such as TAT, [ 12 ] in promoting the transport of nano-
particles across the BBB, the compelling need of enhancing 
delivery to the brain makes it essential to exploit novel mol-
ecules which use different internalization mechanisms. More-
over, the controversy regarding the mechanism of action and 
the growing number of peptides with cell-penetrating prop-
erties has increased the challenge. Recently, great attention 
has been devoted to the study of hydrophobic peptides that 
effi ciently traverse biological membranes, promoting lipid 
membrane-reorganizing processes, such as fusion or pore for-
mation and thus involving temporary membrane destabiliza-
tion and subsequent reorganization. [ 13 ] 
 The nineteen residues peptide gH625, was previously 
identifi ed as a membrane-perturbing domain in the glyco-
protein gH of  Herpes simplex virus type I; [ 14 ] gH625 interacts 
with biological membranes, contributing to the merging of the 
viral envelope and the cellular membrane; it is able to traverse 
the membrane bilayer and to transport a cargo into the cyto-
plasm. [ 15 ] We already reported the ability of the peptide gH625 
to transport quantum dots inside the cytoplasm in an effi cient 
way and only partially involving endocytic pathways. [ 15a ] 
 Here we report the effect of gH625 on the penetration of 
100 nm polystyrene nanoparticles (NPs) through an in vitro 
BBB model based on bEnd3, an immortalized mouse cere-
bral endothelial cell line. 
 We demonstrated that, by opportunely modifying surface 
properties, it is possible to change the fate of nanoparticles. 
In particular, we verifi ed that gH625 conjugation enhances 
nanoparticles transport across the BBB, thereby enhancing 
the CNS bioavailability of an eventual drug. This study holds 
importance for treatment of brain infections and tracking of 
nanoparticles in vivo, a step closer to the development of a 
clinically applicable nanocarrier for treatment as well as 
monitoring brain related disorders. 
 2. Results and Discussion 
 2.1. Characterization of Peptide-Conjugated Nanoparticles 
 To verify the secondary structure of the peptide bound to 
the nanoparticles we performed circular dichroism (CD) 
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experiments. CD data confi rmed that gH625 retains its struc-
ture (helical) when bound to the nanoparticle surface as 
previously reported also for other peptides. [ 16 ] The spectra 
obtained at different percentages of functionalization indi-
cate an helical structure in all conditions ( Figure  1 A,B). 
 To further investigate the effect of the peptide function-
alization (25, 35, and 50%) on the size of nanoparticles, we 
performed dynamic light scattering (DLS) measurements. 
After functionalization, the hydrodynamic size of nanoparti-
cles with 25, 35, and 50% of gH625 in aqueous medium at pH 
7 was found to be respectively 96.68  ± 0.43 nm, 95.64  ± 0.19 
nm and 96.76  ± 0.07 nm, with polydispersity values of ca. 0.08, 
indicating a narrow distribution of the particle size at the pH 
used for all the experiments ( Table  1 ). 
 To elucidate the colloidal stability of functionalized nano-
particles at different pH values, which is a crucial parameter 
correlated to their functionalization, measurements of the 
zeta potential and of the hydrodynamic radius (D H ) were 
carried out (Table  1 ). For NPs alone, the colloidal stability 
is strongly pH-dependent because it is mainly due to elec-
trostatic repulsion between particles. It is widely accepted 
that at high values of z-potential (over 30 mV, positive or 
negative) the electrostatic interactions between particles are 
strong enough for electrostatic stability, while at intermediate 
values of z-potential, near their isoelectric point, particles can 
fl occulate. Table  1 shows both z-potential and mean hydrody-
namic diameter of blank NPs and NPs at different degrees of 
functionalization as a function of pH. In presence of peptide, 
the D H of the functionalized NPs remained nearly constant 
over the entire pH range, with no sign of aggregation in spite 
of the lower values of the zeta potential observed at pH 8. 
Such a behavior highlights that their stabilization is via steric 
hindrance rather than electrostatic repulsion. In particular, 
by increasing the percentage of functionalization NPs zeta 
potential increases from about  + 30 mV to  + 35 mV at pH 7. 
At these zeta potential values, NPs D H remains nearly about 
100 nm. Only at pH 8, we observed a lower zeta potential for 
25% functionalized NPs, indicating that in this condition the 
functionalized nanoparticles are still partially aggregated and 
their behavior is similar to non-functionalized NPs. 
 These data indicate that the peptide bound to the NPs is 
able to retain its helical structure in all the conditions tested 
and is able to completely prevent NPs aggregation at 35 and 
50% of functionalization. 
 2.2. Effect of gH625 Peptide Conjugation on NP 
Intracellular Trafﬁ cking 
 We previously demonstrated that the conjugation of the pep-
tide gH625 enhances cellular uptake of quantum dots [ 15a ] 
 Figure  1 .  Circular dichroism spectra of polystyrene NPs at 25% (a) and 50% (b) degrees of functionalization with gH625 peptide. 
 Table  1.  Zeta potential and size measurements of pure NPs and NPs at different degrees of functionalization as a function of pH. 
 pH pH 4 pH 7 pH 8 pH 9 
NP  ζ potential [mV] a) 44.9  ± 5.26 51.6  ± 1.08 –11.1  ± 0.60 –32  ± 1.22 
Size [d.nm] a) 106.5  ± 2.52 137  ± 1.19 848.4  ± 48.33 473.6  ± 1.81
PDI 0.18 0.31 0.25 0.30
NP-gH625 25%  ζ potential [mV] a) 33.13  ± 1.11 30.77  ± 2.40 10.93  ± 0.76 –33.33  ± 1.36 
Size [d.nm] a) 242.3  ± 1.39 96.58  ± 0.43 103.37  ± 1.14 231.77  ± 6.67
PDI 0.25 0.08 0.13 0.28
NP-gH625 35%  ζ potential [mV] a) 34.13  ± 2.42 30.9  ± 0.79 18.43  ± 0.91 –33.17  ± 1.07 
Size [d.nm] a) 114.93  ± 1.40 95.64  ± 1.09 96.27  ± 0.67 99.92  ± 0.50
PDI 0.14 0.08 0.08 0.10
NP-gH625 50%  ζ potential [mV] a) 33.83  ± 1.98 35.1  ± 2.43 17.77  ± 0.76 –28.03  ± 1.82 
Size [d.nm] a) 102.1  ± 0.36 96.76  ± 0.07 97.53  ± 0.20 99.65  ± 0.70
PDI 0.12 0.09 0.09 0.10
 a) Mean value  ± SD, n  = 3. 
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and liposomes [ 15b ] in HeLa cells in vitro. However, no evi-
dences of the effect of gH625 on nanoparticle uptake in brain 
endothelial cells have been previously reported. Moreover, 
the exact mechanism used by gH625 to facilitate cargos 
transport through cell membranes has not yet been under-
stood in details. Therefore, in this work we studied the effect 
of gH625 on polystyrene NP uptake mechanisms on mouse 
brain endothelial bEnd3 cells. 
 We fi rst tested the cytotoxicity of blank NP and gH625-
NP on bEnd3 cell line by Alamar Blue Assay and we veri-
fi ed that blank NPs and gH625-NPs at 50% functionalization 
did not affect cell viability in the experimental condition used 
for the assay compared to non-treated control cells (data not 
shown). 
 Once internalized, NPs can follow different fates: i.e., par-
ticle degradation inside lysosomal compartments, accumula-
tion in other organelles, recycling to the plasma membrane or 
transcytosis to the basal surface of endothelium. Furthermore, 
the routes of NP intracellular traffi cking might give some 
indications not only about the fate of NP, but also about the 
mechanisms driving cellular uptake. [ 17 ] To address this issue, 
multiple particle tracking (MPT) gives a strong contribution 
compared to traditional techniques (spectroscopy, microscopy, 
etc.). [ 18 ] In particular, MPT technique can provide quantitative 
(diffusivity and velocity) and qualitative (transport mode and 
directionality) information of internalized NPs, by evaluating 
the time-resolved trajectories of tens of NPs. Therefore, in 
order to study the effect of NP surface functionalization with 
gH625 on NP internalization mechanism, we followed and 
analyzed their intracellular motion.  Figure  2 shows a snapshot 
of the detected trajectories generated by MPT routines. By 
shape, trajectories can already be split in two different types: 
i) Brownian-like trajectories, suggesting NPs random move-
ment between cytosolic structures, and ii) pearls-on-a-string 
trajectories, derived by a combination of random and linear 
walk, indicative of motor protein facilitated transport, medi-
ated by endocytic vesicles and motor proteins. [ 19 ] Evaluating 
the time dependence of mean square displacement (MSD) of 
each tracked NP we classifi ed the particles transport mecha-
nisms into diffusive and super-diffusive motion. In particular, 
to perform NPs diffusive mode classifi cation we evaluated the 
exponent of each fi tting MSD curve by the equation described 
in the Methods section. 
 Particle trajectories revealed a substantial heteroge-
neity in particle intracellular dynamics, both for blank NPs 
and gH625-NPs. However, for blank NPs, most trajectories 
resulted in a combination of random and linear walk with a 
pearls-on-a-string trajectory, indicative of motor protein facil-
itated transport, mediated by endocytic vesicles (Figure  2 ). 
Whereas, only a lower percentage of blank NPs appeared to 
follow a purely diffusive behavior (random walk), suggesting 
no particular interaction between NPs and cytosolic struc-
tures (Figure  2 ). 
 Conversely, in presence of peptide functionalization, 
we observed that most trajectories showed a random walk 
behavior while a lower percentage resulted in a pearls-on-a-
string trajectory. In particular, this behavior is more evident 
at lower percentages of functionalization with an optimum at 
35% peptide functionalization degree. 
 These data suggest that the effect of the peptide could 
depend on its concentration/density on the NP surface. In 
fact, we theoretically estimated the surface density of pep-
tide of about 3, 4, and 6 peptides/nm 2 for 25%, 35% and 
50% functionalized NPs, respectively. We hypothesized that 
a lower peptide surface density (3 and 4 peptides/nm 2 ) could 
promote the correct peptide orientation and interaction 
with membrane lipids. Conversely, a higher peptide surface 
density (6 peptides/nm 2 ) hinders the correct orientation of 
peptide aminoacidic residues and their interaction with cell 
membrane. Indeed, recently, we structurally characterized 
gH625 peptide in a membrane-mimicking DPC micellar 
environment to gain insight into how gH fuses with the cell 
membrane. [ 20 ] We reported a model of gH625 peptide struc-
ture and orientation indicating that both electrostatic and 
hydrophobic interactions work in concert to mediate mem-
brane penetration. In particular, the function of the aromatic 
residues is to cause the peptide insertion into the membrane 
interface while the basic residues stabilize this interaction by 
linking the negatively charged headgroups as shown in other 
systems using both NMR [ 21 ] and EPR. [ 22 ] 
 Figure  2 .  MPT analysis of blank and gH625-NPs. Examples of “random walk” (a) and “pearls on a string” (b) trajectories. c) Percentage of “random 
walk” and “pearls on a string” trajectories as a function of functionalization degree. 
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 Since we observed that the 35% functionalized NPs 
showed a good stability in aqueous suspension and the 
ability to penetrate cells using a random walk behavior, we 
performed all the other experiments at this percentage of 
functionalization. 
 2.3. Uptake Kinetics and in vitro BBB Crossing 
of Peptide-Conjugated NPs 
 To study the effect of surface functionalization with gH625 on 
NPs internalization, we performed NP uptake experiments. 
 Figure  3 A shows that after 10 minutes of incubation, both 
functionalized and blank NPs were internalized by bEnd3 
cells and the number of internalized nanoparticles increases 
as a function of incubation time. However, the amount of 
internalized gH625-NPs is higher than blank NPs and this 
effect is more evident at early time of NP uptake kinetic. 
While after longer incubation time the amount of internal-
ized NPs is quite similar, probably due to the saturation of 
the uptake mechanism mediated by the gH625 peptide. 
 bEnd3 cells are able to form a confl uent monolayer that 
mimics permeability properties of primary culture models of 
early passages. [ 23 ] We tested the ability of gH625 peptide to 
enhance NPs crossing of a bEnd3 confl uent monolayer. Data 
reported in Figure  3 B show that gH625-NPs cross more effi -
ciently the endothelial layer than blank NPs. More precisely, 
the permeability (P) of the monolayer was (0.43  ± 0.02)  × 
10  − 6 cm/s for gH625-NPs, almost two fold higher than P value 
reported for blank-NPs ((0.24  ± 0.02)  × 10  − 6 cm/s)( Table  2 ). 
These data are in agreement with cell uptake kinetic results. 
In fact, by focusing at early incubation time, also the uptake 
rate of peptide-conjugated NPs was approximately double 
compared to blank NPs (see the insert in Figure  3 A). More-
over, no changes in BSA-TRITC permeability were observed 
after exposure to both blank and gH625-NPs, indicating that 
these NPs did not perturb the integrity of the cell monolayer 
in the experimental conditions used for the assay (data not 
shown). 
 2.4. Uptake Mechanisms of Peptide-Conjugated NPs 
 Nanoparticles usually enter the cells using a cell-mediated 
mechanism, called endocytosis. After endocytosis, endosomes 
can fuse with lysosomes or can deliver their cargo across the 
cell by transcytosis processes. Several works reported that 
caveolae are involved in the endocytosis and transcytosis 
processes in brain endothelial cells. [ 24 ] Thus, in order to study 
if the nanoparticle functionalization with gH625 could affect 
the mechanisms of NP internalization, we performed con-
focal microscope analyses to investigate the colocalization of 
NPs with lysosomes and caveolae in absence of peptide and 
with 35% of peptide functionalization.  Figure  4 shows that 
both blank and gH625-NPs partially colocalized with lyso-
somes. However, the percentage of colocalization was about 
4.68% for blank NPs and 0.62% for gH625-NPs. On the other 
hand, concerning caveolin1, a molecular marker for caveolar 
structures, no colocalization of gH625-NPs was observed, 
while blank NPs showed 0.74% of colocalization. These data 
indicate that the peptide could change the mechanism of 
nanoparticle uptake by inducing an alternative penetration 
pathway. To further investigate this issue, we treated cells with 
cytochalasin D that inhibits macropynocytosis by disrupting 
microfi laments. Results demonstrate that the uptake of 
blank NPs was drastically reduced after cytochalasin D treat-
ment ( Figure  5 A–F). On the other hand, gH625-NPs uptake 
was almost not affected by microfi lament depolymerization 
(Figure  5 G–L). Indeed, confocal microscope z-sectioning anal-
ysis demonstrate that the most part of gH625-NPs were inside 
the cells and only a small amount (less than 30%) was just 
adsorbed on cell membrane (Figure  5 M). Moreover, quan-
titative analysis of NP uptake showed a decrease of about 
85% and 15% for blank-NP and gH625-NP uptake, respec-
tively, after cytochalasin D treatment (Figure  5 N). Taken all 
together these data indicate that blank NPs might enter the 
cells mainly by macropinocytosis. Conversely, gH625-NPs 
could use a different mechanism to cross cell membrane. 
 Previous works demonstrated that gH625 peptide 
shows a particular tropism for lipidic membranes, which is 
 Figure  3 .  Uptake kinetics of blank and 35% functionalized gH625-NPs in bEnd3 cells (a). Effect of peptide functionalization in NP crossing of a 
confl uent bEnd3 cell monolayer (b). 
 Table  2.  Permeability values of BBB in vitro model to blank and gH625-
functionalized NP. 
 Permeability [ × 10  − 6 cm/s] ( ± SD, n  = 5)
NP 0.24  ± 0.02
gH625-NP 0.43  ± 0.02
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strongly dependent on its amphipathic 
nature. [ 14a , 14d , 14e ] Thus, we hypothesized 
that the presence of the peptide on the 
NP surface could enhance its interaction 
with the cell membrane and promote NPs 
passage through cell membranes. To verify 
this hypothesis, scanning electron micro-
scopy (SEM) analyses were performed. 
SEM micrographs showed that, after 
5 min of incubation, a high number of 
gH625-NPs was visible on the cell surface 
( Figure  6 A,B). Conversely, very few blank 
NPs were present on the cell surface and 
some of these formed small aggregates 
(Figure  6 C,D). SEM results suggest a dif-
ferent interaction of gH625-NPs with cell 
membrane compared to blank-NPs. More-
over, accordingly to cell uptake kinetics 
(Figure  3 ), these observations indicate 
a better and more rapid adsorption of 
gH625-NPs on cell membrane, compared 
to blank-NPs after 10 min incubation, 
probably due to the membrane tropism of 
the peptide and, thus, an enhancement of 
gH625-NP internalization. 
 In order to understand if the dif-
ferent behavior of gH625-NPs implied 
a different intracellular fate of NPs, we 
performed transmission electron micro-
scopy (TEM) analyses.  Figure  7 shows 
 Figure  5 .  Cytochalasin D treated bEnd3 cells incubated with blank NPs (d–f) and gH625-NPs (j–m) for 10 min at 37 ° C. Non-treated control cells 
incubated with blank NPs (a–c) and gH625-NPs (g–i) for 10 min at 37 ° C. Nanoparticles (a,d,g,j); phalloidin stained microfi laments (b,e,h,k); merge 
(c,f,i,l). Green fl uorescent nanoparticles and red fl uorescent WGA stained cell membrane confocal z-sectioning (m). Section thickness: 0.2  μ m. 
Z-stack size: 10  μ m. Magnifi cation bar: 20  μ m. 
 Figure  4 .  Colocalization of non-functionalized (a,b) and gH625-functionalized (c,d) NPs with 
caveolae (a,c) and lysosomes (b,d) after 24h incubation in bEnd3 cells. Green: NPs; red: 
caveolin1 and lysotracker. Magnifi cation bar: 20  μ m. 
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TEM micrographs of gH625-NPs and blank NPs after 24 h 
incubation with bEnd3 cells. Inside the cells, gH625-NPs were 
organized in very small aggregates of 3-4 particles within the 
cytoplasm, mainly localized in vesicular structures, probably 
early endosomes (Figure  7 A) and multi-vesicular bodies 
(MVBs) (Figure  7 C). On the other hand, for blank-NPs, 
many and larger aggregates associated to vesicular structures 
within the cytoplasm were observed (Figure  7 B–D). Further-
more, no gH625- or blank-NPs were localized in the nucleus. 
For obtaining deeper details on the intrac-
ellular distribution of gH625-NPs, we fol-
lowed the formation and the growth of 
gH625- or blank-NP aggregates with time 
by a confocal microscope image analysis. 
 Figure  8 shows gH625- and blank-NP 
aggregates within bEnd3 cell cytoplasm 
after 10 min and 24 h incubation. At early 
times, gH625-NPs formed a huge number 
of small aggregates (Figure  8 A,E). More-
over, by increasing the incubation time, the 
average size of the aggregates remained 
almost unchanged (Figure  8 B,E). Con-
versely, for blank NPs, at early times, the 
average size of aggregates increased with 
time indicating that these NPs tend to 
accumulate in the cell (Figure  8 C,D,F). 
 Taken altogether, these observations 
demonstrate a different behavior between 
gH625- and blank-NPs. In particular, NP 
conjugation with gH625 peptide changes 
NP destination by reducing their accumu-
lation and promoting NP escape/exit from 
the cell. However, further investigations 
are needed to better understand which 
intracellular compartments gH625-NPs 
are localized in and what the intracellular 
pathways are followed by these function-
alized NPs that dictate their fate. 
 3. Conclusion 
 The aim of the present work was to verify if synthetic pep-
tides derived from viral membranotropic sequences can be 
used successfully to deliver biologically active substances 
inside the BBB in order to pose the basis for developing 
new effective strategies for drug delivery into the brain. The 
HSV gH-derived-peptide was covalently 
bonded with polystyrene nanoparticles 
and investigated for the ability to translo-
cate through the BBB in an in vitro model. 
The functionalized nanoparticles were 
thoroughly characterized using a variety 
of complementary techniques to gain a 
better understanding of their properties 
and showed that gH625-NPs only slightly 
modifi ed the particle sizes with a z-poten-
tial indicative of colloidal stability at pH 7. 
gH625-NPs translocated effi ciently across 
cell membranes and cell internalization 
does not seem to exclusively involve clas-
sical endocytosis mechanisms. In fact, con-
jugation with the gH625 facilitated the 
delivery of nanoparticles across the BBB, 
leading to signifi cant higher cell uptake 
and crossing. To the best of our knowl-
edge, the gH625 represent a cell translo-
cation motif never reported before in a 
BBB in vitro analysis and could be applied 
 Figure  6 .  SEM micrographs of bEnd3 cells incubated with gH625-NPs (a,b) and blank NPs 
(c,d) for 5 min at 37  ° C. Dashed squares in panels (a,c) indicate the zoomed areas shown in 
panels (b,d). Magnifi cation bar: 10  μ m (a,c) and 1  μ m (b,d). 
 Figure  7 .  TEM micrographs of bEnd3 cells incubated 24 h with gH625-NPs (a,c) and blank NPs 
(b,d) at 37  ° C. Magnifi cation bar: 1  μ m. 
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to the design of a drug delivery system homing to the brain 
and bypassing the endocytosis entrapment. Therefore, these 
novel nanocarriers could be regarded as a promising strategy 
to design delivery systems for administration of therapeutical 
compounds to the brain, deserving further investigations to 
more precisely characterize the mechanism by which gH625 
crosses the BBB and to address the cell specifi city issue by 
linking to the nanosystem also molecules specifi cally recog-
nized by the brain endothelium. 
 4. Experimental Section 
 Materials : Protected Fmoc-amino acid derivatives, coupling rea-
gents and Wang resin were purchased from Fluka, and the other chem-
icals were purchased from Sigma-Aldrich, Fluka (Buchs, Switzerland) 
or LabScan (Stillorgan, Dublin, Ireland) and were used as received, 
unless otherwise stated. Orange fl uorescent amine-modifi ed polysty-
rene, 100 nm, (NP-NH2) were purchased by Sigma-Aldrich. 
 Peptide Synthesis : The peptide gH625 (Ac-HGLASTLTRWAHY-
NALIRAFGGG-COOH) was synthesized using the standard solid-
phase-9-fl uorenylmethoxycarbonyl (Fmoc) method as previously 
reported. [ 14f ] The peptide was obtained with good yields (30–40%). 
 Peptides Conjugation to NPs : A solution of the peptide, EDC 
(1-ethyl-3(3-dimethylamino-propyl)-carbodiimide, hydrochloride) 
and NHS ( N -Hydroxysuccinimide) in molar ratio of 4:4:1 was pre-
pared in PBS buffer at pH 7.4, at room temperature under stirring 
for 30 min. NPs were conjugated with the preactivated-peptide, in 
MES 0.1 M buffer at pH 5.5 for 3 h at room temperature in presence 
of Tween 20 and the yield of the reaction was higher than 90%. The 
peptide-NPs were purifi ed from the un-conjugated-NPs by exclu-
sion chromatography on a 1  × 18 cm Sephadex G-50 (Amersham 
Biosciences) column pre-equilibrated in PBS buffer at pH7.4. The 
fl uorescence spectra of peptide-NPs and un-conjugated NPs were 
measured in a Cary Eclipse Varian fl uorescence spectrophotometer 
in the same condition. Peptide-NPs were prepared with several 
degrees of functionalization: 25%, 35% and 50%. 
 Circular Dichroism : CD spectra were recorded using a Jasco 
J-715 spectropolarimeter in a 1.0 or 0.1 cm quartz cell at room 
temperature. The spectra are an average of 3 consecutive scans 
from 260 to 195 nm, recorded with a band width of 3 nm, a time 
constant of 16 s, and a scan rate of 10 nm/min. Spectra were 
recorded and corrected for the blank sample. 
 Size and Z-potential : Measurements of zeta potential and size 
of gH625 NPs and blank-NPs were made with a Zetasizer Nano-ZS 
(Malvern Instruments, Worcestershire, UK). The measurements 
were conducted at 25  ° C using a 3.6  × 10 10 NP/ml suspension at 
pH 4, 7, 8 and 9. All measurements were performed in triplicate for 
each sample. 
 Cell Culture : Immortalized mouse cerebral endothelial cells, 
bEnd3 cells (American Type Culture Collection, Manassas, VA) were 
grown in DMEM with 4.5 g/L glucose, 10% Fetal Bovine Serum 
(FBS), 3.7 g/L sodium bicarbonate, and 4 mM glutamine, 100 U/
mL penicillin and 0.1 mg/mL streptomycin in 100 mm diameter 
cell culture dish, in a humidifi ed atmosphere at 37 ° C and 5% CO 2 . 
Cells used in all experiments were at passage 28–35. 
 Multiple Particle Tracking : Images of NPs internalized in End3 
cells were collected in real time for about 100 s with a time resolu-
tion of  ∼ 1 s by using Olympus Cell-R system equipped with 60 × 
oil immersion objective. Tracking algorithm has been described in 
detailed elsewhere. [ 17b ] From the NP trajectories the mean square 
displacement (MSD) was derived. Indicated with  〈 r 2 〉 , MSD was 
related to the NPs diffusion coeffi cient  D by the  Equation (1)
 
〈
r 2
〉
= n tα+ υ2t2D  (1) 
 Figure  8 .  Confocal microscope images of bEnd3 cells incubated with gH625-NPs for 10 min (a) and 1440 min (b) and blank-NPs for 10 min (c) and 
1440 min (d). Blue: nuclei; Green: NPs; Magnifi cation bar: 20  μ m. gH625- (e) and blank-NP (f) aggregate analysis. Charts show the size distribution 
of NP aggregates at different observation time (10, 30, 90, 300, and 1440 min). NP aggregate sizes were split in four intervals: 0.01÷ 0.03  μ m 2 ; 
0.04÷ 0.10  μ m 2 ; 0.11÷ 0.30  μ m 2 ;  > 0.31  μ m 2 . 
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where D is the diffusion coeffi cient, v the NP rate and  α rep-
resents the time dependence. The fi rst term of the equation is 
related to the random diffusion of the nanoparticles, whereas the 
second one refl ects the active motion along the fi laments due to 
the action of molecular motors (for NPs that undergo to Brownian 
motion such term becomes negligible). By fi tting the MSD curve of 
each tracked bead by using  equation (1) , informations concerning 
the nature of particle motion into the cells were gained. In partic-
ular, nanoparticles, exhibiting MSD curve that undergo a power law 
with exponent minor or equal to unity, were classifi ed as Brownian 
( α  = 1) or sub-diffusive ( α  < 1). Particles presenting MSD, whose 
dependence on time was well described by the power law with 
 α  > 1, were indicated as super-diffusive. During the experiments 
the MSD of 226 (NPs-NH 2 ), 105 (NPs-gH625 25%), 38 (NPs-gH625 
35%) and 574 (NPs-gH625 50%) distinct objects was evaluated. 
For each degree of peptide functionalization, at least, 3 cells were 
analyzed. 
 Quantifi cation of Nanoparticle Uptake Kinetics : To evaluate cell 
uptake of NPs as a function of NP surface functionalization with 
gH625 peptide, about 5  × 10 4 cells were seeded in a 96-well. 
Blank-NPs and gH625-NPs were dispersed in cell culture medium 
at the fi nal concentration of 3.6  × 10 10 NP/mL. Cells were incu-
bated with NP suspensions for 0, 10, 60, 180, and 300 min. After 
incubation, cells were rinsed with PBS and lysed with 1% Triton 
 × 100 in PBS. Cell lysates were analyzed by a spectrofl uorometer 
(Wallac 1420 Victor2, Perkin–Elmer, USA) to measure the amount 
of internalized NPs. 
 Permeability Experiments : Cells were seeded at a density 
of 5  × 10 4 cells/cm 2 on Transwell permeable inserts (6.5 mm in 
diameter, 3  μ m pores size; Corning Incorporated, Corning, NY). 
Transendothelial electrical resistance (TEER) was measured by 
using Millicell1-ERS voltohmmeter (Millipore, Billerica, MA) to 
assess the growth of cells on inserts. Permeability experiments 
were performed on the monolayer 7 days after cell seeding, 
allowing suffi cient time for the cells to develop the junctions 
between cells. 
 On the day of experiment, Transwell insert fi lter was washed 
with PBS, and then the media of the donor chamber was fi lled with 
150  μ L cell culture medium w/o phenol red containing 0.5 mg/
mL rhodaminated BSA and 3.6  × 10 10 NPs/mL while the acceptor 
chamber was fi lled with 400  μ L cell culture medium without phenol 
red. The samples of 100  μ L were drawn every 10 min for 90 min 
from the acceptor chamber and were then replaced with the same 
amount of fresh medium. The fl uorescence tracer concentration 
in the samples was determined by a spectrofl uorometer (Victor, 
Wallac, PerkinElmer), and the excitation and emission wavelengths 
were set to 540 and 615 nm and 485 and 535 nm, respectively, for 
BSA and NPs. The solute permeability  P of the monolayer was cal-
culated according to the following equation,
 P =
C A
t VA
CD×S
×
 
 Where  Δ C A / Δ t is the increase in fl uorescence concentration 
in the acceptor chamber during the time interval  Δ t ,  C D is fl uo-
rescence concentration in the donor chamber (assumed to be 
constant during the experiment),  V A is the volume of the acceptor 
chamber, and  S is the surface area of the fi lter. The experiments 
were performed in triplicate. 
 Colocalization with Lysosomes and Caveolae: For indirect 
immunofl uorescence, after NPs incubation, cells were fi rstly rinsed 
twice with PBS to remove non internalised NPs and fi xed with para-
formaldehyde 4% for 20 min. Then, cells were incubated with Triton 
 × 100 0.1% in PBS for 10 min and with PBS-BSA 0.5% for 15 min 
at room temperature (RT). Caveolae were localized by incubating 
samples fi rst with rabbit anti-caveolin 1 (Abcam) primary anti-
bodies. After primary antibodies incubation, Alexa-fl uor 568 goat 
anti-rabbit secondary antibodies (Molecular Probes, Invitrogen) 
were used. Afterward, samples were rinsed three times with PBS. 
For lysosomes localization, LysoTracker Red DND-99 (Molecular 
Probes, Invitrogen) was used following manufacturer’s procedure 
on non-fi xed cells. 
 Immunofl uorescence analyses were performed by means 
of confocal laser scanning microscope (CLSM)(LSM510, Zeiss), 
equipped with an argon laser, at a wavelength of 488 nm, and a 
He–Ne laser, at a wavelength of 543 nm, and 63x objective. Images 
were acquired with a resolution of 1024  × 1024 pixels. Colocaliza-
tion was estimated by an ImageJ software plugin. 
 Cytochalasin D Treatment : To disassemble actin microfi la-
ments, cells were treated with 30  μ M cytochalasin D in cell cul-
ture medium for 30 min at 37 ° C before NP incubation. After 
cytochalasin D treatment, cells were incubated with a NP suspen-
sion for 15 min. Then, cells were rinsed with PBS to remove non-
internalized NPs, fi xed with paraformaldehyde 4% for 20 min and 
observed by CLSM. Quantifi cation of NP uptake was performed as 
described above. 
 Scanning Electron Microscopy (SEM) : After 10 min incuba-
tion with blank NPs and gH625-NPs, cells were rinsed with PBS, 
fi xed with 2.5% glutaraldehyde for 2 h at 4  ° C and dehydrated in 
increasing ethanol series (70%, 80%, 95%, and 100%) and by 
critical point. The samples were gold-sputtered and analyzed by 
ESEM Quanta 200 (FEI Company) at 25 kV and 6.8 mm working 
distance. 
 Transmission Electron Microscopy (TEM) : TEM was performed 
to precisely localise the intracellular nanoparticles. After 24 h 
incubation with blank NPs and gH625-NPs, cells were rinsed with 
PBS and fi xed with 2% paraformaldehyde + 0.2% glutaraldehyde 
for 2 h at room temperature. Afterwards, cells were scraped, 
harvested in centrifuge tubes, embedded in 12% gelatine 
solution in PBS and infused in 2.3 M sucrose at 4  ° C. Sections 
were cut with a Leica Cryo-ultramicrotome and examined with 
Leica EM FC7. 
 Quantifi cation of NP Aggregates : To measure the size of NP 
aggregates within cell cytoplasm, bEnd3 cells were incubated with 
NP suspension for 30, 90, 1440 minutes at 37  ° C. After incuba-
tion, cells were rinsed twice with PBS, fi xed with paraformalde-
hyde 4% for 20 min and observed by confocal microscope (Leica). 
Images were analyzed by an ImageJ software plugin. About 50 cells 
per each sample were analyzed. The size distribution of NP aggre-
gates was split in four intervals (0.01÷ 0.03  μ m 2 ; 0.04÷ 0.10  μ m 2 ; 
0.11÷ 0.30  μ m 2 ;  > 0.31  μ m 2 ) and data reported as percentage of 
NP aggregates respect to the total number of NP aggregates per 
cell. 
 Statistical Analyses : Quantitative data were reported as mean  ± 
standard deviation (SD). Statistical analyses were performed using 
a one-way analysis of variance (ANOVA). Results repeats were com-
pared by analysis of variance (ANOVA), and a p value  < 0.05 was 
considered statistically signifi cant. 
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Microbe-Host Interactions: Structure and Role of Gram-Negative Bacte-
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Abstract: Gram negative bacteria have evolved many mechanisms of attaching to and invading host epithelial and im-
mune cells. In particular, many outer membrane proteins (OMPs) are involved in this initial interaction between the 
pathogen and their host. The outer membrane (OM) of Gram-negative bacteria performs the crucial role of providing an 
extra layer of protection to the organism without compromising the exchange of material required for sustaining life. The 
OM, therefore, represents a sophisticated macromolecular assembly, whose complexity has yet to be fully elucidated. This 
review will summarize the structural information available for porins, a class of OMP, and highlight their role in bacterial 
pathogenesis and their potential as therapeutic targets. 
The functional role of porins in microbe-host interactions during various bacterial infections has emerged only during the 
last few decades, and their interaction with a variety of host tissues for adhesion to and invasion of the cell and for evasion 
of host-defense mechanisms have placed bacterial porins at the forefront of research in bacterial pathogenesis. This review 
will discuss the role that porins play in activating immunological responses, in inducing signaling pathways and their in-
fluence on antibiotic resistance mechanisms that involve modifications of the properties of the OM lipid barrier. 
Keywords: Porin, bacteria, immunobiology, signaling pathways, structure. 
INTRODUCTION 
 Infectious diseases are major threats to human health 
worldwide, and tremendous effort is continuously devoted to 
the understanding of various infectious agents and their 
mechanisms of virulence. The field of bacterial pathogenesis 
is a rapidly evolving and expanding one.  
 The mammalian immune system has in place a line of 
defense specialized in recognizing and eradicating invading 
pathogens; however, sometimes the pathogen evades these 
mechanisms and establishes diseases in its host. The treat-
ment of bacterial infections with antibiotics is one of the key 
concepts of human medicine. Therapies like antibiotics and 
vaccination support the immune system in its fight against 
pathogenic microbes. After several decades of continued 
success of antibiotic therapy, we are now facing a worrying 
prospect: the accelerated evolution of antibiotic resistance of 
important human pathogens, which presents a global health 
problem with a strong social and economic impact. This bac-
terial adaptation to antibiotic use is directly involved in the 
current increase of morbidity and mortality caused by infec- 
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tion diseases. Over time, resistance to antibiotics has devel-
oped due to the intense selective pressure the antibiotics 
place on bacteria. Furthermore, while a number of vaccines 
have been successful, far too many infectious diseases still 
do not have efficacious vaccines. An urgent need for new 
therapeutics exists and understanding the complex relation-
ship among the host and invading pathogens will provide 
important insight for the rational design of therapeutics. 
 Gram negative bacteria comprise a major proportion of 
drug resistant pathogens and display a complex envelope 
with an outer (OM) and an inner (IM) membrane delimiting 
a periplasmic space. This cellular organization results in the 
presence of various protein channels involved in the trans-
port, uptake or efflux, of a large variety of compounds, nutri-
ents or toxic molecules (sugars, drugs, small peptides, 
chemicals).  
 The outer membrane is the first line of defense for Gram-
negative bacteria against toxic compounds. This barrier is 
impermeable to large, charged molecules. Influx is largely 
controlled by porins, which are water-filled open channels 
that span the outer membrane and allow the passive penetra-
tion of hydrophilic molecules. Bacterial pathogenicity is 
largely dependent on its surface structures. Among the com-
ponents of the bacterial outer membrane, outer membrane 
proteins (OMPs), such as the porins, play a fundamental role 
in pathogenicity and in protection and represent useful tar-
gets for therapeutic development [1-3]. 
 1875-5550/12 $58.00+.00 © 2012 Bentham Science Publishers 
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 Porins are involved in the exchange of nutrients over the 
outer membrane of Gram-negative bacteria but are also in-
volved in pathogenesis. The present review will focus on the 
description of the structure and the role of Gram-negative 
bacterial porins in the bacteria-host interactions.  
DESCRIPTION OF BACTERIAL ENVELOPES 
 Bacteria in order to face unpredictable and often hostile 
environments have evolved a sophisticated and complex cell 
envelope that protects them while allowing selective passage 
of nutrients from the outside and waste products from the 
inside. In particular, Gram-negative bacteria can be divided 
into several subcellular compartments [4]. There are three 
principal layers: the outer membrane (OM), the peptidogly-
can cell wall, and the inner membrane (IM). The two mem-
brane layers delimit two aqueous compartments called the 
cytoplasm and the periplasm. Present throughout these com-
partments are proteins with diverse and important biological 
functions (Fig. 1). Some of these proteins are membrane-
embedded and allow the transfer of molecules between com-
partments. Others are soluble enzymes involved in metabolic 
reactions. Much work has been devoted toward understand-
ing how each of these compartments is formed and main-
tained. The OM is a characteristic feature of Gram-negative 
bacteria, and in fact Gram-positive bacteria lack this struc-
ture. The OM is a lipid bilayer intercalated with proteins, 
superficially resembling the plasma membrane; it contains 
phospholipids confined to its inner leaflet, while the outer 
leaflet contains glycolipids, mainly lipopolysaccharide 
(LPS).  
 The barrier property of the OM can be largely attributed 
to the presence and asymmetrical distribution of the complex 
glycolipid LPS. In fact, LPS monomers in the bilayer exhibit 
a strong lateral interaction with other LPS molecules, these 
interactions together with the enrichment of fully saturated 
phospholipids in the inner leaflet of the OM greatly reduce 
the OM fluidity, which is rigid and gel-like in comparison to 
the inner membrane. LPS molecules are made of three dis-
tinct regions: the lipid A, the core oligosaccharide and the 
distal O-antigen (Fig. 2). Lipid A secures LPS in the OM; 
the core is covalently bound to the lipid A through an acidic 
sugar, the 3-deoxy-D-manno-oct-2-ulopyranosonic acid 
(Kdo). The general pattern of the lipid A from diverse Gram-
negative bacteria is highly conserved. The core oligosaccha-
ride is very variable among bacterial species; so different 
species can express uniquely modified types of LPS. The O-
antigen, if present, is the most variable part of LPS and 
shows even a high degree of variability between different 
strains of the same species. 
 With few exceptions, the proteins intercalated in the OM 
can be divided into two classes, proteins that traverse the 
membrane and assume a ?-barrel structure and lipoproteins, 
anchoring the outer membrane to the underlying peptidogly-
can stratum (Fig. 1). Lipoproteins contain lipid moieties that 
embed lipoproteins in the inner leaflet of the OM, and are 
thus not supposed to be transmembrane proteins. The outer 
membrane proteins (OMPs) of Gram-negative bacteria have 
been well characterized and many assume a ?-barrel con-
formation. The OMPs serve as a molecular filter for hydro-
philic substances, mediate the transport of nutrients and ions 
across the membrane into the periplasm, some small ?-
barrels seem to serve primarily as membrane anchors or to 
promote bacterial adhesion to mammalian cells, or are mem-
brane-bound enzymes such as protease, phospholipase. 
 The most abundant proteins of the bacterial outer mem-
brane are porins which are essentially trimeric ?-barrels 
forming channels with various grades of selectivity. Porins 
form passive pores that do not bind their substrates; they 
generally form water-filled pores, through which relatively 
small (<600 Da) solutes diffuse, driven by their concentra-
 
Fig. (1). Schematic representation of the inner and outer bacterial membrane. 
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tion gradient. For nutrients that are present at low concentra-
tions in the extracellular environment, passive diffusion is no 
longer efficient and transport occurs via substrate-specific 
and active transporters [5-9]. 
 
Fig. (2). Schematic representation of the structure of lipopolysac-
charide (LPS). 
BACTERIAL PORINS: STRUCTURE 
 Bacterial porins have been studied in great detail since 
many years; the first high-resolution X-ray structure was 
published in 1990/1991 and was the major outer membrane 
protein of Rhodobacter capsulatus. The structure of this 
trimeric porin showed the archetypical fold of 16 tilted ?- 
strands, all of which are connected by extraplasmic loops 
and periplasmic turns with the particularly long loop L3 
folded inside the barrel (Fig. 3A) [10,11]. Many additional 
porin structures have been determined since then with a high 
similarity in architecture and only smaller variations, mainly 
in loop topology and surface charges [12-15]. Porins made of 
16 strands were classified as general or non-specific porins 
and form pores allowing the diffusion of hydrophilic mole-
cules, showing no particular substrate specificity, despite 
some selectivity for either cations or anions; while 18 strands 
porins were classified as substrate specific porins, both of 
which are trimeric (Fig. 3B) [6,7]. This concept has been 
proved useful for many years and provided a clear structure-
based classification into e.g. sugar-specific channels, such as 
ScrY or LamB with 18 ?-strands, or unspecific channels 
with 16 strands involved in the uptake of small and mostly 
inorganic molecules (e.g. Omp32, OprP and PhoE) [16-18]. 
However, during recent years and owing to the discovery of 
new bacterial cell envelopes and outer membrane protein 
structures, the group of porins became more diverse and a 
simple classification seems more difficult. Recently OmpG 
or CymA (14-stranded monomeric proteins) [19,20] showed 
a different fold and quaternary structure (Fig. 3C). In addi-
tion, a number of porins previously classified as unspecific 
were later proved to bind small, typically negatively charged 
(organic acids or phosphates) ligands, thereby providing a 
structural and functional rationale for the facilitated small 
metabolite uptake in bacteria and their specific lifestyle con-
ditions [16,17].  
 
Fig. (3). Three dimensional structures of three different porins: Gdp from Rhodobacter capsulatus, PhoE and OmpG from Escherichia coli. 
Surface and internal loops are shown in dark grey. The extracellular space is located at the top of the figure and the periplasmic space is at 
the bottom.  
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 The majority of porins studied so far is typically of oval 
shape and have an overall dimension of laterally ?30–35Å 
and ?50 Å in height for the monomer. All these proteins 
share similar properties, such as their high abundance in na-
tive membranes, an increased thermal stability and the regu-
lar content of ?- sheet structures (in the range of 60%), as 
well as their specific conductance profiles in planar mem-
branes [15]. The general characteristic of their structural ar-
chitecture is the closure of the barrel by pairing of the first 
and last ?-strand in an antiparallel way. All strands are con-
nected by eight or nine long loops, facing the extracellular 
side, with seven or eight small turns in the periplasmic space. 
In all porins, the constriction at the barrel center is formed by 
an inserted long loop L3, which is not exposed to the cell 
surface but folds back into the barrel, forming a constriction 
zone at half the height of the channel and contributing sig-
nificantly to the permeability of the pore. The type of resi-
dues outlining the channel determines the specificity of the 
pore. All porins form homotrimers in the OM; each subunit 
produces a channel and the trimer therefore contains three 
channels (Fig. 4). For most porins, loops L1, L2 and L4 are 
important for monomer-monomer interactions within the 
porin trimer; loop L3 is internal; loops L5, L6 and L7 are 
superficial; loop L8 folds back into the barrel interior, con-
tributing to the formation of the channel opening at the ex-
ternal side (Fig. 4A). Peptide sequences corresponding to 
superficial loops are responsible for most of the biological 
activity of porins. Another feature is the presence of aro-
matic girdles with tyrosine and phenylalanine residues lo-
cated at the outer and inner membrane boundaries. Tyrosine 
residues are more frequent at the extraplasmic sites, whereas 
phenylalanine residues are located at the periplasmic side of 
the highly asymmetric membrane [21]. These aromatic gir-
dles are also present in ?-helical membrane proteins and 
presumably adjust secondary structure elements at the bor-
ders of natural membranes [22]. Residues located between 
these girdles and facing the hydrophobic lipid environment 
mainly have high Kyte–Doolittle values (e.g. leucine, valine 
and isoleucine). Additional girdles, often charged, such as 
observed in Omp32, exist in bacterial porins and may have 
some implications in a tighter interaction with lipid head 
groups or with LPS molecules [15]. At the very C-terminus 
almost all porins have a phenylalanine residue, which is an 
important prerequisite for proper import and folding in the 
outer membrane [23,24].  
 The pore diameter ranges from 15 Å for the general 
porins to 6 Å for the highly selective porins. Larger pores 
usually contain charged residues at opposite sides that form a 
local transversal electric field at the pore eyelet. This field 
constitutes an energy barrier for low-polarity solutes so that 
the bacterium can exclude unwanted nonpolar molecules 
such as antibiotics while presenting a spacious eyelet for 
collecting large polar molecules such as sugars. A systematic 
study changing the pore properties by point mutations 
showed a strong correlation between the eyelet cross section 
and diffusion rate [25]. Charge reversals affect selectivity 
and voltage gating. Interesting results were obtained with 
mutations at loop L3, for example the specificity of the su-
crose porin was changed toward that of the maltoporin. 
 The outer membrane contains also porins with specificity 
for certain substrates. The best known proteins of this class 
are the sucrose-specific ScrY from Salmonella typhimurium 
[7,26] and the maltooligosaccharide-specific maltoporin 
LamB from Escherichia coli [27]. Both form homotrimers 
with monomers consisting of 18-stranded antiparallel ?-
strands, with loop L3 folding back inside the barrel and with 
hydrophilic surface exposed loops; unlike general porins, 
their ?-barrel contains 18 (rather than 16) strands, and some 
of the external loops coalesce to form an umbrella that 
shields the underlying pore and restricts its entrance, trans-
forming it in an elongated pore which may adapt to the shape 
of maltodextrins.  
 
Fig. (4). Three-dimensional structure of the porin OmpF from Es-
cherichia coli. Surface and internal loops are shown in dark grey. 
The extracellular space is located at the top of the figure and the 
periplasmic space is at the bottom. The trimer is shown. 
 
 Although porin structures typically contain 16 or 18 ?-
sheets depending on the definition of the protein family [28]. 
Recently several outer membrane proteins have been classi-
fied as porin although their structure is characterized by a 
number of strands lower than 16 (8, 12 and 14 strands) and 
are also monomeric. Other barrel proteins with fewer strands 
have been investigated, most of which have a specific func-
tion not related to the diffusion of hydrophilic molecules and 
are not classified as porins. These proteins are instead de-
signed for the exchange of hydrophobic molecules, such as 
lipids or hydrophobic substances (e.g. toluene) and are typi-
cally closed by loop or cork-domain-like structures 
[29,30,31].  
 The structure of the 14-stranded porin OmpG from Es-
cherichia coli has been determined by X-ray crystallography 
[20,32]. In E. coli the main porins for sugar uptake are LamB 
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[33] and ScrY [7]; in mutants where LamB is either nonfunc-
tional or deleted, the uptake of sugars is facilitated by OmpG 
[32]. OmpG has all features of porins: a signal sequence of 
21 amino acids at its N-terminus, which is cleaved during 
export, absence of long hydrophobic stretches, lack of cys-
teine residues, and a C-terminal phenylalanine, which is im-
portant for membrane insertion. OmpG is a monomer and 
there is no evidence to suggest a physiological oligomer. 
Owing to a missing loop L3, present in the archetypical 
porins, the pore opening is considerably large. A long ex-
tracellular loop assumes two distinct, well-defined conforma-
tions, apparently in response to the pH of the medium. At 
neutral pH this loop projects into the extracellular medium, 
leaving the pore wide open, whereas at low pH it folds 
across the pore channel and blocks it, suggesting a direct role 
in pH dependent pore-gating. 
 NanC belongs to the family of small monomeric related 
porins [34]. NanC folds into a 28 Å high, 12-stranded ?-
barrel, resembling the ?-domain of autotransporter NalP and 
defining an open pore with an average radius of 3.3 Å. The 
channel is lined by two strings of basic residues facing each 
other across the pore, a feature that appears largely con-
served within the substrate specific autotransporter family 
and is likely to facilitate the diffusion of acidic oligosaccha-
rides. Also AlgE from Pseudomonas aeruginosa [35] in-
volved in the secretion of newly synthesized alginate across 
the outer membrane is a monomeric 18-stranded ?-barrel. It 
is characterized by a highly electropositive pore constriction 
formed by an arginine rich conduit that likely acts as selec-
tivity filter for the negatively charged alginate polymer. In-
terestingly, the pore constriction is occluded on both sides by 
extracellular loop L2 and an unusually long periplasmic 
loop, T8.  
 OprP from Pseudomonas aeruginosa is involved in the 
high-affinity acquisition of the concentrations of phosphate 
that are crucial for Pseudomonas growth and proliferation 
[17]. Each monomer of OprP adopts a 16-stranded antiparal-
lel slightly elliptical ?-barrel structure and it forms a promi-
nent trimer in solution, but unlike most of porins, OprP has 
an extended periplasmic N terminus that is involved in stabi-
lizing the trimer through a ‘tricorn’-like strand exchange. 
Three prominent elongated loop regions are evident in OprP 
structure, the extracellular loops L3 and L5 and the perip-
lasmic loop T7. The L3 loop contains ?-helices that extend 
deep into the cavity of the barrel and are responsible for the 
size and constriction of the pore, as seen in other membrane-
spanning ?-barrel proteins. Uniquely in OprP, the L5 loop 
runs along the inner surface of the pore toward the center of 
the channel, creating an electropositive surface to attract ani-
ons. In L5, there are five arginine residues that, together with 
two arginine residues in sheet B2 create a distinct, evenly 
spaced seven-step arginine ladder, creating an electropositive 
slide that propels the phosphate down the inner region of the 
exoplasmic surface toward the constriction zone. On the ex-
tracellular surface of the OprP trimer, each monomer con-
tributes to the formation of a giant funnel. The funnel has 
three separate electropositive arginine ladders that spiral 
down toward the point of greatest constriction near the perip-
lasmic face of the transporter. 
 MspA is a channel protein present in the outer membrane 
of mycobacteria that has been classified as a porin and is 
involved in the uptake of small hydrophilic nutrients [36]. 
The atomic structure of this porin shows a ?-structure that 
differs completely from its counterparts in Gram-negative 
bacteria. The structure is an octamer containing a central 
channel of 16 ?-strands with a diameter of 40Å; the base of 
the barrel contains a second short 16-stranded ?-barrel that 
forms a channel constriction, also called a pore eyelet with a 
diameter of 28 Å. This barrel is similar to that of pore form-
ing toxins such as ?-hemolysin [37,38].  
 Among the porin channels are also found proteins such as 
the P100 protein from Thermus thermophilus. Initially this 
protein was reported to form the S-layer (surface protection 
layer) of this bacterium [39], later it was shown to form a 
densely packed structure of porin molecules in native mem-
branes and to be a multi-domain structure made of a N-
terminal peptidoglycan binding domain, a long coiled-coil 
domain and an unusually large porin domain [40,41].  
ASSEMBLY AND OLIGOMERIZATION 
 Studies of bacteriorhodopsin [42] have largely contrib-
uted to the comprehension of the assembly and folding proc-
esses of ?-helical membrane proteins; on the contrary, even 
though there is a growing understanding of the complex fold-
ing process of ?-barrel membrane proteins, progress has 
been much slower. The membrane insertion process is the 
rate-limiting step, because of the side chain and secondary 
structure rearrangements required for pore formation.  
 Proteins that have to reach the OM must be transported 
from the ribosome to the inner membrane, where they must 
be discriminated from inner-membrane proteins, then trans-
ported across the inner membrane into the periplasm, carried 
across the periplasm and finally assembled within the outer 
membrane in their mature conformations [43]. OMPs are 
synthesized in the cytoplasm with N-terminal cleavable sig-
nal peptides that target them for delivery to the periplasm 
and thanks to their low hydrophobicity they are presumably 
exported into the periplasm just like any other periplasmic 
protein; then, they are refolded into their stable ?-barrel con-
formations and are inserted into the outer membrane. It is not 
clear whether the refolding process precedes insertion or vice 
versa, but nascent, monomeric porins can be assembled into 
the final trimer in vitro, in the presence of phospholipids. It 
has been proposed that the central part of the homotrimer 
including all N and C termini folds in the periplasm like a 
water soluble protein so that the membrane facing parts of 
the ?-barrels dangle as 200 residue loops into the solvent. On 
membrane insertion, these loops can easily meander forming 
the special ?-sheet topology. Studies on OmpA [44-47] pro-
vided most of the information on the folding process of outer 
membrane proteins. The insertion and folding reactions of 
OMP occur spontaneously without the need of accessory 
proteins in vitro; however, the folding kinetics are relatively 
slow suggesting that folding in vivo might be facilitated by 
folding catalysts;[24] in particular, membrane insertion and 
folding of OmpA was most efficient at specific molar ratios 
of OmpA, Skp and LPS [48]. The water-soluble form of 
OmpA is unstructured and upon membrane interaction, a 
membrane-bound intermediate is formed, which is localized 
at the bilayer interface and is composed of single or paired ?-
strands with dynamic and metastable hydrogen-bonding con-
tacts. A new intermediate is formed with some of the charac-
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teristics of ?-barrels which only after an extensive amount of 
rearrangements assumes the mature structure.  
 Its insertion into the outer membrane is mediated by a 
protein complex that contains the OMP BamA and four as-
sociated lipoproteins (BamBCDE) [49-51]. The mechanism 
by which the Bam complex catalyzes the assembly of OMPs 
is not known. Bam is a heteropentamer composed of a very 
highly conserved OM ?-barrel (BamA) and four OM lipo-
proteins (BamBCDE) that dock with BamA. BamA and 
BamD are indispensable in E. coli, and depletion of either 
leads to rapid accumulation of unassembled OMPs in the 
periplasm followed by cell death. The periplasmic domain of 
BamA is essential for its function; it binds the C-terminal 
signal sequences of ?-barrel OMPs, which contain a C-
terminal phenylalanine or tyrosine residue. Binding of an 
OMP causes a conformational change in the C-terminal do-
main of BAM, which allows the OMP to insert into the outer 
membrane. Dissociation of the BAM subunits releases the 
assembled OMPs into the outer membrane, where final con-
formational changes in the cell-surface-exposed loops may 
be induced by interactions with the lipopolysaccharides. 
 Thus, the Bam complex recognizes the C-terminal motif 
in ?-barrel proteins and before its role became clear, it was 
already detected in porins and autotrasporters. There is a 
general mechanism for autotransport, where the different 
types of autotransporters follow the general route for ?-
barrel protein insertion into the OM. An extended signal pep-
tide in many cases ensures slow processing by the Sec ma-
chinery, to gain time for proper OM insertion before the pas-
senger domain is released. Moreover, premature folding in 
the periplasm is inhibited by the known periplasmic chaper-
one systems, and also by sequence intrinsic properties of the 
passenger polypeptides, such as a reduced folding rate, high 
solubility of the unfolded passenger domains and little to no 
propensity to aggregate when in the unfolded state. Most 
probably already during membrane insertion a hairpin struc-
ture is formed, and the sequential folding of the passenger 
domain on the cell surface drives the process to completion. 
ROLE OF BACTERIAL PORINS 
 During their interaction with the host, porins from several 
Gram-negative bacteria have diverse biological activities on 
several eukaryotic cell types, in fact, porins can be consid-
ered important inducers of biological activity in host-cell 
interactions [52]. Several studies have been performed to 
analyze their immunobiological activities, showing that 
porins have important effects in several pathogenic mecha-
nisms. Since comprehensive reviews describing the func-
tional behavior of porin channels are available [28], we will 
mainly focus on three aspects of their role: a) immunological 
activity of porins, b) porins induced signaling pathways, and 
c) porins influence on the emergence of antibiotic resistant 
strains of pathogenic bacteria. 
IMMUNOBIOLOGY OF BACTERIAL PORINS 
 Although the structural features and function of porins 
have been well studied, their role in the pathogenesis of vari-
ous bacterial infections has emerged only during the last 
decade. Bacterial porins interact with a variety of host tissues 
for adhesion to and invasion of the cell and for evasion of 
host-defense mechanisms and are able to elicit innate and 
acquired immune responses. 
 S. typhimurium porins inhibit phagocytic activity in a 
dose dependent fashion by activating the adenylate cyclase 
system [53] and are able to induce the activation of the com-
plement system by acting both on the classic pathway and on 
the alternative pathway [54]. These porins are clearly en-
dowed with pro-inflammatory activity, in fact, when injected 
into the paw of male Wistar rats induced dose-dependent 
edema with long-lasting effects and the induced inflamma-
tion is sensitive to both steroid (dexamethasone) and non-
steroid (indomethacin) anti-inflammatory drugs. In vitro 
studies carried out on rat resident peritoneal cells showed 
that porin-induced inflammation may depend on the release 
of histamine, even though the arachidonic acid metabolites 
may also participate. In fact, in vitro results exclude an in-
crease of 6-keto-prostaglandin and subsequent prostacyclin 
release, whereas in vivo results confirm both the prolonged 
duration of porin-induced edema and its marked inhibition 
by indomethacin. Porin-induced inflammation was also ob-
served in decomplemented animals. Further in vivo experi-
ments were carried out by intraperitoneal inoculation of 100 
μg/ml of porins in guinea pigs [54], therefore, it is unlikely 
that the activation of the complement system plays a major 
role in the inflammation induced by porins [54]. Recognition 
of pathogenic bacteria by host toll-like receptors (TLRs) is 
the first step in the activation of the inflammatory responses 
of the innate immune system [55,56].  
 While CD-14, CD-11/18 and Toll-like receptors 2 and 4 
appear to be very important LPS signal transducer, porin-
specific receptors are still unknown. Therefore, it is possible 
that porin stimulation is not due to binding to specific recep-
tors, but the consequence of the perturbation of the cell 
membrane lipoproteic phase, induced during adsorption or 
porin penetration. CD-14 is a glycosyl-phosphatidyl inositol 
linked 55 kDa protein present on the surface of monocytes 
and polymorphonuclear leucocytes, and it functions as the 
cell surface receptor for LPS and several surface components 
of Gram-positive bacteria. CD14 is also found as a soluble 
protein (sCD14) in human serum. CD14 lacks transmem-
brane and cytokine-binding domains and is not believed to 
have intrinsic signaling capabilities. TLRs make up a family 
of evolutionary conserved pattern recognition molecules that 
are important signal transducers for the induction of mam-
malian innate immunity responses, including cytokine re-
sponses. TLR2 is involved in the recognition of a wide assay 
of bacterial products, including peptidoglycan, lipopeptides, 
zymosan and bacterial lipoproteins, whereas TLR4 is acti-
vated by LPS. CD14 acts as a broad specificity coreceptor 
that can enhance cell activation induced by TLR4 or TLR2 
agonists. In many cases, porins interact with host immune 
cells and can be considered as pathogen associated molecular 
patterns (PAMPS) due to their ability to signal via TLR 
molecules and other pattern recognition receptors.  
 TLR1, TLR2, TLR6, and MD2 have each been suggested 
to be involved in the recognition of a broad range of OMPs 
[57-61] . Data from Haemophilus influenzae (Hib) porin and 
from Neisseria porin (PorB) indicate that porins from differ-
ent bacteria may be recognized by TLR-2 [58]. The Hib 
porin-induced TNF-? and IL-6 production was eliminated in 
macrophages from TLR2 or MyD88 deficient mice. In con-
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trast, macrophages from LPS hyporesponsive C3H/HeJ mice 
which are defective in TLR4 function, responded normally to 
Hib porin. Neisserial porin adjuvant activity was mediated 
by surface expression of B7-2 and class 2 major histocom-
patibility complexes on B cells by TLR-2-dependent mecha-
nisms; the presence of the adaptor molecule MyD88 was also 
required. CD11/18 [58] integrin may also participate in LPS 
signaling. These families of receptors are heterodimer cell 
surface glycoproteins composed of a CD11 and a CD18 
subunit. The release of TNF-?, IL-6 and IL-8 by THP-1 cells 
stimulated by porins is independent of CD14, but is partially 
dependent on CD11/18 integrins. 
 The basis for the recognition of OMPs by TLRs is diffi-
cult to envision because OMPs vary in sequence, structure, 
diameter, and conductance. However, the analysis of the 
crystal structures of PorB and the TLR1/2 heterodimer [62] 
allowed the development of a model for the initial recogni-
tion of OMPs by TLR1/2. PorB and other Gram-negative 
porins have been shown to contain a ring of positively 
charged residues on the extracellular side of the protein that 
interacts with the negatively charged lipopolysaccharides to 
stabilize the porin within the bacterial outer membrane 
[15,63]. An electrostatic analysis of the TLR1/2 heterodimer 
revealed that both ectodomains, which mediate recognition, 
are predominantly negatively charged [64]. The negatively 
charged surface could be attracted to the ring of positive 
charges from PorB by nonspecific electrostatic attraction. 
 Several reports have shown that porins are able to induce 
signal transmission, activation of nuclear factors, activation 
of gene promoters and finally release of cytokines. Porins by 
Salmonella enterica serovar typhimurium induce the release 
of TNF-?, IL-1, IL-6, and TGF by macrophages and IL-4 
and IFN-? by lymphocytes. Salmonella enterica serovar ty-
phimurium porins enhance the synthesis and release of IL-6 
in U937 cells regulating the transcriptional activity of IL-6 
gene by nuclear transduction of NF-?B. The characterization 
of the human IL-6 promoter revealed a highly conserved 
control region of 300bp upstream of the transcriptional ini-
tiation site that contains the elements necessary for its induc-
tion by a variety of stimuli commonly associated with acute 
inflammatory or proliferative states. In particular, electro-
phoresis mobility shift assay, as well as promoter deletion 
and point mutation analysis, revealed the presence of an NF-
?B binding element. In U937 cells stimulated by Salmonella 
porins, NF-?B is able to enhance IL-6 gene promoter activ-
ity. Activation of this nuclear factor may be responsible for 
porin induced expression and release of IL-6 [65]. OmpA 
from Shigella flexneri 2a induces the release of proinflam-
matory cytokines through activation of NF-kB via TLR2 , 
moreover the induction of IFN-? expression in CD4+ T cells, 
through the production of IL-12, in macrophages, demon-
strated that OmpA plays a critical role in the development of 
Th1 adaptive skewed immune response [66]. 
 Haemophilus influenza type b (Hib) porin also induces 
the early release of cytokines in central nervous system cells, 
amplifying the inflammatory response. Hib porin inserted 
into the fourth ventricle of the brain elicited the appearance 
of serum proteins and the development of brain edema. 
These effects were followed by increase in the number of 
neutrophils both in cerebrospinal fluid and in the tissue sec-
tions around the porin inoculation site. IL-1?, TNF-? and 
MIP-2 mRNA appeared quickly in the tissue near the inocu-
lation site [67]. 
 As described in this section, porins are deeply involved 
in inflammation and immune response and several report 
have shown that mice immunization with porin proteins or 
DNA immunization with plasmids containing their genes, 
leads to production of humoral antibodies and also promotes 
a Th1 cell-mediated immune response. Most functional anti-
bodies raised to non-typable Haemophilus influenza (NTHI) 
are directed to loop L5, which is thought to contain strain-
specific and immunodominant epitopes [68], and antibodies 
to loop L6 of NTHI showed complement-dependent bacteri-
cidal activity [69]. Surface exposed loop regions of porins 
are immunodominant as shown by immunizing mice with 
whole bacterial cells [70]; synthetic peptides representing 
epitopes of outer membrane protein F of Pseudomonas aeru-
ginosa elicit antibodies reactive with whole cells of het-
erologous immunotype strains of Pseudomonas aeruginosa 
[71]; major immunogenic epitopes of PorA and FetA of men-
ingococci correspond to contiguous peptide sequences lo-
cated in putative surface-exposed loops of those proteins 
[72,73].  
PORINS INDUCED SIGNALING PATHWAYS 
 The molecular mechanisms during the interaction of 
Gram-negative bacteria with macrophages are well under-
stood, but the mechanisms used by porins to activate cells 
are not well characterized. LPS, porins or other OMPs 
probably activate cells through similar but not identical 
mechanisms [2]. The intracellular signaling pathways are 
complex networks of biochemical events that culminate in 
specific patterns of nuclear gene expression mediated by 
transcription factors. 
 Salmonella enterica serovar typhimurium porins induce 
signal transduction in mouse macrophages [74]. Porin activa-
tion of macrophages results in increased inositol triphosphate 
and intracellular Ca
2+
 mobilization, translocation of protein 
kinase C (PKC) to the membrane, NO release within the 
macrophages and increased binding of infected macrophages 
resulting in macrophage activation and triggering of specific 
signaling pathways. Salmonella enterica serovar typhi-
murium, Mannheimia haemolytica, and Haemophilus influ-
enzae (Hib) porins induce tyrosine phosphorylation in THP-1 
cells and in C3H/HeJ mouse macrophages [67], with Hib 
porin being the most powerful stimulator. The pattern of 
phosphorylation observed following LPS or porin stimula-
tion is essentially similar, but a difference can be observed in 
the cytoplasmic fraction bands of 50-60 kDa, which are more 
evident after treatment with LPS, and in the insoluble frac-
tion band of 80kDa and the cytoplasmic fraction band of 
250kDa, which are more evident after porin treatment. 
 Among the most prominent tyrosine-phosphorylated 
bands in porin-stimulated cells, a number of proteins with a 
molecular mass that is similar to that of the family of tyro-
sine/serine/threonine protein kinases were observed. Salmo-
nella enterica serovar typhimurium porins stimulation of 
U937 cells induces tyrosine phosphorylation of ERK1-2, 
protein kinase A (PKA), PKC and protein-tyrosine kinase 
(NT-PTKs). In the cells pretreated with tyrphostin, a specific 
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PTK inhibitor, or with H-89, a specific PKA inhibitor, or 
calphostin C, a specific PKC inhibitor, decrease of the rele-
vant activity was observed [75].  
 Neisserial porins induced protein tyrosine phosphoryla-
tion and alter the surface expression of the co-stimulatory 
molecule B7-2 [76]. Recent evidence suggests that the Raf-
1-MEK1/2-MAPK pathways are included among the pro-
teins which are phosphorylated following porin stimulation 
[77]. The use of some specific inhibitors of phosphorylation 
pathways such as SB-203580 (p38 inhibitor), PD-098059 
(MEK/ERK kinase inhibitor) and forskolin (Raf-1 inhibitor) 
demonstrated that they modulate in a different way cytokine 
mRNA expression in cells stimulated with porins. Neisserial 
porins induce nuclear translocation of the transcription factor 
NF-?B in B cells and dendritic cells that was maximal by 3 h 
of stimulation [76]. Salmonella enterica serovar typhi-
murium porins also activated AP-1 and NF-?B in U937 cells 
involving the Raf-1-MEK1/2-MAPK pathways [77]. Pre-
treatment with PD-098059 and with SB-203580 markedly 
affected the activation, indicating that the p38 signaling 
pathway is mainly involved in AP-1 and NF-?B activation 
[78]. In fact, PD-098059 is a good and specific inhibitor of 
MEK-1/2 [79]. In contrast, forskolin pretreatment did not 
block transcription factor activation by porins, suggesting 
that a Raf-1-independent pathway may also be involved fol-
lowing porin stimulation. The formation of a different com-
plex represents a further difference between stimulation with 
LPS and stimulation with porins. This may be added to past 
observations where mRNA cytokine expression after stimu-
lation with porin begins after 120 min and continues for 5-6 
h, while following LPS stimulation begins after 30 min and 
decreases at 120 min. Forskolin did not block NF-?B trans-
location after porin stimulation. Raf-1 induces the dissocia-
tion of cytoplasmic NF-?B-I?B complexes [80], suggesting 
that a Raf-1-dependent pathway may be involved in NF-?B 
activation. In fact, Raf-1 plays a central role in regulating 
multiple survival pathways in eukaryotic cells and has been 
also involved in the regulation of the activation of immune 
effector cells [81]. Moreover, Ras?Raf-1 mediated axis has 
been also involved in the triggering of a survival response to 
antiproliferative and immune regulating cytokines such as 
interferon alpha in human epithelial cells [82]. However, it is 
known that PKC triggers the activation of several kinases 
suggesting that MEK/ERK pathways may also participate in 
NF-?B activation by enhancing an AP-1-NF-?B cross-
coupling mechanism. The porin P2 from Hib, like porins 
from Salmonella enterica serovar typhimurium, activates 
mainly but not exclusively the JNK and p38 pathways. Syn-
thetic peptides, corresponding to the amino acid sequences of 
variable loop regions facing the cell exterior are responsible 
for most of the biological activity of porins; in contrast, pep-
tides modeled on internal ?-strands were ineffective in in-
ducing phosphorylation of such pathways [83,84]. In particu-
lar, loop L7 of porin OMPK36 from Klebsiella pneumoniae 
is involved in the interaction with C1q [85]; loops L5, L6 
and L7 of porin P2 from Haemophilus influenzae activate 
JNK and p38 mitogen-activated protein kinase (MAPK) 
pathways [83] and induce the release of TNF-? and IL-6 
[84].  
 A speculative scheme of signal transduction pathways 
involved in porin-mediated responses is depicted in (Fig. 5). 
Accumulating evidence has suggested that the regulation of 
transcriptional factors and the subunit composition by porin 
stimulation may affect the adaptive immune mechanism to 
modulate the production of biologically active proteins or 
peptides. The engagement of multiple pathways during sig-
nal transmission makes the possible use of molecular inhibi-
tors as therapeutic agents very difficult; although recent find-
ings show that peptides complementary to loop regions have 
a certain ability to block the activity of the porin [86]. 
 Activation of the coagulation and fibrinolytic systems is 
an important manifestation of the systemic inflammatory 
response of the host to infection. The in vivo effect of a syn-
thetic peptide corresponding to loop L7 from Haemophilus 
influenzae type b (Hib) porin was compared with the effect 
of the entire protein to evaluate its role on the coagula-
tive/fibrinolytic cascade and the circulating markers of endo-
thelial injury [87]. Plasma was obtained from rats injected 
intravenously with the peptide and tested for fragment 1+2 
(F1+2), tissue-type plasminogen activator (tPA), plasmino-
gen activator inhibitor type I (PAI-1) antigen, von Wille-
brand factor (vWF) and soluble E-selectin (sE-selectin). The 
coagulative/fibrinolytic cascade was impaired as determined 
by the increased level of PAI-1. Concomitantly, E-selectin, a 
marker of endothelial injury, was also significantly elevated. 
In addition either loop L7 or Hib porin injection induced 
hyperglycaemia and inflammatory cytokine production. The 
data were correlated with hemodynamic functions (signifi-
cant reduction of blood pressure and increase of heart rate) 
indicate that loop L7 plays an essential role in the patho-
physiologic events observed during gram-negative infec-
tions.  
PORINS INFLUENCE ON THE EMERGENCE OF 
ANTIBIOTIC RESISTANT STRAINS OF PATHO-
GENIC BACTERIA 
 Multidrug resistance (MDR) is frequently reported in 
clinical Gram-negative bacteria. This problem poses severe 
limits to therapeutic options available to clinicians and is a 
major cause of mortality when acquired as a nosocomial 
infection [88,89]. MDR is prevalent in key Gram-negative 
clinical pathogens, such as Escherichia coli, Salmonella spp., 
Klebsiella spp., Enterobacter spp., Campylobacter spp., 
Acinetobacter spp. and Pseudomonas spp. Three major bac-
terial strategies have emerged for the development of drug 
resistance: the membrane barrier limits the intracellular ac-
cess of an antibiotic; the enzymatic barrier produces detoxi-
fying enzymes that degrade or modify the antibiotic; and the 
target protection barrier impairs target recognition and thus 
antimicrobial activity [90]. These mechanisms can act simul-
taneously in clinical isolates, giving rise to a high level of 
resistance in a single species. The OM of Gram-negative 
bacteria behaves as a highly selective barrier mainly through 
the combined effect of a hydrophobic lipid bilayer together 
with pore-forming proteins of specific size-exclusion proper-
ties. The permeability properties of this barrier, therefore, 
have a major impact on the susceptibility of the microorgan-
ism to antibiotics, which are essentially intracellularly tar-
geted. Small hydrophilic drugs, such as ?-lactams, as well as 
tetracycline, chloramphenicol and fluoroquinolones, use the 
pore-forming porins to gain access to the cell interior, while 
macrolides and other hydrophobic drugs diffuse across the
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Fig. (5). Speculative scheme of porin signal transduction pathways. Putative porin-specific receptors are shown to be transmembrane. The 
solid arrows indicate the known association between superficial porin receptors and activation of several transcription factors; dotted arrows 
indicate hypothetical events. 
lipid bilayer. The emergence of drug-resistant strains in a 
large number of bacterial species due to modifications in the 
lipid or protein composition of the OM highlights the impor-
tance of the OM barrier in antibiotic sensitivity. Resistance 
generally emerges when a decrease in the rate of entry of 
these compounds is generated. There are several reports 
where antibiotic resistance is acquired as a consequence of 
loss or functional impairment of porins in a large number of 
organisms, such as Escherichia coli, Pseudomonas aerugi-
nosa, Neisseria gonorrhoeae, Enterobacter aerogenes and 
Klebsiella pneumonia [1,91-93]. There are two major porin-
based mechanisms for antibiotic resistance that have been 
reported in clinical isolates: 1) alterations of outer membrane 
profiles, including either loss/severe reduction of porins or 
replacement of one or two major porins by another; 2) al-
tered function due to specific mutations reducing permeabil-
ity. Antibiotic-driven tetracylcine resistance can occur by 
exposing sensitive Escherichia coli cells to increasing con-
centrations of the antibiotic, leading to a chromosome-
mediated multiple antibiotic resistance (Mar phenotype). 
Multiple proteins including porins and drug efflux pumps are 
involved, through upregulation of marA which ends up in 
inhibition of OmpF RNA translation [94]. Decreased OmpF 
levels can also derive from periplasmic accumulation of 
other OM proteins, such as TolC and OmpX, which might 
compete with the same substrate for assembly of porins in 
the OM [95]. The substitution of a general-diffusion porins 
normally present on the bacterial surface with a narrower 
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porin is a further mechanism for acquiring antibiotic resis-
tance. This is the case of substitution of OmpK35 and 
OmpK36 from K. pneumoniae with OmpK37, known to 
form smaller pores [96]. Reduced permeation rate as a con-
sequence of altered function of porin represents yet another 
strategy found in antibiotic resistant bacteria. Several muta-
tions in the L3 loop have been described that induce a con-
striction of the pore, for example, a clinical isolate of En-
terobacter aerogenes with a glycine to aspartate substitution 
[97]. This mutation may cause a modification of the loop 
with a reduction of the pore lumen [98] and consequently a 
consistent decrease in porin conductance and reduction in 
cephalosporin sensitivity. Similar alterations have been dem-
onstrated in the amino acid composition of the Neisseria 
gonorrhoeae porin Por [99]. Resistance to carbapenems in P. 
aeruginosa has been described in mutants lacking the porin-
specific OprD and in mutants with deletions in the L2 loop 
of OprD [100]. These examples illustrate the role of porin 
channels in the mechanisms of antibiotic resistance emer-
gence and provide molecular insights which could enable 
identification of new strategies to design more effective an-
timicrobials. 
CONCLUSION  
 Bacteria have developed sophisticated virulence factors 
such as the OM to mount their attack against the host. One of 
the most fascinating aspects of the OM of Gram-negative 
bacteria is its ability to act as a highly selective barrier 
mainly through the combined effect of a hydrophobic lipid 
bilayer together with pore-forming proteins of specific size-
exclusion properties. Porins from several Gram-negative 
bacteria play a fundamental role in the host-pathogen inter-
action, eliciting diverse biological proinflammatory activities 
and immune responses. In fact, porins present an intrinsic 
biological activity when interacting with eukaryotic cells, but 
also behave as antigens stimulating specific immune re-
sponses. While the structure determination of ?-barrel mem-
brane proteins has benefited from both an increased interest 
in the field and by the advancement of new crystallization 
and sample preparation techniques, the field remains an ex-
citing challenge for future research efforts. The structures of 
many unidentified bacterial OM proteins with unknown 
functions are still unsolved, and the mechanism by which ?-
barrels are properly folded and inserted into the OM is still 
poorly understood. Mechanisms affecting the barrier proper-
ties of the OM through the modification of expression and/or 
function of the porin channels may have an huge impact on 
the sensitivity of Gram-negative bacteria to antibiotics, 
therefore a better understanding at the molecular level of 
both the structure and the function of bacterial porins will 
allow improvements of the current drug therapies or the de-
sign of new types of antibiotics that target these surface ex-
posed structures. 
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Abstract
The molecular mechanism of entry of herpesviruses requires a multicomponent fusion system. Cell invasion by Herpes
simplex virus (HSV) requires four virally encoded glycoproteins: namely gD, gB and gH/gL. The role of gB has remained
elusive until recently when the crystal structure of HSV-1 gB became available and the fusion potential of gB was clearly
demonstrated. Although much information on gB structure/function relationship has been gathered in recent years, the
elucidation of the nature of the fine interactions between gB fusion loops and the membrane bilayer may help to
understand the precise molecular mechanism behind herpesvirus-host cell membrane fusion. Here, we report the first
biophysical study on the two fusion peptides of gB, with a particular focus on the effects determined by both peptides on
lipid bilayers of various compositions. The two fusion loops constitute a structural subdomain wherein key hydrophobic
amino acids form a ridge that is supported on both sides by charged residues. When used together the two fusion loops
have the ability to significantly destabilize the target membrane bilayer, notwithstanding their low bilayer penetration when
used separately. These data support the model of gB fusion loops insertion into cholesterol enriched membranes.
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Introduction
Enveloped viruses infect host cells by fusion of viral and target
membranes. The initial apposition step is followed by fusion of the
outer leaflets of membranes (the hemifusion step), leading to the
formation of a transient fusion intermediate, which evolves into
the fusion of inner leaflets and the formation of a pore, with the
mixing of the internal compartments of both fusion partners.
Thus, the viral genome is transferred to the cytoplasm of the host
cell and viral replication ensues [1–3]. This fusion event is
triggered by specific glycoproteins in the viral envelope. Fusion
glycoproteins belong to either class I, class II or the newly
described class III, depending upon their arrangement at the
surface of the virion, their structure and the location within the
protein of a short stretch of hydrophobic amino acids called the
fusion peptide, which is able to induce the initial lipid
destabilization that ends in fusion [4].
Although, viral fusion proteins are divided in three classes and
the cellular membrane undergoing fusion might vary (plasma
membrane vs. endosomal membrane), these proteins have to act
on lipid assemblies. Thus, lipids contribute to fusion through their
physical, mechanical and/or chemical properties and play a role
in determining the preferential partitioning of some amino acid
sequences into membrane microdomains called ‘‘rafts’’, and/or in
modulating the curvature of the membranes involved in the fusion
process [3].
Considering lipids and fusion proteins the necessary partners
involved in the fusion process, it becomes clear that the overall gist
of viral-induced membrane fusion is dictated by several features
common to different families of viruses [1]. All fusion machineries
need to interact with lipids, so they possess hydrophobic segments
(fusion peptides) or are able after rearrangements to make
hydrophobic interactions with membranes; moreover, need to
adopt specific conformations related to the pre and post-fusion
states, since fusion is limited in space and time. Therefore,
different viruses infect their host cells by very similar mechanisms
at the molecular level and fusion peptides represent a key element
of the fusion machinery, being the trigger for controlled
membrane destabilization.
Recently, the novel concept of ‘‘lipid packing sensor’’ emerged,
indicating protein motifs or domains that recognize the curvature
of lipid membranes. The most studied sensor is the amphipathic
helical motif present both in cellular membrane proteins and in
viral proteins [5,6]; but also other structural motifs, such as loops
or unfolded peptides, may be involved in the sensing of the
membrane curvature and in the initial steps of membrane fusion.
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The discovery of sensor motifs opens new perspectives with respect
to viral fusion proteins, which may contain such sensors; and may
help our understanding of the subtle and complex interplay
between protein-induced fusion and lipid modulation and may
represent targets for future antiviral therapies.
Herpes simplex virus type 1 (HSV-1) is a member of the a-
herpesvirus subfamily and enters cells through fusion of the viral
envelope with a cellular membrane in a cascade of molecular
interactions involving multiple viral glycoproteins and cellular
receptors. The envelope glycoproteins gH/gL, gB and gD are all
essential for the entry process [7] and expression of this quartet of
glycoproteins induces the fusion of cellular membranes in the
absence of virus infection [8]. gH/gL and gB, also play important
roles in primary fusion events that occur during egress of the
capsid from the nucleus of infected cells [9]. Recently, it was
shown that gB and gH/gL interact with each other concomitantly
with fusion and that this interaction is triggered by binding of gD
to its cellular receptor [10,11]. Thus, gB may function coopera-
tively with gH/gL, and each may have some fusogenic potential
on its own. Although gB and gH/gL constitute the core fusion
machinery of all members of the Herpesviridae, their mechanisms
of action are still under investigation.
Peptides derived from the ectodomain of gH block virus entry
[12], while others have the ability to bind and disrupt model
membranes [13–18]. The recently solved crystal structure of the
gH-gL complex [19] showed that gH has no structural homology
with any known fusion protein supporting the hypothesis that gH
may act as a regulator of fusion through interactions with gB,
while the crystal structure of the gH-gL complex of EBV presents
considerable differences in the structural arrangements of domains
supporting the view that the complex can undergo dynamic
rearrangements [7,20].
gB is highly conserved within all the members of the
Herpesviridae and is involved in virus attachment, penetration
and cell-to-cell spread. gB may undergo large conformational
changes to bring about fusion and even though evidence for its
refolding has yet to be obtained a model for pre-fusion gB has been
proposed and it seems that gB undergoes a refolding transition
during fusion. The structures of gB from HSV-1 [21] and EBV
[22] demonstrated that gB has structural homology with viral
fusion proteins belonging to other virus families: the vesicular
stomatitis virus (VSV) G protein [23] and the baculovirus protein
gp64 [24] and is probably the key fusion protein; moreover,
several synthetic gB peptides induced the fusion of large
unilamellar vesicles and inhibited herpes virus infection [25,26].
gB belongs to a newly formed group of fusion proteins, class III,
which share similar individual domain structures and contain a
central three-stranded coiled-coil reminiscent of the class I
proteins. Whereas class I proteins have an N-terminal fusion
peptide, class III proteins have internal bipartite fusion loops
within domain I which are similar to the single fusion loop of class
II fusion proteins. The class II fusion loop is composed entirely of
hydrophobic amino acids whereas those of gB have both
hydrophobic and charged residues [21–24]. In particular, the
fusogenic loops correspond to the domains 173–179 and 258–265
of the protein gB.
Hydrophobic amino acids within the gB loops (W174, F175,
G176, Y179, A261) are essential for gB function [27]. Similar
studies of VSV G, gp64 and EBV gB support the notion that
hydrophobic amino acids of both fusion loops are critical for fusion
[28,29] and together constitute a fusion domain. Moreover, also
charged amino acids play a fundamental role, in fact, mutations of
H263 or R264 also negatively affected gB function [27]. These
data support the view that the two fusion loops constitute a
subdomain where key hydrophobic amino acids form a ridge that
is flanked on both sides by charged amino acids that enhance the
ability to interact with target membranes, in fact, one of the two
gB fusion loops (namely HB168–186) was identified by highly
interfacial hydrophobicity analysis without the aid of structural
data [25].
Although much information has been gathered in recent years,
we do not yet know the precise molecular mechanism behind
herpesvirus host cell membrane fusion; thus, elucidating the nature
of the fine interactions between gB fusion loops and the membrane
may help to districate this interesting matter. In the present study,
we report the synthesis and characterization of membrane
interactions of the two fusion peptides present in gB. The goals
of the experiments reported here were to verify the fusion ability of
the two peptides, to assess the dependence of the fusion activity on
the composition of the membrane and in particular on the content
of cholesterol and to verify the eventual presence of a synergic or
cooperative effect when the two isolated peptides are used
together.
As far as we know, this is the first biophysical study on the two
putative fusion peptides of gB, with a particular focus on the effects
determined by both peptides on lipid bilayers of various
compositions.
Results
Design of peptides
The proposed post-fusion structure of gB ectodomain is
comprised of three protomers, and each protomer coils around
the others with a left-handed twist [21]. There are multiple
contacts between protomers throughout the molecule contributing
to trimer stability. Each protomer of gB can be divided into five
distinct domains: I, base; II, middle, III, core; IV crown; and V,
arm (Figure 1). Domain I (Ile154 to Val363) is a b sandwich
composed of two nearly orthogonal b sheets of four and three
strands, with a long loop and short helix covering one opening of
the b sandwich. An insertion (Tyr165 to Ile272) between strands
b4 and b11 creates a subdomain at the base of the trimer,
consisting of a four-stranded b sheet (with three long and one short
strand), the convex side of which is covered with an a helix, a b
hairpin, and a short two-stranded b sheet; the four-stranded b-
sheet presents hydrophobic tips that have been proposed to
represent the fusion peptides of gB (Figure 1). Fusion peptides are
generally considered as being domains with a high interfacial
hydrophobicity calculated with the Wimley-White hydrophobicity
scale which was systematically used for searching fusion peptides in
other viral glycoproteins. HB168–186, comprising the precise
fusion loop HB173–179 [21], is located in the insertion between
strands b4 and b11 and we were able to identify this region on the
basis of its hydrophobicity, and analyse its role in peptide/lipid
fusion assays [25]. The second loop (HB258–265), identified on
the basis of structural data [21] contributes to the formation of the
bipartite fusion peptide, but does not correspond to a hydropho-
bicity peak calculated with the interfacial scale and thus was not
considered in our previous study [25].
Both fusion loops have been characterized by point-mutations
in the protein sequence and showed to be critical for gB function
in cell fusion [30]. In the present study, we report on the structural
characterization of the two fusion loops by using peptides
corresponding to their sequences. We synthesised a short version,
corresponding exactly to the sequences of the loops, and a longer
version, embracing the flanking b-sheets, in order to understand
the contributions of each region that constitutes the gB fusogenic
domain (Table 1). Moreover, we tried to understand the
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contribution of lipids that take part to the interplay between the
membrane and fusogenic peptides.
Ability of peptides to induce lipid mixing
To investigate the fusogenicity of gB peptides, NBD and Rho
labelled PE were used as the donor and acceptor of fluorescence
energy transfer. A population of LUVs labelled with both was
mixed with a population of unlabelled LUVs and increasing
amounts of peptides were added. Dilution of the fluorescent-
labelled vesicles via membrane fusion induced by the peptide
results in a reduction of the fluorescence energy transfer efficiency,
hence dequenching of the donor fluorescence. The dependence of
the extent of lipid mixing on the peptide to lipid molar ratio was
analysed. The fusogenic capacity was monitored by measuring
their ability to induce lipid mixing of model membranes composed
of DOPG, DOPG/Chol (3/2), DOPC, DOPC/Chol (3/2),
POPC/Chol (3/2), and POPC/Chol/SM at various ratios (4/1/1,
2/1/1, 1/1/1).
Interestingly, there was a different behaviour of the peptides
depending on the lipid composition of LUVs. Figure 2A and B
show the results of lipid mixing assays in LUVs of different
compositions for peptides HB168–186 and HB254–270. The
graphs show that in all tested conditions HB168–186 has higher
fusogenic ability. DOPC/Chol, POPC/Chol and DOPG/Chol all
proved to be good fusogenic conditions. Furthermore, it is evident
from the results obtained that DOPG in presence or absence of
cholesterol represents a less fusogenic condition, indicating that the
negatively charged phospholipids are not preferred. This is a
rather interesting result as both peptides contain arginine residues
and thus we could expect a greater interaction with anionic lipids.
Several viruses such as HIV, influenza virus and Semliki Forest
virus have been shown to involve lipid microdomains, which are
enriched in cholesterol during virus budding as well as virus entry.
Also herpesvirus has been shown to require cholesterol [31,32],
and such a need for cholesterol has also been highlighted in our
experiments using model membranes where a significant increase
in fusion is always observed in presence of cholesterol. The lipids
allowing the highest level of fusion are DOPC and POPC which
are both zwitterionic but present a difference in their unsaturation,
with POPC having only one unsaturated acyl chain and DOPC
having two. DOPC results in a more flexible bilayer, which
appears to be an important feature for the fusion activity of the
analyzed peptides. We also tested the peptide fusion ability of
liposomes containing sphingomyelin, a component commonly
found in lipid rafts. The ternary lipid system POPC/Chol/SM is a
good model for lipid rafts and from the ternary phase diagram [33]
it is possible to determine the boundaries for lipid rafts which are
strongly dependent on the percentage of each lipid in the system.
We used three different conditions to probe the activity of our
peptides in LUVs mimicking rafts: POPC/Chol/SM 4/1/1, 2/1/1
and 1/1/1, characterized by different percentages of the liquid
Figure 1. Three dimensional structure of a single gB protomer. The different domains are shown. In the insert are shown molecular details of
the two fusion loops: HB168–186 (green) and HB254–270 (red).
doi:10.1371/journal.pone.0032186.g001
Table 1. Peptides.
Sequence
HB168–186 NH2-VTVSQVWFGHRYSQFMGIF-COOH
HB173–179 NH2-VWFGHRY-COOH
HB254–270 NH2-YNPSRVEAFHRYGTTVN-COOH
HB258–265 NH2-RVEAFHRY-COOH
scrambled NH2-MRWFSVVSYQVIGTQFGFH-COOH
doi:10.1371/journal.pone.0032186.t001
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ordered and liquid disordered phases. The results obtained
(Figure 2 C–D) show that both peptides present a significant
percentage of fusion
Figure 2E shows the results obtained in DOPC/Chol for the
peptides HB168–186 and HB254–270 as well as their shorter
versions corresponding exactly to the loop sequences derived from
Figure 2. Ability of peptides to induce lipid mixing. Peptide-promoted membrane fusion as determined by lipid mixing; peptide aliquots were
added to 0.1 mM LUVs, containing 0.6% NBD and 0.6% Rho. The increase in fluorescence was measured after the addition of peptide aliquots;
reduced Triton-X-100 (0.05% v/v) was referred to as 100% of fusion. In figure is reported the dose dependence of lipid mixing at 37uC: panels A and B
HB168–186 and HB254–270 in LUVs of different composition; panels C and D HB168–186 and HB254–270 in LUVs mimicking lipid rafts; panel E
HB168–186, HB254–270 and shorter versions in DOPC/Chol LUVs; panel F equimolecular mixtures of peptides HB168–186 and HB254–270 in DOPC/
Chol (3/2) and POPC/Chol/SM (2/1/1).
doi:10.1371/journal.pone.0032186.g002
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the crystallographic structure. The two shorter peptides (HB173–
179 and HB258–265) induced lower levels of fusion compared to
longer sequences, suggesting that shorter peptides were unable to
cross or stably position inside the bilayer. This result further
supports the view that fusion loops are structured by the overall
organization of the fusion domain of the protein and longer
peptides are, therefore, necessary to evidence an appreciable
fusion activity.
In the case of the peptide equimolar mixtures (Figure 2F), we
can observe that in DOPC/Chol as well as in POPC/Chol/SM
(2/1/1) we have a significant fusion activity supporting a
cooperative mechanism.
Ability of peptides to induce lipid mixing of inner-
monolayer
In the inner monolayer assay, the fluorescence from the vesicle
membranes’ outer monolayer is eliminated by the addition of an
aqueous reducing agent, and this experiment reveals the extent of
lipid mixing between the inner monolayers of vesicles in solution.
Figure 3A shows a significant fusion of the inner monolayer in
DOPC/Chol. This is slightly lower than the fusion level obtained
in the lipid mixing experiment, since the latter measures both
hemi-fusion and complete fusion. Therefore, this assay clearly
indicates that the two peptides are able to induce fusion of both the
inner and the outer monolayers.
We also verified the ability of peptide equimolar mixtures to
induce lipid mixing of the inner-monolayer. The results obtained
indicate that the peptides cooperate in the fusion process.
Ability of peptides to induce membrane leakage
In order to explore the effects of the peptides in the
destabilization of membrane vesicles, we studied their effect on
the release of encapsulated fluorophores in model membranes
made of DOPC/Chol. A content-mixing assay (Figure 3B) was
employed to monitor any mixing of internal vesicle components as
a result of vesicle exposure to HB168–186 and HB254–270.
Release of ANTS and DPX from vesicle is commonly used as a
measure of bilayer perturbation and interpreted as ‘‘transient pore
formation’’ [34,35]. Content-mixing is manifested by a decrease in
fluorescence intensity if vesicles encapsulating fluorescent cargo
(e.g., ANTS) merge contents with those containing quenchers (e.g.,
DPX). The leakage experiment shows that the probe did not leak
out significantly to the medium after the interaction with any of
the peptides used in this study. Figure 3B shows that no content-
mixing occurs over the same P/L range where substantial outer
and inner monolayer lipid-mixing occurs, confirming that vesicle
fusion may happen within our system without concomitant pore
formation. The low leakage value observed for both peptides
might be due to the fact that they are located at the membrane
interface and do not completely traverse the bilayer. We also
verified the eventual ability of equimolar mixtures of HB168–186
and HB254–270 to induce membrane leakage, but no significant
difference from results obtained for individual peptides was
detected.
Peptide aggregation
The peptide’s aggregation state in buffer and DOPC/Chol
LUVs was assayed using ThT [36], in order to know the possible
effects of the peptide aggregation on the membranes. As observed
in Figure 4 A–B, the two peptides present a completely different
behaviour. The peptide HB168–186 at a concentration of 4 mM
(Figure 4A) is already aggregated in an aqueous medium, in fact,
the fluorescence change increased dramatically after the addition
of the peptide from a stock solution, while in the presence of
DOPC/Chol a lower aggregation is reported. The peptide
HB254–270 is not aggregated in the aqueous medium nor in the
presence of DOPC/Chol at the same concentration. Furthermore,
we studied the intrinsic relationship between the concentration of
the peptides and the aggregation in buffer and in LUVs and we
can interpret the data for HB168–186 reported in Figure 4C as
aggregated both in the aqueous medium and in LUVs at high
concentrations. Our results are consistent with two hypothesis; the
first is an initial aggregation in the aqueous medium, followed by a
disaggregation when initially interacting with the membrane and
again an aggregation inside the membrane bilayer, indicating that
the insertion of the peptide into the membrane could occur in a
monomeric form and only afterwards the peptide aggregates
again; while the second hypothesis is that the peptide can interact
with the membranes already in an oligomerized state.
Tryptophan/tyrosine fluorescence emission analysis
We measured the intrinsic fluorescence of HB168–186 and
HB254–270 (due to the presence of a tryptophan residue in the
sequence of HB168–186 and two tyrosines for HB254–270) to
evaluate the degree of penetration of the peptides into the
membrane bilayer. We compared the fluorescence emission
spectra in DOPC/Chol vesicles with that in buffer (data not
shown). The quantum yield of aromatic residues of a peptide or
protein normally changes when the amino acid is located in a
more hydrophobic environment such as a phospholipid mem-
brane, normally increasing the intensity of the fluorescence
emission and shifting the maximal spectral position toward shorter
wavelengths (blue shift). Changes in the spectral properties were
observed for both peptides, suggesting that the single tryptophan
residue of HB168–186 and the two tyrosines of HB254–270 move
to a less polar environment upon interaction with lipids. Emission
intensity was enhanced and the maxima shifted to lower
wavelength. (Figure S1) Blue shifts of this magnitude are generally
observed when amphiphilic aromatic-containing peptides interact
with phospholipid bilayers and are consistent with the aromatic
moiety becoming partially immersed in the membrane, further
suggesting that the analysed peptides are capable of penetrating a
lipid bilayer [37].
The increase in fluorescence for tryptophan or tyrosines binding
to membrane phospholipids was used for the generation of binding
isotherms for HB168–186 and HB254–270, therefore partition
coefficients could be calculated. The concentrations of peptides
used were low enough to cause minimal aggregation in the
aqueous phase and were assumed not to disrupt the bilayer
structure. To determine the surface partition coefficient, the
fluorescence intensities were converted to moles of bound peptide
per moles of lipid and plotted as a function of the free peptide
concentration as described in material and methods (Figure 5). As
partition coefficients depend on the concentration of lipid
accessible to peptide, the curves obtained by plotting Xb* (the
molar ratio of bound peptide per 60% of the total lipid) vs Cf (the
equilibrium concentration of free peptide in the solution) are
referred to as the conventional binding isotherms. The shape of a
binding isotherm of a peptide can provide information on the
organization of the peptide within the membrane. A straight line
indicates a simple adhesion process. The shape of the binding
isotherm of all the peptides tested was not linear indicating that
peptide accumulation at the surface is not a simple phenomenon
without cooperative association. In particular, this behaviour is the
hallmark for peptides that self-associate at membrane surfaces
upon partitioning. If aggregation occurred only in the water but
not in the bilayer phase, the opposite course of the isotherms
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should be expected: a steep rise at the origin, followed by
pronounced flattening; thus, the shape of the isotherms obtained
could be interpreted as reflecting a process whereby peptides first
incorporate into the membrane and then aggregate there within.
Moreover, there was no evidence of significant aggregation in
water at the concentration used in this experiment (0.1 mM) for
HB254–270, although we have an indication of aggregation in
water for HB168–186 as shown in Figure 4C. In the isotherms
obtained, the total extent of incorporation (Xb
*) slowly increases
until a critical concentration is reached, where massive internal
aggregation apparently starts to develop.
The surface partition coefficients Kp were estimated by
extrapolating the initial slopes of the curves to Cf values of zero.
Curves are shown in Figure 5.
The Kp values for the peptides HB168–186 and HB254–270
are shown in Table 2. The Kp value obtained for HB168–186 is
2.5 104, indicating that the tryptophan in HB168–186 is able to
interact significantly with the bilayer and that most of the peptide
HB168–186 is located inside the liposomes. The Kp value for
HB254–270 is 3.2 104, indicating that the tyrosine residues present
in this peptide are located inside the liposomes and are stably
inserted.
Quenching of tryptophan/tyrosines by Acrylamide
The observed changes in the characteristics of the tryptophan/
tyrosine emission upon binding of peptides HB168–186 and
HB254–270 to lipid vesicles indicate their insertion into the
hydrophobic region of the bilayers. We also studied the
accessibility of the tryptophan/tyrosine residues of membrane-
bound peptides towards acrylamide, a neutral, water-soluble,
highly efficient quenching molecule, which is unable to penetrate
Figure 3. Ability of peptides to induce lipid mixing of inner-monolayer and membrane leakage. Peptide interactions with DOPC/Chol
LUVs (A–B), the dose dependence is reported and each trace represents an average of three independent experiments. A) Inner monolayer assay.
C) Leakage of ANTS/DPX.
doi:10.1371/journal.pone.0032186.g003
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into the hydrophobic core of the lipid bilayer. The more deeply a
tryptophan/tyrosine residue is buried, the less strongly it can be
quenched by acrylamide. Stern-Volmer plots for the quenching of
tryptophan by acrylamide, recorded in the absence and presence
of lipid vesicles, are depicted in Figure 6. Fluorescence of
tryptophan/tyrosine decreased in a concentration-dependent
manner by the addition of acrylamide to the peptide solution
both in the absence and presence of liposomes, without other
effects on the spectra. However, we can observe a substantial
difference between the two peptides. In the presence of liposomes,
a great decrease in fluorescence intensity was evident for HB254–
270, thus revealing that tyrosine residues are less accessible to the
quencher in the presence of LUVs. In fact, the values for Ksv were
lower (Table 3) in LUVs, suggesting that tyrosines were more
buried in the bilayers, becoming more inaccessible for quenching
by acrylamide. From Figure 6, it is evident that we can observe for
the peptide HB168–186 a low accessibility to the quencher both in
absence and presence of liposomes, indicating that the peptide has
a significant tendency to aggregate also in an aqueous solution.
ESR Results
The ESR spectroscopy, by using spin-labelled substances
(peptides and/or lipids) has been proved to give substantial
information on the interaction of peptide deriving from viral fusion
glycoproteins with lipid membranes [38–41]. In the present work,
the association of the two peptides, HB168–186 and HB254–270,
with lipid bilayers was investigated by analysing changes in ESR
spectra of spin-labelled phospholipids. The samples investigated
were phosphatidylcholine spin-labelled at different positions, n, in
the sn-2 chain (n-PCSL, n=5, 7, 10, 14) incorporated in DOPC/
Chol membranes (3/2), in the presence of the peptides.
Preliminarily, the spectra in the absence of the peptides were
registered. Inspection of Figure 7A (solid lines) shows that all the
spectra present a clearly defined axially anisotropic lineshape, an
evidence that, due to the high cholesterol content, the DOPC/
Chol bilayer is in the liquid-ordered state [42]. In an attempt to
quantitatively analyse the spectra, the outer hyperfine splitting,
2Amax, was calculated. The 2Amax variation, shown in Figure 7B,
is an evidence of the flexibility gradient in segmental acyl chain
mobility [38,43], indicating that the lipid bilayer presents a rigid
surface and relatively fluid interior [44–47].
Association of peptides to the lipid bilayer causes a significant
variation in the ESR spectra of spin-labelled phospholipids. In
Figure 7A, ESR spectra of 5-PCSL and 14-PCSL in DOPC/Chol
bilayers, in the presence of HB168–186, HB254–270 and HB168–
186:HB254–270 mixture at a lipid/peptide weight ratio of 1/1,
are also reported. The presence of two peptides induces significant
changes in the spin-label ESR spectra, which are mainly
detectable from the low- and high-field component position and
lineshape. In an attempt to quantify this evidence, the 2Amax
values were determined. Figure 7B shows the dependence of these
parameters on chain position, n, for the n-PCSL spin-labels in
DOPC/Chol membranes, in the absence and in the presence of
the peptides. In all cases, the flexibility gradient with the chain
position of the lipid bilayer membranes is preserved. However,
inspection of the figure reveals a significantly different behaviour
of the lipid chain mobility in the co-presence of the two peptides.
In fact, addition of HB168–186 or HB254–270 significantly
reduces the 2Amax value of 5-PCSL. In both cases, no changes in
the spectra of the spin-labels bearing the nitroxide group in the
more interior positions were observed. Strikingly, addition of the
HB168–186:HB254–270 mixture results in a strongly 2Amax
decrease for all the considered spin-labels. These results show a
cooperation of the peptides in perturbing the bilayer microstruc-
ture in that only in the presence of both of them the increase of
segmental mobility propagates along the whole acyl chains. Thus,
the contemporary interaction of both peptides with the lipid
membrane surface effectively perturbs the local order and
dynamics of the lipid leaflet they come in contact with.
Secondary structure in lipid bilayers
The CD spectra of the peptides in buffer and bound to LUVs
made of DOPC/Chol are shown in Figure 8. The binding of the
peptides to the membrane bilayer did not affect their structure.
The spectra are indicative of random conformation for both
peptides.
Discussion
Membrane fusion is of fundamental importance in the
biological life of a cell and is of particular interest during
enveloped virus infections. A common feature of all fusion events is
the involvement of the fusion peptide in these phenomena and the
key role played by lipids in the conformational changes leading to
the interaction of the fusion peptide with target membranes, and
in the membrane deformation following the initial peptide-
membrane interactions. Extensive research data on viral mem-
brane fusion proteins have disclosed the existence of several
protein domains involved in the viral fusion process. It is, thus, an
accepted view the presence of different membrane-active regions
in viral fusion glycoproteins, although their biological function is
still unclear. It has been hypothesised that these regions may have
a different role on either pore formation and stabilization, viral
budding or both of them.
In the present work we have investigated the role played by the
two fusion loops of HSV-1 gB in the mechanism of membrane
fusion. In particular, three important issues were addressed: the
ability of peptide analogues of the fusion loops to induce fusion of
liposomes, their ability to interact with the membrane bilayer
when alone and when used in equimolar concentrations and the
role of the target membrane composition. For herpesviruses,
cholesterol is thought to play a key role, in fact, lipid raft may act
as a platform allowing cell entry and potential coreceptors
clustering [32] or cholesterol may modulate the HSV entry
process regardless of its ability to promote lipids microdomains
[48]. In this work evidences have been obtained indicating the
ability of the two fusion peptide to induce fusion of liposomes in
vitro, their ability to strongly interact with a membrane bilayer
containing cholesterol and finally their different mode of
interaction with the bilayer indicating that although being both
involved in the fusion mechanism they may play a different role.
The two fusion loops constitute a structural subdomain wherein
key hydrophobic amino acids form a ridge that is supported on
both sides by charged residues. The two charged residues located
on both sides of the ridge represent a novel feature of viral fusion
peptides and probably enhance the ability of the hydrophobic
residues to interact with target membranes and to promote fusion.
Figure 4. Peptide aggregation. Fluorescence variation of ThT after addition of HB168–186 (A) and HB254–270 (B) peptides to an aqueous solution
and in the presence of LUVs of DOPC/Chol at a peptide concentration of 4 mM. (C) Percentage of aggregation as a function of peptide concentration
for HB168–186 and HB254–270 in buffer (closed symbols) and in LUVs (open symbols).
doi:10.1371/journal.pone.0032186.g004
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Figure 5. Tryptophan/tyrosine fluorescence emission analyses. Binding isotherms obtained plotting Xb
* versus Cf for HB168–186 and HB254–
270.
doi:10.1371/journal.pone.0032186.g005
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The analysis of the location of the fusion loops into the three-
dimensional structure of gB points out that the hydrophobic
residues do not appear to be able to insert deeply into a target
membrane. The hydrophilic residues on either side of the
hydrophobic ridge may help to stabilize insertion of gB into
cholesterol enriched membranes or more generally membranes
mimicking lipid rafts, but both fusion loops seem unable to deeply
penetrate into the hydrophobic core of the bilayer.
The fusion ability of the two peptides was analysed using LUVs
with different compositions. Membrane components, such as
anionic lipids (DOPG), unsaturated phospholipids (DOPC,
POPC), sphingolipid (SM) and cholesterol (Chol) were used in
this study. Lipid raft formation occurs by spontaneous aggregation
of certain naturally occurring lipids that aggregate in the plane of
the membrane and are characterized by a higher degree of
molecular order and by being thicker than the surrounding liquid-
disordered lipids in the membrane. To investigate lipid raft
characteristics in model membranes, Chol and SM are commonly
combined with phospholipids having unsaturated and therefore
kinked fatty acyl chains, such as POPC. Our results are consistent
with previous studies showing the specific association of gB with
cholesterol-rich rafts [32]. We found that gB peptides associate
with lower fusion ability with liposomes in the absence of
cholesterol. Our data further suggest that the cholesterol
dependence of gB is not necessarily dependent on a protein
receptor in rafts, but because cholesterol itself enhances insertion
of the fusion loops. In Semliki Forest virus fusion protein E1, a
class II fusion protein that inserts preferentially into membranes
enriched in cholesterol and sphingolipid [49], a point mutation in
the loop adjacent to the fusion loop confers increased cholesterol
independence [50,51].
Lipid mixing, inner-monolayer and leakage are three indepen-
dent experiments which describe different processes during the
interaction of peptides with liposomes. In particular, the lipid
mixing experiment evidences the fusion of both the inner and
outer monolayer, the inner monolayer experiment evidences the
eventual presence of fusion of the inner monolayer, while the
leakage describes the pore formation. Results were consistent
among the three experiments for both peptides, supporting the
hypothesis that the two peptides induce fusion of inner and outer
monolayers but not formation of pores whenever used alone or in
equimolar concentrations. The present results can be used as
qualitative indicators of bilayer perturbation due to its interaction
with the peptides and their superficially positioning. We have not
detected any significant pore formation; in fact, vesicle fusion
events were not accompanied by leakage of the aqueous contents
of the vesicle as also reported for other peptides in a study
published by Thoren et al. [52].
Table 2. Partition coefficient for the binding of peptides with
PC/Chol.
HB168–186 HB254–270
Kp (2.560.3)10
4 (3.260.2)104
doi:10.1371/journal.pone.0032186.t002
Table 3. Stern-Volmer (Ksv) quenching constant calculated
from the equation F0/F = 1+Ksv [Q] for HB168–186 and
HB254–270.
HB168–186 HB254–270
Ksv (M
21) in buffer 8.360.2 71.161.1
Ksv (M
21) in LUVs 6.460.4 8.560.1
doi:10.1371/journal.pone.0032186.t003
Figure 6. Quenching of tryptophan/tyrosines by Acrylamide. Stern-Volmer plots of acrylamide quenching of HB168–186 and HB254–270 in
buffer (closed symbols) and in LUVs (open symbols).
doi:10.1371/journal.pone.0032186.g006
Herpes Virus gB Fusion Peptides
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e32186
Another novel feature revealed in the present work is the
demonstration of oligomerization concomitant to fusion taking
place. Although a correlation between penetration and fusion
awaits further experimental support, our results suggest that
oligomerization is another parameter related to the nature of the
interaction of the peptide with the target membrane and plays a
key role in governing fusion activity. The peptide HB168–186
presents a high tendency to oligomerize both in aqueous solution
and inside the membrane. On the contrary, the peptide HB254–
280 is not oligomerized in aqueous solution but it is able to
oligomerize when interacting with the membranes.
Tryptophan and tyrosine side chains are often found at the
interface between charged phospholipids and hydrophobic fatty
acid chains of lipid membranes. The Kp values for the two
peptides are reported in Table 2. Since Kp values are all of the
same order (104), we concluded that the peptides have similar
membrane-binding affinities. The values of Kp obtained are within
the range of those obtained for membrane-permeating bioactive
peptides such as mellitin and its derivatives [53], the Staphylo-
coccus d-toxin [54], the antibiotic dermaseptin [55], pardaxin
analogues [56]. All the results obtained support a shallow insertion
of the two peptides that may expand the head-group region of one
of the monolayers and generate elastic stresses that are released by
bilayer deformation. Our results demonstrate that these two gB
peptides bind and interact with membranes and could thus be
directly involved in merging of the viral and cellular membranes
and might work cooperatively with other membrane active regions
present on herpesvirus glycoproteins to boost the fusion process.
These results improve the current understanding of the critical
features required for viral fusogenic peptides to cross the
membrane bilayer and seem promising for the development of
new carrier peptides that could exploit viral membranotropic
peptides for intracellular delivery [57–59].
HSV-1 might have several domains involved in the fusion
process which either directly or indirectly, might interact with
biological membranes, contributing to the viral envelope and cell
membrane merging. Although the detailed mechanism of
herpesvirus entry remains unclear, some important insights into
the interplay of the proteins involved in membrane fusion have
been gained recently, but there are still many unsolved questions
such as if the two fusion loops are the only HSV fusion peptide;
what triggers them to be inserted into the target membrane, what
is the role of gH in fusion and if fusion domains present in gH are
directly involved in fusion.
Materials and Methods
Materials
The Phospholipids: 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
choline (POPC), dioleoyl phosphatidylcholine (DOPC), dioleoyl
phosphatidylglycerol (DOPG), N-octadecanoyl-D-erythro-sphingo-
sylphosphorylcholine (SM), the fluorescent probes N-(7-nitro-
benz-2-oxa-1,3-diazol-4-yl)phosphatidylethanolamine (NBD-PE)
and N-(Lissamine-rhodamine-B-sulfonyl) phosphatidylethanol-
amine (Rho-PE) were purchased from Avanti Polar Lipids
(Birmingham, AL, USA), while cholesterol (Chol) and Triton-
6100 were from Sigma (St. Louis, MO, USA). All other reagents
were of analytical grade. Spin-labelled phosphatidylcholines (n-
PCSL) with the nitroxide group at different positions, n, in the sn-2
acyl chain were synthesized as described by Marsh [60]. The spin-
labels were stored at 220uC in ethanol solutions at a concentra-
tion of 1 mg/mL.
Peptide synthesis
Peptides were synthesised using standard solid-phase-9-fluor-
enylmethoxycarbonyl (Fmoc) method as previously reported [25].
All purified peptides (purity higher than 98%) were obtained with
good yields (30–40%). Table 1 shows the sequences of all the
synthesized peptides. Peptide stock solutions were prepared in
buffer with 2% dimethyl sulfoxide (DMSO).
Liposome preparation
Large unilamellar vesicles (LUVs) consisting of DOPG, DOPG/
Chol (3/2), DOPC, DOPC/Chol (3/2), POPC/Chol (3/2),
Figure 7. ESR Results. (A) ESR spectra of 5-PCSL and 14-PCSL spin-
labels in DOPC/Chol membranes in the absence of peptides (solid line)
and in the presence of HB168–186 (dotted line), HB254–270 (dashed
line) and HB168–186–HB254–270 mixture (dashed-dotted line). (B)
Dependence on spin-label position, n, of the outer hyperfine splittings,
2Amax, of the n-PCSL in DOPC/Chol bilayers in the absence (#) and in
the presence of HB168–186 (&), HB254–270 (N) or HB168–186: HB254–
270 (m) at T = 25uC.
doi:10.1371/journal.pone.0032186.g007
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POPC/Chol/SM (4/1/1), POPC/Chol/SM (2/1/1) and POPC/
Chol/SM (1/1/1), and when necessary containing Rho-PE and
NBD-PE, were prepared according to the extrusion method of
Hope et al. [61] in 5 mM HEPES, 100 mM NaCl, pH 7.4. Lipids
were dried from a chloroform solution with a nitrogen gas stream
and lyophilized overnight. For fluorescence and circular dichroism
experiments, dry lipid films were suspended in buffer by vortexing
for 1 h; then the lipid suspension was freeze-thawed 6 times and
extruded 20 times through polycarbonate membranes with 0.1 mm
diameter pores to produce LUVs. Lipid concentrations of
liposome suspensions were determined by phosphate analysis
[62]. For ESR spectroscopy, multi-lamellar vesicles (MLVs) were
prepared. In these samples, 1% (wt/wt) of the spin-label, dissolved
in ethanol, was added to the lipid mixture in organic solvent before
drying. MLVs suspensions were obtained by the same procedure
described above, excluding the extrusion step.
Lipid mixing assays
Membrane lipid mixing was monitored using the resonance
energy transfer assay (RET) reported by Struck et al. [63]. The
assay is based on the dilution of the NBD-PE (donor) and Rho-PE
(acceptor). Dilution due to membrane mixing results in an
increase in NBD-PE fluorescence. The change in donor emission
was monitored as aliquots of peptides were added to vesicles.
Vesicles containing 0.6 mol % of each probe were mixed with
unlabelled vesicles at a 1:4 ratio (final lipid concentration
0.1 mM). Small volumes of peptides in dimethylsulfoxide
(DMSO) were added; the final concentration of DMSO in the
peptide solution was no higher than 2%. The NBD emission at
530 nm was followed with the excitation wavelength set at
465 nm. A cut off filter at 515 nm was used between the sample
and the emission monochromator to avoid scattering interferenc-
es. The fluorescence scale was calibrated such that the zero level
corresponded to the initial residual fluorescence of the labelled
vesicles and the 100% value corresponding to complete mixing of
all lipids in the system was set by the fluorescence intensity of
vesicles upon the addition of Triton X-100 (0.05% v/v) at the
same total lipid concentrations of the fusion assay. Lipid mixing
experiments were repeated at least three times and results were
averaged. Control experiments were performed using a scrambled
peptide and DMSO. All the experiments were performed at
37uC.
Figure 8. Secondary structure in lipid bilayers. CD spectra of HB168–186 and HB254–270 in buffer and in DOPC/Chol LUVs.
doi:10.1371/journal.pone.0032186.g008
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Inner-monolayer phospholipid-mixing (fusion)
measurement
Peptide-induced phospholipid-mixing of the inner monolayer
was measured by a modification of the phospholipid-mixing
measurement reported elsewhere [64]. The concentration of each
of the fluorescent probes within the liposome membrane was 0.6%
mol. LUVs were treated with sodium dithionite 100 mM (from a
stock solution of 1 M dithionite in 1 M TRIS, pH 10.0) to
completely reduce the NBD-labelled phospholipid located at the
outer monolayer of the membrane, for approximately 1 h on ice in
the dark. Sodium dithionite was then removed by size exclusion
chromatography through a Sephadex G-75 50 DNA Grade
filtration column (GE Healthcare) eluted with a buffer containing
10 mM TRIS, 100 mM NaCl, and 1 mM EDTA, pH 7.4.
Measurements of ANTS/DPX leakage
The ANTS/DPX assay [34] was used to measure the ability of
the peptide to induce leakage of ANTS/DPX pre-encapsulated in
liposomes. Details of this assay can be found elsewhere [35]. To
initiate a leakage experiment, the peptide, in a stock solution at
pH 7.4 containing 5 mM Hepes and 100 mM NaCl, was added to
the stirred vesicle suspension (0.1 mM lipid) at 37uC.
Thioflavin T assays for peptide aggregation
Peptide aggregation was assayed using Thioflavin T (ThT).
ThT associates rapidly with aggregated peptides giving rise to a
new excitation maximum at 450 nm and an enhanced emission at
482 nm [36]. LUVs in 100 mM NaCl, 10 mM Tris–HCl, 25 mM
ThT, pH 7.4 (final phospholipid concentration of 0.1 mM) were
titrated with a peptide concentration of 1, 4, 8, 12, 16, 20 mM.
Fluorescence was measured before and after the desired amount of
peptide was added into the cuvette using a Varian Cary Eclipse
fluorescence spectrometer at 37uC. Samples were excited at
450 nm (slit width, 5 nm) and fluorescence emission was recorded
at 482 nm (slit width, 5 nm). Aggregation was quantified
according to the equation, %A= (Ff2F0)/(Fmax2F0)6100, where
Ff is the value of fluorescence after peptide addition, F0 the initial
fluorescence in the absence of peptide and Fmax is the fluorescence
maximum obtained immediately after peptide addition. Kinetic
data were obtained at a concentration of 4 mM.
Tryptophan and Tyrosine fluorescence measurements
Emission spectra of the peptides (1 mM) containing the
tryptophan and tyrosine residue in the absence or presence of
target vesicles (DOPC/Chol 1/1) were recorded: between 300 and
400 nm with an excitation wavelength of 295 nm for the peptide
HB168–186 and 290 and 350 with an excitation wavelength of
274 nm for the peptide HB254–270.The degree of peptide
association with lipid vesicles was measured by adding lipid
vesicles to 1 mM peptides and the fluorescence intensity was
measured as a function of the lipid/peptide molar ratio, in three to
four separate experiments. The fluorescence values were corrected
by taking into account the dilution factor corresponding to the
addition of microliter amounts of liposomes and by subtracting the
corresponding blank. The lipid/peptide molar ratio was 200:1.
The binding of hydrophobic peptides to membranes can be
described as a partition equilibrium: Xb=KpCf where Kp is the
apparent partition coefficient in units of M21, Xb is the molar ratio
of bound peptide per total lipid and Cf is the equilibrium
concentration of the free peptide in solution, as previously
suggested by Schwarz et al. [65]. F‘ was obtained by extrapolation
of a double reciprocal plot of the total peptide fluorescence vs the
total lipid concentration in the outer leaflet, i.e. 1/F vs 1/0.6CL.
The fraction of membrane-bound peptide, fb, was determined by
the formula fb = (F2F0)/(F‘2F0), where F represents the fluores-
cence of peptide after the addition of the vesicles and F0 represents
the fluorescence of the unbound peptide. fb allowed us to calculate
the equilibrium concentration of free peptide in the solution, Cf,
and the extent of peptide binding Xb. Assuming that the peptides
were initially partitioned only over the outer leaflet of the SUV
(60% the total lipid) [66], values of Xb were corrected as follows:
Xb
* =Xb/0.6.
The curve resulting from plotting Xb
* versus the concentration
of the free peptide, Cf, is the binding isotherm.
Tryptophan and Tyrosine quenching by Acrylamide
Aliquots of a 4 M solution of the water-soluble quencher were
added to the solution containing the peptide (1 mM) in the absence
or presence of liposomes at a peptide/lipid molar ratio of 1/200.
The maximal concentration of acrylamide is 0.2 mmol/ml.
Tryptophan fluorescence was measured with an excitation
wavelength of 295 nm, to reduce acrylamide absorbance (and
the resulting inner filter effect), and emission at a wavelength of
340 nm, to eliminate interference from the Raman band of water
[67] and tyrosine fluorescence was measured with an excitation
wavelength of 274 nm, and emission at a wavelength of 305. The
data were analyzed according to the Stern-Volmer equation [68],
F0/F= 1+Ksv [Q], where F0 and F represent the fluorescence
intensities in the absence and the presence of the quencher (Q),
respectively, and Ksv is the Stern-Volmer quenching constant,
which is a measure of the accessibility of tryptophan to acrylamide.
Acrylamide does not significantly partition into the membrane
bilayer [67], and the value for Ksv is a reliable reflection of the
bimolecular rate constant for collisional quenching of the aromatic
residues present in the aqueous phase. Accordingly, Ksv is
determined by the amount of non-vesicle-associated free peptide
as well as the fraction of the peptide residing at the surface of the
bilayer.
Electron Spin Resonance Spectroscopy
ESR spectra were recorded with a 9 GHz Bruker Elexys E-500
spectrometer (Bruker, Rheinstetten, Germany). The lipid suspen-
sions to be investigated were transferred into 25 mL glass
capillaries and flame sealed. The capillaries were placed in a
standard 4 mm quartz sample tube containing light silicone oil for
thermal stability. All the measurements were performed at 25uC.
Spectra were recorded using the following instrumental settings:
sweep width, 100 G; resolution, 1024 points; time constant,
20.48 ms; modulation frequency, 100 kHz; modulation ampli-
tude, 1.0 G; incident power, 6.37 mW. Samples containing the
peptides were prepared by hydrating the lipid film directly with the
peptide solution in buffer. In all samples, the peptide to lipid ratio
was set to 1:1 wt/wt. In samples containing both HB168–186 and
HB254–270, the total peptide to lipid ratio was maintained to 1:1
wt/wt, while the HB168–186:HB254–270 ratio was 1:1 wt/wt.
Several scans, typically 16, were accumulated to improve the
signal-to-noise ratio. Values of the outer hyperfine splitting, 2Amax,
were determined by measuring the difference between the low-
field maximum and the high-field minimum, through a home-
made, MATLAB-based, software routine. This parameter is a
useful empirical measure of the lipid chain dynamics and order in
both gel and fluid phases of lipid bilayers [44–46]. The main
source of error on the 2Amax value is the uncertainty in composition
of samples prepared by mixing few microliters of mother solutions.
For this reason, reproducibility of 2Amax determinations was
estimated by evaluating its value for selected independently
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prepared samples with the same nominal composition. It was
found to be 60.2–0.3 G.
Circular dichroism spectroscopy
CD spectra were recorded using a Jasco J-715 spectropolarim-
eter in a 1.0 cm quartz cell at room temperature. The spectra are
an average of 3 consecutive scans from 260 to 195 nm, recorded
with a band width of 3 nm, a time constant of 16 s, and a scan rate
of 10 nm/min. Spectra were recorded and corrected for the blank
sample. Mean residue ellipticities (MRE) were calculated using the
expression MRE=Obsd/(lcn), where Obsd is the ellipticity mea-
sured in millidegrees, l is the path length of the cell in cm, c is the
peptide concentration in mol/l, and n is the number of amino acid
residues in the peptide. Solutions of 4 mM of HB168–186 and
10 mM of HB254–270 with LUVs were prepared as described
previously [31]. The measurements were performed at peptide/
lipid ratios of 0.5 mol/mol.
Supporting Information
Figure S1 Fluorescence spectra of tryptophan and
tyrosine. Fluorescence spectra of HB168–186 and HB254–270
in buffer and in LUVs.
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Abstract: This contribution reports the synthesis of a poly(amide)-based dendrimer 
 functionalized at the termini with a membrane-interacting peptide derived from the herpes 
simplex virus (HSV) type 1 glycoprotein H, namely gH625-644. This peptide has been shown 
to interact with model membranes and to inhibit viral infectivity. The peptidodendrimer 
inhibits both HSV-1 and HSV-2 at a very early stage of the entry process, most likely through 
an interaction with the viral envelope glycoproteins; thus, preventing the virus from coming 
into close contact with cellular membranes, a prerequisite of viral internalization. The 50% 
inhibitory concentration was 100 and 300 nM against HSV-1 and HSV-2 respectively, with no 
evidence of cell toxicity at these concentrations. These results show that the functionalization 
of a dendrimer with the peptide sequence derived from an HSV glycoprotein shows promising 
inhibitory activity towards viruses of the Herpesviridae family.
Keywords: peptidodendrimer, antiviral activity, membranotropic peptides
Introduction
Herpes simplex viruses (HSVs) are responsible for a wide variety of clinical manifes-
tations and represent a significant worldwide disease and economic burden. There are 
two serotypes of HSV, HSV-1 and HSV-2, which can infect either oral or genital sites 
respectively. For some populations, between 60% and 95% are infected with HSV-1 
and between 6% and 50% with HSV-2.1 Even if HSV infections are often subclinical, 
their incidence and severity have increased over the past decades due to the increasing 
number of immunocompromised patients. In particular, the impact of genital herpes 
as a public health threat is amplified because of its epidemiological synergy with the 
human immunodeficiency virus (HIV). Synthetic nucleoside analogs targeting viral 
DNA polymerase (eg, acyclovir) are routinely used as standard treatment of symptomatic 
HSV infections;2 however, their clinical use in immunocompromised patients receiving 
long-term treatments may lead to treatment failures due to the emergence of antiviral-
resistant strains.3 Thus, it is imperative to develop new anti-HSV agents with antiviral 
activity based on alternative mechanisms of action. Inhibition of HSV attachment and/
or entry represents a particularly attractive antiviral strategy since it may prevent the 
establishment of infection. Target compounds with this mode of action could provide 
a starting point for the development of topical microbicides that block transmission at 
the mucosal surface, thereby providing a method of prophylactic intervention.4
Dendrimers have been extensively studied as vehicles for the delivery of therapeutics 
or as carriers for in vivo imaging.5–10 Dendrimers are highly branched  macromolecules 
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with well defined three-dimensional  architectures.11 The 
appeal of dendrimers lies in their unique perfectly branched 
architectures which affords them different properties than 
corresponding linear polymers of the same composition and 
molecular weights.5 As dendrimers increase in generation, 
they exponentially increase the number of termini, while only 
linearly increasing in radius; thus, the termini become more 
densely packed giving the entire structure a globular shape, 
where the termini radiate outwards from a central core. The 
globular structure of a dendrimer has a significant effect on its 
rheological properties with important biological implications; 
for example, a linear analog of a dendrimer will generally 
see much reduced blood circulation times.12
“Click reactions,” such as the copper catalyzed 1,3-dipo-
lar alkyne/azide cycloaddition (CuAAC),13 have been used 
extensively for polymer functionalizations due to their high 
yielding character.14,15 Using CuAAC, dendrimers have been 
functionalized with amines, peptides, and polysaccharides 
and investigated as antiviral agents.16–19 While the mecha-
nisms of action of the antiviral activity is not fully understood, 
it is thought that the interactions used by viruses to infect cells 
can be inhibited due to the dendrimer physically blocking 
or interfering with the fusion mechanism between the virus 
and the cell.20 Notable is the poly(lysine)-based dendrimer 
SPL7013,21 which is a sulfonate terminated dendrimer gel that 
has been shown to act as a topical virucide against HIV-1,22–24 
and is now undergoing Phase II clinical trials as VivaGel® 
(Starpharma, Melbourne, Australia). Peptide-functionalized 
dendrimers have also been investigated as antiviral agents. 
Both Luganini et al and Donalisio et al have synthesized 
dendritic structures based on a poly(lysine) core containing 
four short (∼10 mer) peptide sequences.20,25,26 These dendrons 
were shown to have antiviral activity. Using a linear analog 
greatly diminishes antiviral activity, suggesting the dendritic 
structure is necessary for the antiviral effect. The peptides 
used by Hunter are lysine-rich, giving the outer surface of 
the dendron a positive charge to interact with biological 
membranes. However, poly(cationic) structures generally 
show cytotoxic effects, which limits their usefulness.27
Herein, the functionalization of a dendrimer terminated 
with a membranotropic peptide sequence, the gH(625–644) 
domain derived from viral fusion proteins that has been 
shown to exhibit antiviral properties is reported.28 The 
current authors have previously identified several regions 
of the herpes simplex virus type I glycoprotein H that 
have membrane-interacting capabilities.29–33 Of these, the 
gH(625-644) domain proved to be a good candidate for the 
purposes of this study: it is mainly hydrophobic in nature 
and displays an amphiphilic character when in an α-helical 
form. Furthermore, it folds easily into a helix in a membrane-
mimetic environment.29–31 Finally, the authors of this present 
paper previously reported the ability of gH625 to inhibit HSV 
entry.31 The gH625 peptide was therefore used to functional-
ize dendrimers and their properties as antiviral agents were 
investigated.
Experimental section
Materials
Fmoc-protected amino acids, coupling reagents, and Rink-
amide p-methylbenzhydrylamine (MBHA) resin were 
purchased from Calbiochem-Novabiochem (San Diego, 
CA, USA). Fmoc-l-propargylglycine (Fmoc-PrA-OH) was 
purchased from NeoSystem (Tysons Corner, VA, USA). 
All other chemicals were purchased from Sigma-Aldrich 
(St Louis, MO, USA), Alfa Aesar (Ward Hill, MA, USA), 
or TCI International (Portland, Oregon, USA). Dialysis 
membranes (SpectraPor 6) were purchased from Spectrum 
Laboratories (Rancho Dominguez, CA, USA) and used after 
rinsing the membrane in water for 30 minutes. Size-exclusion 
chromatography was performed using a 1 cm × 18 cm 
Sephadex G-50 column. The octadecaazidedendrimer (1) 
was synthesized as described in the literature.34
Solid-phase peptide synthesis
Peptides were synthesized on a Syro I Multisynthec GmbH 
(Witten, Germany) automatic synthesizer. Syntheses were 
performed using standard Fmoc solid-phase techniques 
on a 20 µmol scale as previously reported.30 Peptide 
purification was performed on LC8 Shimadzu (Kyoto, 
Japan) high-performance liquid chromatography with a 
Phenomonex (Torrance, CA, USA) C18 column (300Å, 
250 mm × 21.20 mm, 5 µ) and a Waters (Milford, MA, 
USA) ultraviolet (UV) Lambda-Max model 481 detector. 
Peptide purity was analyzed by a Thermo Electron (San Jose, 
CA, USA) Finnigan Surveyor MSQ single quadrupole ESI 
LC-MS with a Phenomenex C18 column and the same elu-
ent system (NH
2
-HGLASTLTRWAHYNALIRAFX-CONH
2
, 
X = PrA, Rt = 9.41 minutes, molecular weight = 2392.7 
[M + 2H]+/2 = 1197 amu).
Peptide functionalization of 1
To obtain compound 2, to a solution of 1 (50 µg, 0.0146 µmol) 
in 208 µL of water/methanol (1:1) was added 660 µL of a 
1:1 methanol water solution of the peptide gH625-PrA (30.33 
eq), 10 µL of a water solution of CuSO
4
 ⋅ 5H
2
O (1.46 mM, 
1 eq), and 50 µL of a water solution of sodium ascorbate 
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(1.17 mM, 4 eq). The mixture was stirred for 12 hours. 
The reaction mixture was then concentrated and peptide 
functionalized dendrimer 2 was purified by size-exclusion 
chromatography. The amount of peptide functionalization 
on 2 was confirmed by UV analysis (ε = 7000 M−1 cm−1 at 
λ = 280 nm).
Cells and viruses
African green monkey kidney cells (Vero) (ATCC CCL-81) 
were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum. HSV-1 (strain 
SC16) and HSV-2 (strain 333), both carrying a lacZ gene 
driven by the CMV IE-1 promoter to express β-galactosidase, 
were propagated on Vero cells monolayers.
Virus entry assays
For all experiments below, compounds 1, 2, and peptide 
gH625 were dissolved in DMEM without serum and used 
at concentrations of 0, 5.5, 55, 280, and 550 nM. The con-
centrations used for the peptide correspond to the quantity 
present on each dendrimer molecule, ie, 18 times the concen-
trations of the dendrimer. All experiments were conducted 
in  triplicate. The percentage of infectivity inhibition was 
calculated by setting the number of plaques obtained in 
positive controls where no antiviral compounds were added 
to the cell monolayers to 0% inhibition. To assess the effect 
of peptides on inhibition of HSV infectivity, cell monolayers 
were treated in different ways:
a. Virus yield reduction assay
 Confluent Vero cell monolayers (12-well plates) were 
washed with phosphate-buffered saline (PBS) and infected 
with either HSV-1 or HSV-2 at multiplicity of infection 
(MOI) of 1 plaque-forming unit (pfu)/cell for 1 hour at 
37°C. The virus inocula were mixed with the antiviral 
compound to be tested in each experiment as stated above. 
Non-penetrated viruses were inactivated by citrate buffer at 
pH 3.0. The infected cells were washed with PBS, covered 
with fresh culture medium, and incubated for 48 hours. 
The infected cells were then scraped into culture medium 
and disrupted by sonication. The total virus yield in each 
well was titrated by plaque assay. Plaques were stained with 
X-gal (5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside) 
and microscopically counted. The mean plaque counts for 
each drug concentration were expressed as a percentage of 
the mean plaque count for the control virus. The number 
of plaques was plotted as a function of drug concentration; 
concentrations producing 50% reductions in plaque forma-
tion were determined as the IC
50
.
b. Posttreatment assay
 Vero cell monolayers (12-well plates) were incubated 
with HSV-1 or HSV-2 for 45 minutes at 37°C. The above 
compounds were then added to the inoculum followed by 
an additional incubation period of 30 minutes at 37°C. For 
all treatments, non-penetrated viruses were inactivated by 
citrate buffer at pH 3.0 after the 45 minute incubation with 
cells at 37°C. The cells were then incubated for 24 hours 
at 37°C in DMEM supplemented with carboxymethyl 
cellulose (CMC). Monolayers were fixed, stained with 
X-gal, and plaque numbers were scored.
c. Cytopathic effect inhibition assay
 Confluent Vero cell monolayers in a 96-well plate were 
infected with HSV-1 and HSV-2 at an MOI of 0.01 pfu/cell 
at 37°C for 1 hour. Following removal of virus inocula, the 
infected cells were washed with citrate buffer at pH 3.0 fol-
lowed by a PBS wash and covered with medium containing 
the above compounds for 3 days at 37°C. The cytopathic 
effect was monitored daily, and an arbitrary score was 
assigned at the end of the incubation period in consideration 
of the protection from the cytopathic effect observed.
d. Attachment
 To assess the effect of the dendrimer and the peptidoden-
drimer on viral attachment, two experimental procedures 
were carried out. Briefly, prechilled Vero cell monolayers 
(12-well plates) were infected with precooled HSV-1 or 
HSV-2 at an MOI of 0.1 pfu/cell for 2 hours at 4°C to allow 
viral attachment. Cells were then washed three times with 
cold MEM to remove unattached virus and treated with 
various concentrations of the above compounds or heparin 
for 3 hours at 37°C prior to inactivation of extracellular 
virus with citrate buffer for 2 minutes at room tempera-
ture. Subsequently, the cells were washed three times with 
warm medium to return the pH to neutral and overlaid 
with CMC and incubated for 2 days at 37°C. Plates were 
then fixed, stained with X-gal, and plaques were counted. 
The second attachment experiment was performed as the 
former, except the prechilled Vero cell monolayers were 
treated with inocula containing both the viruses and the 
antiviral compounds precooled to 4°C. Following a 2 hour 
incubation at 4°C to allow viral attachment, the plates were 
treated as before and shifted at 37°C.
e. Cell pretreatment
 Prechilled Vero cell monolayers were treated as above 
with the above compounds or heparin for 30 minutes at 
4°C and infected with precooled HSV-1 or HSV-2 at an 
MOI of 0.1 pfu/cell for 2 hours at 4°C. Cells were then 
washed three times with cold MEM to remove unattached 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
523
Antiviral activity of peptidodendrimers
International Journal of Nanomedicine 2013:8
virus and compounds, overlaid with CMC, and incubated 
for 2 days at 37°C. Plates were then fixed, stained with 
X-gal, and the number of plaques was scored.
f. Virucidal assay
 The aforementioned compounds were added to aliquots 
of HSV-1 or HSV-2 (104 pfu) and incubated at either 4°C 
or 37°C for 2 hours. After incubation, the samples were 
diluted with medium to reduce the concentration of the 
antiviral compound to one that was not active in an anti-
viral assay. The MOI of HSV-1 and HSV-2 after dilution 
was of 0.01 pfu/cell. The viruses were then titrated on 
Vero cell monolayers. Plates were then fixed, stained with 
X-gal, and the number of plaques was scored.
Cytoxicity
Vero cells were exposed to increasing concentrations of com-
pounds, and the number of viable cells was determined using 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay that is based on the reduction of the 
yellowish MTT to the insoluble and dark blue formazan 
by viable and metabolically active cells.35 Vero cells were 
subcultured in 96-well plates at a seeding density of 2 × 104 
cells/well and treated with compounds 1 or 2 at 0.28, 0.55, 
1.1, 2.8, or 5.5 µM for 3 and 24 hours. The medium was 
then gently aspirated, MTT solution (5 mg/mL) was added 
to each well, and cells were incubated for a further 3 hours 
at 37°C. The medium with MTT solution was removed, 
and the formazan crystals were dissolved with dimethyl 
sulfoxide. The absorption values were measured at 570 nm 
using a Bio-Rad Microplate Reader (Bio-Rad Laboratories, 
Hercules, CA, USA). The viability of Vero cells in each well 
was presented as a percentage of control cells.
Flow cytometry analysis of apoptosis
Vero cells were exposed to compounds 1 and 2 at the 
concentration of 0.55 µM for 24 hours. Annexin V-FITC 
(MedSystems Diagnostics, Vienna, Austria) (fluorescein 
isothiocyanate) was used in conjunction with a vital dye, 
propidium iodide (PI) (Sigma-Aldrich), to distinguish apop-
totic (Annexin V-FITC positive, PI negative; or Annexin 
V-FITC positive, PI positive) from necrotic (Annexin 
V-FITC negative, PI positive) cells. Briefly, cells were 
incubated with Annexin-V-FITC and in a binding buffer 
(10 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM 
MgCl
2
, 2.5 mM CaCl
2
) for 10 minutes at room temperature, 
washed, and resuspended in the same buffer. Analysis of 
apoptotic cells was performed by flow cytometry (FACScan; 
BD, Franklin Lakes, NJ, USA). For each sample, 2 × 104 
events were acquired. Analysis was carried out by triplicate 
determination on at least three separate experiments.
Results
Peptide analysis
The literature describes the potential of fusion peptides 
and/or membranotropic peptides of orthomyxoviruses, 
paramyxoviruses, and HIV as virus entry inhibitors.28,29,31,36–38 
The accepted view is that the inhibition of infectivity may 
be due to the formation of inactive aggregates between the 
fusogenic stretches present in both the viral protein and the 
synthetic peptides.28,30,31 These aggregates are formed as a 
consequence of their nature for intrinsic oligomerization or 
their ability to mimic the modes of binding of their original 
domains in their partner protein; they are thus predicted to 
stabilize a pre-fusion intermediate and prevent merging of 
the bilayers. The Wimley–White interfacial hydrophobicity 
scale was used to identify the sequence gH625 that proved 
to effectively interact with the membrane bilayer and pos-
sess some antiviral activity;30,31 therefore, gH625 has the 
potential of being developed into an inhibitor to prevent 
viral entry and viral infectivity. This sequence was selected 
for coupling to the dendrimer to investigate whether a 
dendrimer-gH625 conjugate can yield an HSV-1 inhibitor. 
The sequence alignment of HSV-1 and HSV-2 gH(625-644) 
(Table 1) shows that the two segments have a high degree of 
sequence identity with the substitution of the histidine with 
the arginine at the N-terminus and two other substitutions in 
the rest of the molecule (L627V and T630V). While His625 
(HSV-1) was proven to be fundamental for the interaction 
with the membrane bilayer and for translocation across the 
membrane,31,33,39–41 the absence of this residue induced similar 
levels of viral inhibition when compared with the full  peptide. 
This indicates a direct correlation between the α-helical 
potential and the inhibitory activity and suggests that the 
substitution of His625 with an arginine residue, as in HSV-2, 
may not exhibit a significant difference in viral inhibitory 
activity. The substitution of Leu627 with a valine residue 
does not alter the hydrophobicity of the peptide, and thus 
should not influence its infectivity inhibition  properties. The 
authors of this present paper have demonstrated  previously 
Table 1 Peptide amino acid sequence of gh625-644 in hSV-1 
and hSV-2
Virus Peptide sequence
hSV-1 hGLASTLTRWAhYNALIRAF
hSV-2 RGVASVLTRWAhYNALIRAF
Abbreviation: hSV, herpes simplex virus.
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that the substitution of leucine with a polar residue (serine) 
substantially reduces the peptide’s inhibitory activity.29 There 
is no evidence from previous works on the substitution of 
Thr630 with a hydrophobic residue, but the current authors 
hypothesize this substitution does not alter the aggregation 
properties of gH625, as the valine is a small hydrophobic 
residue.
Synthesis of peptidodendrimers
The starting point was the poly(amide)-based dendrimer 1 
(Figure 1A) that is based on the 1→3 connectivity scheme 
first reported by Newkome et al.42  Poly(amide)-based 
dendrimers have been reported to exhibit high biocompat-
ibility due to the peptide-like backbone,43 and thus have been 
shown to be suitable delivery vehicles.44 The synthesis of 
1 was performed according to a previous report.34
To obtain compound 2, compound 1 was functionalized 
via the CuAAC using a modified gH625 peptide contain-
ing a PrA residue at the C-terminus (NH
2
-HGLASTL-
TRWAHYNALIRAFX-CONH
2
, X = PrA) (Figure 1B). 
The reaction was run in a water/methanol solution using 
CuSO
4
/sodium ascorbate as catalyst. After purification, 
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Figure 1 (A) Structures of the poly(amide)-based azidodendrimer 1 and cartoon of the peptidodendrimer 2. The helices on the structure represent the gh625 peptide 
sequence. (B) Schematic representation of the CuAAC reaction to functionalize 1 with peptides. Shown is the C-terminal PrA residue.
Abbreviations: CuAAC, copper catalyzed 1,3-dipolar alkyne/azide cycloaddition; PrA, propargylglycine.
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Figure 2 Cell viability measured by the MTT assay for 3 and 24 hours for the dendrimer (1) and peptidodendrimer (2).
Abbreviation: MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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quantitative functionalization was determined by UV 
(ε
peptide
 = 7000 M−1 cm−1 at λ = 280 nm) and infrared (dis-
appearance of signal at 2100 cm−1) analyses.34 See also 
Supplementary materials.
Cytotoxicity studies
To confirm that dendrimer 1 and peptidodendrimer 2 do 
not exert toxic effects on cells, monolayers of Vero cells 
were exposed to different concentrations (0.28, 0.55, 1.1, 
2.8, 5.5 µM) of each compound for 3 and 24 hours, and cell 
viability was quantified by the MTT assay. No statistical 
difference was observed between the viability of control 
(untreated) cells and that of cells exposed to the peptidoden-
drimer (Figure 2) up to the concentration used in antiviral 
testing. Minimal toxicity was observed for the dendrimer 
without the peptides linked to its termini, but only at con-
centrations that were considerably higher than those required 
for antiviral activity.
Thereafter, the effects of treatments with 1 and 2 in 
inducing apoptosis, assessed by FACS analysis after double 
labeling with FITC-Annexin V and PI, were evaluated. It 
was found that neither of the treatments induced apoptosis 
of Vero cell populations (Figure 3 and Table 2). Over 86% 
of cells treated with 1 and over 89% of cells treated with 
2 were alive with only 3% of cells treated with 1 showing 
markers for early apoptosis.
Antiviral studies
To test whether the peptidodendrimer can affect HSV infec-
tivity in vitro, a virus yield reduction assay in which the pepti-
dodendrimer of interest was present in the cell culture during 
and after viral adsorption was used. The extent of HSV-1 and 
HSV-2 replication, assessed by titration of harvested viruses, 
showed a consistent decrease in replication efficiency for both 
viruses with more than 80% inhibition at a peptidodendrimer 
concentration of 280 nM; inhibition of HSV-1 replication 
was able to reach 90% under these  conditions. Dendrimer 1, 
without any peptide  functionalization, was able to produce 
an inhibition close to 35% at a concentration of 280 nM, 
suggesting that the dendrimer structure itself confers an 
antiviral activity which is enhanced by the specific amino 
acid sequence added to its termini. The IC
50
 of the peptido-
dendrimer was 100 and 300 nM against HSV-1 and HSV-2 
respectively, while the IC
50
 of 1 was over 550 nM for both 
viruses (Figure 4).
To elucidate the mechanism of inhibition, the compounds 
were tested under different conditions to identify the step in 
the entry process that was being inhibited by the dendrimer. 
Since inhibition of HSV infectivity could be due to either 
an interference during the early penetration phase or as a 
consequence of a peptidodendrimer action inside the cell at 
a post-entry event, a “posttreatment” test was performed by 
adding the compounds at different concentrations 2 hours after 
virus infection (Figure 5). None of the concentrations used 
significantly reduced HSV-1 and HSV-2 replication. Similarly, 
a cytopathic effect inhibition assay proved that both the den-
drimer and the peptidodendrimer were ineffective once the 
viruses had already gained their access inside the cell. These 
results strongly suggest that both the dendrimer and the pep-
tidodendrimer target an early step of the HSV infection cycle.
To investigate whether the inhibitory activities of 1 and 
the peptidodendrimer 2 are due to the inhibition of HSV entry 
into cells, prechilled Vero monolayers were infected with 
HSV-1 and HSV-2 for 2 hours at 4°C. The incubation at 4°C 
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Figure 3 Apoptotic effects of 1 and 2 on Vero cells. FACS analysis after double labeling with propidium iodide and FITC-Annexin V of Vero cells: (A) untreated cells, 
(B) treated with 1, and (C) treated with 2 for 24 hours at 0.55 µM. The experiments were performed three times, and the results were always similar. 
Note: Insets, percentage of positive cells.
Abbreviations: FACS, fluorescence activated cell sorting; FITC, fluorescein isothiocyanate.
Table 2 Study of apoptosis in Vero cells after treatment with 1 
and 2
24 hour  
Vero
Necrosis Late  
apoptosis
Alive Early  
apoptosis
Untreated 11.6% 0.86% 85.4% 2.1%
1 9.2% 1.14% 86.5% 3.1%
2 8.99% 0.6% 89.5% 0.88%
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blocks the virus’ penetration but allows its attachment to the 
cell surface via its cellular receptors, thereby synchronizing 
cell penetration. Dendrimer 1 and 2 were then added to the 
infected cells which were shifted to 37°C. After 45 minutes at 
37°C, unpenetrated viruses were inactivated by an acid wash 
and overlaid with CMC to measure infectivity of penetrated 
viruses. As shown in Figure 6A, none of the concentrations 
of 1 or 2 investigated was able to affect HSV-1 or HSV-2 
entry and replication. When prechilled Vero monolayers were 
infected with HSV-1 and HSV-2 in the presence of 1 or 2 for 
1 hour at 4°C, however, an inhibitory effect was observed 
(Figure 6B). For this experiment, a modification of the pro-
cedure was introduced, in fact, the same attachment test was 
also performed adding heparin as a control, and as expected, 
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Figure 4 Virus yield reduction assay. Vero cells were infected with either hSV-1 (blue lines) or hSV-2 (red lines) in the presence of increasing concentrations of the 
dendrimer 1 (triangles) or the peptidodendrimer 2 (squares).
Notes: The percentage of inhibition was calculated with respect to no-compound control experiments. Data points represent an average of three experiments, and error 
bars represent standard deviations.
Abbreviation: hSV, herpes simplex virus.
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Figure 5 Posttreatment assay. hSV-1 (blue lines) and hSV-2 (red lines) infected Vero cells were treated with increasing concentrations of the dendrimer 1 (triangles) or the 
peptidodendrimer 2 (squares), then overlaid with CMC and incubated for 24 hours at 37°C. 
Notes: Plaque numbers were scored, and the percentage of inhibition was calculated with respect to no-compound control experiments. Data points represent an average 
of three experiments, and error bars represent standard deviations.
Abbreviations: hSV, herpes simplex virus; CMC, carboxymethyl cellulose.
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heparin was completely able to block the ability of HSV-1 
and HSV-2 to attach to Vero cells, preventing the interaction 
of the virions with cell surface heparin sulfate.
The possibility of 2 to interfere with an early penetration 
step was further explored. Vero cells were pretreated with 
1 or 2 for 1 hour before infection. No significant reduction 
of infectivity with 2 was observed (Figure 7). In contrast, a 
clear activity of the dendrimer itself was observed. Since the 
toxicity of the dendrimer is marginal, it is assumed that it 
may exert an antiviral activity by blocking the cell surface. 
The lack of activity of the peptidodendrimer is probably 
due to the fact that this molecule is able to penetrate inside 
the cell efficiently in virtue of its functionalization with the 
membranotropic HSV-1 gH derived sequence,34,45 therefore, 
during the 1 hour of cell pretreatment, the majority of 2 
may have already translocated inside the cell where it is 
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Figure 6 Effect of 1 and 2 on viral attachment. (A) Vero cell monolayers were infected with hSV-1 (blue lines) or hSV-2 (red lines) at an MOI of 0.1 pfu/cell for 2 hours at 4°C. 
After unattached virus removal, plates were treated with various concentrations of 1 (triangles), 2 (squares), or heparin (circles) for 3 hours at 37°C. Finally, cells were overlaid 
with CMC and incubated for 2 days at 37°C. (B) Vero cell monolayers were treated with inocula containing both the viruses and the antiviral compounds precooled at 4°C.
Notes: Plaque numbers were scored, and the percentage of inhibition was calculated with respect to “no-compound” control experiments. Data are reported in triplicate, 
and error bars represent standard deviations.
Abbreviations: hSV, herpes simplex virus; MOI, multiplicity of infection; pfu, plaque-forming unit; CMC, carboxymethyl cellulose.
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probably  inactive accordingly with the posttreatment assay. 
The amount of peptidodendrimer left on the cell surface may 
be below the concentration needed to maintain an antiviral 
activity.
Since inhibition of HSV penetration might result from 
an irreversible peptidodendrimer-induced inactivation 
of the virions, the possibility that the compounds could 
interfere with HSV particles and inactivate viral infectivity 
was explored. To do this, HSV-1 and HSV-2 aliquots were 
incubated with different concentrations of 1 and 2 at 4°C 
and 37°C for 2 hours. After incubation, the samples were 
diluted to reduce the antiviral agents’ concentrations well 
below the threshold for HSV replication inhibition (0.001 
to 0.1), and the infectivity of preincubated virions was mea-
sured by titration on Vero cells. As shown in Figure 8, the 
incubation of virions with the peptidodendrimer reduced the 
infectivity in both HSV-1 and HSV-2. The pre-incubation of 
virions with 1 also produced a decrease of infectivity, albeit 
of lower intensity.
Discussion
The goal of the research reported herein is to investigate the 
antiviral properties of a dendrimer whose termini have been 
functionalized with the HSV-1 derived peptide gH625 that 
has been shown previously to possess antiviral activity.28,29,31 
The key characteristics of gH625 are: (1) the ability to interact 
with model membranes, (2) penetration of the bilayer with 
its N-terminus, (3) high efficiency of inducing lipid mixing 
of model membranes, and (4) the ability to adopt a helical 
conformation with its hydrophobic residues on one face of the 
helix and polar or charged residues on the opposite face.29,31,33 
The inhibitory effect of gH625 appeared conditioned by its 
ability to partition into membranes and aggregate within 
them. Since gH625 peptides self-associate in aqueous and 
lipidic solutions, it is possible that they bind to their coun-
terparts in the HSV-1 gH fusion protein, suggesting that the 
inhibition of viral entry may occur via peptide association 
with their counterpart on wild-type gH. In this contribution, 
a peptidodendrimer carrying the gH625 peptide at its termini 
was constructed. The functionalization of the dendrimer 
with the gH625 peptide was quantitative as evidenced by 
UV and infrared analyses. Dynamic light-scattering and 
scanning electron microscopy showed the average particle 
size to be 12 nm. Circular dichroism showed that the termi-
nal peptides fold into an α-helix in a membrame-mimetic 
environment.34
To analyze the antiviral activity of the peptidodendrimer, 
a virus yield assay on both HSV-1 and HSV-2 was first 
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Figure 7 Cell pretreatment assay. Vero cell monolayers were treated with various concentrations of 1 (triangles), 2 (squares), or heparin (circles) for 30 minutes at 4°C 
before being infected with precooled hSV-1 (blue lines) or hSV-2 (red lines) at 0.1 pfu/cell in the presence of the compounds for 2 hours at 4°C. After the removal of excess 
compounds, cells were overlaid with CMC, and incubated for 2 days at 37°C.
Notes: Plaque numbers were scored, and the percentage of inhibition was calculated with respect to “no-compound” control experiments. Data points represent an average 
of three experiments, and error bars represent standard deviations.
Abbreviations: hSV, herpes simplex virus; pfu, plaque-forming unit; CMC, carboxymethyl cellulose.
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 performed, and a consistent decrease in replication efficiency 
for both viruses was obtained. Interestingly, the dendrimer 
itself was able to inhibit virus replication, albeit to a lesser 
extent compared with the peptidodendrimer, while the peptide 
on its own was unable to show any inhibition when tested 
at a concentration corresponding to the peptide present on 
the peptidodendrimer. The multivalent display of gH625 on 
the dendrimer scaffold results in an almost sixfold increase 
of antiviral activity for HSV-1 and twofold for HSV-2 in 
comparison to the activity of the dendrimer itself, and a 
more than 100-fold increase in the activity of the unsup-
ported peptide. The IC
50
 of the peptidodendrimer was 100 
and 300 nM against HSV-1 and HSV-2, respectively, while 
the IC
50
 of the unfunctionalized dendrimer was over 550 nM 
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Figure 8 Virucidal assay. Different concentrations of 1 (triangles) and 2 (squares) were added to aliquots (104 pfu) of hSV-1 (blue lines) or hSV-2 (red lines), and incubated 
at either 4°C (A) or 37°C (B) for 2 hours. After incubation, the samples were diluted to reduce the compound concentrations below the threshold for inhibition of viral 
replication, and the virus was titrated on Vero cells.
Notes: Plaque numbers were scored and the percentage of inhibition was calculated with respect to “no-compound” control experiments. Data points represent an average 
of three experiments, and error bars represent standard deviations.
Abbreviations: hSV, herpes simplex virus; pfu, plaque-forming unit.
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for both viruses. The cytotoxicity profile measured by the 
MTT assay showed that the peptidodendrimer was not toxic 
to Vero cells up to the highest concentration investigated in 
antiviral testing, while some toxicity was observed for the 
unfunctionalized dendrimer, especially at higher concen-
trations, demonstrating another advantage of the peptide 
functionalization. To further analyze intact cell activity, a 
FACS analysis was performed after double labeling with 
FITC-Annexin V and PI to evaluate the effects of 1 and 2 
on induction of apoptosis and concluded that the majority of 
cells are still alive and functional after 24 hours at the active 
antiviral concentration.
Further experiments were carried out to identify which 
step in the entry process could be responsible for the observed 
infectivity inhibition. Any inhibitory activity can be excluded 
when the compounds were added at a post-entry step and also 
when cells were pretreated with the dendrimer derivatives. 
Both the peptidodendrimer and the dendrimer are not able 
to interfere with viral replication once the virus has gained 
access to the cellular milieu. When cells were pretreated with 
1 or 2 for 1 hour before infection, the peptidodendrimer was 
unable to yield a significant reduction of infectivity, while a 
clear inhibition was obtained by the dendrimer itself. The lack 
of activity of the peptidodenrimer is probably due to the fact 
that this molecule is able to penetrate inside the cell efficiently 
in virtue of its functionalization with the membranotropic 
HSV-1 gH derived sequence.34 Therefore, during the 1 hour 
of cell pretreatment, the majority of the peptidodendrimer 
may have already translocated inside the cell where it was 
probably inactive according to the posttreatment assay. On the 
other hand, 1 enters much more slowly and, more importantly, 
it partially remains on the cell surface. This allows the den-
drimer to reduce membrane mobility and inhibit viral entry 
or to produce a consistent delay in viral entrance.34 After 
excluding also the attachment step (Figures 6 and 7) as being 
responsible for the antiviral activity, the possibility that the 
peptidodendrimer could directly inactivate the virions was 
explored. The results of virus-pretreatment assay showed a 
strong and consistent inhibition of viral infectivity for HSV-1 
and a slightly lower inhibition of HSV-2. The pre-incubation 
of virions with the unfunctionalized dendrimer also produced 
a decrease of infectivity, albeit of lower intensity. The authors 
hypothesize that the peptidodendrimer might sterically hin-
der the gH relative domain, either in a pre-fusogenic or in 
an intermediate conformation, preventing a complete and 
functional interaction between gH and the membrane to fuse. 
Due to the high degree of complexity of the interaction of 
HSV surface glycoproteins during the fusion process, it was 
not able to unequivocally identify the path of antiviral action 
of the peptidodendrimer. It may act by binding to gH itself 
through oligomerization of the gH625-644 domain pres-
ent on the glycoprotein, in a probable rearrangement of its 
structural domains. Alternatively, the gH sequence present on 
the peptidodendrimer may interact with other glycoproteins 
present on the virion envelope, such as gB or gD.
The results of this study indicate that the modification 
of a dendrimer scaffold with antiviral peptides represent an 
attractive strategy for the design of a new class of antiviral 
drugs that exert their effect, coupling the intrinsic anti-
viral properties of the dendrimer with the activity of 
antiviral peptides. These antiviral drugs possess several 
advantageous features, such as target specificity, low tox-
icity, and the possibility to modify surface characteristics 
easily. Moreover, peptidodendrimers have the potential of 
being developed as multifunctionalized scaffolds to provide 
a therapeutic molecule that could be directly delivered to 
its target.
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Supplementary materials
Materials and methods
The analysis of the three molecules: crude peptidoden-
drimer, peptide and dendrimer was carried out on an 
analytical Agilent Technologies (Santa Clara, CA, USA) 
1200 Series HPLC system with a Phenomenex (Tor-
rance, CA, USA) analytical C
5
 column (Jupiter 5 µ 300Å, 
150 mm × 4.60 mm, 5 micron). The mobile phase used 
was: H
2
O 0.1% trifluoroacetic acid as eluent A and CH
3
CN 
0.1% TFA as eluent B from 30% to 95% over 20 minutes at 
1 mL min−1 flow. The compounds were dissolved in a 30% 
CH
3
CN 0.1% TFA and 70% H
2
O 0.1% TFA solution before 
being loaded onto the column: the coupling was performed 
using one equivalent of dendrimer and two equivalents of 
peptide.
Discussion
The peptidodendrimer presents a different retention time 
from both the peptide and dendrimer alone. As we can see 
from the crude peptidodendrimer chromatogram, the peak 
relative to the dendrimer disappears, confirming that all the 
dendrimer is bound to peptide.
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Figure S1 LC-MSQ spectra of gh625-PRA peptide. gh625-PRA (MW: 2392.7) purity and identity was assessed by analytical LC-MS analyses using Finnigan Surveyor MSQ 
single quadrupole electrospray ionization (Thermo Electron, San Jose, CA, USA), column: C18-Phenomenex eluted with h2O/0.1% TFA (A) and Ch3CN/0.1% TFA (B) from 
20% to 80% over 10 minutes at a flow rate of 0.8 mL min−1. 
Notes: The final yield of purified peptide was approximately 40%. NH2-hGLASTLTRWAhYNALIRAFX-CONh2, X = PrA, Rt = 9.4 minutes; (MW = 2392.7) 
[M + 2h]+/2 = 1197 amu.
Abbreviations: LC-MS, liquid chromatography-mass spectrometry; LC-MSQ, liquid chromatography-mass spectrometry quadrupole; MW, molecular weight; TFA, trifluoro-
acetic acid.
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Clickable Functionalization of Liposomes with the gH625 Peptide from
Herpes simplex Virus Type I for Intracellular Drug Delivery
Rossella Tarallo,[a] Antonella Accardo,[a] Annarita Falanga,[a] Daniela Guarnieri,[b]
Giuseppe Vitiello,[c] Paolo Netti,[b] Gerardino D’Errico,[c] Giancarlo Morelli,*[a] and
Stefania Galdiero*[a]
Introduction
Intracellular delivery of therapeutic molecules is one of the
key problems in drug development: many drugs are poorly
internalized by cells because they cross the membrane
rather inefficiently.[1] Cell-penetrating peptides (CPP) are
short and usually basic amino acid rich peptides originating
from proteins that are able to cross biological barriers, such
as the viral Tat protein. CPPs are considered as the most
promising tools for the intracellular delivery of therapeutics,
both in vitro and in vivo.[2] Although the mechanism of their
cellular uptake is still under debate, CPPs are able to trans-
locate various entities into cells, including small molecules,
peptides, proteins, DNA/RNA, liposomes, and other supra-
molecular aggregates. Endosomal entrapment may limit
their utility, though some peptides and other biologically
active molecules can escape this environment to achieve a
specific desired biological action. Therefore, it is fundamen-
tal to exploit novel molecules, which use different internali-
zation mechanisms. Recently, great attention has been de-
voted to the study of hydrophobic peptides that efficiently
traverse biological membranes, promoting lipid-membrane-
reorganizing processes, such as fusion or pore formation and
thus, involving temporary membrane destabilization and
subsequent reorganization.[3]
The nineteen residues peptide gH625, was previously
identified as a membrane-perturbing domain in the gH pro-
tein of Herpes simplex virus type I;[4] gH625 interacts with
biological membranes, contributing to the merging of the
viral envelope and the cellular membrane; it is able to tra-
verse the membrane bilayer and to transport a cargo into
the cytoplasm.[5] We already reported the ability of gH625 to
transport quantum dots inside the cytoplasm in an efficient
way and only partially involving endocytic pathways.[5] We
are now studying gH625 as a potential transporter of lipo-
somes loaded with anticancer drugs, such as doxorubicin.
Liposomal aggregates have attracted great attention due
to their success as in vivo carriers of active principles.[6] Lip-
osomes display some unique pharmacokinetic properties
and can be adapted to a wide range of therapeutic agents;
in particular, they are non-toxic, biodegradable, and non-im-
munogenic, thanks to their size ranging in mean diameter
from 50 to 300 nm. Benefits associated with liposomal drugs
Abstract: Liposomes externally modi-
fied with the nineteen residues gH625
peptide, previously identified as a
membrane-perturbing domain in the
gH glycoprotein of Herpes simplex
virus type I, have been prepared in
order to improve the intracellular
uptake of an encapsulated drug. An
easy and versatile synthetic strategy,
based on click chemistry, has been used
to bind, in a controlled way, several
copies of the hydrophobic gH625 pep-
tide on the external surface of 1,2-dio-
leoyl-sn-glycero-3-phosphocholine
(DOPG)-based liposomes. Electron
paramagnetic resonance studies, on lip-
osomes derivatized with gH625 pep-
tides, which are modified with the
2,2,6,6-tetramethylpiperidine-1-oxyl-4-
amino-4-carboxylic acid (TOAC) spin
label in several peptide positions, con-
firm the positioning of the coupled
peptides on the liposome external sur-
face, whereas dynamic light scattering
measurements indicate an increase of
the diameter of the liposomes of ap-
proximately 30% after peptide intro-
duction. Liposomes have been loaded
with the cytotoxic drug doxorubicin
and their ability to penetrate inside
cells has been evaluated by confocal
microscopy experiments. Results sug-
gest that liposomes functionalized with
gH625 may act as promising intracellu-
lar targeting carriers for efficient deliv-
ery of drugs, such as chemotherapeutic
agents, into tumor cells.
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can arise from protection of encapsulated drugs from chemi-
cal or metabolic degradation after injection, reduced toxicity
through decreased exposure of antineoplastics to susceptible
healthy tissues, and increased antitumor activity resulting
from a relatively long systemic circulation time, an extended
exposure and tumor selective accumulation in sites of tumor
growth. Moreover, liposomes exhibit preferential extravasa-
tion and accumulation at the site of solid tumors due to in-
creased endothelial permeability and reduced lymphatic
drainage in these tissues, which has been defined as en-
hanced permeability and retention effect, respectively.[7]
Thus, associating a drug with liposomes markedly changes
its pharmacokinetic and pharmacodynamic properties and
lowers systemic toxicity; furthermore, the drug is prevented
from early degradation and/or inactivation.[8]
To enhance the antitumor efficacy of liposomal drugs,
many research groups are working to improve the cellular
internalization of liposomes through the addition of surface
ligands. Recently, several peptides, such as penetratin[9] and
Tat,[10] have been successfully used for the intracellular de-
livery of liposomes.
CPPs, by interacting with charged phospholipids on the
outer surface of the cell membrane and destabilizing the bi-
layer, are capable of carrying hydrophilic compounds across
the plasma membrane, which may be useful in facilitating
the intracellular delivery of liposomal drugs.[11] Here, we
report the synthesis and the structural characterization of
liposomes decorated with the novel viral peptide gH625
loaded with doxorubicin. Different synthetic procedures can
be used to introduce a bioactive molecule on the external
surface of liposomes.[12] The different strategies involve the
coupling of the peptide to the lipid moiety before or after
the assembly of the liposome.
The strategy is strongly dependent on the peptide that has
to be linked to the liposomes; in fact the coupling of
charged peptides can be performed before the formation of
the liposome, although this strategy has the disadvantage
that a fraction of the conjugated peptide remains entrapped
in the interior region of the liposome. The coupling of a hy-
drophobic peptide is complicated by the low solubility of
the compound and by the higher tendency of the peptide to
locate in the hydrophobic region of the bilayer rather than
the external surface. Thus, the preferable way to obtain lipo-
somes functionalized on the surface with a hydrophobic pep-
tide consists in the coupling of peptide derivatives on pre-as-
sembled liposome.
The conjugation of a ligand
on the surface of pre-assembled
liposomes can be performed by
using a variety of techniques,
including physical adsorption,
electrostatic binding, specific
recognition, and covalent cou-
pling, each of which has its own
advantages and disadvantages.
Chemically controlled conjuga-
tion on pre-assembled lipo-
somes that carry functionalized lipid anchors should ideally
combine several features, such as mild reaction conditions in
aqueous media, high yields, and chemoselectivity. The appli-
cation of click chemistry is particularly appealing because of
its regiospecificity, chemoselectivity, and mainly tolerance to
a wide variety of other functional groups.
In the present study the gH625-modified liposomes are
prepared by using a post-aggregation strategy based on click
chemistry (see Scheme 1).[13] This procedure consists in the
preparation of liposomes containing accessible azido func-
tions on their external surface and subsequently in the cou-
pling of the azido functions with alkyne moieties present in
the peptide derivative, according to click-chemistry proce-
dures.[14] The positioning of the coupled peptide relative to
the liposome surface is investigated by electron paramagnet-
ic resonance (EPR) spectroscopy, by using peptides modi-
fied according to a site-directed spin-labeling approach. The
ability of gH625-functionalized liposomes, loaded with dox-
orubicin, to penetrate inside cells is evaluated by confocal
microscopy experiments.
Results and Discussion
Peptide synthesis and conjugation of gH625 peptides to the
surface of preformed liposomes : The coupling of a bioactive
ligand on the surface of liposomes can be obtained accord-
ing to several synthetic approaches. The choice of the strat-
egy depends on whether it is necessary to perform the cou-
pling before or after the liposome assembly. The coupling
before the assembly of liposomes is, in principle, chemically
less complicate, but has the disadvantage that a fraction of
the ligand remains entrapped in the liposome inner region
and is not available to play its biological function. This strat-
egy is the preferred choice for amphiphilic peptides, but it
remains unsuitable for poorly hydrophilic or mainly hydro-
phobic peptides. In these cases the coupling of the ligand
can be performed after the assembly of the liposomes by
using activated functional groups introduced onto the exter-
nal side of unilamellar liposomes. Activated functional
groups must be compatible with liposome preparation and
they should remain available on the surface for an efficient
chemical ligation of the ligand.
gH625 is a hydrophobic peptide (see Table 1 for the
amino acid sequence of gH625 and of the gH625 derivatives
Table 1. Peptide sequences and their molecular weight.
Peptide Sequence MW
gH625 NH2-HGLASTLTRWAHYNALIRAF-CONH2 2297.1
gH625-Pra NH2-HGLASTLTRWAHYNALIRAF-Pra-CONH2 2391.3
A643K ACHTUNGTRENNUNG(TOAC)-gH625-Pra[a] NH2-HGLASTLTRWAHYNALIRK ACHTUNGTRENNUNG(TOAC)F-Pra-CONH2 2644.6
A639K ACHTUNGTRENNUNG(TOAC)-gH625-Pra NH2-HGLASTLTRWAHYNK ACHTUNGTRENNUNG(TOAC)LIRAF-Pra-CONH2 2644.6
A635K ACHTUNGTRENNUNG(TOAC)-gH625-Pra NH2-HGLASTLTRWK ACHTUNGTRENNUNG(TOAC)HYNALIRAF-Pra-CONH2 2644.6
A628K ACHTUNGTRENNUNG(TOAC)-gH625-Pra NH2-HGLK ACHTUNGTRENNUNG(TOAC)STLTRWAHYNALIRAF-Pra-CONH2 2644.6
NBD-gH625-Pra NBD-HGLASTLTRWAHYNALIRAF-Pra-CONH2 2537.9
NBD-Pra NBD-Pra-CONH2 258.9
[a] TOAC=2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid.
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used in this study) with high tendency to locate in the hy-
drophobic portion of liposomes; thus, for the preparation of
liposomes decorated by gH625 a post-aggregation pathway
based on click chemistry methods was chosen (Scheme 1).
This procedure involves a copper(I)-catalyzed Huisgen
1,3-dipolar cycloaddition reaction of azides and alkynes
yielding 1,4-disubstituted 1,2,3-triazole-linked con-
ACHTUNGTRENNUNGjugates.[7a,8c] The unreactive nature of both azides and al-
kynes towards any other functional group present in the bio-
molecules, as well as the thermal and hydrolytical stability
of their cycloaddition product make this reaction particular-
ly appealing for the functionalization of liposomes with pep-
tides.
The click reaction was performed between 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPG)/ACHTUNGTRENNUNG(C18)2L-N3 liposomes
(90:10 molar ratio), obtained according to classical proce-
Scheme 1. A) Schematic representation of the synthetic monomer (C18)2L-N3. B) Scheme for the solid-phase synthesis of the (C18)2L-N3 monomer. The
Rink-amide resin is schematically represented as an empty circle. C) Coupling of the gH625-Pra peptide to azide-functionalized liposomes by a click-
chemistry reaction. Fmoc=9-fluorenylmethoxycarbonyl, Pip=piperidine, Mtt=4-methyltrityl, Fmoc-AdOO-OH=Fmoc-8-amino-3,6-dioxaoctanoic acid,
HOBt=1-hydroxybenzotriazole, PyBOP=benzotriazole-1-yl-oxy trispyrrolidinophosphonium hexafluorophosphonate, DIPEA=N,N-diisopropylethyl-
ACHTUNGTRENNUNGamine, Tf= trifluoromethanesulfonyl, TIS= triisopropylsilane, TFA= trifluoroacetic acid, DTT=dithiothreitol, Pra=propargylglycine.
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dures for the preparation of mixed liposomes, and the pep-
tide gH625 bearing a propargylglycine moiety (gH625-Pra).
The click reaction, performed in an aqueous solvent system,
was catalyzed by CuI generated, in situ, by reduction of
CuSO4 with ascorbic acid
[7a] (Scheme 1C).
The click-chemistry reactants, that is, the gH625-Pra pep-
tide and the liposome component (C18)2L-N3, were synthe-
sized by solid-phase methods according to standard solid-
phase peptide synthesis (SPPS) protocols with Fmoc/tBu
(tBu= tert-butyl) chemistry. In the case of gH625-Pra (see
Table 1), the alkyne moiety was introduced in the peptide
sequence at the C-terminal position as l-propargylglycine.
(C18)2L-N3 (Scheme 1A) was synthesized on solid phase fol-
lowing a modified protocol of the classical Fmoc/tBu strat-
egy, as indicated in Scheme 1B. Fmoc-LysACHTUNGTRENNUNG(Mtt)-OH was
anchored to the Rink amide resin. After removal of the
Fmoc protecting group, an ethoxylic linker was introduced,
and its NH2 function was converted into an azide function
by diazo transfer by using a sulfonyl azide, as previously re-
ported in the literature.[15] After removal of the Mtt group
from the Ne amino function of the lysine, the lipid chains
were added. As expected, no reductive side reaction of the
azide-functionalized derivative was observed during the
cleavage step of the lysine derivative from the resin (data
not shown).[16] Both gH625-Pra and (C18)2L-N3 were collect-
ed in good yields (20–40% and 85%, respectively) after
HPLC-RP purification, and analyzed by mass spectrometry
(MALDI-TOF), 1H and 13C NMR spectroscopy (for
(C18)2L-N3), and HPLC to confirm the compound identity
and the purity.
In order to determine the number of functional groups
present on the external surface of the liposomes and the
number of molecules of gH625 that were effectively linked
to the liposome, the 7-nitrobenzofurazan (NBD)-labeled Pra
and NBD-labeled gH625-Pra fluorescent derivatives were
used. NBD fluorescence emission at l=530 nm was mea-
sured after the click reaction, on both the liposome and the
NBD-Pra-containing fractions, and the percentage of func-
tionalization was calculated as the ratio of bound NBD-Pra
to its total amount. The results confirm that about 50% of
the azido functions are located on the external leaflet of the
liposome. When starting with an equimolar mixture of
NBD-gH625-Pra and azido functions on the liposome sur-
face, the expected gH625-functionalized liposomes were ob-
tained with a yield higher than 90% after 12 h at room tem-
perature.
In the absence of the copper catalyst no reaction was ob-
served. gH625-Pra analogues, labeled with the TOAC radi-
cal group through a site-directed spin-labeling approach,
were synthesized for EPR studies. Because the spin label is
relatively hydrophobic,[17] it was introduced in the peptide
sequence at the Ala positions. As the four Ala are almost
equally spaced along the peptide sequence (in position 628,
635, 639, and 643, the numbering being that of the entire gH
protein), we obtained four labeled peptides (A628K-
ACHTUNGTRENNUNG(TOAC)-gH625-Pra, A635K ACHTUNGTRENNUNG(TOAC)-gH625-Pra, A639K-
ACHTUNGTRENNUNG(TOAC)-gH625-Pra, and A643K ACHTUNGTRENNUNG(TOAC)-gH625-Pra) bear-
ing the reporter moiety in positions regularly distributed
from the N to the C terminus. For the synthesis of the four
TOAC-labeled peptide derivatives, the four alanine residues
were replaced one by one by LysACHTUNGTRENNUNG(Mtt). After removal of the
Mtt moiety from the side chain of the lysine, the coupling of
the TOAC residue was performed by using (7-azabenzotria-
zole-1-yl)tetramthyluronium hexafluorophosphate (HATU)
as activating agent.[18] The TOAC-containing Pra peptides
have been purified by HPLC by using standard TFA-con-
taining eluents and gradients; treatment of the peptide in
aqueous ammonia (pH 9.0) for 6 h at room temperature is
required in order to restore the chemical integrity of the ni-
troxide moiety after HPLC elution.[18] Liposomes derivat-
ized with TOAC-containing Pra peptides were obtained by
using the click chemistry procedures, as above reported in
the case of gH625-Pra peptide derivative.
Structural characterization of peptide–liposomes : Dynamic
light scattering (DLS) measurements were performed at q=
908 on liposomes composed of DOPG/ACHTUNGTRENNUNG(C18)2l-N3 at a molar
ratio of 90:10 and on liposomes functionalized with gH625
as well as liposomes functionalized with TOAC peptide de-
rivatives. Inspection of Figure 1 shows that all liposome sol-
utions present a monomodal distribution due to a transla-
tional diffusion process, which could be attributed to lipo-
some aggregates. The Stokes–Einstein equation [Eq. (1)] is
used to evaluate the hydrodynamic radius (RH), at infinite
dilution.
RH ¼
KBT
6phD0
ð1Þ
D0 is the translational diffusion coefficient at infinite dilu-
tion, KB is the Boltzmann constant, T is the absolute temper-
ature, and h is the solvent viscosity.[19] Due to the high solu-
tion dilution (c=1104m) of the studied systems, we have
approximately DD0, and Equation (1) can be reasonably
used to estimate the hydrodynamic radius of the aggregates.
Diffusion coefficients, together with hydrodynamic radius
values obtained through Equation (2) (see the Experimental
Section), are reported in Table 2. The hydrodynamic radius
of DOPG/ ACHTUNGTRENNUNG(C18)2L-N3 liposome (90:10 molar ratio) is
(69.4323.36) nm. As expected, the introduction of a small
amount of the synthetic monomer (C18)2L-N3 does not in-
fluence the size of the DOPG liposomes.[20] Figures 1B and
C display the structural evolution of liposomes obtained
after click reaction of gH625-Pra and four TOAC-labeled
Pra-peptides. In all cases, liposomes decorated by peptides
show an increase of about 30% in diameter (see Table 2).
From a structural point of view, this increase in size is in
good agreement with the other targeted liposomal systems
reported in literature;[14] moreover, the TOAC moieties do
not cause additional significant structural variations in the
size of the aggregates.
Secondary structure of gH625 : The secondary structures of
gH625 and of all the analogues with Lys ACHTUNGTRENNUNG(TOAC) in substitu-
tion for alanine residues were determined by CD spectros-
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copy (Figure 2). As previously reported,[4a,b,c] gH625 assumes
a random conformation in aqueous buffer solution, whereas
it assumes an a-helical structure in membrane mimetic envi-
ronments. gH625 and the LysACHTUNGTRENNUNG(TOAC) derivatives in water
solution containing 20% TFE, show a helical structure with
a slightly increase in ellipticity for the peptides where the
modification are localized in the center of the peptide, as
clearly evident from the spectra of the gH625 native peptide
and of the Lys ACHTUNGTRENNUNG(TOAC) peptide derivatives. These data clear-
ly show that the introduction of the TOAC moiety does not
modify the gH625 peptide conformation, and LysACHTUNGTRENNUNG(TOAC)
gH625 derivatives could be used in EPR studies to define
peptide positioning.
Determination of the position of gH625 by EPR spectrosco-
py: The peptide positioning relative to the liposome surface
was investigated by EPR spectroscopy. To this aim gH625-
Pra analogues, labeled with the TOAC radical group
through a site-directed spin-labeling approach, were used.
The EPR spectra of the free, labeled peptides dissolved in
HEPES buffer (10 mm) consist of three narrow lines (see
Figure 3A for an example), typical of an unstructured pep-
tide with few constraints on the motion of the reporter
group and consistent with the observed random coil CD
spectrum. Subsequently, the labeled peptides were chemical-
ly linked to the DOPG/ ACHTUNGTRENNUNG(C18)2L-N3 liposomes by following
the same procedure used for the parent unlabelled peptide,
yielding four suspensions of functionalized liposomes. The
analysis of their EPR spectra (see Figure 3A) gives informa-
tion on the positioning of the gH625 relative to the surface
of the liposome to which it is linked. In all cases a clearly
defined axially anisotropic line shape is observed, indicating
that the reporter group, wherever positioned along the pep-
tide sequence, assumes a well-defined orientation relative to
the bilayer. This behavior indicates that the peptide does
not protrude in the aqueous medium surrounding the lipo-
some, in which the label would have assumed a much higher
mobility freedom, but rather interacts with the surface of
the lipid bilayer.
Analysis of Figure 3 shows that the spectrum anisotropy
increases in going from A628K ACHTUNGTRENNUNG(TOAK)-gH625 to A643K-
ACHTUNGTRENNUNG(TOAC)-gH625, indicating that the peptide segments closer
to the C terminus, which is chemically linked to the lipid,
Figure 1. DLS spectra at 25 8C with a liposome concentration of 1
104m. A) DOPG/ ACHTUNGTRENNUNG(C18)2L-N3 (90:10 molar ratio) liposomes; B) DOPG/ ACHTUNG-
TRENNUNG(C18)2L-gH625 liposomes obtained after click reaction; C) DOPG/ ACHTUNG-
TRENNUNG(C18)2L-A635K ACHTUNGTRENNUNG(TOAC)-gH625 liposomes.
Table 2. Diffusion coefficients and hydrodynamic radii obtained from dy-
namic light scattering measurements for the studied systems.
System D
[1012 m2 s1]
RH
[nm]
DOPG/ ACHTUNGTRENNUNG(C18)2L-N3 ACHTUNGTRENNUNG(2.90.7) (69.4323.36)
DOPG/ ACHTUNGTRENNUNG(C18)2L-gH625 ACHTUNGTRENNUNG(2.20.3) (90.3813.50)
DOPG/ ACHTUNGTRENNUNG(C18)2L-A643K ACHTUNGTRENNUNG(TOAC)-gH625 ACHTUNGTRENNUNG(2.10.5) (95.4023.80)
DOPG/ ACHTUNGTRENNUNG(C18)2L-A639K ACHTUNGTRENNUNG(TOAC)-gH625 ACHTUNGTRENNUNG(2.10.5) (92.3225.22)
DOPG/ ACHTUNGTRENNUNG(C18)2L-A635K ACHTUNGTRENNUNG(TOAC)-gH625 ACHTUNGTRENNUNG(2.00.5) (97.6025.01)
DOPG/ ACHTUNGTRENNUNG(C18)2L-A628K ACHTUNGTRENNUNG(TOAC)-gH625 ACHTUNGTRENNUNG(2.20.5) (91.3224.45)
Figure 2. Circular dichroism spectra of gH625 (&) and its analogues with
Lys ACHTUNGTRENNUNG(TOAC) in substitution for alanine residues (*=A643K ACHTUNGTRENNUNG(TOAC)-
gH625, ~=A639K ACHTUNGTRENNUNG(TOAC)-gH625, &=A635K ACHTUNGTRENNUNG(TOAC)-gH625, *=
A628K ACHTUNGTRENNUNG(TOAC)-gH625), obtained in 2-(4-(2-hydroxyethyl)-1-piperazin-
yl)-
ethanesulfonic acid (HEPES) buffer containing 20% trifluoroethanol
(TFE).
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are more strictly oriented relative to the bilayer. This evi-
dence can be easily quantified by measuring the outer hy-
perfine splitting, 2Amax, which is a reliable and easy to per-
form estimate of the segmental chain mobility. 2Amax is de-
fined as separation, expressed in Gauss, between the low-
field maximum and the high-field minimum of the spectrum,
and tends to increase with increasing the restriction in the
label mobility. Figure 3B shows that, as the label position is
moved from position 628 to 643, 2Amax increases. This evi-
dence suggests that the peptide does not insert in the bilayer
hydrophobic core, but rather remains adsorbed on its sur-
face, remaining exposed to the aqueous environment. This
result confirms the possibility of using our synthetic strategy
to bind an hydrophobic peptide on the liposome external
surface; the use of a short linker may also provide steric re-
strictions for the peptide insertion inside the liposome.
Doxorubicin loading : Cytotoxic doxorubicin (Dox) was
loaded into DOPG/ACHTUNGTRENNUNG(C18)2L-N3 liposomes by using the well-
assessed procedures based on an ammonium sulfate gradi-
ent;[21] in particular, solution containing doxorubicin was in-
cubated under stirring for 30 min at 60 8C. Subsequently, un-
loaded doxorubicin was removed on a Sephadex G50
column pre-equilibrated with HEPES buffer (10 mm) at
pH 7.4. The drug/lipid weight ratio chosen for the loading
experiments was 0.1. The doxorubicin loading content
(DLC) was calculated by UV/Vis measurements at l=
480 nm and was above 95% of the total. The resulting Dox-
loaded liposomes were then efficiently modified with the
gH625-Pra peptide according to the click-chemistry proce-
dure used in the case of empty liposomes.
Determination of the cellular uptake by confocal microsco-
py: To study the cellular internalization of doxorubicin-
loaded liposomes functionalized with gH625, we examined
their uptake and intracellular localization in living HeLa
cells by confocal microscopy. Cells were incubated with a
1 mm solution of free Dox or of Dox-loaded, gH625-func-
tionalized liposomes for 1, 5, 17 h at 37 8C. The results ob-
tained after 5 h of incubation are reported in Figure 4. As
expected, after 5 h free Dox is able to enter the cell and
translocate into the nucleus as indicated by the green fluo-
rescence in the center of the cell body (Figure 4A–C). Also
in the case of DOPG/ ACHTUNGTRENNUNG(C18)2L-N3/Dox liposomes, cell nuclei
appear fluorescent due to Dox accumulation in DNA and a
slight diffuse fluorescence in the cytoplasm is observed, sug-
gesting a Dox release from the liposomes (Figure 4D–F).
Conversely, gH625-functionalized liposomes encapsulating
Dox accumulate in the cytoplasm, without entering into the
nucleus (Figure 4G–I). Indeed, cell nuclei are dark and only
green fluorescent spots, distributed in the cytoplasm, are
visible. These results suggest that the functionalization of
liposomes with gH625 could affect the uptake mechanism of
liposomes and, thus, their intracellular distribution and Dox
release. This evidence could be useful in the design of carri-
ers for a controlled delivery and release of Dox in order to
avoid side effects associated to Dox itself.
Conclusion
Liposomes composed of a phospholipid bilayer, which en-
tirely surrounds an internal aqueous core, used for drug en-
capsulation have been shown to be optimal for the delivery
of chemotherapeutic agents to tumor cells.[22] Being larger
than micelles they have the ability to deliver greater
amounts of the chemotherapeutic agent to the tumor site,
while minimizing the risk associated with premature leak-
age. In addition, liposomes also have the ability to accom-
Figure 3. A) EPR spectra of TOAC-labeled peptides linked to DOPG/ ACHTUNG-
TRENNUNG(C18)2L-N3 liposomes. An EPR spectrum of the free peptide A639K-
ACHTUNGTRENNUNG(TOAC)-gH625-Pra in aqueous buffer is also shown. B) Dependence of
the outer hyperfine splitting, 2Amax on the spin-label position along the
peptide sequence the of TOAC-labeled peptides linked to DOPG/ ACHTUNG-
TRENNUNG(C18)2L-N3 liposomes.
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modate both hydrophilic as well as hydrophobic drugs
either in the internal aqueous core or in the lipid bilayer.
When compared with conventional drugs, liposomal treat-
ment has been shown to dramatically reduce some of the
traditional side effects associated with chemotherapy, such
as nausea and vomiting.[23]
Current research is aimed at actively targeting liposomes
to tumor cells. In this view the development of chemical
procedures for the attachment of bioactive ligands to the
liposome external surface is particularly important.
Here, we have demonstrated the utility of the click
chemistry for modification of the external surface of
DOPG-based liposomes with the hydrophobic peptide
gH625, previously identified as a membrane-perturbing
domain in the gH protein of Herpes simplex virus type I.
According to this synthetic procedure, azide-modified,
DOPG-based liposomes react, under mild conditions, with
Pra-modified gH625, giving stable and well-defined peptide-
modified liposomes. The click-chemistry procedure de-
scribed here, appears of a general utility for liposome func-
tionalization; in fact azide-modified liposomes could consti-
tute a stable and ready-to-use
suspension of reactive lipo-
somes that could be functional-
ized with different Pra-modified
peptides. In our case, an in-
crease of the liposome diameter
of approximately 30% after
peptide introduction is ob-
served by DLS measurement.
Moreover, the peptide position-
ing relative to the liposome sur-
face has been investigated by
EPR spectroscopy; the data ob-
tained indicated that the pep-
tide does not insert in the bilay-
er hydrophobic core, but rather
remains exposed to the aqueous
environment adsorbed on the
liposomal surface and, thus,
able to achieve its biological
function.
To be effective as a chemo-
therapeutic agent, it has to be
active against cancer cells,
while having minimal toxic ef-
fects on healthy cells, tissues,
and organs. Thus, once carriers
loaded with chemotherapeutic
agents are systemically intro-
duced, their uptake by the re-
ticuloendothelial system (RES)
must be minimized, allowing
prolonged circulation of the
carriers in the blood.[24] The
longer the drug circulates in the
blood, the more likely it en-
counters the tumor as a result of the enhanced permeability
of leaky tumor blood vessels. The enhanced permeability
and retention effect is considered the primary mechanism of
preferential accumulation of long-circulating nanoparticles
in solid tumors. Polymeric drug carrier systems that use vari-
ous approaches to address these challenges have been inten-
sively developed,[25] and adding a targeting moiety, such as a
peptide or an antibody was shown to help the cellular
uptake and to reduce systemic clearance of anticancer drug.
Here, we verified the drug carrier ability of gH625-function-
alized, DOPG-based liposomes encapsulating Dox, which is
an intrinsically fluorescent anticancer drug. The exact mech-
anism of doxorubicin antitumor activity still remains un-
clear; it is known that it intercalates into DNA, which re-
sults in the blocking of topoisomerase II activity, preventing
DNA replication and cell division. In general, the use of lip-
osome-encapsulated Dox reduces toxicity. The presence of
the carrier hinders the intercalation of Dox into DNA; in
fact, confocal microscopy reveals differences between the
uptake mechanism of free and encapsulated Dox.[8] The nu-
clear accumulation of free Dox can be attributed to diffu-
Figure 4. Confocal microscopy images of HeLa cells after 5 h incubation with a 1 mm solution of free Dox (A–
C), a 1 mm solution of DOPG/ ACHTUNGTRENNUNG(C18)2L-N3/Dox (D–F), or a 1 mm solution of DOPG/ ACHTUNGTRENNUNG(C18)2L-gH625/Dox (G–I).
A,D,G) Fluorescence images of Dox accumulation within the cells. B,E,H) Transmission images of HeLa cells.
C,F,I) Merge of fluorescence and transmitted light images. The white line indicates the cell boundaries; scale
bar=20 mm.
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sion. In contrast, encapsulated Dox remains mostly in the
cytoplasm with negligible nuclear accumulation.[8]
Our experiments provide proof of principle for efficient
gH625-mediated delivery of DOPG-based liposomes into
cells. gH625 attached to the liposome surface needs to be
non-shielded and accessible for cell membrane experiments
and we showed that coupling the peptide on the pre-assem-
bles liposomes allows the obtainment of liposomes decorat-
ed on their surface with the peptide. Although the mecha-
nism still remains to be established, our results seem to sup-
port the hypothesis that the peptide allows a better penetra-
tion of liposomes. The approach described may have impor-
tant application for drug and DNA delivery into the cell
cytoplasm in different protocols for drug administration or
ex vivo treatments.
Experimental Section
Materials : Fmoc-protected amino acid derivatives, coupling reagents, and
Rink amide p-methylbenzhydrylamine (MBHA) resin were purchased
from Calbiochem-Novabiochem (Laufelfingen, Switzerland). Fmoc-8-
amino-3,6-dioxaoctanoic acid (Fmoc-AdOO-OH) and Fmoc-l-propargyl-
glycine (Fmoc-Pra-OH) were purchased from Neosystem (Strasbourg,
France). 4-Chloro-7-nitrobenzofurazan (NBD-Cl), doxorubicin hydro-
chloride, and the other chemicals were purchased from Sigma–Aldrich,
Fluka (Buchs, Switzerland), or LabScan (Stillorgan, Ireland) and were
used as received, unless otherwise stated. 1,2-Dioleoyl-sn-glycero-3-phos-
phocholine (DOPG) was purchased from Avanti Polar Lipids (Alabaster,
AL). Fmoc-TOAC-OH ((2,2,6,6-tetramethylpiperidine-N-oxide-4-(9-fluo-
renylmethyloxycarbonyl-amino)-4-carboxylic acid) spin label was kindly
provided by Prof. C. Toniolo of the University of Padua (Italy).
Solid-phase peptide synthesis : Peptides (for amino acid sequences and
peptide modifications see Table 1) were synthesized by using standard
solid-phase 9-fluorenylmethoxycarbonyl (Fmoc) procedures by using a
Syro I MultiSynThec GmbH (Wullener, Germany) automatic synthesizer.
The Rink amide MBHA resin (substitution 0.51 mmolg1) was used as
the solid-phase support, and syntheses were performed on a scale of
20 mmol. Fmoc-protected amino acids (4 equiv relative to resin loading),
were coupled according to the PyBop/HOBt/DIPEA method: Fmoc-
amino acid (1 equiv), PyBOP (1 equiv), HOBt (0.5 mm in DMF, 1 equiv),
and DIPEA (1.0 mm in DMF, 2 equiv). The Fmoc protecting group was
removed with 30% piperidine in DMF (v/v). All couplings were per-
formed twice for 1 h. Fmoc-Pra-OH was coupled once for 45 min with
2 equivalents of PyBop/HOBt and 2 equivalents of DIPEA. Peptides
were fully deprotected and cleaved from the resin with TFA with 2.5%
(v/v) water, 2.0% (v/v) anisole, and 2.0% (v/v) thioanisole as scavengers,
at room temperature, and then precipitated with ice-cold ethyl ether, fil-
tered, dissolved in water, and lyophilized. The crude peptides were puri-
fied by RP-HPLC on a LC8 Shimadzu HPLC system (Shimadzu Corpo-
ration, Kyoto, Japan) equipped with a UV lambda-Max Model 481 detec-
tor using a Phenomenex (Torrance, CA) C18 (300 , 25021.20 mm,
5 m) column eluted with H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B)
from 20–80% over 20 min at a flow rate of 20 mLmin1. Purity and iden-
tity were assessed by analytical LC-MS analyses by using Finnigan Sur-
veyor MSQ single quadrupole electrospray ionization (Finnigan/Thermo
Electron Corporation San Jose, CA), column: C18-Phenomenex eluted
with H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B) from 20–80% over
10 min at a flow rate of 0.8 mLmin1. The final yields of purified peptides
ranged between 20 and 40%.
Peptides labeled with TOAC (A628K ACHTUNGTRENNUNG(TOAC)-gH625-Pra, A635K-
ACHTUNGTRENNUNG(TOAC)-gH625-Pra, A639K ACHTUNGTRENNUNG(TOAC)-gH625-Pra, and A643K ACHTUNGTRENNUNG(TOAC)-
gH625-Pra) were synthesized by introducing the spin label directly on
the solid phase. For the incorporation of the TOAC moiety, peptides con-
taining Lys ACHTUNGTRENNUNG(Mtt) in substitution for the Ala residues were first synthe-
sized: A628K ACHTUNGTRENNUNG(Mtt)-gH625-Pra, A635K ACHTUNGTRENNUNG(Mtt)-gH625-Pra, A639K ACHTUNGTRENNUNG(Mtt)-
gH625-Pra, and A643K ACHTUNGTRENNUNG(Mtt)-gH625-Pra. The Mtt protecting group from
the side chain of the lysine residue was cleaved by treatment with 1%
TFA, 5% TIS, 94% CH2Cl2 (10 times for 1 min). The TOAC residue was
doubly coupled for 3 h by using 2-fold molar excess of Fmoc-TOAC-OH
(40 mmol) and HATU (40 mmol) as activating agent in presence of
DIPEA (1:1:2). The Fmoc protecting group was removed with 30% pi-
peridine in DMF (v/v). After TFA cleavage and HPLC purification,
TOAC-containing peptides were submitted to alkaline treatment with
aqueous ammonia (pH 9.5) for 6 h at room temperature to regenerate
the chemical integrity of the nitroxide moiety.[18, 26] The identities of the
TOAC peptides were confirmed by LC-MS.
When necessary, NBD-labeling was performed on resin-bound peptides
as previously reported by Rapaport and Shai.[27] Briefly, after removal of
the Fmoc protecting group of the N-terminal amino-acid, the resin-
bound peptide was treated with NBD-Cl in DIPEA (2m in DMF, 3–4
equiv). After 24 h, the resin-bound peptides were washed thoroughly
with CH2Cl2 and the peptides were cleaved and purified as previously de-
scribed. The identity of the NBD peptides was confirmed by LC-MS.
Preparation of trifluoromethanesulfonyl azide (TfN3): Sodium azide
(650 mg, 10 mmol) was dissolved in distilled water (1.5 mL) and then di-
chloromethane (2.4 mL) was added. The mixture was cooled in an ice
bath for 20 min. Trifluoromethanesulfonyl anhydride (336 mL, 2 mmol)
was added slowly over 5 min and the mixture was stirred for 2 h. The
mixture was extracted with CH2Cl2 two times. The organic portions, con-
taining the trifluoromethanesulfonyl azide, were pooled, washed once
with saturated aqueous Na2CO3 solution, and evaporated to dryness.
Synthesis of azide-AdOO-Lys(C(O)CH2CH2C(O)N-(C18H37)2)-amide
((C18)2L-N3): (C18)2L-N3 monomer was synthesized on the solid phase
under standard conditions by using the Fmoc/tBu strategy. Rink-amide
MBHA resin (0.51 mmolg1, 0.1 mmol, 0.196 g) was used as polymeric
support. The Fmoc protecting group on the resin was removed by a
DMF/piperidine (70:30) mixture. Fmoc-Lys ACHTUNGTRENNUNG(Mtt)-OH (0.125 g, 0.2 mmol)
was activated with PyBop (1 equiv) and HOBt (1 equiv) and DIPEA
(2 equiv) in DMF and coupled on the resin, while stirring the suspension
for 1 h. The Na amine function of the lysine residue was deprotected, and
Fmoc-AdOO-OH (2 equiv) was coupled under standard condition in
DMF for 1 h. After Fmoc removal the peptidyl-resin was washed three
times with DMF and three times with MeOH, and treated with a solution
containing K2CO3 (0.04 mmol), CuSO4·5H2O (0.01 mol), and TfN3
(2 mmol) in water (1 mL). The reaction mixture was stirred at room tem-
perature overnight. The solution was filtered and the resin was washed
four times with CH2Cl2; the Mtt protecting group on the Ne amino func-
tion of lysine was removed by treatment with CH2Cl2/TIS/TFA (94:5:1,
5.0 mL) for 2 min. This procedure was repeated several times until the
solution became colorless. The resin was washed three times with CH2Cl2
and three times with DMF. Then, N,N-dioctadecylsuccinamic acid
(0.249 g, 0.4 mmol) was coupled twice for 1 h in NMP (N-methylpyrroli-
done)/DCM (1:1). N,N-Dioctadecylsuccinamic acid was synthesized ac-
cording to a published procedure.[28] The lipophilic moiety was activated
in situ by the standard HOBt/PyBop/DIPEA procedure. The coupling
was monitored by the qualitative Kaiser test. The resin was washed three
times with DMF, three times with CH2Cl2, and three times with ethyl
ether. (C18)2L-N3 was removed from the resin by treatment with TFA
containing TIS (2.5%), dithiothreitol (DTT, 2.5%), and water (2.5%)
under vortexing for 2 h. The crude product was slowly precipitated at
0 8C by adding water dropwise. The precipitate was washed several time
with small portions of water and lyophilized in order to remove the sol-
vent. The white solid was recrystallized from MeOH/H2O and recovered
with high yields (>85%). The product was identified by MS (ESI+) and
NMR spectroscopy. 1H NMR and 13C NMR spectra were recorded on a
Varian 400MHz spectrometer (Palo Alto, CA). ACHTUNGTRENNUNG(C18)2L-N3 :
1H NMR
(400 MHz, CDCl3/CD3OD 50:50): d=4.3 (m, 1H; CHLysa), 4.04 (m,
2H; OCH2CONH), 3.70 (s, 4H; OCH2CH2O), 3.42 (t, J=7.61 Hz, 2H;
N3CH2CH2O), 3.25–3.20 (m, 4H; N-CH2), 3.23 (t, J=8.01 Hz, 2H;
CH2Lyse), 3.20 (t, J=8.01 Hz, 2H; N3CH2CH2O), 2.64–2.49 (m, 4H;
NHCOCH2CH2CO), 1.74 (m, 2H; CH2Lysb), 1.55 (m, 2H; CH2Lysd),
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1.45 (m, 2H; CH2Lysg), 1.40 (m, 4H; RCH2CH3), 1.25 (m, 60H; CH2 ali-
phatic), 0.88 ppm (t, J=6.86 Hz, 6H; CH3);
13C NMR (100.512 MHz,
CDCl3/CD3OD 50:50): d=173.98 (CONH2), 173.27 (CONH), 171.94
(CH3ACHTUNGTRENNUNG(CH2)17NCO), 170.55 (CONH), 72.3 (COCH2O), 70.0 (CH2N3),
69.4 ACHTUNGTRENNUNG(OCH2CH2O), 52.4 (NHACHTUNGTRENNUNG(CH2)4CH), 51.05 (NHCH2ACHTUNGTRENNUNG(CH2)3CH), 48.6
(CH3ACHTUNGTRENNUNG(CH2)16CH2N), 46.8 (CH3 ACHTUNGTRENNUNG(CH2)15CH2CH2N), 39.3 (NH-
ACHTUNGTRENNUNG(CH2)3CH2CH), 32.4–32.0 (NHCH2 ACHTUNGTRENNUNG(CH2)2CH2CH), 29.2
(NCOCH2CH2CONH), 30.2–27.5 (CH3CH2 ACHTUNGTRENNUNG(CH2)14CH2CH2N), 23.17
(CH3CH2 ACHTUNGTRENNUNG(CH2)16), 14.60 ppm (CH3CH2ACHTUNGTRENNUNG(CH2)16): MS (ESI+): m/z (%)
calcd for H101C52N7O6 [MH+]:916.64; found: 915 (100).
Preparation of liposomes : Mixed aggregates of DOPG and (C18)2L-N3
(90:10 molar ratio) were prepared by dissolving the two amphiphiles in a
small amount of chloroform, and subsequently evaporating the solvent
by slowly rotating the tube containing the solution under a stream of ni-
trogen. In this way a thin film of amphiphiles was obtained. A dry lipid
film was suspended in HEPES buffer (10 mm) at pH 7.4 by vortexing;
then the lipid suspension was freeze–thawed ten times and extruded
twenty times thought a polycarbonate membrane with 100 nm pore size
by using a mini-extruder purchased from Avanti Polar Lipids (Usa,
Canada).
Procedure for the “click” reaction : The Click reaction was carried out on
DOPG/ ACHTUNGTRENNUNG(C18)2L-N3 liposomes at 110
3m concentration in HEPES
buffer (10 mm) at pH 7.4. The reaction was carried out by adding
CuSO4·5H2O (4.4 equiv), ascorbic acid (6.7 equiv), and the peptide deriv-
ative (1 equiv) with respect to the azido moiety. In particular, solutions
containing CuSO4·5H2O (40 mm, solution A), ascorbic acid (57 mm, solu-
tion B), and the alkyn-modified peptide (0.8 mm, solution C) were freshly
prepared in water. Solution A (43.6 mL), solution B (48 mL), and solu-
tion C (408.4 mL) were added to a suspension of azido-functionalized lip-
osomes in HEPES buffer (500 mL). The concentration of solution C was
determined by measuring the absorbance on a UV/Vis Jasco V-5505 spec-
trophotometer. The reaction mixture was stirred at 40 8C for 30 min and
successively left overnight at room temperature. After the conjugation
step the liposomes were purified by exclusion chromatography on a 1
18 cm Sephadex G-50 (Amersham Biosciences) column pre-equilibrated
with HEPES buffer.
Functionalization of liposomes : The number of functional groups present
on the external surface of the liposomes and the number of molecules of
gH625 that were effectively linked to the liposome were determined by
using NBD-labeled Pra and NBD-labeled gH625-Pra. The amount of
NBD-Pra or NBD-gH625-Pra grafted to the liposome surface were esti-
mated by fluorescence spectroscopy by using calibration curves obtained
by measuring the fluorescence emission at l=530 nm. Fluorescence spec-
tra were recorded at room temperature on a Jasco Model FP-750 spectro-
fluorophotometer in a 1.0 cm path length quartz cell. Equal excitation
and emission bandwidths were used throughout the experiments, with a
recording speed of 125 nmmin1 and automatic selection of the time con-
stant. The percentage of functionalization was calculated as the ratio of
bound NBD-Pra or NBD-gH625-Pra to their total amount.
DLS characterization : For DLS measurements self-assembled liposomes
in isotonic HEPES buffer were prepared with a final concentration of 1
104m. Samples were centrifuged at room temperature at 13000 rpm for
5 min. Dynamic light scattering measurements were performed with a
setup composed of a Photocor compact goniometer, a SMD 6000 Laser
Quantum 50 mW light source operating at 5325 , and a PMT and corre-
lator obtained from Correlator.com. All the measurements were per-
formed at (25.000.05)8C with the use of a thermostat bath. In the DLS
experiments, the intensity autocorrelation function g(2)(t) is measured
and related to the electric field autocorrelation g(1)(t) by the Siegert re-
lation;[29] g(1)(t) can in turn be related through a Laplace transform to
the distribution function of the relaxation rates G from which the z aver-
age of the diffusion coefficient D may be obtained [Eq. (2)]:[30]
D ¼ lim
q!0
G
q2
ð2Þ
in which q=4pn0/lsin ACHTUNGTRENNUNG(q/2) is the modulus of the scattering vector, n0 is
the refractive index of the solution, l is the incident wavelength, and q
represents the scattering angle. D is thus obtained from the limit slope of
G as a function of q2, in which G is measured at different scattering
angles.
Circular dichroism measurements : Far-UV CD spectra were recorded
from l=260–195 nm on a Jasco J-810 spectropolarimeter equipped with
a NesLab RTE111 thermal controller unit by using a 0.1 mm quartz cell
at 25 8C. CD spectra of gH625-Pra and of its analogues in which each Ala
residue was replaced by a Lys ACHTUNGTRENNUNG(TOAC) residue were recorded at a con-
centration of 8104m in HEPES buffer in presence and in absence of
20% TFE. Other experimental settings were: scan speed: 10 nmmin1,
sensitivity: 50 mdeg, time constant: 16 s, bandwidth: 1 nm. Each spectrum
was obtained through averaging three scans, subtracting the contributions
from other species in solution, and converting the signal to mean residue
ellipticity.
EPR measurements : EPR spectra of spin-labeled peptides chemically
linked to the liposome surface were recorded on a Elexys E-500 EPR
spectrometer from Bruker (Rheinstetten, Germany) operating in the X
band. As references, spectra of the “free” spin-labeled peptides in aque-
ous buffer and in the presence of liposomes were also registered. Flame-
sealed capillaries containing the samples were placed in a standard 4 mm
quartz sample tube. The temperature of the sample was regulated and
maintained constant during the measurement by blowing thermo-stated
nitrogen gas through a quartz Dewar. The samples were investigated at
25 8C. The instrumental settings were as follows: sweep width: 120 G, res-
olution: 1024 points, modulation frequency: 100 kHz, modulation ampli-
tude: 1.0 G, time constant: 20.5 ms, sweep time: 42 s, incident power:
5.0 mW. For samples subjected to the click-chemistry reaction up to 128
scans were accumulated to improve the signal-to-noise ratio.[31] For all
the other samples, eight scans were accumulated.
Doxorubicin loading : Doxorubicin was remote-loaded in DOPG/ ACHTUNG-
TRENNUNG(C18)2L-N3 liposomes through an ammonium sulfate gradient method
and the free Dox was removed by gel filtration. Briefly, a liposomal solu-
tion (1 mm) was prepared as reported above in an ammonium sulfate so-
lution (250 mm) at pH 5.5. Next, liposomes were passed on a Sephadex
G-50 column pre-equilibrated with HEPES buffer (10 mm) at pH 7.4, and
a Dox solution in water (27 mL, 2.54103m) was added to an aliquot of
the liposomal solution (500 mL). This suspension was stirred for 30 min at
60 8C and subsequently unloaded doxorubicin was removed by using a
Sephadex G50 column. The Dox concentration was determined by spec-
troscopic measurements (UV and fluorescence) by using calibration
curves obtained by measuring the absorbance at l=480 nm or the fluo-
rescence emission at l=590 nm. Emission spectra were recorded at room
temperature. The Dox loading content (DLC, defined as the weight ratio
of encapsulated Dox vs. the amphiphilic moieties) was quantified by sub-
traction of the amount of Dox removed from the total amount of Dox
loaded. Finally, Dox pre-loaded liposomes were modified with gH625 by
using the click-chemistry reaction procedure, as reported above for
empty liposomes.
Cellular uptake by confocal microscopy : Uptake kinetic experiments
were performed on non-fixed living cells. HeLa cells were incubated with
liposomes functionalized with gH625 and pre-loaded with Dox with a
concentration of Dox of 1 mm at 37 8C for 1, 5, and 17 h. After incubation,
the cells were rinsed twice with phosphate-buffered saline (PBS) and
fresh cell culture medium without phenol red was added. All the samples
were observed by a confocal laser scanning microscope
(CLSM)(LSM510, Zeiss) equipped with an argon laser line at l=488 nm,
with a 63 objective.
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Abstract
Cell membranes are impermeable to most molecules that are not actively imported by living cells, including all macromolecules and even
small molecules whose physiochemical properties prevent passive membrane diffusion. However, recently, we have seen the development of
increasingly sophisticated methodology for intracellular drug delivery. Cell-penetrating peptides (CPPs), short peptides believed to enter cells
by penetrating cell membranes, have attracted great interest in the hope of enhancing gene therapy, vaccine development and drug delivery.
Nevertheless, to achieve an efficient intracellular delivery, further strategies to bypass the endocytotic pathway must be investigated. We
report on a novel peptide molecule derived from glycoprotein gH of herpes simplex type I virus that is able to traverse the membrane bilayer
and to transport a cargo into the cytoplasm with novel properties in comparison with existing CPPs. We use as cargo molecule quantum dots
that do not significantly traverse the membrane bilayer on their own.
From the Clinical Editor: Cell-penetrating peptides have recently attracted great interest in optimizing gene therapy, vaccine development
and drug delivery. In this study, a peptide derived from glycoprotein gH of herpes simplex I is investigated from this standpoint.
© 2011 Elsevier Inc. All rights reserved.
Key words: Peptide; Quantum dots; Delivery; Virus
The efficacy of a molecule that is to be used as a therapeutic
agent in biomedical research and in the pharmaceutical industry
is subject to its pharmacodistribution properties. In particular
many pharmaceutical agents should be delivered intracellularly
to exert their therapeutic action inside the cytoplasm or onto
individual organelles, such as nuclei (targets for gene and
antisense therapy), lysosomes (target for the delivery of deficient
lysosomal enzymes) and mitochondria (targets for pro-apoptotic
anticancer drugs). Most drugs are poorly internalized by cells
because the drugs cross the membrane rather inefficiently. Thus,
intracellular delivery of therapeutic molecules is one of the key
problems in drug delivery.
To date, multiple but only partially successful attempts have
been made to bring various drugs and drug-loaded pharma-
ceutical carriers directly into the cell cytoplasm, bypassing the
endocytic pathway to protect them from the lysosomal
degradation. In fact, any molecule entering the cell via the
endocytic pathway becomes entrapped into the endosome and
eventually ends in the lysosome, where active degradation
processes take place. Thus, even if an efficient cellular uptake
via endocytosis were observed, the delivery of intact peptides
and proteins is compromised by an insufficient endosomal
escape and subsequent lysosomal degradation. Other methods,
such as microinjection or electroporation, used for the delivery
of membrane-impermeable molecules are generally invasive
and could damage cellular membrane.1,2 Certain peptides
efficiently traverse biological membranes, promoting lipid
membrane-reorganizing processes, such as fusion or pore
formation involving temporary membrane destabilization and
subsequent reorganization.
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Cell-penetrating peptides (CPPs) can enter cells and have been
used for intracellular delivery of various cargoes with molecular
weights significantly greater than their own.3,4 They are now
considered to be the most promising tool for the intracellular
delivery of therapeutics both in vitro and in vivo.5-7 Examples of
CPP are penetratin,8 VP22,9 transportan,10 model amphipathic
peptide (MAP),11 signal sequence-based peptides,12 synthetic
polyarginines,13 and TAT peptide.3,4 Such proteins or peptides
contain domains of fewer than 20 amino acids that are highly rich
in basic residues. The peptide TAT is one of the most studied and
efficient CPP known to date. TAT is a small basic peptide based
on the arginine-rich region of the human immunodeficiency virus
type 1 transcription transactivating protein and has been proved to
have little cytotoxicity. Although its mechanism of cellular
uptake is still debated, it has been shown to translocate various
entities into cells, including small molecules, peptides, proteins,
DNA/RNA, liposomes and particles. CPPs can either require
chemical linkage or involve formation of stable noncovalent
complexes.14 The noncovalent strategy has been used for short
amphipathic peptides, proteins, oligonucleotides and siRNAs to
improve their delivery into mammalian cells.14
Early attempts to define a mechanism for the cellular import of
CPPs, including TAT, indicated that the direct transport of
peptides across the lipid bilayer was independent of both receptor
recognition and energy-requiring processes, such as endocytosis
in its various forms.4 Although such mechanisms may still be
valid in part and are perhaps more likely at very high peptide
concentrations, more recent observations, using a fluorescently
labeled TAT-derived CPP, indicate a fundamental role of
endocytosis.15,16 Other authors17 have confirmed further that an
energy-dependent route may be a common internalization
mechanism for the cellular entry of polycationic CPPs. They
have stressed the involvement of cell-surface polysaccharides,
including heparan sulphate, as a binding site for cationic peptides.
In particular, Brooks18 proposed that TAT, because of its
adherence to negatively charged membrane constituents, is
internalized by any pinocytic process occurring at cell mem-
branes. Endosomal entrapment may thus limit their utility, though
some peptides and/or biologically active cargoes can escape this
environment to achieve a specific desired biological action.
Therefore, it is essential to identify novel molecules that use
different internalization mechanisms. We previously reported the
identification of a membrane-perturbing domain in the protein
gH of herpes simplex virus type 1.19-22 The peptide gH625 is a
mainly hydrophobic peptide that interacts with biological
membranes, contributing to the merging of the viral envelope
and the cellular membrane. When gH625 is in helical
conformation, the polar residues concentrate on one face of the
helix, giving an amphiphilic character common to fusion
peptides of most fusion glycoproteins of enveloped viruses;
moreover, gH625 is very effective in inducing lipid mixing of
model membranes.
To evaluate the possibility of using this peptide as a more
effective transport vector, we determined the relationships among
several physicochemical properties such as cell association,
cellular uptake, lipid membrane binding and conformation. Flow
cytometry was used to measure cellular uptake of gH625 in HeLa
cells. For peptides that strongly bind to the cell plasma membranes
and remain associated with cells even after repeated washings,
FACS analysis cannot be used to evaluate cellular uptake with
validity unless a protease digestion step of the adsorbed CPP is
included in the protocol. In our study to measure the fraction of
internalized peptide accurately, we used a method based on the
selective chemical extinction by dithionite of the 4-chloro-7-
nitrobenz-2-oxa-1,3-diazole (NBD)moiety attached to the peptide.
This membrane-impermeable reagent was used previously to
measure cellular uptake of penetratin.23 We also report confocal
microscopy experiments showing the cellular uptake of gH625.
To assess the ability of the peptide gH625 to deliver drugs
inside the cell, we used quantum dots (QDs) as a model cargo.
QDs have been demonstrated as a new type of fluorescence
probe24 with high luminescence efficiency and with their
emission peak tunable depending on their size. In addition, the
excellent photostability of QDs gives them great potential in
cellular labeling and bioimaging, and a number of works have
shown these characteristics in different kinds of biological
systems. QDs are advantageous due to their nanometer size,
broad excitation, narrow emission, bright photoluminescence
and high photostability. However, wide application of QDs to
intracellular and molecular imaging has been hampered by
their insufficient ability to traverse cell membranes. Thus, to
use QDs as biological probes for intracellular applications,
their delivery has to be improved significantly. Several authors
recently reported on the functionalization of QDs with the
TAT peptide or other positively charged CPPs as enhancer of
cell penetration and reported on the endosomal uptake of QDs
and escape from the endosomal system.25-29 Here we describe
a novel and mainly hydrophobic peptide derived from a viral
protein involved in membrane fusion and its application to QD
delivery. Similar delivery methods may enable the implemen-
tation of the next generation of QDs capable of long-term
intracellular monitoring.
Methods
Peptide synthesis
Peptides (gH625: Ac-HGLASTLTRWAHYNALIRAFGGG-
COOH; TAT: Ac-GRKKRRQRRRGGG-COOH) were synthe-
sized using the standard solid-phase-9-fluorenylmethoxycarbo-
nyl (Fmoc) method as previously reported.19 All purified
peptides were obtained with good yields (30–40%).
NBD labeling of peptides
Labeling was performed on resin-bound peptides as previously
reported by Rapaport and Shai.30 Briefly, 30–70 mg of resin-
bound peptide (10–25 μmol) was treated with piperidine in DMF
to remove the Fmoc-protecting group of the N-terminal amino acid
of the linked peptide. The resin-bound peptide was then reacted
with 4-chloro-7-nitrobenz-2-oxa-1,3-diazole (NBD-Cl) in DIPEA
2 M (3–4 equivalent) in DMF. After 24 hours the resin-bound
peptides were washed thoroughly with methylene chloride, and
the peptides were cleaved from the resin and purified. The
identity of the NBD-peptides was confirmed by liquid
chromatography–mass spectrometry (LC/MS).
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Peptides conjugation to QDs
Solution of peptides, EDC (1-Ethyl-3(3-dimethylamino-
propyl)-carbodiimide, hydrochloride) and NHS (N-Hydroxysuc-
cinimide) were prepared in PBS buffer at pH 7.2 in molar ratio of
4:4:1. QDs were conjugated with the preactivated peptides in a
molar ratio of 1:200, in MES buffer at pH 5.5 for 3 hours. The
fluorescence spectra of peptide QDs and un-conjugated QDs
were measured in a Cary Eclipse Varian fluorescence spectro-
photometer in the same condition. In all the reported confocal
experiments we used the same peptide concentration and thus the
QDs' concentration was 200 times lower.
MTT assay for cell viability
Methylthiazolyldiphenyl-tetrazolium (MTT) bromide reduc-
tion was used to examine the metabolic activity of the cells. The
MTT assay is based on the reduction of the yellowish MTT to the
insoluble and dark blue formazan by viable and metabolically
active cells.31 HeLa cells were subcultured in 96-well plates at a
seeding density of 2 × 104 cells per well. For assessing the
cytotoxic effect of gH625 and TAT peptides, HeLa cells were
incubated with different concentration of peptides (10, 50, 100,
200, 400 μM) for 24 hours. Then, the medium was gently
aspirated, MTT solution (5 mg/mL) was added to each well and
cells were incubated for a further 3 hours at 37°C. The medium
with MTT solution was removed, and the formazan crystals were
dissolved with DMSO. The absorption values were measured at
570 nm using a Bio-Rad Microplate Reader (Bio-Rad Labora-
tories, Inc., Hercules, California). The viability of HeLa cells in
each well was presented as a percentage of control cells.
LDH assay
Lactate dehydrogenase (LDH) released into the culture
medium was measured by monitoring fluorometrically the
production of nicotinamide adenine dinucleotide (NAD+) from
NADH during the conversion of pyruvate to lactate.32 For
assessing the plasma membrane integration upon the exposure to
gH625 and TAT peptides, HeLa cells were subcultured in 96-
well plates at a seeding density of 2 × 104 cells per well. Twenty-
four hours later, cells were incubated with different concentra-
tion of peptides (10, 50, 100, 200, 400 μM) for 24 hours. The cell
supernatant (100 μL) was incubated with 0.18 mM NADPH and
0.60 mM pyruvate in 50 mM phosphate buffer (pH 7.4). The rate
of NAD+ formation was monitored for 1 minute by reading the
fluorescence in a fluorescence reader with the excitation filter set
at 360 nm and the emission filter set at 460 nm. LDH leakage
was expressed as a percentage of untreated or control cells,
which was designated as 100%.
Liposome preparation
Large unilamellar vesicles (LUVs) consisting of PC/Chol
(1:1), and when necessary containing Rho-PE and NBD-PE,
were prepared according to the extrusion method of Hope et al33
in 5 mMHepes, 100 mMNaCl, pH 7.4. Lipids were dried from a
chloroform solution with a nitrogen-gas stream and lysophilized
overnight. For fluorescence experiments, dry lipid films were
suspended in buffer by vortexing; the lipid suspension was
freeze-thawed 6 times and extruded 20 times through polycar-
bonate membranes with 0.1 μm diameter pores to produce large
unilamellar vesicles. Lipid concentrations were determined by
phosphate analysis.34
Inner-monolayer phospholipid-mixing measurement
Peptide-induced phospholipid mixing of the inner monolayer
was measured by a modification of the phospholipid-mixing
measurement as reported elsewhere.35 The concentration of each
of the fluorescent probes within the liposome membrane was
0.6% mol. LUVs were treated with sodium dithionite to
completely reduce the NBD-labeled phospholipid located at
the outer monolayer of the membrane. The final concentration of
sodium dithionite was 100 mM (from a stock solution of 1 M
dithionite in 1 M TRIS, pH 10.0) and it was incubated for
approximately 1 hour on ice in the dark. Sodium dithionite was
then removed by size exclusion chromatography through a
Sephadex G-75 filtration column (Pharmacia, Uppsala, Sweden)
eluted with buffer containing 10 mM TRIS, 100 mMNaCl, and 1
mM EDTA, pH 7.4. The NBD emission at 530 nm was followed
Figure 1. Effect of peptides on the viability of HeLa cells. Cytotoxic effect of
gH625 and TAT peptides determined by the MTT (panel A) assay and by
measuring the efflux of lactate dehydrogenase (LDH) into the culture
medium (panel B). HeLa cells were treated with the indicated concentrations
of peptides for 24 h. The values shown are the percentages of viable cells and
LDH release relative to control cells.
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with the excitation wavelength set at 465 nm. A cut-off filter at
515 nm was used between the sample and the emission
monochromator to avoid scattering interferences. The fluores-
cence scale was calibrated such that the zero level corresponded
to the initial residual fluorescence of the labeled vesicles and the
100% value corresponding to complete mixing of all lipids upon
the addition of Triton X-100 (0.05% v/v). All fluorescence
measurements were conducted in PC/Chol (1:1) LUVs, were
repeated at least 3 times and results were averaged. All the
experiments were performed at 37°C.
Figure 2. Peptide interaction with PC/Chol LUVs (A,B,C), the dose dependence is reported and each trace represents an average of 3 independent experiments.
(A) Lipid mixing; (B) Inner monolayer assay. (C) Leakage of ANTS/DPX. NBD-peptide cellular uptake (D-E-F), the percentage of internalized and bound
peptides are reported. HeLa cells were incubated with (D) increasing concentrations of NBD-peptides (1, 5, 10, 20 μM) for 60 min. (E) 10 μM NBD-peptides
for 10, 30 and 60 min. (F) NBD-peptides at 37° and 4°C.
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Measurements of ANTS/DPX leakage
The ANTS/DPX assay36 was used to measure the ability of
the peptide to induce leakage of ANTS/DPX pre-encapsulated in
liposomes. Details of this assay can be found elsewhere.37 To
initiate a leakage experiment, the peptide, in a stock solution at
pH 7.4 containing 5 mMHepes and 100 mMNaCl, was added to
the stirred vesicle suspension (0.1 mM lipid) at 37°C.
Flow cytometry of cell association of peptide
HeLa cells were cultured in RPMI medium supplemented with
10% fetal bovine serum. Cells were diluted at 3 × 105 cells mL-1 1
day before the experiment. Cell association was measured by flow
cytometry using a FACScan (Becton Dickinson, Franklin Lakes,
New Jersey). NBD-labeled peptides (1, 5, 10, 20 μM) were
incubated with HeLa cells (5 × 105 cells mL-1) in Opti-MEM
medium at 37°C for various periods of time (10, 30, and 60
minutes) in a final volume of 0.5 mL. Thereafter, the cells were
washed twice and then resuspended in 0.5 mL of ice-cold NaCl/Pi
for flow cytometric analysis. Cell-associated fluorophores were
excited at 465 nm and fluorescence was measured at 530 nm. A
histogram of fluorescence intensity per cell (1 × 104) was obtained
and the calculated mean of this distribution was considered as
representative of the amount of cell-associated peptide. A stock
solution of dithionite (1 M) was freshly prepared in 1 M Tris
solution (pH 10). Following flow cytometric analysis, 5 μL of
dithionite stock solution was added to cells maintained at 4°C and
the fluorescence of internalized peptides was measured after 5
minutes.
To further study the mechanism of internalization, experi-
ments were performed at 4°C until the end of the cell fixation
procedure. Cells were preincubated for 30 minutes at 4°C before
being incubated with the peptide solution.
Cellular uptake of peptides by confocal microscopy
For cellular uptake experiments, peptides were diluted in cell
culture medium; the final concentration of NBD conjugated to
the peptides is 1, 10 and 20 μM; the final concentration of QDs
conjugated to the peptide is 5, 50 and 100 nm. In addition, 70%
confluent HeLa cells, seeded on 12-mm diameter glass
coverslips, were incubated with 200 μl of peptide conjugated
to the NBD or to QDs at 37°C for 1 hour and at 4°C for 10
minutes. For localization of peptides in lysosome organelles,
LysoTracker reagent (Molecular Probes, Invitrogen, Carlsbad,
California) was added to cell culture medium containing peptides
and incubated with cells for 1 hour at 37°C according to
manufacturer's procedure. After incubation, cells were rinsed
twice with PBS to remove noninternalized peptides and fixed
with 4% paraformaldehyde for 20 minutes.
For peptide uptake-kinetics experiments on nonfixed living
cells, HeLa cells were incubated with 10 μM of NBD-peptide
solutions and with 50 nm QD-peptide solutions at 37°C for 1, 5
and 17 hours. After incubation, cells were rinsed twice with PBS
and fresh cell culture medium without phenol red was added. To
inhibit the endocytosis pathway, 40 μM sodium azide were
added to the cell culture medium for 30 minutes followed by 1
hour of incubation with peptides.
All the samples were observed by a confocal laser scanning
microscope (CLSM) (LSM510, Zeiss, Thornwood, New York)
equipped with a He-Ne and anArgon laser lines at the wavelengths
of 543 nm and 488 nm, respectively, with a 63× objective.
Results
Toxicity of peptides
The cell viability was measured using MTT and LDH assays.
LDH is of great value as an in vitro marker for cellular toxicity.
Figure 1, A shows the results obtained with the MTT assay, and
Figure 1, B shows the results of the LDH assay. To evaluate the
cell toxicity of both gH625 and TAT peptides, escalating doses
of the peptides were applied to HeLa cells. The addition of TAT
or gH625 did not affect HeLa cell viability up to 200 μM. A low
level of toxicity was observed when the peptides' concentration
reached 400 μM. In the conditions used, different sensitivity was
observed for the 2 assays, with the MTT assay being slightly
more sensitive in detecting cytotoxic events in comparison with
the LDH leakage assay. In conclusion, both peptides were not
toxic at concentrations lower than 400 μM, and at this
concentration, TAT was slightly more toxic than gH625.
Peptide interaction with LUVs
The peptide gH625 has been previously characterized.19-22
indicating its strong interaction with LUVs, although the exact
mechanism of interaction awaits complete understanding. We
previously showed that gH625 penetrates into the membrane by
studying the tryptophan or NBD fluorescence emissions, which
are environmentally sensitive. The depth of insertion was also
determined by means of differential quenching using brominated
lipids at different positions, which indicated that the peptide was
not adsorbed on the top of the membrane but had a deep
interfacial partitioning. Membrane disturbance upon peptide
insertion was previously evaluated by vesicle fusion21 in several
liposomes composed of different lipids showing the best
fusogenic activity in PC/Chol as shown in Figure 2, A. As
transmembrane-pore formation has been suggested to explain the
uptake of other translocating peptide38-40 we previously tested
this possibility for gH625 using surface plasmon resonance41;
the values of the ratio of the binding affinity to bilayers in
comparison with to monolayers demonstrates that the peptide is
not influenced by the membrane inner layer.
Here, to further support the hypothesis that the peptide is able
to diffuse inside lipidic vesicles without involving pore
formation, we performed the inner monolayer fusion and leakage
experiments as indicators of the interaction and perturbation of
the lipid membrane caused by the peptide.
In the inner monolayer, the fluorescence from the vesicle
membranes' outer monolayer is eliminated by the addition of an
aqueous reducing agent, and this experiment reveals the extent of
lipid mixing between the inner monolayers of vesicles in solution.
Figure 2, B shows that a small fusion of the inner monolayer is
observed only at a peptide lipid ratio of approximately 0.8, and
the occurrence of the same level of membrane fusion by the lipid
mixing experiment, whether it is hemifusion or complete fusion,
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was observed at a peptide lipid ratio of 0.01. This assay clearly
indicates that the peptide gH625 induces only hemifusion at
peptide-to-lipid ratios between 0 and 0.1.
A contents-mixing assay was employed to monitor any mixing
of internal vesicle components because of vesicle exposure to
gH625. Release of ANTS and DPX from vesicles is commonly
used as a measure of bilayer perturbation and interpreted as
“transient pore formation.”36, 37 Contents mixing is manifested by a
decrease in fluorescence intensity if vesicles encapsulating
fluorescent cargo (e.g., ANTS) merge contents with those contain-
ing quenchers (e.g., DPX). Figure 2, C shows that no contents
mixing occurs over the same P/L range where substantial outer
monolayer lipid mixing occurs, corroborating the presence of
vesicle hemifusion in our system. The agreement of contents-
mixing assays and inner monolayer lipid-mixing assays gives full
confidence in the finding of peptide-induced hemifusion for gH625.
These results can be used as qualitative indicators of peptide
translocation or bilayer perturbation with relevance for the
direct-penetration mode of cell entry, or for the steps of
endosomal membrane translocation or endosomal escape. We
have not detected any significant pore formation; vesicle fusion
events not accompanied by leakage of the aqueous contents of
the vesicle were also reported for other peptides in a study
published by Thoren et al.42
Determination of NBD-peptide cellular uptake
We have determined the fraction of NBD-labeled peptide
taken up into HeLa cells by flow cytometry. The experiment is
based on a method previously introduced by McIntyre and
Sleight43 to measure the transbilayer distribution of NBD-
phospholipid analogues. The distribution is determined by
comparing the fluorescence intensity before and after addition
of sodium dithionite, an essentially membrane-impermeant
molecule, which suppresses irreversibly the fluorescence of the
accessible NBD-moiety localized on the external cell surface.
We incubated gH625-NBD with HeLa cells at 37°C at
different concentrations (1, 5, 10, 20 μM). After 1 hour of
Figure 3. Fluorescence images of QD-peptides at 5 and 50 nM and NBD-peptides, at 1 and 10 μM. Panel A shows the peptide in green; Panel B shows the
LysoTracker in red and Panel C shows the merge of the two images. Bar = 10 μm.
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incubation, we measured the quenching of the peptide by
dithionite treatment. The dithionite reaction was performed at
low temperature (4°C) because the dithionite crossing of
biological membranes is strongly reduced44 in comparison
with high temperatures. Upon stabilization of the initial
fluorescence, dithionite was added to initiate quenching. Before
the addition of dithionite we observed that approximately 90% of
gH625-NBD was not washed away and thus was internalized or
bound to the membrane bilayer; after the addition of dithionite
the internalized peptide was 80% (Figure 2, D). We performed
the same experiment on TAT-NBD as a reference; and before the
addition of dithionite we observed that approximately 70% of the
peptide was internalized or bound to the membrane bilayer; after
the addition of dithionite, the internalized peptide was approx-
imately 60% (Figure 2, D). Increasing dithionite concentration
did not result in a modification of the extent of quenching,
indicating that the entire accessible NBD label was quenched by
1 M dithionite (data not shown). These results show that the use
of dithionite permits efficient measurement of the fraction of
internalized peptide inside the cells. To exclude the possibility
that the fluorescence signal could have been due to the
internalization of the fluorochrome itself, the NBD moiety was
used in the same in vitro assay conditions, and no cellular
fluorescence was observed at concentrations up to 20 μM (data
not shown).
To measure the kinetics of import of gH625-NBD into
cells, we incubated the peptide with cells at 37°C for various
times (10, 30, and 60 minutes) and then determined the
remaining fluorescence following treatment with dithionite.
Figure 2, E shows the fraction of peptide taken up by cells.
The uptake is very rapid and seems to reach a plateau after 1
hour of incubation.
The influence of temperature on the intracellular accumula-
tion was studied to see whether the uptake depended on a
translocation mechanism or a cellular process. We incubated the
peptide with HeLa cells at both 37°C and 4°C; the amount of
internalized gH625-NBD at low temperature (Figure 2, F) is
reduced for both peptides, with an increase in the quantity bound
to the membrane and a substantial decrease of the quantity of
internalized peptide. The reduction of internalized or bound
peptide was more significant for TAT peptide.
NBD-peptide localization
To confirm the peptide internalization, we examined its
uptake and intracellular localization by confocal microscopy. We
used concentrations of 1 and 10 μM and a time of 60 minutes as
selected by the flow cytometry experiments. Both peptides are
efficiently internalized and we observe a significant colocaliza-
tion with the LysoTracker, indicating a partial confinement
within the endosomal compartments (Figure 3).
Recently, it has been reported that cell-fixation protocols
induce the apparent translocation and nuclear localization of
positively charged peptides and this has been previously proved
for the TAT peptide.15 We have examined the possibility that the
translocation observed for gH625 could be the result of such an
effect. As shown in Figure 4, although the penetration of the
TAT-NBD in living cells is lower than with fixed cells,
indicating that a large portion of surface-bound peptide diffuses
into the cytoplasm during the fixation step, the penetration of
gH625-NBD is not affected by fixing protocols. The NBD alone
at a concentration of 10 μM is almost unable to penetrate inside
cells as shown in Figure 5.
Delivery of QDs
Delivery of QDs to living cells should consist of 2 phases:
QDs are initially bound to plasma membrane of cells, and then
are gradually internalized by cells. QDs alone have a poor
affinity for the plasma membrane of HeLa cells at the
concentration of 50 nm used in these experiments (Figure 5).
The peptide conjugation to QDs enhanced their membrane-
bound ability providing a favorable condition for the cellular
internalization. Figure 4 clearly shows their intracellular
distribution in HeLa cells at concentrations of 5 and 50 nm.
Figure 4. Uptake kinetics of QD-peptides (50 nm) and NBD-peptides (10 μM) in HeLa cells after 1, 5 and 17 h of incubation at 37°C. Bar = 50 μm.
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The images indicate a more efficient internalization of QDs
linked to the peptide gH625 in comparison with TAT, with a
more significant colocalization with the LysoTracker for the
TAT. Experiments performed in living cells show a marked
difference at 5 hours in the penetration of QDs conjugated to the
TAT and to gH625, with a clearly detectable major increase of
penetration when linked to gH625. Additionally, with QDs
conjugated with gH625 we can deduce that the translocation
observed is not the result of such fixing protocols.
Metabolic inhibitors
The influence of temperature and metabolic inhibitors on the
intracellular penetration of NBD-peptides or QD-peptides was
studied to see whether the uptake depended on a translocation
mechanism or a cellular process. We compared the images
obtained at 4°C to determine the degree of endocytosis in the
cellular uptake (Figure 6, C). The analysis of the results indicates
that the endocytosis is more significant for TAT than for gH625.
Sodium azide is an oxidative phosphorylation inhibitor com-
monly used to abolish ATP production within the cell
membrane.45 As shown in Figure 6, A, B, and C, a marked
decrease of TAT internalization was observed both when
conjugated to NBD and when conjugated to QDs, indicating
that endocytosis is the main process involved in TAT
penetration. On the contrary, gH625 penetration is not influenced
significantly by the treatment with sodium azide, indicating that
endocytosis does not affect gH625 transduction.
Discussion
Our objective was to describe a new molecule that could be
used for the intracellular delivery. We sought to achieve this by
combining flow cytometry, a quantitative method that allows
accurate measurement of peptide internalization, with confocal
microscopy. Labeling the peptide with the NBD group allowed
the comparison of cellular uptake with phospholipid binding and
analysis of the physicochemical properties required for translo-
cation. To measure cellular uptake of NBD-labeled peptide we
have used the dithionite method, which allows the estimation of
the peptide fraction localized inside the cell. We determined by
flow cytometry that after 1 hour of incubation with HeLa cells at
37°C and 4°C, most of gH625-NBD was localized intracellu-
larly; our results show that the peptide internalization in HeLa
cells can occur at 37°C and to a lesser extent at 4°C, supporting
the view that the internalization mechanism does not involve
only endocytosis. The kinetic of internalization of gH625-NBD
is rapid and reaches a plateau after 1 hour. We confirmed by
confocal microscopy that indeed the NBD-peptide is inside the
cell and its penetration is not induced by cell-fixation protocols
as previously found for the TAT peptide.15
The amount of cell-associated peptide represents the sum of
internalized peptide and of peptide remaining on the cell surface
after cells wash. We previously reported results from surface
plasmon-resonance21, 41 assays on peptide gH625, which allowed
us to examine the contribution of the inner leaflet of the
membrane with regard to the binding properties of viral
membranotropic peptides. This approach was used to discrimi-
nate between transmembrane pore formation and membrane
perturbation. We showed that the peptide stably inserts into the
PC/Chol membrane but is unable to form pores; here, we confirm
this result showing that it is unable to fuse the inner monolayer as
well as inducing leakage of vesicles. The ANTS and DPX assay
indicates that no permeabilization occurs upon binding of peptide
to a lipid bilayer; this suggests that the peptide interacts with the
lipid membrane but does not form pores inside the membrane,
further supporting the view that the mechanism of lipid/peptide
association plays a key role in the translocation activity.
Additionally, gH625 cellular uptake is associated with its ability
to interact with membrane lipids and to form a transient helical
structure that temporarily affects membrane organization, thereby
facilitating insertion into the membrane and translocation.
The main objective of this study was to analyze the
internalization of the peptide gH625 in the absence of an
attached cargo for a better understanding of the behavior of this
membranotropic domain and to test the hypothesis regarding its
use for delivering macromolecules. We therefore report an
example of the application of gH625 to the delivery of QDs into
the cells.
QDs are a new class of fluorescent probes under intense
research and development for broad applications in molecular,
cellular and in vivo imaging. QDs have unique functional and
structural properties, such as size and composition-tunable
fluorescence emission, large absorption cross sections and
exceptional brightness and photostability when compared with
organic dyes and fluorescent proteins. Although considerable
success has been achieved in using QDs for labeling fixed cells
and for imaging cell membrane proteins, only limited progress
has been made for molecular imaging inside living cells. A major
problem is the lack of efficient methods for delivering single
QDs into the cytoplasm of living cells. Our results clearly
indicate that the gH625-QDs are internalized more effectively
than TAT-QDs and their internalization only partially involves
the endocytic pathway. Further assays have been undertaken to
understand the exact mechanism of internalization of gH625-
QDs conjugates better.
Figure 5. Uptake of QD (A), Tat-QD (B) and gH625-QD (C) at 50 nm and
NBD (D), Tat-NBD (E) and gH625-NBD (F) at 10 μM in HeLa cells after 5
h of incubation at 37°C. Bar = 50 μm
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Furthermore, gH625 has showed very low toxicity during in
vitro studies when used at concentrations up to 400 μM;
therefore, it seems suitable for being used as a delivery system.
Of importance is that when conjugated with QDs, gH625
exerts an action of translocation through cellular plasma
membranes, which seems to be only relatively dependent on
the endocytic route of entry. It has been previously reported
that TAT peptide conjugated with small molecules enters
cytoplasm and eventually the cell nuclei and that TAT-QDs
remain trapped in vesicles. This difference in the intracellular
fate of TAT peptide-conjugated molecules and TAT-QDs is
likely caused by differences in the sizes of the cargoes. QDs
are much larger than standard molecules and are thus less able
to escape from vesicles. On the contrary, gH625-QDs are
present in the cytoplasm in a more punctuated form in
comparison with TAT-QDs. Therefore, we can hypothesize a
different mechanism of entry between TAT-QDs and gH625-
QDs, and this is of particular interest because peptides with
different biophysical characteristics are able to condition the
entry pathway of the same macromolecular cargo. These results
make gH625-QDs an interesting compound for recognizing
specific targets in the cytoplasm.
Our results provide new insights into the mechanism of
gH625-mediated delivery and for the development of nanopar-
ticle probes for intracellular targeting and imaging, and for
biology and medicine.
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1. Introduction  
The magnitude of septic shock as a clinical problem is often understated. Despite advances 
in our ability to diagnose and treat infectious diseases, severe sepsis leading to shock due to 
gram-negative infections remains one of the leading causes of mortality worldwide. Septic 
shock develops because of a disregulation in the host response, and the mechanisms initially 
recruited to fight infection produce life-threatening tissue damage and death. Recent 
research has witnessed a significant increase in our understanding of host-pathogen 
interactions, particularly in the area of innate immunity and the molecular recognition of 
gram-positive and gram-negative bacteria. Important new mediators of sepsis and novel 
mechanisms of host-cell toxicity have been identified and, together with clinical trials 
targeting pathways considered central to sepsis pathogenesis, provide new insight into the 
molecular and cellular basis of sepsis for the formulation of new strategies of intervention. 
Research on septic shock pathogenesis by gram-negative bacteria is mainly focused on the 
understanding of the molecular and cellular role played by lipopolysaccharide (LPS). Strong 
experimental evidence and clinical observations suggest that the release of proinflammatory 
cytokine mediators by LPS-responsive cells (mainly macrophages, endothelial cells and 
neutrophils) in response to toxic products sets in motion the genetic and physiologic 
program that manifests as shock. The best characterized of these toxic components is LPS, 
which is considered as a paradigm for other less well-characterized toxic microbial 
molecules. The immune protection stimulated by highly purified LPS in animals does not 
resolve the symptomatology of septic shock, while LPS mixed to outer membrane proteins 
shows a better protective activity. Several studies evidence the major role played by outer 
membrane proteins in the molecular interaction between the host cell and the gram-negative 
bacteria. Endotoxin-associated proteins consist of a complex of several major proteins that 
are intimately associated with the LPS. Very little is known about release of non-LPS gram-
negative outer membrane components such as OMPs in sepsis. Among the OMPs, porins 
have been shown to play an important role in pathogenesis of bacterial infections. Porins 
were pyrogenic in rabbits and elicited a localized reaction when used as the sensiting and 
eliciting agent. Porins were also shown to kill D-galactosamine sensitized LPS-responsive 
and LPS-unresponsive mice. Treatment of Human Umbilical Vein Endothelial Cells: 
(HUVEC) with porins increased the transmigration of different leukocyte populations, in 
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particular of neutrophils. Porins by several gram-negative bacteria induce cytokine release 
by human leukocytes as well as enhancement of cytokine gene expression. Also, other 
components of the bacterial envelope are important in the induction and pathogenesis of 
septic shock such as bacterial lipoproteins (LP). As anti-LPS therapies does not seem to 
improve by the addition of proteins from the outer membrane or small fragments of these 
proteins, a great alternative to existing strategies will involve the blockage of signal 
transduction pathways, cytokine and inflammatory mechanisms.  
2. The outer membrane of gram-negative bacteria 
Bacteria in order to face unpredictable and often hostile environment have evolved a 
sophisticated and complex cell envelope that protects them while allowing selective passage 
of nutrients from the outside and waste products from the inside. There are three principal 
layers in the envelope: the outer membrane (OM), the peptidoglycan cell wall, and the inner 
membrane (IM). The two membrane layers delimit an aqueous cellular compartment called 
periplasm. The OM is a characteristic feature of Gram-negative bacteria, and in fact Gram-
positive bacteria lack this structure. The OM is a lipid bilayer intercalated with proteins, 
superficially resembling the plasma membrane. The OM does contain phospholipids but 
they are confined to the inner leaflet of this membrane. The outer leaflet is composed of 
glycolipids, mainly lipopolysaccharide (LPS).  
 
 
Fig. 1. Schematic representation of the structure of lipopolysaccharide (LPS). 
LPS is a complex glycolipid exclusively present in the outer leaflet of the OM of gram-
negative bacteria. LPS is one of the molecules responsible for the endotoxic shock associated 
with the septicemia, and is a sure indicator of infection as the human innate system is 
sensitized to this molecule. LPS molecules consist of a bisphosphorylated lipid (lipid A) 
forming the hydrophilic region of the outermost membrane leaflet which is stabilized by 
divalent cations and a hydrophilic polysaccharide (PS), extending outward from the 
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bacterium. A schematic structure for LPS from Escherichia coli together with the chemical 
structure of lipid A (Figure 1) reveals its key features. The LPS consists generally of two 
distinct regions, a core oligosaccharide chain of repeating units, the O-specific chain, which 
constitutes the major anti-LPS immune response. The core is covalently bound to the lipid A 
through an acidic sugar, the 3-deoxy-D-manno-oct-2-ulopyranosonic acid (Kdo). The outer 
core region consists of neutral or amino hexoses such as D-glucose, D-galactose, D-
glucosamine, D-galactosamine or N-acetyl derivatives, while the inner core also contains 
heptose residues which are often substituted by phosphate, pyrophosphate or 
diphosphoethanolamine. Kdo represent a covalent bridge between lipid A and heptose units 
joined by diester phosphate linkages. The general pattern of the lipid A from diverse gram-
negative bacteria is highly conserved. The lipid A from E. coli has a β-1,6-linked  
D-glucosamine disaccharide phosphorylated in positions 1 and 4’. Lipid A often contains up 
to four moles of (R)-3-hydroxytetradecanoic acids symmetrically distributed on the two 
glucosamine residues of the backbone. The hydroxyl in position 6’ is linked to Kdo (Figure 
1). The core oligosaccharide is very variable among bacterial species; so different species  
can express uniquely modified types of LPS. The O-antigen, if present, is the most variable 
part of LPS and shows even a high degree of variability between different strains of the 
same species. 
 
 
Fig. 2. Schematic representation of the inner and outer bacterial membrane. 
With few exceptions, the proteins intercalated in the OM can be divided into two classes, 
proteins that traverse the membrane and assume a β-barrel structure and lipoproteins, 
anchoring the outer membrane to the underlying peptidoglycan stratum (Figure 2). 
Lipoproteins contain lipid moieties that are attached to an amino-terminal cysteine residue. 
It is generally thought that these lipid moieties embed lipoproteins in the inner leaflet of the 
OM, and are thus not supposed to be transmembrane proteins. Lipoproteins are low 
molecular weight proteins and are considered to be the most abundant proteins in the E. coli 
cell on the basis of molecular members. Lipoproteins are generally covalently linked to the 
peptidoglycan, but may also be present without covalent bonds.  
The outer membrane proteins (OMPs) of gram-negative bacteria have been well 
characterized; they assume a β-barrel conformation. The OMPs serve as a molecular filter for 
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hydrophilic substances, and mediate the transport of nutrients and ions across the 
membrane into the periplasm. The OMPs can be divided into three classes (Nikaido, 2003): 
porins, substrate specific transporters and active transporters. Porins are a group of trimeric 
proteins that form pores of a fixed diameter through the lipid bilayer of the membrane. They 
constitute the major component of the OM and are thus indicated as “major outer 
membrane proteins” of high molecular weight.  
Porins form passive pores that do not bind their substrates; they form trimeric, water-filled 
pores, through which relatively small (<600 Da) solutes diffuse, driven by their 
concentration gradient. For nutrients that are present at low concentrations in the 
extracellular environment, passive diffusion is no longer efficient and transport occurs via 
substrate-specific (substrate specific porins and transporters) and active transporters 
(Galdiero, 2007). The active transporters (FepA and FhuA) bind their substrates with high 
affinity and transport them against a concentration gradient. This process requires energy, 
which is provided by the inner membrane protein Ton B. The substrate-specific porins and 
transporters contain low affinity substrate saturable binding sites that allow efficient 
diffusion of substrates at very low concentration gradients. Among the substrate specific 
porins are LamB (maltose and maltodextrins) and SerY (sucrose); among the substrate 
specific transporters are Tsx and FadL, while among auto-transporters are NaLP and Hia. 
Whereas the composition, structure and function of the OM are well known, its assembly in 
the absence of energy sources has remained largely enigmatic. All the components of the 
OM are synthesized in the cytoplasm or at the cytoplasmic face of the IM, and they have to 
be transported across the IM and through the periplasm to reach their destination and to 
assemble into the OM. 
3. The porins  
The most abundant proteins of the bacterial outer membrane are porins which form 
channels with various degrees of selectivity (Schulz, 2002). Porins form β-barrels and their 
structures typically contain 14, 16 or 18 β-sheets. The majority of porins studied so far 
belong to the 16 or 18 stranded bacterial porins; and the general motif of their structural 
architecture is the closure of the barrel by pairing of the first and last β-strand in an 
antiparallel way. All strands are connected by eight or nine long loops, facing the 
extracellular side, with seven or eight small turns in the periplasmic space. In all porins, the 
constriction at the barrel center is formed by an inserted long loop L3, which is not exposed 
to the cell surface but folds back into the barrel, forming a constriction zone at half the 
height of the channel and contributing significantly to the permeability of the pore. Another 
feature is the presence of aromatic girdles with tyrosine and phenylalanine residues located 
at the outer and inner membrane boundaries. Residues located between these girdles and 
facing the hydrophobic lipid environment are mainly leucine, valine and isoleucine 
residues. At the very C-terminus almost all porins have a phenylalanine residue that is 
fundamental for proper import and folding in the outer membrane.   
Porins made of 16 strands are called general or non-specific porins and form pores allowing 
the diffusion of hydrophilic molecules, showing no particular substrate specificity, despite 
some selectivity for either cations or anions; while 18 strands porins are substrate specific 
porins. Porins are passive diffusion channels with a pore diameter ranging from 15 Å for the 
general porins to 6 Å for the highly selective porins. Larger pores usually contain charged 
residues at opposite sides that form a local transversal electric field at the pore eyelet. This 
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field constitutes an energy barrier for low-polarity solutes so that the bacterium can exclude 
unwanted nonpolar molecules such as antibiotics while presenting a spacious eyelet for 
collecting large polar molecules such as sugars. A systematic study changing the pore 
properties by point mutations showed a strong correlation between the eyelet cross section 
and diffusion rate. Charge reversals affect selectivity and voltage gating. Interesting results 
were obtained with mutations at loop L3, for example the specificity of the sucrose porin 
was changed toward that of the maltoporin. 
 
 
Fig. 3. Three dimensional model of the P2 monomer from Haemophilus influenzae type b. 
Surface loops are shown in green except L7 that is red. The extracellular space is located at 
the top of the figure and the periplasmic space is at the bottom. The position of the 
membrane bilayer is shown. 
All porins form homotrimers in the OM; each subunit produces a channel and the trimer 
therefore contains three channels. For most porins, loops L1, L2 and L4 are important for 
monomer-monomer interactions within the porin trimer; loop L3 is internal; loops L5, L6 
and L7 are superficial; loop L8 folds back into the barrel interior, contributing to the 
formation of the channel opening at the external side (Figure 3). Data from the literature 
indicate that peptide sequences corresponding to superficial loops are responsible for most 
of the biological activity of porins. In particular, loop L7 of porin OMPK36 from Klebsiella 
pneumoniae is involved in the interaction with C1q (Alberti, 1995); loops L5, L6 and L7 of 
porin P2 from Haemophilus influenzae activate JNK and p38 mitogen-activated protein kinase 
(MAPK) pathways (Galdiero, 2003) and induce the release of TNF-α and IL-6 (Galdiero, 
2006); most functional antibodies raised to NTHI are directed to loop L5, which is thought to 
contain strain-specific and immunodominant epitopes (Yi, 1997); antibodies to loop L6 of 
NTHI showed complement-dependent bactericidal activity (Haase, 1994); the surface 
exposed loop regions are immunodominant as shown by immunizing mice with whole 
bacterial cells (Neary, 2001); synthetic peptides representing epitopes of outer membrane 
protein F of Pseudomonas aeruginosa elicit antibodies reactive with whole cells of 
heterologous immunotype strains of Pseudomonas aeruginosa (Hughes, 1992); major 
immunogenic epitopes of PorA and FetA of meningococci correspond to contiguous peptide 
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sequences located in putative surface-exposed loops of those proteins (Maiden, 1991; 
Thompson, 2003).  
4. Lipoproteins 
Lipoproteins are a major component of the outer membrane of bacteria, with low molecular 
weights (about 7000 Da). Lipid modification of bacterial proteins enables the anchoring of 
hydrophilic proteins to hydrophobic surfaces through the hydrophobic interaction of the 
attached acyl groups to the cell wall phospholipids, allowing the protein to function 
effectively in the aqueous environment (Kamalakkannan, 2004). Lipoproteins can localize in 
various places of the cell. E. coli has more than 90 lipoproteins, the majority of which is 
located at the periplasmic face of the OM, with some present at the periplasmic face of the 
IM (Narita, 2004). Although all the known lipoproteins in E. coli face the periplasm, in some 
gram-negative bacteria, lipoproteins are also present on the outer leaflet of the OM. 
However, little is known about the exact mechanism of how they translocate across the OM 
whether they are exposed or not to the outside surface of the outer membrane. Moreover, in 
those E. coli strains that have defects in LPS structure, the lipoproteins seem to react with 
antilipoprotein serum.  
Lipoproteins are low molecular weight proteins lacking histidine, tryptophan, glycine, 
proline and phenylalanine. They are linked by the ε-amino group of their C-terminal lysine 
to the carboxyl group of every tenth to twelfth meso-diaminopimelic acid residue of the 
peptidoglycan. The N-terminal portion of the lipoprotein consists of glycerylcysteine to 
which two fatty acids are linked by two ether linkages and one fatty acid by an amide 
linkage. The amide-linked fatty acid consists of 65% palmitate, with the rest being mainly 
monosaturated fatty acids. The fatty acid bound as esters are similar to the fatty acids found 
in the phospholipids of the inner layer of the membrane. Lipoproteins exist in the 
membrane also as free form without covalent bonds to the peptidoglycan. There are about 
2.4 x 105 molecules of the bound form per cell, and about twice as much of the free form. The 
total free and bound lipoprotein molecules 7.2 x 105 make lipoproteins the numerically most 
abundant protein in the membrane. Lipoproteins are required for virulence and play a 
variety of roles in host-pathogen interactions, from surface adhesion to initiation of 
inflammatory processes (Kovacs-Simon, 2011). 
5. Outer membrane blebbing 
Extracellular secretion is the major mechanism by which gram-negative pathogens 
communicate with and damage host cells. Vesicles released from the envelope of the 
growing bacteria serve as secretory vehicles for protein and lipids of gram-negative bacteria. 
Vesicles production occurs in infected tissues and is influenced by environmental factors. 
Vesicles play an important role in colonization, carrying and transmitting virulence factors 
into host cells and modulating host defense and immune response. Gram-negative bacteria 
release membrane vesicles of average diameter 10-300 nm into the environment during all 
stages of normal growth as well as in a variety of growth environments such as infected 
tissues. The amount of released vesicles is increased several folds during periods of bacterial 
stress such as exposure of microorganisms to antibiotics or human serum. The vesicles are 
formed by protrusions of the bacterial outer membrane that are released into the 
environment (Ellis, 2010). Outer membrane vesicles (OMVs) are formed by blebbing and 
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pinching off segments of the bacterial outer membrane (Kulp, 2010). These vesicles contain 
the main components of the outer membrane such as LPS, OMPs and fractions of the 
underlying bacterial periplasm. Importantly, OMVs are not a product of cell death since 
they are produced without concomitant bacterial lysis and newly synthesized proteins are 
present. Active concentrations of both LPS and porins are often accumulated at infection 
sites from either gram-negative bacteria outer membrane blebbing or bacterial lysis.  
Gram-negative bacteria contain about 105 molecules of porin per cell (molecular mass, about 
36kDa) and about 3.4 x 106 molecules of LPS (molecular mass, about 4,5KDa), therefore, 106 
to 109 bacterial cells are enough to reach a concentration of 500 ng/ml to 20 µg/ml (about 
0.02 to 0.8 µM) for porin or a concentration of 100 ng/ml to 10 µg/ml (about 0.05 to 5 µM) 
for LPS.  
OMVs from pathogenic bacteria contribute to the pathogenicity in vivo (Ellis, 2010). Thus, 
OMVs are likely a key factor in effecting an inflammatory response to pathogens, being 
immunogenic and capable of eliciting proinflammatory responses. Immunization with 
Vibrio cholera OMVs induces protection in mice (Schild, 2008); the OMVs immunized mice 
were protected against Salmonella infections (Alaniz, 2007). Furthermore, OMVs influence 
inflammation and disease in vivo; it was shown that, in response to Helicobacter pylori and 
Pseudomonas aeruginosa OMVs (Bauman, 2006), epithelial cells produce interleukin-8, a 
cytokine that plays a fundamental role in neutrophil and monocyte recruitment.  
Septic shock has been associated with an early excessive inflammatory response to LPS and 
other bacterial components, among which OMPs and lipoproteins. During sepsis and septic 
shock large quantities of OMVs are released into serum and tissues. In particular, fragments 
containing LPS, OMPA and a protein of 17kDa, were affinity purified from filtrate of human 
serum incubated with Salmonella enterica serovar Abortus equi using O-chain-specific anti-
LPS IgG (Freudenberg, 1992); similarly, complexes containing LPS and at least three OMPs, 
with molecular masses of 35, 18 and 5-9 kDa were affinity purified from filtrates of normal 
human serum incubated with Escherichia coli cells, using O-chain-specific anti-LPS IgG 
(Hellman, 2000). These molecules or macromolecular complexes have been shown to derive 
from the OMVs formed by the blebbing of bacterial cells.  
6. OMPs and endothelial cells 
Bacteria or bacterial products may constitute important inducers of surface molecule 
expression on endothelial cells (Rawadi, 1996). The microvascular endothelium plays an 
important role in regulating the exchange of fluids, macromolecules and cells between the 
blood and the extravascular tissues. The endothelium is a pervasive organ covering a 
surface area of 4000-7000 m2. Endothelial cells are highly active, constantly responding to 
alteration in the local extracellular environment, as might occur in the setting of transient 
bacteremia or other important stress such as septic invasion. Endothelial cell activation 
occurs as a normal adaptative response, the nature and duration of which depends on the 
type of stimulus. Endothelial cell injury contributes significantly to the pathophysiology of 
bacterial sepsis and endotoxic shock. Components of the bacterial surface activate pattern 
recognition receptors on the surface of the endothelium. Gram-negative bacteria contain 
several surface molecules interacting with endothelial cells. The role of LPS is well known 
while the roles of other surface molecules of gram-negative bacteria are less understood. 
Several studies have recently shown the activity of major outer membrane proteins on 
endothelial cells. The bacterial surface contains a wide assortment of molecules that interfere 
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with the complex network regulating the leucocyte traffic. The initial adhesion of circulating 
leukocyte to vascular endothelium is induced by interaction of constitutively functional 
leukocyte homing receptors with regulated endothelial cell ligands or counter receptors. 
Leukocyte-endothelial cell interactions both in vivo and in vitro are active multistep 
processes, as clearly demonstrated in studies of neutrophil interactions with inflamed sites 
(Von Andrian, 1991). During sepsis a dramatic increase of endothelial cell surface molecules 
expression occurs that facilitate adhesion of blood leukocytes. These kinds of interactions 
have been mainly studied in brain microvascular endothelial cells (BMEC). 
The crossing of the blood-barrier by circulating bacteria is a complex process, requiring 
several bacterial and host factors and their interactions, such as a high degree of bacteremia, 
binding to and invasion of BMEC, BMEC actin cytoskeleton rearrangements and related 
signaling pathways. Among E. coli structures necessary for crossing of the blood-brain 
barrier in vitro and in vivo, outer membrane protein A (OmpA) contributes to E. coli K1 
invasion of BMEC (Kim, 2002). OmpA has been implicated as an important virulence factor 
in several gram-negative bacterial infections such as E. coli K1, a leading cause of neonatal 
meningitis associated with significant mortality and morbidity (Mittal, 2011). E. coli K1 
OMPA interacts with a gp96 protein on human BMEC. Purified OMPA as well as gp96 and 
gp96 antibody inhibited E. coli K1 invasion of human BMEC in a dose dependent fashion. 
OMPA is a major outer membrane protein of E. coli; it is present as an 8-stranded and anti-
parallel β-barrel structure in the membrane, connected by large hydrophilic surface exposed 
loops and short periplasmic turns (Smith, 2007). Although OMPA’s role in pathogenesis has 
been demonstrated, the exact role of individual loops is still to be determined (Maruvada, 
2011). In particular, the synthetic peptides representing a part of the first loop and the tip of 
the second loop of OMPA have been shown to inhibit E. coli adhesion to BMEC (Prasadarao, 
1996). The first and second loops are shown to be the sites for the interaction with the 
carbohydrate epitope of the BMEC receptor glycoprotein. OmpA extracellular loops play a 
fundamental role in the pathogenesis of meningitis and may help in designing effective 
preventive strategies against this deadly disease (Mittal, 2011). Loop regions 1 and 2 play an 
important role in the survival of E. coli K1 inside neutrophils and dendritic cells, and loop 
regions 1 and 3 are needed for survival in macrophages. Mutations in loop 4 of OmpA 
enhance the severity of the pathogenesis by allowing the pathogen to survive better in 
circulation and to produce high bacteremia levels. Loop 2 appears to be involved in the 
majority of the interactions and represents an interesting target for immunization. 
Among the major surface proteins, the 34K and 36K porins from Salmonella typhimurium 
modulate leukocyte migration by acting on endothelial cells and leukocytes. The 
transmigration increase was dose-dependent and optimal endothelial activation occurred 
after 4-6 hours using porin as stimulus, after 2-4 hours using LPS. Stimulation of leukocytes 
with either porins or LPS slightly increased their transmigration through porin-non-
activated endothelial cells. The simultaneous stimulation in vitro of HUVEC with IL-1β and 
either porins or LPS causes overlapping effects leading to a very high migration index 
(Galdiero, 1999). In natural inflammatory process the combination of several stimuli induces 
high endothelial permeability of vessels to migrating cells. The main adhesion molecules of 
endothelial cells are activated by porins. Neutrophil transmigration through HUVEC cells 
treated with porins was partially inhibited by MoAbs binding to E-selectin; the 
transmigration of lymphocytes and monocytes was partially inhibited by MoAb anti-
VCAM-1; the transmigration of neutrophils, lymphocytes and monocytes was partially 
inhibited by MoAb anti ICAM-1. Soluble E-selectin and ICAM-1 were found in the 
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supernatants from IL-1 and TNF-α activated endothelial cells. Also porins were able to 
stimulate the release of soluble E-selectin and soluble ICAM-1. Protein H from Pasteurella 
multocida in vitro induces neutrophil adhesion and transmigration through bovine 
endothelial cells (Galdiero, 2000). An increase of the expression of the vascular cell adhesion 
molecule 1 on the aortic endothelium has been reported in rabbit experimentally infected 
with Pasteurella multocida (Galdiero, 2000). These results evidence a local and systemic 
microcirculatory dysfunction that is considered central in the development of multiple 
organ dysfunction syndromes in septic shock. 
7. OMPs and host-cells 
Among surface components, porins and LPS may be important inducers of biological 
activity in host-interactions. Several studies have been carried out to dissect the 
immunobiological activities of Salmonella enterica or typhimurium porins, showing that these 
proteins have important effects on macrophage viability and functions; in particular, porins 
inhibit their phagocytic activity in a dose dependent fashion by activating the adenylate 
cyclase system (Di Donato, 1986). Porins induce the activation of the complement system by 
acting both on the classic pathway and on the alternative pathway (Galdiero, 1984), acting as 
mitogens for B lymphocytes. Furthermore, in rats they increase the toxicity of cardio-toxic 
molecules (Galdiero, 1986) and damage renal tubules (Tufano, 1987). Porins are clearly 
endowed with pro-inflammatory activity; when injected into the rat paw induce dose-
dependent edema with long-lasting effects. The inflammation induced by porins is sensitive 
to both steroid (dexamethasone) and non-steroid (indomethacin) anti-inflammatory drugs. 
The in vitro studies carried out on peritoneal cells of the rat show that porins are able to 
induce the release of histamine and also of prostacyclin. Porin-induced inflammation may 
depend on the release of histamine, even though the arachidonic acid metabolites may also 
participate. In fact, in vitro results exclude an increase of 6-keto-prostaglandin and 
subsequent prostacyclin release, whereas in vivo results confirm both the prolonged 
duration of porin-induced edema and its marked inhibition by indomethacin. Porin-induced 
inflammation was also observed in decomplemented animals; therefore, it is unlikely that 
the activation of the complement system plays a major role in the inflammation induced by 
porins (Galdiero, 1984). Porins isolated from S. typhimurium are lethal at the dose of 100 ng 
to both LPS-responder (BALB/cByS) and non responder (C3H/HeJ) mice sensitized with D-
galactosamine. The lethal action could be prevented by anti-TNF-α serum. Porins were also 
pyrogenic to rabbits and elicited a Shwartzman reaction when used as the sensitizing and 
eliciting agent (Galdiero, 1994). Haemophilus influenza type b (Hib) porin also induces the 
early release of cytokines in central nervous system cells, amplifying the inflammatory 
response. Hib porin inserted into the fourth ventricle of the brain elicited the appearance of 
serum proteins and the development of brain edema. These modifications were followed by 
increase in the number of neutrophils both in cerebrospinal fluid and in the tissue sections 
around the porin inoculation site. IL-1α, TNF-α and MIP-2 mRNA appeared quickly in the 
tissue near the inoculation site (Galdiero, 2001a).  
Activation of the coagulation and fibrinolytic systems is an important manifestation of the 
systemic inflammatory response of the host to infection. The in vivo effect of a synthetic 
peptide corresponding to loop L7 from Haemophilus influenzae type b (Hib) porin was 
compared with the effect of the entire protein to evaluate its role on the 
coagulative/fibrinolytic cascade and the circulating markers of endothelial injury (Vitiello, 
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2008). Plasma was obtained from rats injected intravenously with the peptide and tested for 
fragment 1+2 (F1+2), tissue-type plasminogen activator (tPA), plasminogen activator 
inhibitor type I (PAI-1) antigen, von Willebrand factor (vWF) and soluble E-selectin (sE-
selectin). The coagulative/fibrinolytic cascade was impaired as determined by the increased 
level of PAI-1. Concomitantly, E-selectin, a marker of endothelial injury, was also 
significantly elevated. In addition either loop L7 or Hib porin injection induced 
hyperglycaemia and inflammatory cytokine production. The data were correlated with 
hemodynamic functions (significant reduction of blood pressure and increase of heart rate). 
The results indicated that, in that experimental model, the loop L7 plays an essential role in 
the pathophysiologic events observed during gram-negative infection.  
OMPA from E. coli K1 plays a fundamental role in pathogenesis and great importance are 
correlated with the host signaling events underlying its entry into host cells. OMPA 
contributes to endothelial cells activation through a ligand- receptor interaction. OMPA 
activates PI3K but exhibited no effect on RhoA activation. The RhoA and PI3K host cell 
signaling pathways involvement in E. coli K1 invasion of human BMEC was further 
supported by the treatment of human BMEC with Rho kinase inhibitor (Y27632) and PI3K 
inhibitor (LY294002) which resulted in significant greater inhibition of E. coli K1 invasion 
compared to individual inhibitors alone.  
The properties of Lipid-A associated proteins (LAP) have been extensively reviewed by 
Hitchcock and Morris (Hitchcock, 1984). Preparations of LAP from S. typhimurium have IL-1 
like properties. LAP from Actinobacillus actinomycetemcomitans, an aquaporin associated with 
various forms of inflammatory periodontal disease, stimulate the release of IL-1β and IL-6 
from human monocytes or human gingival fibroblast. LAP from Porphyromonas gingivalis, 
one of the causative organisms of peridontitis, are potent stimulators of IL-6 release from 
human gingivalis fibroblasts (Reddi, 1995).  
8. Activation of eukaryotic cell signaling and transcriptional activation 
induced by OMPs 
The molecular mechanisms during the interaction of gram-negative bacteria with 
macrophages are well understood, but the mechanisms used by porins to activate cells is not 
well characterized. LPS, porins or other OMPs probably activate cells through similar but 
not identical mechanisms (Galdiero, 2003b). A variety of extracellular factors, such as 
growth factors or bacterial surface components, induce a complex cellular signaling by 
binding specific transmembrane receptors on the host cell membrane. The intracellular 
signaling pathways are complex networks of biochemical events that culminate in specific 
patterns of nuclear gene expression mediated by transcription factors. Signal transduction 
pathways and transcriptional activation known to occur during immune cell activation have 
been investigated by numerous authors and protein tyrosine phosphorylation plays a 
central role in transduction mediated by bacteria or LPS or toxins (Evans, 1998; Rosenshine, 
1992; Weinstein, 1992). Cytoplasmic signal transduction is regulated by several enzymatic 
pathways among which the mitogen-activated protein kinase (MAPK) pathway is especially 
activated during the adhesion and penetration of bacteria into the host cell (Evans, 1998; 
Rosenshine, 1992) and when stimulating the cell with products of bacterial origin 
(Weinstein, 1992).  
MAPK/extracellular signal-regulated kinases are serine/threonine protein kinase members 
of sequential protein phosphorylation pathways involving c-Jun N-terminal kinases (JNKs) 
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and ERKs (Davis, 2000). The MAPK pathway activates a number of transcription factors 
such as activating protein-1 (AP-1) and nuclear factor-kappa B (NFκB). The contribution of 
AP-1 family members to transcriptional regulation is controlled by a number of well 
characterized mechanisms (Karin, 1997). AP-1 is a ubiquitous class of gene regulatory 
factors and AP-1 proteins form either Jun-Jun homodimers comprised of members of the Jun 
family (c-Jun, JunD, and JunB) or Fos-Jun heterodimers derived from the various Fos family 
members. The AP-1 family members differ in their abilities to transactivate or repress 
transcription (Karin, 1997). NF-κB is a dimeric transcription factor and has multiple 
functions in immunity and is also critical for development and cellular survival. Mammalian 
cells contain five NF-κB subunits (p65, c-Rel, RelB, p50and p52) which form various hetero- 
and homodimers. NF-κB is present in the cytoplasm of resting cells bound to its inhibitor IκBα. 
The activation of NF-κB requires sequential phosphorylation, ubiquitination, and degradation 
of IκB. Multiple kinases have been shown to phosphorylate IκB at specific amino-terminal 
serine residues. In response to a large spectrum of chemically diverse agents and cellular stress 
conditions including LPS and porins, microbial and viral pathogens, cytokines and growth 
factors, NF-κB translocates in the nucleus, activating expression of target genes mainly 
involved in inflammatory and immunological responses (Caamano, 2002).  
Several studies have addressed the mechanism by which porins stimulate cells. S. enterica 
serovar typhimurium porins induce signal transduction in mouse macrophages (Gupta, 
1999). Porin activation of macrophages results in increased inositol triphosphate and 
intracellular Ca2+ mobilization, translocation of protein kinase C (PKC) to the membrane, 
NO release within the macrophages and increased binding of infected macrophages 
resulting in macrophage activation and triggering of specific signaling pathways. S. enterica 
serovar typhimurium, Mannheimia haemolytica, and Haemophilus influenzae (Hib) porins 
induce tyrosine phosphorylation in THP-1 cells and in C3H/HeJ mouse macrophages 
(Galdiero, 2001), with Hib porin being the most powerful stimulator. Incubation of porins 
with either THP-1 or macrophages from C3H/HeJ mice resulted in tyrosine 
phosphorylation of specific host cell proteins with the appearance of tyrosine-
phosphorylated proteins in the soluble cytoplasmic fraction, in the membrane fraction and 
in the insoluble protein fraction. The pattern of phosphorylation observed following LPS or 
porin stimulation is essentially similar, but a difference can be observed in the cytoplasmic 
fraction bands of 50-60 kDa, which are more evident after treatment with LPS, and in the 
insoluble fraction band of 80kDa and the cytoplasmic fraction band of 250kDa, which are 
more evident after porin treatment. 
Among the most prominent tyrosine-phosphorylated bands in porin-stimulated cells, a 
number of proteins with a molecular mass that is similar to that of the family of 
tyrosine/serine/threonine protein kinases were observed. S. enterica serovar typhimurium 
porins induce tyrosine phosphorylation of ERK1-2. Porins of S. enterica serovar 
typhimurium were also able to stimulate protein kinase A (PKA), PKC and protein-tyrosine 
kinase (NT-PTKs) in U937 cells. In the cells pretreated with tyrphostin, a specific PTK 
inhibitor, or with H-89, a specific PKA inhibitor, or calphostin C, a specific PKC inhibitor, 
decrease of the relevant activity was observed (Galdiero, 2003a). 
Neisserial porins induce protein tyrosine phosphorylation and alter the surface expression 
of the co-stimulatory molecule B7-2 (Massari, 2003). Recent evidence suggests that the Raf-1-
MEK1/2-MAPK pathways are included among the proteins which are phosphorylated 
following porin stimulation (Galdiero, 2002). The use of some specific inhibitors of 
phosphorylation pathways such as SB-203580 (p38 inhibitor), PD-098059 (MEK/ERK kinase 
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inhibitor) and forskolin (Raf-1 inhibitor) demonstrated that they modulate in a different way 
cytokine mRNA expression in cells stimulated with porins. Neisserial porins induce nuclear 
translocation of the transcription factor NF-κB in B cells and dendritic cells that was 
maximal by 3 h of stimulation (Massari, 2003). S. enterica serovar typhimurium porins also 
activate AP-1 and NF-κB in U937 cells involving the Raf-1-MEK1/2-MAPK pathways 
(Galdiero, 2002); pretreatment with PD-098059 and with SB-203580 markedly affected the 
activation, indicating that the p38 signaling pathway is mainly involved in AP-1 and NF-κB 
activation. In contrast, forskolin pretreatment did not block transcription factor activation by 
porins, suggesting that a Raf-1-independent pathway may also be involved following porin 
stimulation. Electrophoresis mobility shift assays, using antibodies to specific transcription 
factor protein subunits, showed that in U937 cells the AP-1 complex contains Jun-D and c-
Fos heterodimers and probably no other homodimers or heterodimers. In U937 cells treated 
with LPS, AP-1 complexes containing Jun-D, c-Fos and c-Jun appeared, while stimulation by 
porins induces AP-1 complexes containing fra-2 in addition to the other subunits. The 
formation of a different complex represents a further difference between stimulation with 
LPS and stimulation with porins. This may be added to past observations where mRNA  
 
 
Fig. 4. Speculative scheme of porin signal transduction pathways. Putative porin-specific 
receptors are shown to be transmembrane. The solid arrows indicate the known association 
between superficial porin receptors and activation of several transcription factors; dotted 
arrows indicate hypothetical events. 
 
Septic Shock by Gram-Negative Infections: Role of Outer Membrane Proteins 
 
39 
cytokine expression after stimulation with porin begins after 120 min and continues for 5-6 
h, while following LPS stimulation begins after 30 min and decreases at 120 min. Forskolin 
did not block NF-κB translocation after porin stimulation. Raf-1 induces the dissociation of 
cytoplasmic NF-κB-IκB complexes (Li, 1993), suggesting that a Raf-1-dependent pathway 
may be involved in NF-κB activation. However, it is known that PKC triggers the activation 
of several kinases suggesting that MEK/ERK pathways may also participate in NF-κB 
activation by enhancing an AP-1-NF-κB cross-coupling mechanism. The porin P2 from Hib, 
like porins from S. enterica serovar typhimurium, activates mainly but not exclusively the 
JNK and p38 pathways. Synthetic peptides, corresponding to the amino acid sequences of 
variable loop regions facing the cell exterior and thus more probably involved in the initial 
interaction with the host cell, proved to be able to activate the MEK1-MEK2/MAPK 
pathways similarly to the entire protein. In contrast, peptides modelled on internal β-
strands were ineffective in inducing phosphorylation of such pathways (Galdiero, 2003c). 
A speculative scheme of signal transduction pathways involved in porin-mediated 
responses is depicted in Figure 4. Accumulating evidence has suggested that the regulation 
of transcriptional factors and the subunit composition by porin stimulation may affect the 
adaptive immune mechanism to modulate the production of biologically active proteins or 
peptides. The engagement of multiple pathways during signal transmission makes the 
possible use of molecular inhibitors as therapeutic agents very difficult; although recent 
findings show that peptides complementary to loop regions have a certain ability to block 
the activity of the porin (Cantisani, 2011).  
9. OMPs and septic shock  
Septic shock is a major cause of death in the world. Gram-negative infection frequently 
results in systemic manifestations of sepsis and septic shock. The systemic syndrome is 
caused by the host response to gram-negative surface components. This response may set in 
motion a cascade of pathophysiologic consequences that result in multiple organ systemic 
failure and death. The host response to gram-negative bacterial infection is complex and 
multifaceted. Strong experimental evidence and clinical observations suggest that the 
release of proinflammatory cytokine mediators in response to toxic bacterial products set in 
motion an uncontrolled pathophysiologic program that manifests as sepsis or septic shock. 
The best characterized and most important of these toxic products is gram-negative 
endotoxin. For the general scientific public, the terms endotoxin and LPS are 
interchangeable. The term lipopolysaccharide (LPS) obtained by using the Westphal 
extraction procedure (Westphal, 1952), should be reserved for purified bacterial LPS extracts 
which are free of detectable contaminants, particularly proteins. In contrast, the term 
endotoxin should be used to refer to macromolecular complexes of LPS, protein and 
phospholipid normally obtained by extraction of bacteria with trichloroacetic acid, butanol 
and EDTA. Endotoxin associated protein consist of complex of four or five major proteins 
that range in size from 10 to 35 kDa. Originally considered to be a superfluous carrier of 
LPS, endotoxin associated proteins are now recognized to have potent biological activities 
(Mangan, 1992). Endotoxin associated proteins are powerful mitogen for C3H/HeJ mice, 
which are hyporesponsive to LPS. Techniques previously used in the extraction of stable 
LPS from the endotoxin had greatly favored the study of this portion of the molecule, 
ignoring the denaturable protein fraction, allowing the identification of most of the effects of 
endotoxin with those of LPS. Subsequent extraction techniques for membrane proteins (in 
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their native form) then allowed the study of the protein fraction, which was extracted 
globally in the endotoxin (Hindennach, 1975). Although much is known about the role of 
LPS in septic shock, little is known about the role of the proteic components. Approximately 
50% of the dry mass of the outer membrane of the gram-negative bacteria consists of 
proteins and more than 20 immunochemically distinct proteins (OMPs) have been identified 
in E. coli. Several OMPs have been shown to be potent inducers of cytokine synthesis. The 
most abundant of OMPs are porins. Porins isolated from Salmonella enterica serovar 
typhimurium, Yersimia enterocolitica, and Mannheimia haemolytica have been shown to 
stimulate the release of a range of proinflammatory and immunomodulating cytokines 
including IL-1, IL-4, Il-6, IL-8, TNF-α and INN-γ by monocytes and lymphocytes. Porins 
stimulate also the release of granulocyte-monocyte colony stimulating factor (GM-CSF), 
soluble intercellular adhesion molecule-1 (ICAM-1) and soluble E-selectin (SE-selectin) in a 
dose-dependent fashion by HUVEC cells (Donnarumma, 1996). 
In vitro and in vivo experiments supported the involvement of porins in the septic shock 
pathogenesis. The administration of porin to animals affects their hemodynamics, body 
temperature, blood clotting, cellular and humoral immunities proliferation of B lymphocytes 
and macrophages, and release of various endogenous mediators. The role played by porins 
and in general by OMPs in sepsis has been further supported by conflicting results obtained 
with the immunotherapy. The notion that the core regions of most strains of gram-negative 
bacterial LPS were quite similar, supported the development of a broadly effective 
immunotherapy for gram-negative sepsis using antibodies raised against LPS, through the use 
of a bacterial strain with an outer membrane that features no side chains, while bearing only 
the conserved core elements of LPS. The strain selected was the J5 mutant of E. coli O111:B4, 
whose LPS contains only the core determinants, primarily lipid A. Although it has generally 
been assumed that immunoglobulins to rough mutant E. coli J5 protect by binding to LPS, it 
has been demonstrated that IgG in those antisera bind only weakly to LPS from heterologous 
gram-negative strains. Also anti-lipid A monoclonal antibodies did not induce the expected 
results (Siber, 1985). Recently, it has been demonstrated that IgG in polyclonal antiserum 
raised to heat-killed E. coli J5 binds to three conserved gram-negative bacterial outer-
membrane proteins. (5-9, 18, and 35 kDa). These OMPs are exposed on the surface of bacterial 
cells and are released into human serum in complexes that also contain LPS (Binkley, 1945). 
The role of porins in pathogenesis is also confirmed by studies on the development of an 
effective vaccine against serogroup B Neisseria meningitides. The nonimmunogenicity of 
serogroup B capsular polysaccharide has led to the development of outer membrane vesicle 
(OMV) vaccines, based on the presence of PorB (Jolley, 2001; Wright, 2002). The porin proteins 
adopt a β-sheet structure within the outer membrane with surface exposed loops (Van der Ley, 
1991). OMPs epitopes mainly involved in the interaction with the host cells are those on the 
surface. The wide antigenic variability of gram-negative bacteria is due also to the great 
sequence amino acid variability of surface exposed loops. Although, cross-reactivity of the 
major OMPs of Enterobacteriacae has been reported by several investigators (Hofstra 1979, 
Hofstra, 1980), their role in the pathogenesis of sepsis and shock has not been fully dissected. 
Bacterial lipoproteins are important in the induction and pathogenesis of septic shock; in 
fact, they induce proinflammatory cytokine production in macrophages and lethal shock in 
LPS-responsive and nonresponsive mice. Lipoproteins are released from growing bacteria 
and released lipoproteins may play an important role in the induction of cytokine 
production and pathologic changes associated with gram-negative bacterial infections; 
treatment of bacteria with antibiotics significantly enhances lipoprotein release. 
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Lipoproteins activate macrophages; induce lethal shock in mice, and act synergistically with 
LPS to induce these responses (Zhang, 1997). Some gram-negative microorganisms have the 
ability to secrete lipoproteins to the extracellular environment; among those peptidoglycan-
associated lipoproteins, Pal is released into the bloodstream during infection, and this 
process contributes to the development of septic shock (Hellman, 2002; Liang, 2005). 
Lipoproteins play an important role in septic shock induced by bacteria; moreover, they act 
synergistically with LPS to induce lethal shock which suggest that they activate cells 
through different mechanisms. Bacterial lipoproteins have been shown to affect both the 
innate and acquired immune system via TLR2 signaling and generation of cytotoxic T 
lymphocytes and bactericidal antibodies (Masignani, 2003). 
10. Novel perspectives for therapies  
Gram-negative sepsis remains a significant cause of morbidity and mortality in site of the 
ongoing development of new antimicrobial agents (Lazaron, 1999); the reason may be 
attributed to the failure of antimicrobial therapy to address the described pathogenetic 
mechanism involved in the systemic inflammatory response due to gram-negative bacteria. 
The systemic syndrome is caused by the host response to gram-negative infection; which sets 
in motion a cascade of pathophysiologic consequences that result in dysregulation of 
hemodynamics, oxygen use, and intermediate metabolism, and often results in multiple organ 
failure with further increased morbidity and mortality; these may happen also after apparent 
eradication of the original infection. The immunotherapy in the treatment of sepsis and shock 
did not produce the expected results. In fact, polyclonal E. coli J5 antiserum is not suitable for 
commercial development, especially for the viability of antiserum activity. The mass 
production of IgM monoclonal antibodies allowed the obtainment of an antibody E5 binding 
more specifically to Lipid A. E5 monoclonal antiserum, tested in two randomized placebo-
controlled clinical trials demonstrated no clinical benefit to patients with gram-negative sepsis 
(Greenman, 1991). Also a human hybrid monoclonal antibody, HA-1A has been problematic. 
Anti-LPS core directed antibodies have not shown a survival benefit in clinical trials. The 
sometimes protective results observed using polyclonal E. coli J5 antiserum, may be attributed 
to the presence of antibodies against surface epitopes of OMPs.  The great variability of surface 
loops of OMPs makes it rather difficult the preparation of specific antiserum that could be 
used for all gram-negative infections. As death by septic shock has been derived by an early 
excessive inflammatory response, therapeutic strategies have been designed to block the 
cytokines and other mediators involved into pathogenesis. However, the sepsis and septic 
shock are not restricted only to the activation of the inflammatory response, but also to 
compensatory anti-inflammatory mechanism usually leading to immunosuppression. Patients 
in this state have a poor prognosis; in fact, the majority of deaths occur in patients with sepsis 
who are immunosuppressed (Adib-Conquy, 2009). 
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